,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,11,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-18 Non-Small Cell Lung cell line,Confirmatory,,
6,13,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
7,15,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
8,17,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the LXFL 529 Non-Small Cell Lung cell line,Confirmatory,,
9,19,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
10,21,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
11,23,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
12,25,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
13,27,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the M19-MEL Melanoma cell line,Confirmatory,,
14,29,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
15,31,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
16,33,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
17,35,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
18,37,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
19,39,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
20,41,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
21,43,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
22,45,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
23,47,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
24,49,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
25,51,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the XF 498 Central Nervous System cell line,Confirmatory,,
26,53,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
27,55,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
28,57,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-78 Central Nervous System cell line,Confirmatory,,
29,59,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
30,61,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 273 Small Cell Lung cell line,Confirmatory,,
31,63,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 114 Small Cell Lung cell line,Confirmatory,,
32,65,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
33,67,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
34,69,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DLD-1 Colon cell line,Confirmatory,,
35,71,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
36,73,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
37,75,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM20L2 Colon cell line,Confirmatory,,
38,77,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
39,79,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
40,81,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
41,83,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
42,85,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
43,87,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
44,89,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
45,91,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
46,93,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
47,95,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
48,97,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
49,99,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
50,101,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
51,103,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
52,105,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
53,107,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
54,109,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
55,111,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the P388 Leukemia cell line,Confirmatory,,
56,113,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
57,115,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
58,117,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the P388/ADR Leukemia cell line,Confirmatory,,
59,119,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
60,121,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
61,123,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
62,125,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
63,127,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12K1 Renal cell line,Confirmatory,,
64,129,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
65,131,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
66,133,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
67,135,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF-631 Renal cell line,Confirmatory,,
68,137,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
69,139,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
70,141,1,1,,67627,126941,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
71,143,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
72,145,1,1,,67627,126941,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
73,147,1,1,,67627,126941,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad52 strain,Other,,
74,149,1,1,,67627,126941,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the wt1 strain,Other,,
75,151,1,1,,67627,126941,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50EPP+ strain,Other,,
76,153,1,1,,67627,126941,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mgt1 strain,Other,,
77,155,1,1,,67627,126941,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
78,157,1,1,,67627,126941,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
79,159,1,1,,67627,126941,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad14 strain,Other,,
80,161,1,1,,67627,126941,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
81,163,1,1,,67627,126941,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the CLN2oe strain,Other,,
82,165,1,1,,67627,126941,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
83,167,1,1,,67627,126941,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
84,169,1,1,,67627,126941,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the wt2 strain,Other,,
85,171,1,1,,67627,126941,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 strain,Other,,
86,173,1,1,,67627,126941,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 strain,Other,,
87,175,1,1,,67627,126941,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
88,177,1,1,,67627,126941,Active,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad18 strain,Other,,
89,179,1,1,,67627,126941,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
90,180,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Adenocarcinoma 755 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
91,182,1,1,,67627,126941,Active,,,,,"NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Adriamycin; NSC 123127, Developed at Scr 06 and 41 (intraperitoneal) in B6D2F1 (BDF1) mice",Other,,
92,184,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  ADJ-PC-6 (intraperitoneal) in BALB/cJ mice,Other,,
93,186,1,1,,67627,126941,Unspecified,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Nontumored Animals (Toxicity Test) in B6D2F1 (BDF1) mice,Other,,
94,188,1,1,,67627,126941,Unspecified,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Nontumored Animals (Toxicity Test) in CD2F1 (CDF1) mice,Other,,
95,190,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphoma AKR (Transplanted) (intraperitoneal) in AKR/Lw mice,Other,,
96,192,1,1,,67627,126941,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
97,194,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
98,196,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intracerebral) in B6D2F1 (BDF1) mice,Other,,
99,198,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in C57BL/6 mice,Other,,
100,200,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6C3F1 mice,Other,,
101,206,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
102,208,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
103,210,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon 26 Adenocarcinoma (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
104,212,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
105,214,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6C3F1 mice,Other,,
106,216,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P288 Lymphocytic Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
107,218,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Adenocarcinoma 755 (subcutaneous) in C57BL/6 mice,Other,,
108,220,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,Other,,
109,224,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P335 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
110,226,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Ependymoblastoma (intracerebral) in B6C3F1 mice,Other,,
111,228,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Friend Virus Leukemia (Solid) (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
112,230,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphosarcoma Gardner 6C3HED (intraperitoneal) in C3H/He mice,Other,,
113,232,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphosarcoma Gardner 6C3HED (intraperitoneal) in C3AKF1 (CHKRF1) mice,Other,,
114,236,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  AK4 Lymphoid Leukemia (intraperitoneal) in C3AKF1 (CHKRF1) mice,Other,,
115,242,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphoma 8 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
116,244,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphoma 8 (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
117,246,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1081 Chloroleukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
118,248,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
119,250,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
120,252,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intracerebral) in B6D2F1 (BDF1) mice,Other,,
121,254,1,1,,67627,126941,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intravenous) in B6D2F1 (BDF1) mice,Other,,
122,256,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
123,258,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in CD2F1 (CDF1) mice,Other,,
124,260,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intracerebral) in CD2F1 (CDF1) mice,Other,,
125,264,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
126,266,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
127,270,1,1,,67627,126941,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
128,272,1,1,,67627,126941,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intramuscular) in B6D2F1 (BDF1) mice,Other,,
129,274,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6D2F1 (BDF1) mice,Other,,
130,276,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6C3F1 mice,Other,,
131,278,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  A549 Human Adenocarcinoma of Lung with characteristics of Type II Alveolar Epithelial cells (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
132,280,1,1,,67627,126941,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Amelanotic Melanoma (LOX) (intraperitoneal) in NU/NU BALB/C (nude) mice,Other,,
133,282,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to A Terephthalanilide; NSC 38280 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
134,284,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to Methotrexate; NSC 740 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
135,286,1,1,,67627,126941,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma M5076 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
136,288,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma M5076 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
137,290,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1798 Lymphosarcoma (subcutaneous) in unknown mice,Other,,
138,292,1,1,,67627,126941,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma M5076 (intraperitoneal) in B6C3F1 mice,Other,,
139,296,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
140,298,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
141,300,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Madison 109 Lung Carcinoma (intramuscular) in unknown mice,Other,,
142,306,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to Methyl-GAG; NSC 32946 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
143,308,1,1,,67627,126941,Active,,,,,"NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to 6-MP and 6-Thioguanine; NSC 755, NSC 752 (intraperitoneal) in B6D2F1 (BDF1) mice",Other,,
144,312,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  C1498 Myeloid Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
145,316,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1534 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
146,320,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P329 Reticulum Cell Sarcoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
147,322,1,1,,67627,126941,Active,,,,,"NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Adriamycin; NSC 123127, Developed at Scr 08 (intraperitoneal) in CD2F1 (CDF1) mice",Other,,
148,324,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to AMSA; NSC 249992 (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
149,326,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Dihydroxy Anthracenedione; NSC 299195 (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
150,328,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
151,330,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
152,332,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  ADJ-PC-20 Plasma Cell (subcutaneous) in unknown mice,Other,,
153,334,1,1,,67627,126941,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intracerebral) in CD2F1 (CDF1) mice,Other,,
154,336,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to Vincristine; NSC 67574 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
155,338,1,1,,67627,126941,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia resistant to A Terephthalanilide; NSC 38280 (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
156,340,1,1,,67627,126941,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Reticulum Cell Sarcoma (Kelley Mouse) (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
157,342,1,1,,67627,126941,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma 180 (subcutaneous) in Swiss mice,Other,,
158,344,1,1,,67627,126941,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lieberman Plasma Cell No. 1 (LPC-1) (intraperitoneal) in unknown mice,Other,,
159,377,1,3,,10321387,126941,Inconclusive,42741659.0,5243.0,,,MDR-1,Other,,
160,410,1,5,,11113978,126941,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
161,411,2,1,,11113978,126941,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
162,422,1,5,,17404585,126941,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
163,429,1,5,,17404585,126941,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
164,429,1,5,,17404585,126941,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
165,436,2,1,,17404585,126941,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
166,445,3,1,,11113978,126941,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
167,447,1,1,,11113978,126941,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
168,448,1,2,,11113978,126941,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
169,450,1,2,,11113978,126941,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
170,451,1,2,,11113978,126941,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
171,526,1,1,,11113978,126941,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
172,530,1,1,,11113978,126941,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
173,547,1,4,,17404585,126941,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
174,584,1,3,,11113978,126941,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
175,585,1,4,,11113978,126941,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
176,595,1,3,,11113978,126941,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
177,596,1,2,,11113978,126941,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
178,597,1,3,,11113978,126941,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
179,603,1,2,,11113978,126941,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
180,605,1,2,,11113978,126941,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
181,607,1,3,,11113978,126941,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
182,662,1,1,,11113978,126941,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
183,694,1,1,,17404585,126941,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
184,732,1,2,,17404585,126941,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
185,875,1,2,,11113978,126941,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
186,879,1,2,,11113978,126941,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
187,879,1,2,,11113978,126941,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
188,880,2,1,,11113978,126941,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
189,880,2,1,,11113978,126941,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
190,880,2,1,,26752120,126941,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
191,880,2,1,,26752120,126941,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
192,880,2,1,,26752121,126941,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
193,880,2,1,,26752121,126941,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
194,880,2,1,,50104777,126941,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
195,880,2,1,,50104777,126941,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
196,881,2,2,,11113978,126941,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
197,883,1,3,,11113978,126941,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
198,884,1,2,,11113978,126941,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
199,885,1,2,,11113978,126941,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
200,886,1,2,,11113978,126941,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
201,886,1,2,,11113978,126941,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
202,887,1,2,,11113978,126941,Inconclusive,1832253.0,246.0,10.0,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
203,889,1,3,,11113978,126941,Inconclusive,1730092.0,840.0,15.8489,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
204,891,1,2,,11113978,126941,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
205,892,1,2,,11113978,126941,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
206,893,1,2,,11113978,126941,Active,122921310.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
207,893,1,2,,11113978,126941,Active,122921311.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
208,894,2,1,,11113978,126941,Inconclusive,31542939.0,3248.0,25.1189,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
209,894,2,1,,50104777,126941,Inconclusive,31542939.0,3248.0,35.4813,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
210,895,1,2,,11113978,126941,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
211,899,1,2,,11113978,126941,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
212,900,1,3,,11113978,126941,Inconclusive,15431328.0,834.0,15.8489,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
213,901,1,2,,11113978,126941,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
214,902,1,2,,11113978,126941,Inconclusive,120407068.0,7157.0,0.1,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
215,912,1,2,,11113978,126941,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
216,917,1,3,,11113978,126941,Inactive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
217,918,1,3,,11113978,126941,Inconclusive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
218,923,1,2,,11113978,126941,Inconclusive,,,15.8489,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
219,924,1,2,,11113978,126941,Inconclusive,120407068.0,7157.0,0.1,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
220,926,1,2,,11113978,126941,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
221,927,1,3,,11113978,126941,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
222,928,1,2,,11113978,126941,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
223,938,1,2,,11113978,126941,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
224,940,1,2,,17404585,126941,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
225,943,1,2,,11113978,126941,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
226,944,1,2,,11113978,126941,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
227,945,1,4,,11113978,126941,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
228,954,1,2,,11113978,126941,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
229,957,1,2,,11113978,126941,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
230,958,1,2,,11113978,126941,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
231,959,1,4,,11113978,126941,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
232,992,1,3,,11113978,126941,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
233,995,1,2,,11113978,126941,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
234,997,1,2,,11113978,126941,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
235,998,1,2,,11113978,126941,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
236,1030,2,1,,11113978,126941,Inconclusive,30582681.0,216.0,35.4813,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
237,1030,2,1,,26752121,126941,Inconclusive,30582681.0,216.0,22.3872,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
238,1030,2,1,,50104777,126941,Inconclusive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
239,1189,1,5,,48413987,126941,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
240,1191,1,3,,48413987,126941,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Hamster Bioassay Results,Other,,
241,1194,1,3,,48413987,126941,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
242,1195,1,2,,48416247,126941,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
243,1199,1,3,,48413987,126941,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
244,1205,1,4,,48413987,126941,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
245,1208,1,3,,48413987,126941,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
246,1332,1,1,,49761632,126941,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
247,1379,1,2,,11113978,126941,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
248,1379,1,2,,50104777,126941,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
249,1422,1,1,,17404585,126941,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
250,1452,1,1,,11113978,126941,Inactive,154426292.0,239.0,39.8107,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
251,1454,1,1,,11113978,126941,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
252,1454,1,1,,50104777,126941,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
253,1457,1,1,,11113978,126941,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
254,1457,1,1,,26752121,126941,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
255,1457,1,1,,50104777,126941,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
256,1458,1,1,,26752121,126941,Inactive,10937869.0,6607.0,0.0891,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
257,1458,1,1,,50104777,126941,Inactive,10937869.0,6607.0,0.1413,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
258,1459,1,1,,50104777,126941,Inconclusive,27436948.0,4000.0,0.1778,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
259,1460,1,3,,11113978,126941,Inconclusive,92096784.0,4137.0,39.8107,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
260,1460,1,3,,26752121,126941,Inconclusive,92096784.0,4137.0,17.7828,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
261,1460,1,3,,50104777,126941,Inconclusive,92096784.0,4137.0,19.9526,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
262,1461,1,2,,50104777,126941,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
263,1463,1,1,,11113978,126941,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
264,1463,1,1,,26752121,126941,Inconclusive,,,19.9526,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
265,1463,1,1,,50104777,126941,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
266,1467,1,3,,11113978,126941,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
267,1467,1,3,,50104777,126941,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
268,1468,1,1,,11113978,126941,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
269,1468,1,1,,26752121,126941,Inconclusive,92096784.0,4137.0,10.0,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
270,1468,1,1,,50104777,126941,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
271,1469,1,1,,11113978,126941,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
272,1469,1,1,,26752120,126941,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
273,1469,1,1,,26752121,126941,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
274,1469,1,1,,26752122,126941,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
275,1469,1,1,,50104777,126941,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
276,1471,2,1,,11113978,126941,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
277,1471,2,1,,26752120,126941,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
278,1471,2,1,,26752121,126941,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
279,1476,2,1,,11113978,126941,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
280,1476,2,1,,50104777,126941,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
281,1477,1,1,,11113978,126941,Inconclusive,,,14.1254,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
282,1477,1,1,,26752121,126941,Inconclusive,,,44.6684,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
283,1477,1,1,,50104777,126941,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
284,1478,2,1,,11113978,126941,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
285,1478,2,1,,50104777,126941,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
286,1479,1,2,,11113978,126941,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
287,1479,1,2,,26752120,126941,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
288,1479,1,2,,26752121,126941,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
289,1479,1,2,,26752122,126941,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
290,1479,1,2,,50104777,126941,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
291,1487,1,1,,26752120,126941,Inconclusive,27436948.0,4000.0,0.0045,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
292,1487,1,1,,50104777,126941,Inconclusive,27436948.0,4000.0,0.0282,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
293,1490,2,1,,11113978,126941,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
294,1490,2,1,,26752120,126941,Inconclusive,10954339.0,,50.1187,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
295,1490,2,1,,26752121,126941,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
296,1519,1,3,,11113978,126941,Inconclusive,,,5.6234,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
297,1519,1,3,,50104777,126941,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
298,1580,1,1,,8149420,126941,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
299,1581,1,1,,8149420,126941,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
300,1582,1,1,,8149420,126941,Active,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
301,1583,1,1,,8149420,126941,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
302,1584,1,1,,8149420,126941,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
303,1585,1,1,,8149420,126941,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
304,1586,1,1,,8149420,126941,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
305,1587,1,1,,8149420,126941,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
306,1588,1,1,,8149420,126941,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
307,1589,1,1,,8149420,126941,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
308,1590,1,1,,8149420,126941,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
309,1593,1,1,,8149420,126941,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
310,1594,1,1,,8149420,126941,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
311,1595,1,1,,8149420,126941,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
312,1596,1,1,,8149420,126941,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
313,1597,1,1,,8149420,126941,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
314,1598,1,1,,8149420,126941,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
315,1599,1,1,,8149420,126941,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
316,1600,1,1,,8149420,126941,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
317,1601,1,1,,8149420,126941,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
318,1602,1,1,,8149420,126941,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
319,1603,1,1,,8149420,126941,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
320,1604,1,1,,8149420,126941,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
321,1605,1,1,,8149420,126941,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
322,1606,1,1,,8149420,126941,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
323,1607,1,1,,8149420,126941,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
324,1608,1,1,,8149420,126941,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
325,1609,1,1,,8149420,126941,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
326,1610,1,1,,8149420,126941,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
327,1611,1,1,,8149420,126941,Unspecified,,,,,Screen for compounds that induce the human heat shock transcriptional response (HSEluc),Other,,
328,1612,1,1,,8149420,126941,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
329,1613,1,1,,8149420,126941,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
330,1614,1,1,,8149420,126941,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
331,1616,1,1,,8149420,126941,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
332,1688,1,1,,26752120,126941,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
333,1705,1,2,,50104777,126941,Active,6980812.0,,19.9526,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
334,1707,1,3,,50104777,126941,Inconclusive,,,28.1838,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
335,1708,1,3,,50104777,126941,Inactive,405898.0,,,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
336,1766,1,1,,11113978,126941,Inconclusive,18860839.0,4221.0,39.8107,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
337,1766,1,1,,11113978,126941,Inconclusive,56550039.0,4297.0,39.8107,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
338,1766,1,1,,26752120,126941,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
339,1766,1,1,,26752120,126941,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
340,1766,1,1,,50104777,126941,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
341,1766,1,1,,50104777,126941,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
342,1768,1,1,,11113978,126941,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
343,1768,1,1,,11113978,126941,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
344,1768,1,1,,26752120,126941,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
345,1768,1,1,,26752120,126941,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
346,1768,1,1,,50104777,126941,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
347,1768,1,1,,50104777,126941,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
348,1811,3,2,,46391726,126941,Active,493970.0,,,,Experimentally measured binding affinity data derived from PDB,Other,8265622.0,
349,1811,3,2,,46391727,126941,Active,493972.0,,,,Experimentally measured binding affinity data derived from PDB,Other,8265622.0,
350,1811,3,2,,46394046,126941,Active,494769.0,,,,Experimentally measured binding affinity data derived from PDB,Other,1932031.0,
351,1815,1,1,,50104777,126941,Active,,,0.1259,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
352,1816,1,1,,50104777,126941,Active,,,0.0398,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
353,1828,2,1,,50104777,126941,Active,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
354,1850,2,1,,56463665,126941,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
355,1851,1,2,,11113978,126941,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
356,1851,1,2,1.0,11113978,126941,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
357,1851,1,2,2.0,11113978,126941,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
358,1851,1,2,3.0,11113978,126941,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
359,1851,1,2,4.0,11113978,126941,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
360,1851,1,2,5.0,11113978,126941,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
361,1863,2,1,,56463665,126941,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
362,1865,1,1,,11113978,126941,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
363,1865,1,1,,26752121,126941,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
364,1865,1,1,,50104777,126941,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
365,1876,1,1,,50104777,126941,Active,,,0.0708,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
366,1877,1,1,,50104777,126941,Active,,,0.0398,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
367,1882,1,1,,50104777,126941,Active,,,0.0794,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
368,1883,1,1,,50104777,126941,Active,,,0.0398,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
369,1886,1,1,,50104777,126941,Active,,,0.0708,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
370,1899,1,3,,56463665,126941,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
371,1903,2,3,,56463665,126941,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
372,1906,1,3,,56463665,126941,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
373,1947,1,2,,56463665,126941,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
374,1948,1,1,,11113978,126941,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
375,1948,1,1,,50104777,126941,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
376,1950,1,3,,56463665,126941,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
377,1962,1,2,,56463665,126941,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
378,1967,1,1,,50104777,126941,Inactive,4505907.0,5376.0,,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
379,1974,1,2,,56463665,126941,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
380,1987,1,2,,56463665,126941,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
381,2016,1,3,,56463665,126941,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
382,2023,1,3,,56463665,126941,Active,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
383,2025,1,3,,56463665,126941,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
384,2029,1,3,,56463665,126941,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
385,2052,2,1,,56463665,126941,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
386,2057,1,2,,56463665,126941,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
387,2066,1,4,,56463665,126941,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
388,2101,1,1,,11113978,126941,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
389,2101,1,1,,26752121,126941,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
390,2101,1,1,,50104777,126941,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
391,2107,1,1,,11113978,126941,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
392,2107,1,1,,26752121,126941,Inconclusive,757912.0,2717.0,14.1254,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
393,2107,1,1,,50104777,126941,Inconclusive,757912.0,2717.0,25.1189,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
394,2112,1,1,,11113978,126941,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
395,2112,1,1,,26752121,126941,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
396,2112,1,1,,50104777,126941,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
397,2129,1,2,,56463665,126941,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
398,2130,1,3,,56463665,126941,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
399,2147,1,1,,11113978,126941,Inconclusive,221046486.0,,31.6228,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
400,2147,1,1,,50104777,126941,Inconclusive,221046486.0,,28.1838,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
401,2174,1,3,,56463665,126941,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
402,2177,1,3,,56463665,126941,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
403,2234,1,2,,56463665,126941,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
404,2235,1,2,,56463665,126941,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
405,2280,2,3,,56463665,126941,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
406,2297,1,2,,85860315,126941,Unspecified,,,,,Inhibition Frequency Index,Other,,
407,2300,1,3,,56463665,126941,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
408,2302,1,2,,85860315,126941,Unspecified,111034851.0,,,,Inhibition of P. falciparum Dd2,Screening,,
409,2303,1,2,,85860315,126941,Inactive,,,,,Inhibition of HepG2 cell line,Screening,,
410,2304,1,2,,85860315,126941,Inactive,111034851.0,,,,Inhibition of P. falciparum LDH,Screening,,
411,2305,1,2,,85860315,126941,Unspecified,,,,XC50_3D7,XC50 for P. falciparum 3D7,Confirmatory,,
412,2306,1,2,,85860315,126941,Active,124513266.0,814112.0,,,Inhibition of P. falciparum 3D7,Screening,,
413,2323,1,1,,50104777,126941,Inactive,254220970.0,,39.8107,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
414,2326,1,1,,50104777,126941,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
415,2353,1,3,,50104777,126941,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
416,2364,1,2,,50104777,126941,Inconclusive,4557365.0,641.0,19.9526,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
417,2380,1,2,,56463665,126941,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
418,2391,1,1,,56463665,126941,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
419,2435,1,2,,56463665,126941,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
420,2445,1,2,,56463665,126941,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
421,2451,1,2,,11113978,126941,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
422,2451,1,2,,50104777,126941,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
423,2462,1,1,,56463665,126941,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
424,2462,1,1,,56463665,126941,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
425,2472,1,2,,11113978,126941,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
426,2517,2,1,,11113978,126941,Inconclusive,6980812.0,,28.1838,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
427,2517,2,1,,26752121,126941,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
428,2517,2,1,,50104777,126941,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
429,2520,1,4,,56463665,126941,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
430,2521,1,3,,56463665,126941,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
431,2524,1,2,,56463665,126941,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
432,2528,1,2,,11113978,126941,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
433,2528,1,2,,26752120,126941,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
434,2528,1,2,,50104777,126941,Inconclusive,4557365.0,641.0,19.9526,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
435,2540,1,2,,56463665,126941,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
436,2544,1,2,,56463665,126941,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
437,2546,1,1,,11113978,126941,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
438,2546,1,1,,26752120,126941,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
439,2549,1,1,,11113978,126941,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
440,2549,1,1,,26752121,126941,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
441,2549,1,1,,50104777,126941,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
442,2551,1,1,,11113978,126941,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
443,2551,1,1,,26752120,126941,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
444,2557,1,3,,56463665,126941,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
445,2599,1,2,,56463665,126941,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
446,2606,1,2,,56463665,126941,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
447,2621,1,3,,56463665,126941,Active,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically LAP4 Second Cherry Pick Compounds,Screening,,
448,2622,1,3,,56463665,126941,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically MEP2 Second Cherry Pick Compounds,Screening,,
449,2623,1,3,,56463665,126941,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically RPL19A Second Cherry Pick Compounds,Screening,,
450,2624,1,3,,56463665,126941,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically CIT2 Second Cherry Pick Compounds,Screening,,
451,2629,1,1,,56463665,126941,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
452,2643,1,4,,56463665,126941,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically AGP1 Second Cherry Pick Compounds,Screening,,
453,2650,2,1,,56463665,126941,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
454,2660,1,1,,90340825,126941,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
455,2661,1,1,,56463665,126941,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
456,2662,2,1,,26752120,126941,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
457,2662,2,1,,50104777,126941,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
458,2666,1,1,,90340825,126941,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
459,2667,1,1,,90340825,126941,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
460,2668,1,1,,90340825,126941,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
461,2675,1,1,,50104777,126941,Inconclusive,41281591.0,4154.0,11.2202,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
462,2690,1,2,,56463665,126941,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
463,2716,1,1,,56463665,126941,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
464,2717,1,2,,56463665,126941,Active,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
465,2718,1,1,,56463665,126941,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
466,2732,1,1,,17404585,126941,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
467,2740,1,2,,56463665,126941,Inactive,536029.0,,,EC50_MICROM,Dose Response of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically RPL19A based on MLPCN hits,Confirmatory,,
468,2742,1,2,,56463665,126941,Inactive,1302091.0,,,EC50_MICROM,Dose Response of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically MEP2 based on MLPCN hits,Confirmatory,,
469,2743,1,2,,56463665,126941,Inactive,85666113.0,850333.0,,EC50_MICROM,Dose Response of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically AGP1 based on MLPCN hits,Confirmatory,,
470,2744,1,2,,56463665,126941,Inactive,171229.0,,,EC50_MICROM,Dose Response of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically CIT2 based on MLPCN hits,Confirmatory,,
471,2745,1,1,,56463665,126941,Inactive,486173.0,,,EC50_MICROM,Dose Response of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae specifically LAP4 based on MLPCN hits,Confirmatory,,
472,2751,2,2,,56463665,126941,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
473,2757,1,2,,56463665,126941,Inactive,,,,,Test compound autofluorescence in Saccharomyes cerevisiae specifically s288c,Other,,
474,2774,1,3,,92303735,126941,Inactive,,,,,LOPAC Circadian Assay,Screening,,
475,2796,1,4,,56463665,126941,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
476,2797,1,2,,56463665,126941,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
477,2805,2,2,,56463665,126941,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
478,2806,2,2,,56463665,126941,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
479,2825,1,2,,56463665,126941,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
480,2906,4,4,,104234169,126941,Active,,,0.0088,IC50,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,Confirmatory,8632413.0,
481,7051,4,4,,104234169,126941,Active,,,0.033,IC50,The IC50 value was measured on 786-0 cell line in renal tumor type.,Confirmatory,9022795.0,
482,8225,4,4,,104234169,126941,Active,,,0.033,IC50,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Confirmatory,9857098.0,
483,8276,4,4,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Confirmatory,9857098.0,
484,8659,4,4,,104234169,126941,Active,,,0.031,IC50,Cytotoxic activity evaluated against A549 tumor cells,Confirmatory,8632413.0,
485,8668,4,4,,104234169,126941,Active,,,0.023,IC50,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,Confirmatory,9022795.0,
486,9064,8,2,,104234169,126941,Unspecified,,,,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells.,Other,1847428.0,
487,9274,4,4,,104234169,126941,Active,,,0.033,IC50,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),Confirmatory,9857098.0,
488,9809,6,2,,104234169,126941,Active,,,3.0,EC50,Growth inhibition against Human squamous cell line(A 253),Confirmatory,7473577.0,
489,9810,4,4,,104234169,126941,Active,,,0.017,EC50,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,Confirmatory,7783147.0,
490,9811,6,2,,104234169,126941,Active,,,0.013000000000000001,EC50,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,Confirmatory,7562910.0,
491,9812,4,4,,104234169,126941,Active,,,0.019,EC50,Growth inhibition of A253 cell lines.,Confirmatory,11384244.0,
492,9813,4,4,,104234169,126941,Active,,,0.0145,EC50,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),Confirmatory,10956221.0,
493,10025,4,4,,104234169,126941,Active,,,0.04,IC50,The IC50 value was measured on ACHN cell line in renal tumor type.,Confirmatory,9022795.0,
494,10046,4,4,,104234169,126941,Active,,,0.04,IC50,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Confirmatory,9857098.0,
495,10655,3,3,,104234169,126941,Unspecified,,,,,plasma half life was observed after intravenous administration in rat,Other,11052790.0,
496,10784,6,3,,104234169,126941,Unspecified,,,,,plasma clearance was observed after intravenous administration in rat,Other,11052790.0,
497,10905,3,3,,104234169,126941,Unspecified,,,,,time required to reach maximum concentration (Cmax) after oral administration in rat,Other,11052790.0,
498,11488,5,2,,104234169,126941,Unspecified,,,,,volume of distribution at steady state was observed after intravenous administration in rat,Other,11052790.0,
499,12014,7,1,,104234169,126941,Unspecified,,,,,mean peak plasma concentration was observed after intravenous administration in rat,Other,11052790.0,
500,12015,7,1,,104234169,126941,Unspecified,,,,,mean peak plasma concentration was observed after oral administration in rat,Other,11052790.0,
501,12150,9,1,,104234169,126941,Unspecified,,,,,Area under curve in male SD rats was observed after oral administration in rat,Other,11052790.0,
502,12743,8,1,,104234169,126941,Unspecified,,,,,Area under curve in male SD rats was observed after intravenous administration in rat,Other,11052790.0,
503,13650,3,3,,104234169,126941,Unspecified,,,,,Oral bioavailability,Other,11052790.0,
504,15616,3,3,,104234169,126941,Unspecified,,,,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,Other,8632413.0,
505,15617,3,4,,104234169,126941,Unspecified,,,,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,Other,8632413.0,
506,16875,3,3,,104234169,126941,Unspecified,,,,,The efflux rate constant of the compound,Other,7143361.0,
507,18069,4,1,,104234169,126941,Unspecified,,,,,Apparent Km (Michaelis-Menten constant) of the compound.,Other,1992148.0,
508,20346,3,4,,104234169,126941,Unspecified,,,,,Activity relative to saturating aminopterine at 100 uM against CCRF-CEM Folyl-polyglutamate synthetase,Other,8277497.0,
509,22603,8,1,,104234169,126941,Unspecified,,,,,Influx velocity of the compound,Other,7143361.0,
510,22930,3,4,,104234169,126941,Unspecified,,,,,First-order rate constant of the compound,Other,1447744.0,
511,23271,4,4,,104234169,126941,Unspecified,,,,,Partition coefficient (logD7.4),Other,2362268.0,
512,23337,3,3,,104234169,126941,Unspecified,,,,,Relative maximum volume distribution of the compound.,Other,1992148.0,
513,23703,3,5,,104234169,126941,Unspecified,,,,,log P value was reported at a pH 2.0,Other,6699880.0,
514,26351,4,4,,104234169,126941,Unspecified,,,,,pKa value was determined,Other,6818345.0,
515,27167,3,4,,104234169,126941,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
516,27329,6,2,,104234169,126941,Active,,,42.0,Km,Kinetic constant(Km) was determined in FPGS-catalyzed reaction,Confirmatory,2308134.0,
517,28234,3,4,,104234169,126941,Unspecified,,,,,% absorbed in human GI-tract,Other,11300874.0,
518,28639,3,3,,104234169,126941,Unspecified,,,,,Kinetic constant relative(Vmax) was determined in FPGS-catalyzed reaction,Other,2308134.0,
519,28679,3,4,,104234169,126941,Unspecified,,,,,Partition coefficient (logD6.8),Other,11300874.0,
520,28681,3,4,,104234169,126941,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
521,28924,3,3,,104234169,126941,Unspecified,,,,,Effective permeability (Pe) across a hexadecane membrane (pH 6.8),Other,11300874.0,
522,28925,3,3,,104234169,126941,Unspecified,,,,,Highest effective permeability across hexadecane membrane (pH 4-8),Other,11300874.0,
523,29359,3,3,,104234169,126941,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
524,29813,3,3,,104234169,126941,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
525,30123,3,3,,104234169,126941,Unspecified,,,,,Kinetic constant Vmax relative to aminopterin,Other,12408727.0,
526,31281,9,3,,104234169,126941,Unspecified,,,20.0,IC50,Inhibitory activity against AICAR formyltransferase of Lactobacillus casei,Confirmatory,3121855.0,
527,31824,6,2,,104234169,126941,Active,,,0.018000000000000002,IC50,Evaluated for the inhibition of human gastrointestinal adenocarcinoma cells in vitro by HT-29 assay,Confirmatory,3968685.0,
528,31825,6,2,,104234169,126941,Active,,,0.009000000000000001,IC50,Evaluated for the inhibition of human gastrointestinal adenocarcinoma cells in vitro by HuTu 80 assay,Confirmatory,3968685.0,
529,31826,6,2,,104234169,126941,Active,,,0.015,IC50,Evaluated for the inhibition of human gastrointestinal adenocarcinoma cells in vitro by SW480 assay,Confirmatory,3968685.0,
530,31827,6,2,,104234169,126941,Active,,,0.025,IC50,Evaluated for the inhibition of human gastrointestinal adenocarcinoma cells in vitro by WIDR assay,Confirmatory,3968685.0,
531,38021,8,2,,104234169,126941,Unspecified,,,,,Inhibitory activity against LPS-stimulated B cell proliferation.,Other,9379448.0,
532,39264,5,1,,104234169,126941,Unspecified,,,,,Compound was tested in vitro for growth inhibitory activity against murine B16 melanoma cell line,Other,8258836.0,
533,42294,4,5,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against BT-549 breast cancer cell lines (Human tumor cells ),Confirmatory,9857098.0,
534,43236,4,4,,104234169,126941,Active,,,0.012,EC50,Concentration required to decrease cell growth by 50% in CCRF-CEM human leukemia cell line,Confirmatory,12408727.0,
535,43237,4,5,,104234169,126941,Active,,,0.0138,EC50,Concentration required to inhibit growth against CCRF-CEM cell,Confirmatory,11052789.0,
536,43238,4,4,,104234169,126941,Active,,,0.013999999999999999,EC50,Growth inhibition of parental CCRF-CEM cells.,Confirmatory,11384244.0,
537,43240,4,4,,104234169,126941,Active,,,0.0145,EC50,Inhibition of growth of CCRF-CEM human leukemia cells (n=4),Confirmatory,11960504.0,
538,43373,6,2,,104234169,126941,Unspecified,,,,,Compound was tested for cytotoxic activity in CCRF-CEM Human Leukemia cells by in vitro cytotoxicity assay,Other,11428931.0,
539,43385,4,4,,104234169,126941,Active,,,0.595,EC50,"Compound was evaluated for the growth inhibition of R1, a CCRF-CEM subline resistant to MTX solely as a result of a 20-fold increase in wild-type DHFR protein and activity",Confirmatory,7783147.0,
540,43386,4,4,,104234169,126941,Active,,,3.1,EC50,"Compound was evaluated for the growth inhibition of R2, a CCRF-CEM subline resistant to MTX as a result of deffective uptake.",Confirmatory,7783147.0,
541,43387,4,4,,104234169,126941,Active,,,0.0145,EC50,"Compound was evaluated for the growth inhibition of R30dm, a CCRF-CEM subline resistant to intermittent MTX exposure solely as a result of decreased polyglutamylation.",Confirmatory,7783147.0,
542,43388,4,4,,104234169,126941,Active,,,0.0145,EC50,Compound was evaluated for the growth inhibition of parental CCRF-CEM,Confirmatory,7783147.0,
543,43391,6,2,,104234169,126941,Active,,,0.018000000000000002,EC50,Growth inhibition against Human leukemic cell line (Methotrexate resistant CCRF-CEM),Confirmatory,7473577.0,
544,43392,6,2,,104234169,126941,Active,,,0.013999999999999999,EC50,Growth inhibition against Human leukemic cell line(CCRF-CEM),Confirmatory,7473577.0,
545,43394,4,4,,104234169,126941,Active,,,0.0137,EC50,Growth inhibition of CCRF-CEM Human Leukemia Cell was determined,Confirmatory,12570380.0,
546,43396,6,2,,104234169,126941,Active,,,0.018000000000000002,EC50,The compound was tested for Growth inhibition of Methotrexate-resistant human T-lymphoblastic leukemia cell line CCRF-CEM(sub line R30dm),Confirmatory,7562910.0,
547,43397,6,2,,104234169,126941,Active,,,0.013999999999999999,EC50,he compound was tested for Growth inhibition of the Human T-lymphoblastic Leukemia cell line CCRF-CEM,Confirmatory,7562910.0,
548,43398,4,4,,104234169,126941,Active,,,0.016,EC50,"the growth inhibition of, (during continuous exposure) human T-lymphoblastic leukemia cell line CCRF-CEM at resistance mechanism- sensitive",Confirmatory,8164259.0,
549,43399,5,1,,104234169,126941,Active,,,0.0137,ED50,Compound was evaluated for growth inhibition of parental CCRF-CEM during continuous (120 h) exposure to MTX,Confirmatory,8568828.0,
550,43520,5,1,,104234169,126941,Active,,,0.655,ED50,Growth inhibition of CCRF-CEM subline resistant to MTX solely as a result of a 25-fold increase in wild-type DHFR activity during continuous (120 h) exposure to MTX,Confirmatory,8568828.0,
551,43521,5,1,,104234169,126941,Active,,,2.55,ED50,Growth inhibition of CCRF-CEM subline resistant to MTX solely as a result of decreased MTX influx during continuous (120 h) exposure.,Confirmatory,8568828.0,
552,43522,5,1,,104234169,126941,Active,,,0.0155,ED50,Growth inhibition of CCRF-CEM subline resistant to MTX solely as a result of decreased polyglutamylation during continuous (120 h) exposure.,Confirmatory,8568828.0,
553,43523,5,1,,104234169,126941,Active,,,0.0145,ED50,Inhibitory activity against growth of CCRF-CEM human leukemia cells.,Confirmatory,8691451.0,
554,43681,4,4,,104234169,126941,Active,,,0.028999999999999998,IC50,Compound was evaluated for in vitro activity against CCRF-CEM leukemia cell lines (Human tumor cells ),Confirmatory,9857098.0,
555,43722,4,4,,104234169,126941,Active,,,0.0105,IC50,Tested for inhibitory concentration of cell growth against CCRF-CEM cell lines of human leukemic lymphoblast,Confirmatory,8035423.0,
556,43856,6,2,,104234169,126941,Active,,,4.48,Ki,Tested for the inhibition of [14C]-DDATHF influx in CCRF-CEM cells of human leukemic lymphoblast,Confirmatory,8035423.0,
557,44004,4,4,,104234169,126941,Active,,,0.0143,EC50,Growth inhibition was measured as for inhibition of growth in CCRF-CEM cells.,Confirmatory,9554874.0,
558,44005,4,4,,104234169,126941,Active,,,0.5670000000000001,EC50,Growth inhibition was measured for inhibition of growth in CCRF-CEM subline resistant to MTX solely as a result of a 20-fold increase in wild-type DHFR protein and activity.,Confirmatory,9554874.0,
559,44006,4,4,,104234169,126941,Active,,,0.008,EC50,Growth inhibition was measured for inhibition of growth in CCRF-CEM sublines resistant to MTX solely as a result of decreased polyglutamation.,Confirmatory,9554874.0,
560,44184,3,4,,104234169,126941,Unspecified,,,,,Protection of CCRF-CEm cells from the growth inhibitory effect of compound (30 nM) at leucovorin concentration 0,Other,12408727.0,
561,44185,3,4,,104234169,126941,Unspecified,,,,,Protection of CCRF-CEm cells from the growth inhibitory effect of compound (30 nM) at leucovorin concentration 0.1 uM,Other,12408727.0,
562,44186,3,4,,104234169,126941,Unspecified,,,,,Protection of CCRF-CEm cells from the growth inhibitory effect of compound (30 nM) at leucovorin concentration 1 mocroM,Other,12408727.0,
563,44187,3,4,,104234169,126941,Unspecified,,,,,Protection of CCRF-CEm cells from the growth inhibitory effect of compound (30 nM) at leucovorin concentration 10 mocroM,Other,12408727.0,
564,44188,3,4,,104234169,126941,Unspecified,,,,,Protection of CCRF-CEm cells from the growth inhibitory effect of compound (40 nM) at leucovorin concentration 0,Other,12408727.0,
565,44189,3,4,,104234169,126941,Unspecified,,,,,Protection of CCRF-CEm cells from the growth inhibitory effect of compound (40 nM) at leucovorin concentration 0.1 uM,Other,12408727.0,
566,44190,3,4,,104234169,126941,Unspecified,,,,,Protection of CCRF-CEm cells from the growth inhibitory effect of compound (40 nM) at leucovorin concentration 1 uM,Other,12408727.0,
567,44191,3,4,,104234169,126941,Unspecified,,,,,Protection of CCRF-CEm cells from the growth inhibitory effect of compound (40 nM) at leucovorin concentration 10 uM,Other,12408727.0,
568,44197,3,5,,104234169,126941,Unspecified,,,,,Relative activity when compared to the activity of aminopterin in CCRF-CEM Human leukemia cell at a concentration of 50 uM,Other,1992121.0,
569,44204,4,5,,104234169,126941,Unspecified,,,,,Protection of human CCRF-CEM cells by hypoxanthine from growth inhibition induced by the compound,Other,11052789.0,
570,44205,3,5,,104234169,126941,Unspecified,,,,,Protection of human CCRF-CEM cells by thymidine and hypoxanthine from growth inhibition induced by the compound,Other,11052789.0,
571,44206,3,5,,104234169,126941,Unspecified,,,,,Protection of human CCRF-CEM cells by thymidine from growth inhibition induced by the compound,Other,11052789.0,
572,44209,4,4,,104234169,126941,Active,,,0.6,EC50,"Growth inhibition of DHFR-overexpressing cells, defined mechanisms of MTX resistance during continuous (0-120 h) exposure",Confirmatory,11384244.0,
573,44212,4,4,,104234169,126941,Active,,,1.9,EC50,"Growth inhibition of DHFR-uptake, defined mechanisms of MTX resistance during continuous (0-120 h) exposure",Confirmatory,11384244.0,
574,44214,4,4,,104234169,126941,Active,,,0.015,EC50,Growth inhibition of CCRF-CEM cells resistant to MTX,Confirmatory,11384244.0,
575,44215,4,5,,104234169,126941,Active,,,2.03,EC50,Tested for their growth inhibition of CCRF-CEM human leukemia subline resistant as a result of decrease in uptake.,Confirmatory,11052789.0,
576,44216,4,5,,104234169,126941,Active,,,0.0155,EC50,Tested for their growth inhibition of CCRF-CEM human leukemia subline resistant as a result of decrease polyglutamylation.,Confirmatory,11052789.0,
577,44217,4,5,,104234169,126941,Active,,,0.66,EC50,Tested for their growth inhibition of CCRF-CEM human leukemia subline resistant as a result of increase in wild type DHFR protein and activity.,Confirmatory,11052789.0,
578,44340,4,4,,104234169,126941,Active,,,0.0144,EC50,Growth inhibition of CCRF-CEM human leukemia cells.,Confirmatory,10956221.0,
579,45399,3,4,,104234169,126941,Unspecified,,,,,Cross resistance of chinese hamster cells resistant to actinomycin D as log of ratio of molar concentration of compound inducing 50% inhibition of growth in resistant and sensitive cells,Other,2362268.0,
580,45436,6,2,,104234169,126941,Unspecified,,,,,Inhibition of colony formation of Caki-1 cells by MTX,Other,2810330.0,
581,45437,6,2,,104234169,126941,Unspecified,,,,,Inhibition of colony formation of Caki-1 cells by amide-linked conjugate (regiospecific coupling) of MTX and Dal K-20,Other,2810330.0,
582,45438,6,2,,104234169,126941,Unspecified,,,,,Inhibition of colony formation of Caki-1 cells by amide-linked conjugate of MTX and Dal K-20,Other,2810330.0,
583,45439,6,2,,104234169,126941,Unspecified,,,,,Inhibition of colony formation of Caki-1 cells by hydrazone-linked conjugate (regiospecific coupling) of MTX and Dal K-20,Other,2810330.0,
584,45440,6,2,,104234169,126941,Unspecified,,,,,Inhibition of colony formation of Caki-1 cells by hydrazone-linked conjugate of MTX and Dal K-20,Other,2810330.0,
585,46212,4,4,,104234169,126941,Active,,,2.76,EC50,"the growth inhibition of, (during continuous exposure) methotrexate resistant human T-lymphoblastic leukemia cell subline CEM/MTX at resistance mechanism - decreased influx",Confirmatory,8164259.0,
586,46392,6,2,,104234169,126941,Active,,,0.025,IC50,In vitro cytotoxicity by its growth inhibitory activity against human leukemic lymphoblasts (CEM cells).,Confirmatory,6585550.0,
587,46479,4,4,,104234169,126941,Active,,,0.87,IC50,Compound was evaluated for in vitro activity against COLO 205 Colon cell lines (Human tumor cells ),Confirmatory,9857098.0,
588,46600,4,4,,104234169,126941,Active,,,2.55,IC50,Tested for inhibitory concentration of cell growth against CEM/MTX cell lines of human leukemic lymphoblast,Confirmatory,8035423.0,
589,46760,8,1,,104234169,126941,Active,,,0.003,ID50,Compound is tested for the inhibition of growth of human lymphoblastic leukemia cells (CEM),Confirmatory,6787199.0,
590,46774,6,2,,104234169,126941,Active,,,9.74,Ki,Tested for inhibition of [14C]-DDATHF influx in CEM/MTX cells of human leukemic lymphoblasts,Confirmatory,8035423.0,
591,46810,6,2,,104234169,126941,Active,,,6.6,IC50,Cell growth inhibition against CEM/MTX cell from human leukemic lymphoblasts,Confirmatory,3872941.0,
592,46811,6,2,,104234169,126941,Active,,,6.6,IC50,Tested for cell-growth inhibition against human leukemic lymphoblast CEM/MTX cells,Confirmatory,2898531.0,
593,47282,6,2,,104234169,126941,Active,,,0.032,IC50,Cell growth inhibition against CEM cell from human leukemic lymphoblasts,Confirmatory,3872941.0,
594,47440,6,2,,104234169,126941,Active,,,0.032,IC50,Tested for cell-growth inhibition against human leukemic lymphoblast CEM cells,Confirmatory,2898531.0,
595,48501,6,2,,104234169,126941,Active,,,4.84,Km,Tested for substrate activity of compound for Carboxypeptidase G1,Confirmatory,6139480.0,
596,48502,3,3,,104234169,126941,Unspecified,,,,,Tested for substrate activity of compound for Carboxypeptidase G1,Other,6139480.0,
597,50576,4,5,,104234169,126941,Active,,,0.066,IC50,Inhibitory concentration of compound was tested against Colon 38 tumor growth cell line,Confirmatory,8201595.0,
598,52545,4,3,,104234169,126941,Active,,,0.013999999999999999,IC50,Concentration required to inhibit the growth of chang liver cells,Confirmatory,9022804.0,
599,52546,4,3,,104234169,126941,Active,,,0.013999999999999999,IC50,Concentration required to inhibit the growth of chang liver cells.,Confirmatory,9022805.0,
600,52667,6,2,,104234169,126941,Unspecified,,,40.0,IC50,Inhibitory concentration of compound was tested against Colon 26 Mouse Colorectal Carcinoma on 4 hour exposure,Confirmatory,8201595.0,
601,55581,4,4,,104234169,126941,Active,,,0.016,IC50,Cytotoxic Activity was evaluated against D54 tumor cells,Confirmatory,8632413.0,
602,55689,9,5,,104234169,126941,Active,118998.0,,0.001,IC50,Inhibition of Pneumocystis carinii (pc) Dihydrofolate reductase,Confirmatory,7783147.0,
603,55694,9,5,,104234169,126941,Active,118998.0,,0.0011,IC50,Inhibitory activity against pneumocystis carinii Dihydrofolate reductase,Confirmatory,12408727.0,
604,55703,9,5,,104234169,126941,Active,118998.0,,0.001,IC50,Inhibition against Dihydrofolate reductase in Pneumocystis carinii,Confirmatory,9089339.0,
605,55723,3,7,,104234169,126941,Unspecified,,,,,Binding affinity against Dihydrofolate reductase,Other,12061879.0,
606,55830,9,5,,104234169,126941,Active,118998.0,,0.0013,IC50,Inhibitory activity against Dihydrofolate reductase from Pneumocystis carinii was evaluated using 90 uM dihydrofolic acid as substrate,Confirmatory,9301666.0,
607,55834,11,2,,104234169,126941,Active,118998.0,,0.88,IC50,Inhibitory activity was determined against dihydrofolate reductase in Pneumocystis carinii.,Confirmatory,7490723.0,
608,55836,9,5,,104234169,126941,Active,118998.0,,0.0013,IC50,Inhibitory activity against dihydrofolate reductase in Pneumocystis carinii at 37 centigrade.,Confirmatory,7490723.0,
609,55842,13,2,,104234169,126941,Active,118998.0,,0.0138,IC50,Inhibitory concentration against isolated Pneumocystis carinii DHFR (Dihydrofolate reductase),Confirmatory,11052789.0,
610,55851,8,5,,104234169,126941,Active,118998.0,,8e-06,Ki,Binding affinity was reported with purified recombinant Pneumocystis carinii Dihydrofolate reductase,Confirmatory,7490723.0,
611,55855,8,5,,104234169,126941,Active,118998.0,,0.0013,IC50,Inhibitory activity against Pneumocystis carinii dihydrofolate reductase (in 90 uM dihydrofolic acid),Confirmatory,8691474.0,
612,55857,9,5,,104234169,126941,Active,118998.0,,0.001,IC50,Inhibitory concentration for DHFR in Pneumocystis carinii,Confirmatory,8164259.0,
613,55858,9,5,,104234169,126941,Active,118998.0,,0.001,IC50,Inhibition of Pneumocystis carinii dihydrofolate reductase,Confirmatory,9554874.0,
614,55944,4,4,,104234169,126941,Active,,,0.009000000000000001,IC50,Cytotoxic activity was evaluated against Daoy tumor cells,Confirmatory,8632413.0,
615,56150,9,2,,104234169,126941,Active,,,0.0012,IC50,Concentration required for 50% inhibition against dihydrofolate reductase of Streptococcus faecium,Confirmatory,6403710.0,
616,56151,3,7,,104234169,126941,Unspecified,,,,,Compound was evaluated for 50% inhibition of the enzyme Dihydrofolate reductase (DHFR) from Streptococcus faecium,Other,6699882.0,
617,56153,7,2,,104234169,126941,Active,,,0.0022,IC50,Inhibitory activity against recombinant sf dihydrofolate reductase(in 50 uM dihydrofolic acid),Confirmatory,8691474.0,
618,56159,9,2,,104234169,126941,Active,,,0.0027,IC50,Inhibitory activity against dihydrofolate reductase of Streptococcus faecium,Confirmatory,3091832.0,
619,56167,10,5,,104234169,126941,Active,729370.0,,0.013999999999999999,IC50,Inhibition of Toxoplasma gondii (tc) Dihydrofolate reductase,Confirmatory,7783147.0,
620,56171,10,5,,104234169,126941,Active,729370.0,,0.022000000000000002,IC50,Inhibitory activity against Toxoplasma gondii (tg) Dihydrofolate reductase (DHFR),Confirmatory,12408727.0,
621,56180,10,5,,104234169,126941,Active,729370.0,,0.013999999999999999,IC50,Inhibition against Dihydrofolate reductase in Toxoplasma gondii,Confirmatory,9089339.0,
622,56181,10,5,,104234169,126941,Active,729370.0,,0.011000000000000001,IC50,Inhibition of Toxoplasma gondii dihydrofolate reductase (DHFR),Confirmatory,11960504.0,
623,56187,10,5,,104234169,126941,Active,729370.0,,1.1,IC50,Inhibitory activity against Toxoplasma gondii dihydrofolate reductase,Confirmatory,11384244.0,
624,56314,10,5,,104234169,126941,Active,729370.0,,0.0014,IC50,Inhibitory activity against Dihydrofolate reductase from Toxoplasma gondii was evaluated using 90 uM dihydrofolic acid as substrate,Confirmatory,9301666.0,
625,56320,10,5,,104234169,126941,Active,729370.0,,0.022000000000000002,IC50,Inhibitory concentration against Toxoplasma gondii Dihydrofolate reductase,Confirmatory,10956221.0,
626,56327,9,5,,104234169,126941,Active,729370.0,,0.022000000000000002,IC50,Inhibitory concentration against isolated Toxoplasma gondii DHFR (dihydrofolate reductase),Confirmatory,11052789.0,
627,56328,10,5,,104234169,126941,Active,729370.0,,0.013999999999999999,IC50,Inhibitory concentration for DHFR in Toxoplasma gondii,Confirmatory,8164259.0,
628,56329,10,5,,104234169,126941,Active,729370.0,,0.013999999999999999,IC50,Inhibition of Toxoplasma gondii Dihydrofolate reductase,Confirmatory,9554874.0,
629,56341,8,5,,104234169,126941,Active,729370.0,,0.022000000000000002,IC50,Inhibitory activity against Toxoplasma gondii dihydrofolate reductase (in 50 uM dihydrofolic acid),Confirmatory,8691474.0,
630,56345,8,5,,104234169,126941,Active,729370.0,,0.013999999999999999,IC50,Inhibitory activity against Toxoplasma gondii dihydrofolate reductase (in 90 uM dihydrofolic acid),Confirmatory,8691474.0,
631,56458,7,2,,104234169,126941,Active,,,3.8e-05,Ki,Inhibitory activity against Trypanosoma cruzi dihydrofolate reductase,Confirmatory,10360757.0,
632,56463,9,5,,104234169,126941,Active,118985.0,427317.0,0.09,IC50,Evaluated for the inhibition of chicken liver Dihydrofolate reductase by using standard enzyme assay,Confirmatory,7069726.0,
633,56465,8,5,,104234169,126941,Active,118985.0,427317.0,0.019,IC50,Compound was evaluated for the inhibition of dihydrofolate reductase (DHFR) derived from Chicken liver,Confirmatory,3712374.0,
634,56472,3,11,,104234169,126941,Unspecified,118985.0,427317.0,,,Molar ratio of inhibitor to Dihydrofolate reductase from chicken liver for 100% inhibition,Other,6402592.0,
635,56487,10,5,,104234169,126941,Active,109940075.0,508809.0,0.0033,IC50,In vitro ability to inhibit the Dihydrofolate reductase extracted from beef liver.,Confirmatory,6585550.0,
636,56488,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Concentration required for inhibition of beef liver dihydrofolate reductase,Other,2810330.0,
637,56489,12,2,,104234169,126941,Active,109940075.0,508809.0,0.0017,IC50,In vitro inhibitory concentration against beef liver dihydrofolate reductase,Confirmatory,4009615.0,
638,56490,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate (regiospecific coupling) of MTX (4 M/M of IgG)and IgG1 in experiment 1,Other,2810330.0,
639,56491,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate (regiospecific coupling) of MTX (4 M/M of IgG)and IgG1 in experiment 2,Other,2810330.0,
640,56492,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate (regiospecific coupling) of MTX (4 M/M of IgG)and rabbit IgG (NRG) in experiment 1,Other,2810330.0,
641,56493,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate (regiospecific coupling) of MTX (4 M/M of IgG)and rabbit IgG (NRG) in experiment 2,Other,2810330.0,
642,56494,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate (regiospecific coupling) of MTX (6 M/M of IgG)and rabbit IgG (NRG) in experiment 1,Other,2810330.0,
643,56495,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate (regiospecific coupling) of MTX (6 M/M of IgG)and rabbit IgG (NRG) in experiment 2,Other,2810330.0,
644,56496,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate (regiospecific coupling) of MTX (7 M/M of IgG)and Dal K-20 in experiment 1,Other,2810330.0,
645,56497,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate (regiospecific coupling) of MTX (7 M/M of IgG)and Dal K-20 in experiment 2,Other,2810330.0,
646,56498,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate of MTX (4 M/M of IgG) and rabbit IgG (NRG) in experiment 1,Other,2810330.0,
647,56622,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate of MTX (4 M/M of IgG) and rabbit IgG (NRG) in experiment 2,Other,2810330.0,
648,56623,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate of MTX (6 M/M of IgG) and rabbit IgG (NRG) in experiment 1,Other,2810330.0,
649,56624,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate of MTX (6 M/M of IgG) and rabbit IgG (NRG) in experiment 2,Other,2810330.0,
650,56625,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate of MTX (6 M/M of IgG)and IgG1 in experiment 1,Other,2810330.0,
651,56626,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate of MTX (6 M/M of IgG)and IgG1 in experiment 2,Other,2810330.0,
652,56627,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate of MTX (7 M/M of IgG)and Dal K-20 in experiment 1,Other,2810330.0,
653,56628,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by amide-linked conjugate of MTX (7 M/M of IgG)and Dal K-20 in experiment 2,Other,2810330.0,
654,56629,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by free MTX in experiment 1,Other,2810330.0,
655,56630,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by free MTX in experiment 2,Other,2810330.0,
656,56631,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by hydrazone-linked conjugate (regiospecific coupling) of MTX (5M/M of IgG) and rabbit IgG (NRG) in experiment 1,Other,2810330.0,
657,56632,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by hydrazone-linked conjugate (regiospecific coupling) of MTX (5M/M of IgG) and rabbit IgG (NRG) in experiment 2,Other,2810330.0,
658,56633,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by hydrazone-linked conjugate (regiospecific coupling) of MTX (6 M/M of IgG)and Dal K-20 in experiment 1,Other,2810330.0,
659,56634,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by hydrazone-linked conjugate (regiospecific coupling) of MTX (6 M/M of IgG)and Dal K-20 in experiment 2,Other,2810330.0,
660,56635,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by hydrazone-linked conjugate (regiospecific coupling) of MTX (7 M/M of IgG) and rabbit IgG (NRG) in experiment 2,Other,2810330.0,
661,56636,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by hydrazone-linked conjugate (regiospecific coupling) of MTX (7 M/mL of IgG) and rabbit IgG (NRG) in experiment 1,Other,2810330.0,
662,56637,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by hydrazone-linked conjugate of MTX (6 M/M of IgG) and rabbit IgG (NRG) in experiment 1,Other,2810330.0,
663,56638,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by hydrazone-linked conjugate of MTX (6 M/M of IgG) and rabbit IgG (NRG) in experiment 2,Other,2810330.0,
664,56639,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by hydrazone-linked conjugate of MTX (7 M/M of IgG) and rabbit IgG (NRG) in experiment 1,Other,2810330.0,
665,56640,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by hydrazone-linked conjugate of MTX (7 M/M of IgG) and rabbit IgG (NRG) in experiment 2,Other,2810330.0,
666,56641,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by hydrazone-linked conjugate of MTX (7 M/M of IgG)and Dal K-20 in experiment 1,Other,2810330.0,
667,56642,7,6,,104234169,126941,Unspecified,109940075.0,508809.0,,,Inhibition of beef liver dihydrofolate reductase by hydrazone-linked conjugate of MTX (7 M/M of IgG)and Dal K-20 in experiment 2,Other,2810330.0,
668,56643,8,1,,104234169,126941,Unspecified,109940075.0,508809.0,,ID50,Inhibition of bovine dihydrofolate reductase,Confirmatory,6948961.0,
669,56644,3,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXA-Dal K-20 (r) to IC50 of compound x 100 in experiment 1,Other,2810330.0,
670,56645,3,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXA-Dal K-20 (r) to IC50 of compound x 100 in experiment 2,Other,2810330.0,
671,56646,3,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXA-Dal K-20 to IC50 of compound x 100 in experiment 1,Other,2810330.0,
672,56647,3,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXA-Dal K-20 to IC50 of compound x 100 in experiment 2,Other,2810330.0,
673,56648,3,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXA-IgG1 (r) to IC50 of compound x 100 in experiment 1,Other,2810330.0,
674,56649,3,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXA-IgG1 (r) to IC50 of compound x 100 in experiment 2,Other,2810330.0,
675,56650,3,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXA-IgG1 to IC50 of compound x 100 in experiment 1,Other,2810330.0,
676,56651,3,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXA-IgG1 to IC50 of compound x 100 in experiment 2,Other,2810330.0,
677,56652,4,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXA-NRG (r) to IC50 of compound x 100 in experiment 1,Other,2810330.0,
678,56653,4,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXA-NRG (r) to IC50 of compound x 100 in experiment 2,Other,2810330.0,
679,56654,4,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXA-NRG to IC50 of compound x 100 in experiment 1,Other,2810330.0,
680,56655,4,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXA-NRG to IC50 of compound x 100 in experiment 2,Other,2810330.0,
681,56656,3,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXH-Dal K-20 (r) to IC50 of compound x 100 in experiment 1,Other,2810330.0,
682,56657,3,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXH-Dal K-20 (r) to IC50 of compound x 100 in experiment 2,Other,2810330.0,
683,56658,3,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXH-Dal K-20 to IC50 of compound x 100 in experiment 1,Other,2810330.0,
684,56740,9,1,,104234169,126941,Active,,,0.02,IC50,Compound was tested for its inhibitory concentration to inhibit the enzyme Dihydro Folate Reductase (DHFR) from murine L1210 leukemia cells.,Confirmatory,3462394.0,
685,56741,3,6,,104234169,126941,Unspecified,,,,,Compound was tested for inhibition of the enzyme DiHydroFolate Reductase (DHFR) from murine L1210 leukemia cells,Other,3462394.0,
686,56772,3,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXH-Dal K-20 to IC50 of compound x 100 in experiment 2,Other,2810330.0,
687,56773,4,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXH-NRG (r) to IC50 of compound x 100 in experiment 1,Other,2810330.0,
688,56774,4,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXH-NRG (r) to IC50 of compound x 100 in experiment 2,Other,2810330.0,
689,56775,4,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXH-NRG to IC50 of compound x 100 in experiment 1,Other,2810330.0,
690,56776,4,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX conjugate MTXH-NRG to IC50 of compound x 100 in experiment 2,Other,2810330.0,
691,56778,3,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX to IC50 of compound x 100 in experiment 1,Other,2810330.0,
692,56779,3,10,,104234169,126941,Unspecified,109940075.0,508809.0,,,Compound was evaluated for inhibition index as ratio of IC50 of MTX to IC50 of compound x 100 in experiment 2,Other,2810330.0,
693,56786,7,1,,104234169,126941,Active,,,0.0013,IC50,Compound was tested for the inhibition of dihydrofolate reductase in Bovine liver,Confirmatory,8201595.0,
694,56791,4,2,,104234169,126941,Unspecified,109940075.0,508809.0,7943.28,IC50,In vitro inhibition of Bovine liver dihydrofolate reductase.,Confirmatory,2404122.0,
695,56800,3,8,,104234169,126941,Unspecified,,,,,Molar ratio of inhibitor to Dihydrofolate reductase from WIL2 for 100% inhibition,Other,6402592.0,
696,56803,10,1,,104234169,126941,Active,,,0.0079,IC50,Ability to inhibit human leukemia cell dihydrofolate reductase in vitro was determined,Confirmatory,6772788.0,
697,56810,11,1,,104234169,126941,Active,,,0.0043,IC50,Inhibition of human Dihydrofolate reductase by the compound was evaluated.,Confirmatory,2738891.0,
698,56811,9,2,,104234169,126941,Active,,,0.0043,IC50,Inhibition of human WIL2/dihydrofolate reductase activity,Confirmatory,2704031.0,
699,56813,9,1,,104234169,126941,Active,,,0.0038,IC50,Inhibitory activity against dihydrofolate reductase (DHFR) obtained from human WIL2 cells,Confirmatory,3339615.0,
700,56815,9,2,,104234169,126941,Active,,,0.025,IC50,Ability to inhibit purified Dihydrofolate reductase from human leukemic lymphoblasts was determined spectrophotometrically at 340 nM.,Confirmatory,1992118.0,
701,56816,9,2,,104234169,126941,Active,,,0.002,IC50,Ability to inhibit recombinant human dihydrofolate reductase.,Confirmatory,11052790.0,
702,56945,9,2,,104234169,126941,Active,,,0.022000000000000002,IC50,Compound was evaluated as inhibitor of human Dihydrofolate reductase,Confirmatory,12570380.0,
703,56949,9,1,,104234169,126941,Active,,,0.02,IC50,"Compound was tested for its inhibitory activity against dihydrofolate reductase (DHFR), isolated from MTX-resistant WI-L2 cells",Confirmatory,2918496.0,
704,56950,9,2,,104234169,126941,Active,,,0.0027,IC50,In vitro inhibition of human dihydrofolate reductase (DHFR),Confirmatory,1578484.0,
705,56955,7,1,,104234169,126941,Active,,,0.024,IC50,Inhibition of dihydrofolate reductase (DHFR) from human cells (WI-L2/M4).,Confirmatory,1995880.0,
706,56958,9,2,,104234169,126941,Active,,,0.022000000000000002,IC50,Inhibition of rh dihydrofolate reductase (DHFR),Confirmatory,11960504.0,
707,56962,9,1,,104234169,126941,Active,,,0.72,IC50,Inhibitory activity against purified human dihydrofolate reductase (DHFR) in human leukemia cells (CCRF-CEM),Confirmatory,8568828.0,
708,56963,9,2,,104234169,126941,Active,,,0.022000000000000002,IC50,Inhibitory activity against recombinant human Dihydrofolate reductase,Confirmatory,12408727.0,
709,56964,9,5,,104234169,126941,Active,118992.0,1719.0,0.066,IC50,Inhibitory activity against human dihydrofolate reductase,Confirmatory,11384244.0,
710,56964,9,5,,104234169,126941,Active,118992.0,573971.0,0.066,IC50,Inhibitory activity against human dihydrofolate reductase,Confirmatory,11384244.0,
711,56966,7,1,,104234169,126941,Active,,,0.00118,IC50,Inhibitory activity against Dihydrofolate reductase (DHFR) isolated from CCRF-CEM human leukemia cells in experiment 1,Confirmatory,8568827.0,
712,56967,7,1,,104234169,126941,Active,,,0.0014,IC50,Inhibitory activity against Dihydrofolate reductase (DHFR) isolated from CCRF-CEM human leukemia cells in experiment 2,Confirmatory,8568827.0,
713,56969,8,5,,104234169,126941,Active,118992.0,1719.0,0.038,IC50,Inhibitory activity against recombinant human dihydrofolate reductase(in 50 uM dihydrofolic acid),Confirmatory,8691474.0,
714,56969,8,5,,104234169,126941,Active,118992.0,573971.0,0.038,IC50,Inhibitory activity against recombinant human dihydrofolate reductase(in 50 uM dihydrofolic acid),Confirmatory,8691474.0,
715,56970,9,1,,104234169,126941,Active,,,0.03,IC50,Inhibitory activity towards dihydrofolate reductase derived from human manca leukemia cells,Confirmatory,2296020.0,
716,56972,9,1,,104234169,126941,Active,,,0.00082,IC50,Inhibitory concentration against dihydrofolate reductase (DHFR) enzyme isolated from CCRF-CEM human leukemia cells.,Confirmatory,8691451.0,
717,56978,12,1,,104234169,126941,Active,,,0.0145,IC50,Inhibitory concentration against isolated human Dihydrofolate reductase,Confirmatory,11052789.0,
718,56979,9,2,,104234169,126941,Active,,,0.022000000000000002,IC50,Inhibitory concentration against recombinant human (rh) Dihydrofolate reductase,Confirmatory,10956221.0,
719,56980,9,2,,104234169,126941,Active,,,0.0007,IC50,Inhibitory concentration against CCRF-CEM leukemic cell DHFR(Dihydro folate reductase).,Confirmatory,7562910.0,
720,56981,9,2,,104234169,126941,Active,,,0.04,IC50,Inhibitory concentration against recombinant human DHFR(Dihydro folate reductase).,Confirmatory,7562910.0,
721,56982,9,2,,104234169,126941,Active,,,0.004,IC50,Inhibitory concentration for DHFR in recombinant human,Confirmatory,8164259.0,
722,56984,7,2,,104234169,126941,Active,,,0.0112,IC50,Tested for inhibitory concentration against human dihydrofolate reductase(DHFR),Confirmatory,8035423.0,
723,57067,9,2,,104234169,126941,Active,,,0.024,IC50,Compound was evaluated for Dihydrofolate Reductase (DHFR) inhibition,Confirmatory,1992122.0,
724,57068,7,2,,104234169,126941,Active,,,0.0039,IC50,Compound was tested for its inhibitory activity on Recombinant Human Dihydrofolate Reductase.,Confirmatory,1992121.0,
725,57113,3,6,,104234169,126941,Unspecified,,,,,Inhibitory activity against human recombinant dihydrofolate reductase enzyme (rhDHFR) expressed in Escherichia coli,Other,9022795.0,
726,57132,8,4,,104234169,126941,Active,,,5.19e-06,Ki,Compound was evaluated for the inhibition of Dihydrofolate reductase at concentration ranged from 0.15-0.50 uM,Confirmatory,9857098.0,
727,57137,7,2,,104234169,126941,Active,,,0.00017900000000000001,Ki,Inhibitory activity against dihydrofolate reductase in humans,Confirmatory,10360757.0,
728,57140,7,2,,104234169,126941,Active,,,0.00011,Ki,Inhibitory activity against Leu22-Phe mutant human Dihydrofolate reductase,Confirmatory,7877140.0,
729,57235,10,5,,104234169,126941,Active,165971782.0,,0.006999999999999999,IC50,Compound was evaluated as inhibitor of Escherichia coli Dihydrofolate reductase,Confirmatory,12570380.0,
730,57236,10,5,,104234169,126941,Active,165971782.0,,0.009000000000000001,IC50,Inhibition of Escherichia coli dihydrofolate reductase (DHFR),Confirmatory,11960504.0,
731,57240,10,5,,104234169,126941,Active,165971782.0,,4.4,IC50,Inhibitory activity against recombinant Escherichia coli dihydrofolate reductase,Confirmatory,11384244.0,
732,57241,10,5,,104234169,126941,Active,165971782.0,,0.009000000000000001,IC50,Inhibitory concentration against Escherichia coli Dihydrofolate reductase,Confirmatory,10956221.0,
733,57243,10,5,,104234169,126941,Active,165971782.0,,0.006,IC50,Inhibitory concentration against isolated Escherichia coli Dihydrofolate reductase,Confirmatory,11052789.0,
734,57248,4,11,,104234169,126941,Active,165971782.0,,0.001,Kd,Inhibitory activity against dihydrofolate reductase,Confirmatory,15081026.0,
735,57250,10,5,,104234169,126941,Active,165971782.0,,2.3e-05,Kd,Thermodynamic Dissociation Constant for compound-Phe31-dihydrofolate reductase (DHFR) complex at pH 6,Confirmatory,3275776.0,
736,57252,12,2,,104234169,126941,Active,165971782.0,,9.6e-05,Kd,Thermodynamic Dissociation Constant for compound-Phe31-dihydrofolate reductase (DHFR) complex at pH 8,Confirmatory,3275776.0,
737,57254,12,2,,104234169,126941,Active,165971782.0,,0.031,Kd,Thermodynamic Dissociation Constant for compound-Phe31-dihydrofolate reductase (DHFR) complex at pH 9.5,Confirmatory,3275776.0,
738,57255,10,5,,104234169,126941,Active,165971782.0,,0.0023,Kd,Thermodynamic Dissociation Constant for compound-Tyr31-dihydrofolate reductase (DHFR) complex at pH 6,Confirmatory,3275776.0,
739,57257,12,2,,104234169,126941,Active,165971782.0,,0.14,Kd,Thermodynamic Dissociation Constant for compound-Tyr31-dihydrofolate reductase (DHFR) complex at pH 8,Confirmatory,3275776.0,
740,57259,12,2,,104234169,126941,Active,165971782.0,,1.7,Kd,Thermodynamic Dissociation Constant for compound-Tyr31-dihydrofolate reductase (DHFR) complex at pH 9.5,Confirmatory,3275776.0,
741,57260,12,2,,104234169,126941,Active,165971782.0,,0.0032,Kd,Thermodynamic Dissociation Constant for compound-Val31-dihydrofolate reductase (DHFR) complex at pH 6,Confirmatory,3275776.0,
742,57263,12,2,,104234169,126941,Active,165971782.0,,0.084,Kd,Thermodynamic Dissociation Constant for compound-Val31-dihydrofolate reductase (DHFR) complex at pH 8,Confirmatory,3275776.0,
743,57265,12,2,,104234169,126941,Active,165971782.0,,1.1,Kd,Thermodynamic Dissociation Constant for compound-Val31-dihydrofolate reductase (DHFR) complex at pH 9.5,Confirmatory,3275776.0,
744,57270,3,10,,104234169,126941,Unspecified,165971782.0,,,,Binding constant (Keq)to dihydrofolate reductase (DHFR) Phe -31 was determined,Other,3275776.0,
745,57271,3,10,,104234169,126941,Unspecified,165971782.0,,,,Binding constant(Kf) to dihydrofolate reductase (DHFR) Phe -31 was determined,Other,3275776.0,
746,57272,3,10,,104234169,126941,Unspecified,165971782.0,,,,Binding constant(Kf) to dihydrofolate reductase (DHFR) Tyr -31 was determined,Other,3275776.0,
747,57273,3,10,,104234169,126941,Unspecified,165971782.0,,,,Binding constant(Kf) to dihydrofolate reductase (DHFR) Val -31 was determined,Other,3275776.0,
748,57292,9,1,,104234169,126941,Active,,,0.045,IC50,Evaluated for the inhibition of dihydrofolate reductase from L1210 mouse leukemia cells,Confirmatory,3968685.0,
749,57293,9,1,,104234169,126941,Active,,,0.035,IC50,Compound was tested for its ability to inhibit dihydrofolate reductase purified from murine L1210 cells,Confirmatory,2428979.0,
750,57294,9,1,,104234169,126941,Active,,,0.035,IC50,Compound was tested for its ability to inhibit purified dihydrofolate reductase(DHFR) from L1210/R81 cells,Confirmatory,2871191.0,
751,57295,7,1,,104234169,126941,Active,,,0.0066,IC50,Compound was tested for the inhibition of dihydrofolate reductase in P388 cells,Confirmatory,8201595.0,
752,57296,10,5,,104234169,126941,Active,1706542.0,13361.0,0.025,IC50,Inhibition of dihydrofolate reductase (DHFR) from murine leukemia cells,Confirmatory,3385730.0,
753,57298,7,1,,104234169,126941,Active,,,0.025,IC50,Inhibition of dihydrofolate reductase (DHFR) from mouse cells (L1210/R71).,Confirmatory,1995880.0,
754,57300,7,1,,104234169,126941,Active,,,0.025,IC50,Inhibition of dihydrofolate reductase(DHFR) from L1210/R81 cells,Confirmatory,3112397.0,
755,57304,7,1,,104234169,126941,Active,,,0.05,IC50,Inhibitory activity towards dihydrofolate reductase in L1210 murine leukemia cell lines,Confirmatory,6737432.0,
756,57305,9,1,,104234169,126941,Active,,,0.025,IC50,Tested for inhibition against purified Dihydrofolate reductase from L1210 murine leukemia cells,Confirmatory,2898531.0,
757,57307,9,1,,104234169,126941,Active,,,0.073,IC50,compound was evaluated for the inhibitory activity against Dihydrofolate reductase in permeabilised L1210 cells.,Confirmatory,8863812.0,
758,57308,3,6,,104234169,126941,Unspecified,,,,,"Compound was tested for its ability to inhibit dihydrofolate reductase purified from murine L1210 cells, activity expressed as IC50/[E]",Other,2428979.0,
759,57310,5,1,,104234169,126941,Active,,,0.032,ID50,Binding affinity to Dihydrofolate reductase of L1210 /R71 using spectrophotometric assay,Confirmatory,6139480.0,
760,57312,5,1,,104234169,126941,Active,,,0.009000000000000001,ID50,Binding affinity to Dihydrofolate reductase of L1210 using spectrophotometric assay,Confirmatory,6139480.0,
761,57314,5,1,,104234169,126941,Active,,,0.002,ID50,Binding affinity to Dihydrofolate reductase of L1210 cell line using [H]MTX as radioligand,Confirmatory,6139480.0,
762,57316,8,1,,104234169,126941,Active,,,0.05,ID50,Compound was evaluated for its antitumor activity by the inhibition of L1210 murine leukemia dihydrofolate reductase,Confirmatory,6546949.0,
763,57395,12,2,,104234169,126941,Active,165971782.0,,2.1e-05,Ki,Binding affinity against Dihydrofolate reductase of Escherichia coli,Confirmatory,3973902.0,
764,57397,12,2,,104234169,126941,Active,165971782.0,,0.33,Ki,Binding constant(Ki) to dihydrofolate reductase (DHFR) Phe -31 was determined,Confirmatory,3275776.0,
765,57398,12,2,,104234169,126941,Active,165971782.0,,2.4,Ki,Binding constant(Ki) to dihydrofolate reductase (DHFR) Tyr -31 was determined,Confirmatory,3275776.0,
766,57399,7,6,,104234169,126941,Unspecified,165971782.0,,170.0,Ki,Binding constant(Ki) to dihydrofolate reductase (DHFR) Val -31 was determined,Confirmatory,3275776.0,
767,57412,3,10,,104234169,126941,Unspecified,165971782.0,,,,Binding constant(Kiso) to dihydrofolate reductase (DHFR) Phe -31 was determined,Other,3275776.0,
768,57413,3,10,,104234169,126941,Unspecified,165971782.0,,,,Binding constant(Kiso) to dihydrofolate reductase (DHFR) Tyr -31 was determined,Other,3275776.0,
769,57414,3,10,,104234169,126941,Unspecified,165971782.0,,,,Binding constant(Kiso) to dihydrofolate reductase (DHFR) Val -31 was determined,Other,3275776.0,
770,57415,3,10,,104234169,126941,Unspecified,165971782.0,,,,Dissociation constant at Val-31(Kon)of dihydrofolate reductase (DHFR),Other,3275776.0,
771,57416,3,10,,104234169,126941,Unspecified,165971782.0,,,,Dissociation constant at(Koff) Tyr-31 of dihydrofolate reductase (DHFR),Other,3275776.0,
772,57417,3,10,,104234169,126941,Unspecified,165971782.0,,,,Dissociation constant(Koff) at Phe-31 of dihydrofolate reductase (DHFR),Other,3275776.0,
773,57418,4,6,,104234169,126941,Unspecified,165971782.0,,,,Association constant (Kon) at Phe-31 of dihydrofolate reductase (DHFR),Other,3275776.0,
774,57419,4,6,,104234169,126941,Unspecified,165971782.0,,,,Association constant at Val-31(Kon) of dihydrofolate reductase (DHFR),Other,3275776.0,
775,57420,4,6,,104234169,126941,Unspecified,165971782.0,,,,Association constant(Kon) at Tyr-31 of dihydrofolate reductase (DHFR),Other,3275776.0,
776,57421,3,10,,104234169,126941,Unspecified,165971782.0,,,,Constant at Tyr-31(Kr) of dihydrofolate reductase (DHFR),Other,3275776.0,
777,57422,3,10,,104234169,126941,Unspecified,165971782.0,,,,Constant(Kr) at Phe-31 of dihydrofolate reductase (DHFR),Other,3275776.0,
778,57423,3,10,,104234169,126941,Unspecified,165971782.0,,,,"Constant, Kr at Phe-31 of dihydrofolate reductase (DHFR)",Other,3275776.0,
779,57439,5,1,,104234169,126941,Active,,,0.0027,ID50,Concentration of inhibitor to decrease binding of [3H]MTX radioligand to Dihydrofolate reductase from L1210 cells by 50%.,Confirmatory,6811744.0,
780,57443,9,1,,104234169,126941,Active,,,3.9,Ki,Binding affinity towards Dihydrofolate reductase derived from L1210 cells using [3H]- MTX as the radioligand,Confirmatory,2296020.0,
781,57446,9,5,,104234169,126941,Active,1706542.0,13361.0,4.2999999999999995e-06,Ki,Inhibition of Dihydrofolate reductase in mouse L1210 cells,Confirmatory,7057425.0,
782,57447,9,1,,104234169,126941,Active,,,4.42e-06,Ki,Compound was evaluated for binding affinity against Dihydrofolate reductase of L1210 cells,Confirmatory,3712374.0,
783,57448,8,3,,104234169,126941,Active,,,5.48e-06,Ki,Compound was evaluated for inhibitory effect on dihydrofolate reductase (DHFR) from L1210 cells at Inhibitory constant (n=3),Confirmatory,2423690.0,
784,57449,9,1,,104234169,126941,Active,,,4.82e-06,Ki,In vitro inhibition of dihydrofolate reductase (DHFR) in L1210 cells,Confirmatory,1501226.0,
785,57451,7,3,,104234169,126941,Active,,,5.6e-06,Ki,Concentration inhibiting dihydrofolate reductase derived from L1210 cells,Confirmatory,2296020.0,
786,57452,9,1,,104234169,126941,Active,,,5.45e-06,Ki,Evaluated for inhibition of dihydrofolate reductase (DHFR) isolated from L1210 cells,Confirmatory,3184124.0,
787,57453,11,2,,104234169,126941,Active,1706542.0,13361.0,6e-06,Ki,In vitro inhibitory activity against Dihydrofolate reductase in L1210 cell in mice,Confirmatory,4020824.0,
788,57454,8,1,,104234169,126941,Active,,,6e-06,Ki,In vitro inhibitory activity against L1210 dihydrofolate reductase in rodent neoplastic cells,Confirmatory,7108907.0,
789,57455,9,1,,104234169,126941,Active,,,5.75e-06,Ki,Inhibition of Dihydrofolate reductase (DHFR) enzyme derived from L1210 cells expressed as Ki (pM),Confirmatory,8340923.0,
790,57456,8,1,,104234169,126941,Active,,,6e-06,Ki,Inhibition of the dihydrofolate reductase enzyme(DHFR) derived from L1210 murine leukemia cells.,Confirmatory,1732549.0,
791,57457,8,1,,104234169,126941,Active,,,6e-06,Ki,Inhibitory activity of Dihydrofolate reductase derived from L1210 cell line.,Confirmatory,2299633.0,
792,57458,9,1,,104234169,126941,Active,,,4.82e-06,Ki,Inhibitory activity of Dihydrofolate reductase in L1210 cells,Confirmatory,8277497.0,
793,57460,7,5,,104234169,126941,Active,,,3.2e-06,Ki,Tested for inhibition of dihydrofolate reductase enzyme,Confirmatory,7143361.0,
794,57462,8,3,,104234169,126941,Active,,,5.28e-06,Ki,The compound was tested for its inhibitory activity against Dihydrofolate reductase derived from L1210 cells.,Confirmatory,1732551.0,
795,57464,3,6,,104234169,126941,Unspecified,,,,,Activity relative to methotrexate for inhibition of Dihydrofolate reductase from L1210 murine leukemia cell lines,Other,6737432.0,
796,57467,3,6,,104234169,126941,Unspecified,,,,,Inhibitory activity against Dihydrofolate reductase isolated from murine L5178Y tumor cells resistant to methotrexate,Other,6699880.0,
797,57468,3,6,,104234169,126941,Unspecified,,,,,Inhibitory activity against Dihydrofolate reductase isolated from murine L5178Y tumor cells sensitive to methotrexate,Other,6699880.0,
798,57576,3,10,,104234169,126941,Unspecified,165971782.0,,,,Binding constant(Keq) to dihydrofolate reductase (DHFR) Tyr-31 was determined,Other,3275776.0,
799,57577,3,10,,104234169,126941,Unspecified,165971782.0,,,,Binding constant(Keq) to dihydrofolate reductase (DHFR) Val-31 was determined,Other,3275776.0,
800,57592,10,5,,104234169,126941,Active,165971782.0,,0.006,IC50,Inhibitory activity against Escherichia coli (ec) Dihydrofolate reductase,Confirmatory,12408727.0,
801,57593,8,5,,104234169,126941,Active,165971782.0,,0.0022,IC50,Inhibitory activity against recombinant ec dihydrofolate reductase(in 50 uM dihydrofolic acid),Confirmatory,8691474.0,
802,57606,3,11,,104234169,126941,Unspecified,7227951.0,,,,Molar ratio of inhibitor to Dihydrofolate reductase from Lactobacillus casei for 100% inhibition,Other,6402592.0,
803,57607,9,5,,104234169,126941,Active,7227951.0,,0.0096,IC50,Ability to inhibit Lactobacillus casei dihydrofolate reductase in vitro was determined,Confirmatory,6772788.0,
804,57617,9,1,,104234169,126941,Active,,,0.026000000000000002,IC50,Tested for inhibition against dihydro folate reductase in Pigeon liver,Confirmatory,7365749.0,
805,57739,9,5,,104234169,126941,Active,7227951.0,,0.022000000000000002,IC50,Compound was evaluated as inhibitor of Lactobacillus casei Dihydrofolate reductase,Confirmatory,12570380.0,
806,57743,9,6,,104234169,126941,Unspecified,7227951.0,,,,Compound was evaluated for inhibitory effect on the dihydrofolate reductase (DHFR) of Lactobacillus casei.,Other,2423690.0,
807,57745,8,5,,104234169,126941,Active,7227951.0,,0.01,IC50,Compound was evaluated for the inhibition of dihydrofolate reductase (DHFR) derived from Lactobacillus casei ATCC 7469,Confirmatory,3712374.0,
808,57746,9,5,,104234169,126941,Active,7227951.0,,0.01,IC50,Compound was evaluated for the inhibition of dihydrofolate reductase (DHFR)derived from Lactobacillus casei,Confirmatory,3091834.0,
809,57747,12,2,,104234169,126941,Unspecified,7227951.0,,,IC50,Concentration required to inhibit Lactobacillus casei derived Dihydrofolate reductase activity by 50%,Confirmatory,6793726.0,
810,57748,9,5,,104234169,126941,Active,7227951.0,,0.008,IC50,Concentration required for 50% inhibition against dihydrofolate reductase of Lactobacillus casei,Confirmatory,6403710.0,
811,57750,7,6,,104234169,126941,Active,7227951.0,,0.012,IC50,In vitro inhibition of Dihydrofolate reductase activity against Lactobacillus casei enzyme,Confirmatory,7108907.0,
812,57755,9,5,,104234169,126941,Active,7227951.0,,0.008,IC50,Inhibitory activity against dihydrofolate reductase derived from Lactobacillus casei,Confirmatory,3100797.0,
813,57756,9,5,,104234169,126941,Active,7227951.0,,0.016,IC50,Inhibitory activity against dihydrofolate reductase of Lactobacillus casei,Confirmatory,3121855.0,
814,57757,9,5,,104234169,126941,Active,7227951.0,,0.0085,IC50,Inhibitory activity against dihydrofolate reductase of Lactobacillus casei,Confirmatory,3091832.0,
815,57758,9,5,,104234169,126941,Active,7227951.0,,0.011000000000000001,IC50,Inhibitory concentration against Lactobacillus casei Dihydrofolate reductase,Confirmatory,10956221.0,
816,57759,10,5,,104234169,126941,Active,7227951.0,,0.044000000000000004,IC50,Inhibitory concentration against isolated Lactobacillus casei Dihydrofolate reductase,Confirmatory,11052789.0,
817,57761,9,5,,104234169,126941,Active,7227951.0,,0.006,IC50,Inhibitory concentration for DHFR in Lactobacillus casei,Confirmatory,8164259.0,
818,57763,9,5,,104234169,126941,Active,7227951.0,,0.006,IC50,inhibitory concentration against Lactobacillus casei DHFR(Dihydro folate reductase).,Confirmatory,7562910.0,
819,57765,5,3,,104234169,126941,Active,7227951.0,,0.011000000000000001,ID50,Binding affinity to Dihydrofolate reductase of Lactobacillus casei using [H]MTX as radioligand,Confirmatory,6139480.0,
820,57766,5,3,,104234169,126941,Active,7227951.0,,0.011000000000000001,ID50,Binding affinity to Dihydrofolate reductase of Lactobacillus casei using spectrophotometric assay,Confirmatory,6139480.0,
821,57772,5,3,,104234169,126941,Active,7227951.0,,0.016,ID50,Concentration of inhibitor required to decrease binding of [3H]MTX radioligand to Lactobacillus casei dihydrofolate reductase by 50%.,Confirmatory,6811744.0,
822,57774,5,3,,104234169,126941,Active,7227951.0,,0.0062,ID50,Tested for 50% reversible inhibition of Lactobacillus casei dihydrofolate reductase (spectrophotometric assay).,Confirmatory,6811744.0,
823,57775,3,10,,104234169,126941,Unspecified,7227951.0,,,,Compound was evaluated for 50% inhibition of the enzyme Dihydrofolate reductase (DHFR) from Lactobacillus casei,Other,6699882.0,
824,57776,8,5,,104234169,126941,Active,7227951.0,,4e-06,Ki,Inhibition constant of compound against Lactobacillus casei Dihydrofolate reductase,Confirmatory,6438320.0,
825,57795,9,1,,104234169,126941,Active,,,0.002,IC50,Ability to inhibit recombinant rat liver dihydrofolate reductase.,Confirmatory,11052790.0,
826,57814,9,1,,104234169,126941,Active,,,0.003,IC50,Inhibition against Dihydrofolate reductase in rat liver,Confirmatory,9089339.0,
827,57818,9,1,,104234169,126941,Active,,,0.0046,IC50,Inhibition of rat liver dihydrofolate reductase assayed spectrophotometrically at 340 nM,Confirmatory,3968685.0,
828,57886,4,4,,104234169,126941,Active,,,0.023,IC50,The IC50 value was measured on DU-145 cell line in prostate tumor type.,Confirmatory,9022795.0,
829,57930,3,9,,104234169,126941,Unspecified,7227951.0,,,,Inhibitory concentration against Lactobacillus casei dihydrofolate reductase enzyme,Other,7143361.0,
830,57931,9,5,,104234169,126941,Active,7227951.0,,0.016,IC50,Evaluated for inhibition of dihydrofolate reductase (DHFR) from Lactobacillus casei,Confirmatory,3184124.0,
831,57932,5,6,,104234169,126941,Active,7227951.0,,0.016,IC50,Inhibitory activity against dihydrofolate reductase in Lactobacillus casei was determined (glutamate residue 2),Confirmatory,2447278.0,
832,57933,5,6,,104234169,126941,Active,7227951.0,,0.016,IC50,Inhibitory activity against dihydrofolate reductase in Lactobacillus casei was determined (glutamate residue 3),Confirmatory,2447278.0,
833,57934,5,6,,104234169,126941,Active,7227951.0,,0.015,IC50,Inhibitory activity against dihydrofolate reductase in Lactobacillus casei was determined (glutamate residue 4),Confirmatory,2447278.0,
834,57935,5,6,,104234169,126941,Active,7227951.0,,0.015,IC50,Inhibitory activity against dihydrofolate reductase in Lactobacillus casei was determined (glutamate residue 5),Confirmatory,2447278.0,
835,57936,5,6,,104234169,126941,Active,7227951.0,,0.016,IC50,Inhibitory activity against dihydrofolate reductase in Lactobacillus casei was determined (glutamate residue 6),Confirmatory,2447278.0,
836,57938,8,5,,104234169,126941,Active,7227951.0,,0.055,IC50,Inhibitory activity against recombinant lc dihydrofolate reductase(in 50 uM dihydrofolic acid),Confirmatory,8691474.0,
837,57942,3,9,,104234169,126941,Unspecified,7227951.0,,,,Tested for pK value of histidine residue(His-28) of Dihydrofolate reductase from Lactobacillus casei,Other,6438320.0,
838,57949,6,5,,104234169,126941,Active,118936.0,,0.000129,Ki,Inhibition of dihydrofolate reductase (DHFR) from Leishmania major,Confirmatory,3599028.0,
839,57963,8,5,,104234169,126941,Active,81871579.0,24312.0,0.0025,IC50,Inhibition of rat liver Dihydrofolate reductase (rlDHFR),Confirmatory,12877583.0,
840,57965,9,1,,104234169,126941,Active,,,0.0025,IC50,Inhibitory activity against Dihydrofolate reductase from rat liver was evaluated using 90 uM dihydrofolic acid as substrate,Confirmatory,9301666.0,
841,57970,8,1,,104234169,126941,Active,,,0.0025,IC50,Inhibitory activity against rat liver dihydrofolate reductase (in 90 uM dihydrofolic acid),Confirmatory,8691474.0,
842,57983,9,1,,104234169,126941,Active,,,0.003,IC50,Inhibitory concentration for DHFR in rat liver,Confirmatory,8164259.0,
843,57984,10,5,,104234169,126941,Active,81871579.0,24312.0,0.003,IC50,Inhibition of rat liver Dihydrofolate reductase,Confirmatory,7783147.0,
844,57985,9,5,,104234169,126941,Active,81871579.0,24312.0,0.003,IC50,Inhibition of Dihydrofolate reductase of rat liver,Confirmatory,9554874.0,
845,58060,4,4,,104234169,126941,Active,,,0.045,IC50,Compound was evaluated for in vitro activity against DU-145 prostate cell lines (Human tumor cells ),Confirmatory,9857098.0,
846,58159,3,6,,104234169,126941,Unspecified,,,,,The concentration required to inhibit dihydrofolate reductase in rat liver,Other,6737433.0,
847,58164,3,7,,104234169,126941,Unspecified,,,,,Concentration required for inhibition of rat liver dihydrofolate reductase (DHFR),Other,6864738.0,
848,65357,4,3,,104234169,126941,Unspecified,,,,,Inhibition of growth of methotrexate-sensitive (MB1417) strain of Escherichia coli cells.,Other,3934385.0,
849,65359,4,3,,104234169,126941,Unspecified,,,,,Inhibition of growth of methotrexate-resistant (MB1428) strain of Escherichia coli cells.,Other,3934385.0,
850,66151,6,2,,104234169,126941,Active,,,10.1,Ki,Rate of influx of compound into the Ehrlich cells,Confirmatory,6793726.0,
851,66154,6,2,,104234169,126941,Active,,,0.0126,IC50,Concentration required for 50% inhibition against Ehrlich cells,Confirmatory,6403710.0,
852,66157,6,2,,104234169,126941,Active,,,10.1,Km,In vitro membrane transport activity in Ehrlich cells in rodent,Confirmatory,7108907.0,
853,67102,3,4,,104234169,126941,Unspecified,,,,,Percent colony reduction in cell growth in EBV-positive nasopharyngeal cell lines (D98/HR1) after administration of 0.3 ug/mL dose,Other,6685770.0,
854,67103,3,4,,104234169,126941,Unspecified,,,,,Percent colony reduction in cell growth in EBV-positive nasopharyngeal cell lines (D98/HR1) after administration of 100 ug/mL dose,Other,6685770.0,
855,67105,3,5,,104234169,126941,Unspecified,,,,,EBV-positive nasopharyngeal cells (D98/HR1) survived at concentration of 0.3 ug/mL of compound,Other,6685770.0,
856,67106,3,5,,104234169,126941,Unspecified,,,,,EBV-positive nasopharyngeal cells (D98/HR1) survived at concentration of 100 ug/mL of compound,Other,6685770.0,
857,67442,4,4,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against EKVX lung cancer cell lines (Human tumor cells ),Confirmatory,9857098.0,
858,67445,4,4,,104234169,126941,Unspecified,,,1.0,IC50,The IC50 value was measured on EKVX cell line in NSCL tumor type.,Confirmatory,9022795.0,
859,70064,8,1,,104234169,126941,Active,,,0.001,ED50,Concentration required for inhibition of colony formation (cytotoxicity) against human epidermoid carcinoma cell number 2,Confirmatory,6948961.0,
860,70359,7,1,,104234169,126941,Active,,,,,"In vitro antitumor activity against Erlich cell line,",Other,4020824.0,
861,71351,11,1,,104234169,126941,Active,,,3.2,IC50,Compound was evaluated for the inhibitory activity against Folyl-polyglutamate synthase from CCRF-CEM human leukemia cells.,Confirmatory,8863812.0,
862,71356,6,4,,104234169,126941,Active,,,49.0,Km,Activity of compound calculated as Km was tested as substrate for human Folyl-polyglutamate synthase,Confirmatory,12570380.0,
863,71361,7,1,,104234169,126941,Active,,,,,Activity of compound calculated as maximum activity of substrate for human Folyl-polyglutamate synthase relative to the maximum activity for aminopterin,Other,12570380.0,
864,71364,6,2,,104234169,126941,Active,,,14.5,IC50,Inhibitory activity against uptake of [3H]-MTX at Folyl-polyglutamate synthase by human leukemia cells (CCRF-CEM),Confirmatory,8568828.0,
865,71367,6,2,,104234169,126941,Active,,,42.0,Km,Michaelis-Menten constant was determined against CCRF-CEM Folyl-polyglutamate synthase,Confirmatory,8277497.0,
866,71370,7,1,,104234169,126941,Active,,,,,Concentration required go get half the maximal reaction with Folyl-polyglutamate synthase,Other,6148421.0,
867,71375,9,1,,104234169,126941,Unspecified,,,166.0,Ki,Compound was tested for its ability to inhibit Folyl-polyglutamate synthase from mouse liver,Confirmatory,2871191.0,
868,71382,6,3,,104234169,126941,Unspecified,,,165.0,Km,The apparent Km of compound as a substrate for partially purified mouse liver Folyl-polyglutamate synthase,Confirmatory,2918520.0,
869,71488,7,1,,104234169,126941,Unspecified,,,,,Compound was evaluated for reaction rate of compound in mouse liver Folyl-polyglutamate synthase ([3H]L-glutamate incorporated),Other,6148421.0,
870,71490,3,7,,104234169,126941,Unspecified,,,,,Specific activity of L1210 Folyl-polyglutamate synthase,Other,8277497.0,
871,71509,5,7,,104234169,126941,Unspecified,,,,,Substrate activity for Folyl-polyglutamate synthase (FGPS) at 100 uM,Other,9016334.0,
872,71529,6,4,,104234169,126941,Unspecified,,,116.0,Km,Substrate activity against folyl-poly-glutamate synthetase isolated from hog liver,Confirmatory,,
873,71531,5,8,,104234169,126941,Unspecified,,,,,Substrate activity against folyl-poly-glutamate synthetase isolated from hog liver,Other,,
874,72165,6,4,,104234169,126941,Active,,,49.0,Km,Ability to act as a substrate for human folyglutamate synthetase (FPGS),Confirmatory,12408727.0,
875,72187,3,4,,104234169,126941,Unspecified,,,,,Protection against the growth inhibition against Human squamous cell line(Fadu),Other,7473577.0,
876,72188,3,4,,104234169,126941,Unspecified,,,,,Protection by 10 uM LV against the growth inhibition against Human squamous cell line(Fadu),Other,7473577.0,
877,72189,3,4,,104234169,126941,Unspecified,,,,,Protection by 10 uM LV(leucovorin) against the growth inhibition of FaDu cells induced by the compound,Other,7562910.0,
878,72190,3,5,,104234169,126941,Unspecified,,,,,"Protection by 40 uM against the Growth inhibition against Human squamous cell line(Fadu), in the presence of 40 uM thymidine",Other,7473577.0,
879,72192,3,4,,104234169,126941,Unspecified,,,,,Protection by 40 uM TdR(thymidine) against the growth inhibition of FaDu cells induced by the compound,Other,7562910.0,
880,72193,3,4,,104234169,126941,Unspecified,,,,,Protection by 50 uM against the Growth inhibition against Human squamous cell line(Fadu),Other,7473577.0,
881,72194,3,4,,104234169,126941,Unspecified,,,,,"Protection by 50 uM+40 uM against Growth inhibition against Human squamous cell line(Fadu), in the presence of 50 uM hypoxanthine +40 uM thymidine",Other,7473577.0,
882,72195,3,4,,104234169,126941,Unspecified,,,,,Protection by 50 uM Hx (Hypoxanthine) against the growth inhibition of FaDu cells induced by the compound,Other,7562910.0,
883,72197,3,4,,104234169,126941,Unspecified,,,,,Protection by combination of 50 uM Hx (Hypoxanthine) + 40 uM TdR(thymidine) against the growth inhibition of FaDu cells induced by the compound,Other,7562910.0,
884,72324,3,4,,104234169,126941,Unspecified,,,,,The compound was tested for growth inhibition against FaDu cells,Other,7562910.0,
885,72325,6,2,,104234169,126941,Active,,,0.017,EC50,Growth inhibition against Human squamous cell line(Fadu),Confirmatory,7473577.0,
886,72326,4,4,,104234169,126941,Active,,,0.031,EC50,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound FaDu cell line,Confirmatory,7783147.0,
887,72328,6,2,,104234169,126941,Active,,,0.017,EC50,The compound was tested for Growth inhibition of the human squamous cell carcinoma FaDu cells,Confirmatory,7562910.0,
888,72329,4,4,,104234169,126941,Active,,,0.019,EC50,"the growth inhibition of, (during continuous exposure) human squamous cell carcinoma FaDu at resistance mechanism - sensitive",Confirmatory,8164259.0,
889,72330,3,4,,104234169,126941,Unspecified,,,,,Protection of FaDu cells from growth inhibitory effects of compound by 10 uM leucovorin (LV),Other,8164259.0,
890,72331,3,4,,104234169,126941,Unspecified,,,,,Protection of FaDu cells from growth inhibitory effects of compound by 40 uM thymidine (TdR),Other,8164259.0,
891,72332,3,4,,104234169,126941,Unspecified,,,,,Protection of FaDu cells from growth inhibitory effects of compound by 50 uM hypoxanthine (Hx),Other,8164259.0,
892,72333,3,4,,104234169,126941,Unspecified,,,,,Protection of FaDu cells from growth inhibitory effects of compound by combination of 50 uM hypoxanthine (Hx) and 40 uM thymidine (TdR),Other,8164259.0,
893,72334,3,4,,104234169,126941,Unspecified,,,,,Protection of FaDu cells from growth inhibitory effects of compound with no addition,Other,8164259.0,
894,72335,4,4,,104234169,126941,Active,,,0.017,EC50,Growth inhibition of FaDu human head and neck squamous cell carcinoma cell lines.,Confirmatory,11384244.0,
895,72336,4,4,,104234169,126941,Active,,,0.0113,EC50,Growth inhibition of human squamous cell carcinoma FaDu cells during continuous Exposure (0-12 h),Confirmatory,10956221.0,
896,72338,3,4,,104234169,126941,Unspecified,,,,,Relative growth inhibition of FaDu cells at 50 nM drug concentration and in presence of 10 uM Leucovorin.,Other,11384244.0,
897,72339,3,4,,104234169,126941,Unspecified,,,,,Relative growth inhibition of FaDu cells at 50 nM drug concentration and in presence of 40 uM Thymidine.,Other,11384244.0,
898,72340,3,4,,104234169,126941,Unspecified,,,,,Relative growth inhibition of FaDu cells at 50 nM drug concentration and in presence of 50 uM Hypoxanthine.,Other,11384244.0,
899,72341,3,4,,104234169,126941,Unspecified,,,,,Relative growth inhibition of FaDu cells at 50 nM drug concentration and in presence of thymidine and hypoxanthine.,Other,11384244.0,
900,72346,3,4,,104234169,126941,Unspecified,,,,,Relative growth inhibition of FaDu cells in absence of metabolite at 50 nM concentration.,Other,11384244.0,
901,72349,3,4,,104234169,126941,Unspecified,,,,,protection of FaDu cells from the growth inhibitory effects by 40 uM of thymidine (TdR).,Other,10956221.0,
902,72351,3,4,,104234169,126941,Unspecified,,,,,protection of FaDu cells from the growth inhibitory effects by 50 uM of hypoxanthine (HX),Other,10956221.0,
903,72352,3,4,,104234169,126941,Unspecified,,,,,protection of FaDu cells from the growth inhibitory effects by combination of 50 uM of thymidine (TdR).,Other,10956221.0,
904,72354,3,4,,104234169,126941,Unspecified,,,,,protection of FaDu cells from the growth inhibitory effects of the compound.,Other,10956221.0,
905,72355,4,5,,104234169,126941,Unspecified,,,,,Protection of human FaDu cells by hypoxanthine from growth inhibition induced by the compound,Other,11052789.0,
906,72357,3,5,,104234169,126941,Unspecified,,,,,Protection of human FaDu cells by thymidine from growth inhibition induced by the compound,Other,11052789.0,
907,72359,3,5,,104234169,126941,Unspecified,,,,,Protection of humanFaDu cells by thymidine and hypoxanthine from growth inhibition induced by the compound,Other,11052789.0,
908,72360,4,3,,104234169,126941,Active,,,0.0172,EC50,Growth inhibition was measured for inhibition of growth in FaDu human squamous cell carcinoma of the head and neck.,Confirmatory,9554874.0,
909,72749,7,4,,104234169,126941,Unspecified,,,20.0,IC50,Inhibitory activity against GAR transformylase of Lactobacillus casei,Confirmatory,3121855.0,
910,72752,6,4,,104234169,126941,Unspecified,,,20.0,IC50,Inhibition of GAR transformylase from Lactobacillus casei,Confirmatory,3184124.0,
911,72863,6,3,,104234169,126941,Unspecified,,,20.0,IC50,Inhibition of GAR transformylase from mammalian L1210 cells,Confirmatory,3184124.0,
912,73473,8,1,,104234169,126941,Active,,,0.02,ID50,Compound concentration required to reduce by 50% the number of fibroblast-like cells (Vero) after three cell cycles,Confirmatory,1548681.0,
913,78403,4,4,,104234169,126941,Active,,,0.0095,IC50,Cytotoxic Activity was evaluated against H460 tumor cells,Confirmatory,8632413.0,
914,78623,4,4,,104234169,126941,Active,,,0.03,IC50,Compound was evaluated for in vitro activity against HCT-15 Colon cell lines (Human tumor cells ),Confirmatory,9857098.0,
915,78632,4,4,,104234169,126941,Active,,,0.03,IC50,The IC50 value was measured on HCT-15 cell line in colon tumor type.,Confirmatory,9022795.0,
916,79134,8,1,,104234169,126941,Active,,,0.03,ID50,Compound concentration required to reduce by 50% the number of H9 cells chronically infected with the HIV-1 (H9/IIIB) after three cell cycles,Confirmatory,1548681.0,
917,79418,5,1,,104234169,126941,Active,,,0.0024,ED50,Tested for cloning suppression test against H.Ep.-2 cells,Confirmatory,7365749.0,
918,79423,8,1,,104234169,126941,Active,,,0.0024,ED50,Effective dose against H.Ep.-2 cells,Confirmatory,7057425.0,
919,79784,4,4,,104234169,126941,Active,,,0.11,IC50,Compound was evaluated for in vitro activity against HCC2998 Colon cell lines (Human tumor cells ),Confirmatory,9857098.0,
920,80548,4,4,,104234169,126941,Active,,,0.03,IC50,Compound was evaluated for in vitro activity against HCT116 Colon cell lines (Human tumor cells ),Confirmatory,9857098.0,
921,80667,6,2,,104234169,126941,Active,,,0.085,IC50,Compound was tested for growth inhibition of H35 Hepatoma cells.,Confirmatory,1992121.0,
922,80668,6,2,,104234169,126941,Active,,,18.0,IC50,Compound was tested for inhibition of folinic acid transport in H35 Hepatoma cells.,Confirmatory,1992121.0,
923,80670,6,2,,104234169,126941,Active,,,0.01,IC50,Growth inhibition of H35 cell lines,Confirmatory,6737432.0,
924,80671,3,4,,104234169,126941,Unspecified,,,,,Cytotoxic activity with respect to methotrexate,Other,6737432.0,
925,80705,4,4,,104234169,126941,Active,,,0.03,IC50,The IC50 value was measured on HCT116 cell line in colon tumor type.,Confirmatory,9022795.0,
926,80814,4,3,,104234169,126941,Active,,,0.01,IC50,Inhibition of growth of H35FF cells,Confirmatory,2542557.0,
927,80816,4,3,,104234169,126941,Active,,,0.01,IC50,Inhibition of growth of H35N cells,Confirmatory,2542557.0,
928,80817,6,2,,104234169,126941,Active,,,1.8,IC50,Growth inhibition of H35R0.3 cell lines,Confirmatory,6737432.0,
929,80818,3,4,,104234169,126941,Unspecified,,,,,Cytotoxic activity with respect to methotrexate,Other,6737432.0,
930,80820,4,4,,104234169,126941,Active,,,0.9059999999999999,IC50,Inhibition of growth of H35R cells,Confirmatory,2542557.0,
931,80965,6,1,,104234169,126941,Active,,,0.012,IC50,Compound was tested for its anticancer activity against HL-60 cells.,Confirmatory,,
932,81490,6,3,,104234169,126941,Active,,,0.012,IC50,Tested for the cytostatic activity as inhibitory concentration against leukemia HL-60 cells,Confirmatory,,
933,81534,4,4,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against HOP-92 lung cancer cell lines (Human tumor cells ),Confirmatory,9857098.0,
934,82178,8,1,,104234169,126941,Active,,,0.1,ED50,Inhibition of [6-3H]-dUrd incorporation into DNA in HL-60 cells,Confirmatory,3373490.0,
935,82179,8,1,,104234169,126941,Unspecified,,,609.0,ED50,Median-effective concentration for inhibition of human HL-60 cell growth at 24 h,Confirmatory,3373490.0,
936,82180,8,1,,104234169,126941,Active,,,0.05,ED50,Median-effective concentration for inhibition of human HL-60 cell growth at 48 h,Confirmatory,3373490.0,
937,82181,8,1,,104234169,126941,Unspecified,,,0.05,ED50,Median-effective concentration for inhibition of human HL-60 cell growth at 72 h,Confirmatory,3373490.0,
938,82324,3,4,,104234169,126941,Unspecified,,,,,Compound was evaluated for inhibition of human HL-60 cell growth at 1 (uM) at 24 hr,Other,3373490.0,
939,82325,3,4,,104234169,126941,Unspecified,,,,,Compound was evaluated for inhibition of human HL-60 cell growth at 1 (uM) at 48 hr,Other,3373490.0,
940,82326,3,4,,104234169,126941,Unspecified,,,,,Compound was evaluated for inhibition of human HL-60 cell growth at 1 (uM) at 72 hr,Other,3373490.0,
941,82660,4,4,,104234169,126941,Active,,,0.039,IC50,Compound was evaluated for in vitro activity against HL-60(TB) leukemia cell lines (Human tumor cells ),Confirmatory,9857098.0,
942,82844,4,5,,104234169,126941,Active,,,0.0081,IC50,Tested for the ability to inhibit growth in vitro against HL60,Confirmatory,8277497.0,
943,84449,6,2,,104234169,126941,Active,,,0.018000000000000002,IC50,Inhibition of cell growth against HT-29 human gastrointestinal adenocarcinoma cell lines in vitro,Confirmatory,3612694.0,
944,84457,4,4,,104234169,126941,Active,,,0.032,IC50,The IC50 value was measured on HT-29 cell line in colon tumor type.,Confirmatory,9022795.0,
945,84474,6,2,,104234169,126941,Active,,,0.018000000000000002,IC50,In vitro inhibition of growth of the human gastrointestinal adenocarcinoma cells HT-29,Confirmatory,6694171.0,
946,85235,4,5,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against Hs 578.T breast cancer cell lines (Human tumor cells ),Confirmatory,9857098.0,
947,85622,6,2,,104234169,126941,Active,,,0.009000000000000001,IC50,In vitro inhibition of growth of the human gastrointestinal adenocarcinoma cells HaTu80,Confirmatory,6694171.0,
948,89332,6,2,,104234169,126941,Active,,,0.032,IC50,Compound was tested for its inhibitory concentration against human leukemic lymphoblasts (CEM Cells),Confirmatory,3462394.0,
949,89333,6,2,,104234169,126941,Active,,,6.6,IC50,Compound was tested for its inhibitory concentration against human leukemic lymphoblasts (CEM Cells) and a resistant subline (CEM / MTX).,Confirmatory,3462394.0,
950,89920,4,1,,104234169,126941,Unspecified,,,,,Dissociation constant towards DHFR mutant F31W,Other,8627598.0,
951,89922,4,1,,104234169,126941,Unspecified,,,,,Dissociation constant towards human DHFR mutant hF31S,Other,8627598.0,
952,89924,4,1,,104234169,126941,Unspecified,,,,,Dissociation constant towards human wild type DHFR,Other,8627598.0,
953,89928,4,1,,104234169,126941,Unspecified,,,,,Binding affinity towards DHFR mutant F31W,Other,8627598.0,
954,89929,4,1,,104234169,126941,Unspecified,,,,,Binding affinity towards human DHFR mutant hF31S,Other,8627598.0,
955,89930,4,1,,104234169,126941,Unspecified,,,,,Binding affinity towards human wild type DHFR,Other,8627598.0,
956,91046,4,4,,104234169,126941,Active,,,0.0045,EC50,Inhibition of growth (cytotoxicity) of HuTu 80 cell line in vitro,Confirmatory,6410066.0,
957,91047,6,2,,104234169,126941,Active,,,0.009000000000000001,IC50,Inhibition of cell growth against HuTu 80 human gastrointestinal adenocarcinoma cell lines in vitro,Confirmatory,3612694.0,
958,91481,4,7,,104234169,126941,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
959,91656,4,3,,104234169,126941,Active,,,0.061,IC50,In vitro growth inhibition of human synovial cells (hSC),Confirmatory,9016334.0,
960,93505,4,4,,104234169,126941,Active,,,0.065,IC50,Compound was evaluated for in vitro activity against IGROV1 Ovary cell lines (Human tumor cells ),Confirmatory,9857098.0,
961,93920,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity (T/C) evaluated against L1210 leukemia from the median survival time of treated mice (T) over that of control mice (C) at a dose of 0.75 mg/kg as experiment 2,Other,1995880.0,
962,93921,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity (T/C) evaluated against L1210 leukemia from the median survival time of treated mice (T) over that of control mice (C) at a dose of 1 mg/kg,Other,1995880.0,
963,93922,4,4,,104234169,126941,Unspecified,,,,,Antitumor activity (T/C) evaluated against L1210 leukemia from the median survival time of treated mice (T) over that of control mice (C) at a dose of 4 mg/kg,Other,1995880.0,
964,93923,3,5,,104234169,126941,Unspecified,,,,,Antitumor activity (T/C) evaluated against L1210 leukemia from the median survival time of treated mice (T) over that of control mice (C) at a dose of 8 g/kg as experiment 1,Other,1995880.0,
965,93934,6,2,,104234169,126941,Unspecified,,,205.0,IC50,"Evaluated for 50% inhibition of growth of L1210 / R81 cells (48 h), relative to untreated controls",Confirmatory,3968685.0,
966,93936,6,2,,104234169,126941,Active,,,0.012,IC50,Evaluated for the growth inhibition of L1210 /S cells,Confirmatory,3968685.0,
967,94426,6,2,,104234169,126941,Active,,,3.5,Ki,Ki value was measured as influx in L1210 cell membrane transport.,Confirmatory,7057425.0,
968,94427,6,2,,104234169,126941,Active,,,3.3,Km,Km value was measured as influx in L1210 cell membrane transport.,Confirmatory,7057425.0,
969,94430,3,4,,104234169,126941,Unspecified,,,,,k value was measured as efflux in L1210 cell membrane transport.,Other,7057425.0,
970,94554,5,1,,104234169,126941,Unspecified,,,,,Compound was tested in vitro for growth inhibitory activity against murine L1210 leukemia cell line,Other,8258836.0,
971,94657,4,4,,104234169,126941,Active,,,0.026000000000000002,IC50,Compound was evaluated for in vitro activity against K562 leukemia cell lines (Human tumor cells ),Confirmatory,9857098.0,
972,94697,4,4,,104234169,126941,Active,,,0.033,IC50,Compound was evaluated for in vitro activity against KM-12 Colon cell lines (Human tumor cells ),Confirmatory,9857098.0,
973,94698,4,4,,104234169,126941,Active,,,0.042,IC50,The IC50 value was measured on KM-12 cell line in colon tumor type.,Confirmatory,9022795.0,
974,94710,4,4,,104234169,126941,Active,,,0.0083,IC50,Cytotoxic activity was evaluated against L tumor cells,Confirmatory,8632413.0,
975,94734,6,2,,104234169,126941,Active,,,0.0045,IC50,Inhibition of cell growth of murine L-1210 cells,Confirmatory,3373490.0,
976,95237,6,3,,104234169,126941,Active,,,9.2,IC50,In vitro activity against the amastigote stage of the parasite cultured in mouse fibroblasts (L-6 cells),Confirmatory,10360757.0,
977,95771,7,2,,104234169,126941,Unspecified,,,,,Compound was measured for the 50% growth inhibition of Lactobacillus casei ATCC 7469 microorganism.,Other,6767031.0,
978,95772,7,2,,104234169,126941,Unspecified,,,,,Compound was measured for the 50% growth inhibition of Lactobacillus casei MTX resistant microorganism.,Other,6767031.0,
979,95773,8,2,,104234169,126941,Unspecified,,,,,Compound was evaluated for growth inhibition against Lactobacillus casei ATCC 7469,Other,3712374.0,
980,95774,8,1,,104234169,126941,Active,,,2e-08,IC50,Inhibition of the growth of Lactobacillus casei,Confirmatory,2498518.0,
981,95776,5,2,,104234169,126941,Unspecified,,,1e-08,IC50,Tested for growth inhibition of Lactobacillus casei (MTX resistant),Confirmatory,3121855.0,
982,95870,4,4,,104234169,126941,Active,,,0.019,IC50,Inhibitory concentration of compound was tested against KB tumor growth cell line,Confirmatory,8201595.0,
983,96367,8,2,,104234169,126941,Unspecified,,,,,In vitro growth inhibitory activity against KB human epidermoid carcinoma cells.,Other,1847428.0,
984,96458,4,4,,104234169,126941,Active,,,0.0046,IC50,Compound was evaluated for the growth inhibition of L1210 cells,Confirmatory,1995880.0,
985,96572,6,2,,104234169,126941,Active,,,5.61,Ki,Compound was evaluated for transport properties against L1210 cells for influx,Confirmatory,3712374.0,
986,96580,6,2,,104234169,126941,Active,,,3.51,Km,Compound was evaluated for influx of L1210 cells,Confirmatory,1501226.0,
987,96581,6,2,,104234169,126941,Active,,,3.3,Km,Compound was evaluated for the influx (Km) mediated transport with respect to L1210 cells,Confirmatory,2423690.0,
988,96583,6,2,,104234169,126941,Active,,,3.95,Km,Influx characteristics toward L1210 cells was evaluated,Confirmatory,3184124.0,
989,96584,6,2,,104234169,126941,Active,,,4.86,Km,Km value for its transport after influx into L1210 cells,Confirmatory,1732551.0,
990,96605,7,1,,104234169,126941,Active,,,0.00248,MIC50,Compound was evaluated for growth inhibition and minimal inhibitory concentration was reported against L1210 cells.,Confirmatory,3712374.0,
991,96629,8,1,,104234169,126941,Active,,,0.01,ID50,Compound is tested for the inhibition of growth of murine leukemia cells (L1210),Confirmatory,6787199.0,
992,96653,5,1,,104234169,126941,Active,,,0.02,ID50,cytotoxicity against L1210 cells,Confirmatory,6139480.0,
993,96664,8,1,,104234169,126941,Active,,,0.01,ID50,Growth inhibitory activity against L1210 mouse leukemia cell line,Confirmatory,6796689.0,
994,96859,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity against L1210 leukemia in 19 mice measured as median survival range at 15 mg/kg; Value ranges from(13-22),Other,6620303.0,
995,96954,3,4,,104234169,126941,Unspecified,,,,,% increase in lifespan was measured at 15 mg/kg dosage after ip administration,Other,7143361.0,
996,96955,3,4,,104234169,126941,Unspecified,,,,,% increase in lifespan was measured at 3 mg/kg dosage after ip administration,Other,7143361.0,
997,97073,6,1,,104234169,126941,Unspecified,,,,,Range for the survival of mice infected with L1210 leukemia after an intraperitoneal dose of 4 mg/kg for 9 days,Other,2898531.0,
998,97092,3,4,,104234169,126941,Unspecified,,,,,Compound was evaluated for rate of anabolism to polyglutamate accumulation in L1210 cells,Other,2423690.0,
999,97122,3,4,,104234169,126941,Unspecified,,,,,"Compound is evaluated for percent increase in against L1210 leukemia in mice, at dose 15 mg/kg",Other,6787199.0,
1000,97123,4,4,,104234169,126941,Unspecified,,,,,"Compound is evaluated for percent increase in against L1210 leukemia in mice, at dose 30 mg/kg",Other,6787199.0,
1001,97150,3,4,,104234169,126941,Unspecified,,,,,Cytotoxic activity with respect to methotrexate,Other,6737432.0,
1002,97258,3,4,,104234169,126941,Unspecified,,,,,In vitro for antitumor activity against L1210 leukemia in mice at a dose of 15 mg/Kg(sc) was reported as percentage increase in life span,Other,7108907.0,
1003,97261,3,5,,104234169,126941,Unspecified,,,,,"In vivo activity(%ILS) at optimal dose of 4 mg/kg, by intraperitoneal administration in BDF1 mice against L1210 leukemia cells",Other,4009615.0,
1004,97397,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity against L1210 leukemia in 19 mice measured as Increased life span.,Other,6620303.0,
1005,97411,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity as increase in life span in mice with L1210 10E6 tumor cell implanted intraperitoneally; optimal dose is 12 mg/kg.,Other,4020824.0,
1006,97716,7,1,,104234169,126941,Active,,,,,Antitumor activity against L1210 cell line as cell membrane transport activity,Other,4020824.0,
1007,97746,3,4,,104234169,126941,Unspecified,,,,,Inhibition of thymidylate synthesis in L1210 cells at 100 uM,Other,3091832.0,
1008,97748,3,4,,104234169,126941,Unspecified,,,,,Inhibition of thymidylate synthesis in L1210 intact cells at 10 uM,Other,3091832.0,
1009,97896,6,2,,104234169,126941,Active,,,3.65,Ki,Rate of influx into the L1210 cells,Confirmatory,6793726.0,
1010,97897,6,2,,104234169,126941,Active,,,3.93,Ki,Tested for transport into L1210 cells measured as cell influx,Confirmatory,8277497.0,
1011,97900,6,2,,104234169,126941,Active,,,3.7,Km,In vitro membrane transport activity in L1210 cells in rodent,Confirmatory,7108907.0,
1012,97944,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity against L1210 leukemia in 16 mice measured as T/C values(days); T/C = 16/9,Other,6620303.0,
1013,98001,6,2,,104234169,126941,Active,,,0.0046,IC50,Ability to inhibit L1210 murine leukemia tumor cell growth in culture after 48 hr of its exposure.,Confirmatory,1992118.0,
1014,98023,4,4,,104234169,126941,Active,,,0.0032,EC50,Inhibition of growth (cytotoxicity) of L1210 cell line in vitro,Confirmatory,6410066.0,
1015,98036,8,1,,104234169,126941,Active,,,0.016,ED50,Cytotoxic activity against the L1210 cell cultures,Confirmatory,6928967.0,
1016,98127,6,2,,104234169,126941,Active,,,0.002,IC50,Cell growth inhibition against mouse leukemia L1210 cells,Confirmatory,3872941.0,
1017,98130,6,2,,104234169,126941,Active,,,0.009000000000000001,IC50,Compound was evaluated for cell growth inhibition of murine (L1210) leukemic cells,Confirmatory,1992122.0,
1018,98131,6,2,,104234169,126941,Active,,,0.0025,IC50,Compound was evaluated for growth inhibition in L1210 murine leukemia cells,Confirmatory,3091834.0,
1019,98132,4,4,,104234169,126941,Active,,,0.00255,IC50,Compound was evaluated for inhibitory effect on growth of L1210 cells at IC50 (n=4),Confirmatory,2423690.0,
1020,98138,6,2,,104234169,126941,Active,,,0.0034,IC50,In vitro inhibition of L1210 cell growth,Confirmatory,1501226.0,
1021,98147,6,2,,104234169,126941,Active,,,0.002,IC50,Compound was tested for its ability to inhibit growth of L1210 mouse leukemia cells,Confirmatory,2871191.0,
1022,98160,4,4,,104234169,126941,Active,,,0.005,IC50,Concentration inhibiting L1210 cell growth in culture,Confirmatory,2296020.0,
1023,98166,6,2,,104234169,126941,Active,,,0.00084,IC50,Concentration required for 50% inhibition against L1210 cells,Confirmatory,6403710.0,
1024,98168,4,4,,104234169,126941,Active,,,0.0039,IC50,Concentration required to inhibit 50% growth of L1210 cells in culture.,Confirmatory,1732549.0,
1025,98184,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity L1210 cell line as cell membrane transport activity,Other,4020824.0,
1026,98197,6,2,,104234169,126941,Active,,,1.0,IC50,Evaluated for the uptake of Methotrexate in L1210 leukemia cells,Confirmatory,3968685.0,
1027,98314,4,4,,104234169,126941,Active,,,0.0021,IC50,Evaluated for cell growth inhibition of L1210 cells in cultures,Confirmatory,3184124.0,
1028,98338,5,3,,104234169,126941,Active,,,5e-06,IC50,Inhibition of L1210 cultured murine leukemia cell growth,Confirmatory,3112397.0,
1029,98344,4,4,,104234169,126941,Active,,,0.0095,IC50,Inhibition of growth in L1210 murine leukemia cells in culture expressed as IC50 (nM),Confirmatory,8340923.0,
1030,98348,6,2,,104234169,126941,Active,,,0.005,IC50,Inhibitory activity against cultured L1210 cells,Confirmatory,3351853.0,
1031,98352,6,2,,104234169,126941,Active,,,0.0046,IC50,Inhibitory concentration against growth of L1210 cell line,Confirmatory,3385730.0,
1032,98368,6,2,,104234169,126941,Active,,,1.3,IC50,Compound was evaluated for the inhibition of L1210 murine leukemia cell growth.(From ref 12b),Confirmatory,8863812.0,
1033,98369,6,2,,104234169,126941,Active,,,0.006999999999999999,IC50,Compound was evaluated for the inhibition of L1210 murine leukemia cell growth.(In this study),Confirmatory,8863812.0,
1034,98393,6,2,,104234169,126941,Active,,,0.2,IC50,Compound was tested for its ability to inhibit L1210 cell growth,Confirmatory,2428979.0,
1035,98419,6,1,,104234169,126941,Active,,,0.00271,MIC50,Minimum inhibitory concentration of compound was tested for growth inhibition of L1210 cells,Confirmatory,7143361.0,
1036,98445,6,1,,104234169,126941,Unspecified,,,,,Antitumor activity expressed as mean survival time against L1210 leukemia cells in mice after ip administration at dose 15 mg/kg,Other,7143361.0,
1037,98446,6,1,,104234169,126941,Unspecified,,,,,Antitumor activity expressed as mean survival time against L1210 leukemia cells in mice after ip administration at dose 3 mg/kg,Other,7143361.0,
1038,98448,6,1,,104234169,126941,Unspecified,,,,,In vitro for antitumor activity against L1210 leukemia in mice at a dose of 15 mg/Kg(sc) was reported as maximum survival time,Other,7108907.0,
1039,98492,4,4,,104234169,126941,Active,,,0.00451,IC50,Inhibitory concentration was evaluated as the concentration required for inhibition of L1210 cells.,Confirmatory,1732551.0,
1040,98499,6,2,,104234169,126941,Active,,,0.0046,IC50,Tested for cell-growth inhibition against mouse leukemic L1210 cells,Confirmatory,2898531.0,
1041,98528,8,1,,104234169,126941,Active,,,0.04,ID50,Compound concentration required to reduce by 50% the number of murine lymphocytic leukemia (L1210) cells after three cell cycles,Confirmatory,1548681.0,
1042,98547,4,4,,104234169,126941,Active,,,0.02,IC50,Concentration required to inhibit the growth of L1210 cells,Confirmatory,9022804.0,
1043,98548,4,4,,104234169,126941,Active,,,0.02,IC50,Concentration required to inhibit the growth of L1210 cells.,Confirmatory,9022805.0,
1044,98621,5,2,,104234169,126941,Inconclusive,,,,,"Compound is evaluated for activity against L1210 leukemia in mice, at dose 15 mg/kg; no data",Other,6787199.0,
1045,98622,5,2,,104234169,126941,Inconclusive,,,,,"Compound is evaluated for activity against L1210 leukemia in mice, at dose 30 mg/kg; no data",Other,6787199.0,
1046,98623,5,2,,104234169,126941,Inconclusive,,,,,"Compound is evaluated for activity against L1210 leukemia in mice, at dose 60 mg/kg; no data",Other,6787199.0,
1047,98642,3,4,,104234169,126941,Unspecified,,,,,In vitro for antitumor activity against L1210 leukemia in mice at a dose of 15 mg/Kg(sc) was reported as weight at termination of the therapy,Other,7108907.0,
1048,98654,3,4,,104234169,126941,Unspecified,,,,,In vitro antitumor activity against L1210 cell line.,Other,4020824.0,
1049,98713,6,2,,104234169,126941,Active,,,0.024,IC50,Growth inhibition of L1210 cell lines,Confirmatory,6737432.0,
1050,98750,4,4,,104234169,126941,Active,,,0.0027,IC50,In vitro inhibition of L1210 cell growth in rodent neoplastic cells,Confirmatory,7108907.0,
1051,98802,3,6,,104234169,126941,Unspecified,,,,,Increase life span of mice bearing L1210 leukemia at dose 10 mg/kg on subcutaneous administration,Other,3968685.0,
1052,98803,3,6,,104234169,126941,Unspecified,,,,,Increase life span of mice bearing L1210 leukemia at dose 15 mg/kg on subcutaneous administration,Other,3968685.0,
1053,98807,3,4,,104234169,126941,Unspecified,,,,,In vitro membrane transport activity in L1210 cells in rodent,Other,7108907.0,
1054,98827,6,1,,104234169,126941,Unspecified,,,,,Mean survival time of mice bearing L1210 leukemia at dose 10 mg/kg on subcutaneous administration,Other,3968685.0,
1055,98828,6,1,,104234169,126941,Unspecified,,,,,Mean survival time of mice bearing L1210 leukemia at dose 15 mg/kg on subcutaneous administration,Other,3968685.0,
1056,98855,3,4,,104234169,126941,Unspecified,,,,,Increase in life span of mice infected with L1210 leukemia after an intraperitoneal dose of 4 mg/kg for 9 days,Other,2898531.0,
1057,98895,6,2,,104234169,126941,Unspecified,,,60.0,IC50,Inhibition of thymidylate synthesis in permeabilised cells,Confirmatory,3091832.0,
1058,98896,8,1,,104234169,126941,Active,,,0.00328,IC50,Inhibition of L1210 cell growth in mice.,Confirmatory,4020824.0,
1059,98912,4,4,,104234169,126941,Active,,,0.00392,IC50,Inhibitory activity for the growth inhibition of L1210 cell line.,Confirmatory,2299633.0,
1060,98917,6,2,,104234169,126941,Active,,,0.01,IC50,Inhibitory concentration against the growth of L1210 murine leukemia cells in tissue culture.,Confirmatory,4009615.0,
1061,98918,6,2,,104234169,126941,Active,,,0.0027,IC50,Inhibitory concentration of compound in growth of L-1210 cells,Confirmatory,6793726.0,
1062,98938,4,5,,104234169,126941,Active,,,0.009000000000000001,IC50,Tested for the ability to inhibit growth in vitro against L1210,Confirmatory,8277497.0,
1063,99050,3,4,,104234169,126941,Unspecified,,,,,Compound was evaluated for the efflux (K) mediated transport with respect to L1210 cells,Other,2423690.0,
1064,99054,6,2,,104234169,126941,Active,,,3.2e-06,Ki,Compound was evaluated for inhibitory activity against DHFR in L1210 cells,Confirmatory,3091834.0,
1065,99151,4,4,,104234169,126941,Active,,,0.2,IC50,Inhibition of L1210/R81 murine leukemia cell growth,Confirmatory,3112397.0,
1066,99174,6,2,,104234169,126941,Active,,,19.0,IC50,Cell growth inhibition against mouse leukemia L1210/R71 cells,Confirmatory,3872941.0,
1067,99177,6,2,,104234169,126941,Unspecified,,,220.0,IC50,Compound was tested for its ability to inhibit growth of L1210/R81 cells,Confirmatory,2871191.0,
1068,99179,6,2,,104234169,126941,Unspecified,,,200.0,IC50,Inhibitory concentration against growth of L1210/R81 cell line,Confirmatory,3385730.0,
1069,99181,6,2,,104234169,126941,Unspecified,,,197.0,IC50,Tested for cell-growth inhibition against mouse leukemic L1210/R81 cells,Confirmatory,2898531.0,
1070,99182,6,2,,104234169,126941,Unspecified,,,200.0,IC50,Ability to inhibit MTX-resistant L1210/R81 tumor cell growth was determined.,Confirmatory,1992118.0,
1071,99183,6,2,,104234169,126941,Unspecified,,,220.0,IC50,Cell growth inhibition against mouse leukemia L1210/R81 cells,Confirmatory,3872941.0,
1072,99343,7,1,,104234169,126941,Active,,,,,In vitro antitumor activity against L1210 cell line.,Other,4020824.0,
1073,99382,3,3,,104234169,126941,Unspecified,,,,,Concentration required for the 50% growth inhibition of Lactobacillus casei ATCC 7469 organism at 1 ng/mL folate concentration,Other,7143361.0,
1074,99383,3,3,,104234169,126941,Unspecified,,,,,Concentration required for the 50% growth inhibition of Streptococcus faecium ATCC 8043 organism at 1 ng/mL folate concentration,Other,7143361.0,
1075,99387,8,2,,104234169,126941,Unspecified,,,,,Compound was evaluated for growth inhibition in Lactobacillus casei ATCC 7469,Other,3091834.0,
1076,99388,8,2,,104234169,126941,Unspecified,,,,,Compound was evaluated for growth inhibition in Lactobacillus casei MTX-resistant,Other,3091834.0,
1077,99390,8,2,,104234169,126941,Unspecified,,,,,Concentration required to inhibit growth of Lactobacillus casei by 50%,Other,6793726.0,
1078,99391,8,2,,104234169,126941,Unspecified,,,,,Concentration required for 50% inhibition against Lactobacillus casei (ATCC 7469),Other,6403710.0,
1079,99392,8,2,,104234169,126941,Unspecified,,,,,Concentration required for 50% inhibition against Lactobacillus casei MTX resistant,Other,6403710.0,
1080,99393,6,2,,104234169,126941,Active,,,0.013000000000000001,IC50,In vitro antibacterial activity against Lactobacillus casei (ATCC 7469),Confirmatory,7108907.0,
1081,99394,6,2,,104234169,126941,Unspecified,,,10000.0,IC50,In vitro antibacterial activity against MTX-resistance Lactobacillus casei,Confirmatory,7108907.0,
1082,99396,8,2,,104234169,126941,Unspecified,,,,,Inhibitory activity against Lactobacillus casei ATCC 7469,Other,3100797.0,
1083,99397,8,2,,104234169,126941,Unspecified,,,,,Inhibitory activity against Lactobacillus casei MTX-resistant,Other,3100797.0,
1084,99398,4,3,,104234169,126941,Active,,,2.9999999999999997e-05,IC50,Inhibitory activity against Lactobacillus casei ATCC 7469,Confirmatory,3091832.0,
1085,99399,5,2,,104234169,126941,Unspecified,,,1000.0,IC50,Inhibitory activity against Lactobacillus casei MTX-resistant,Confirmatory,3091832.0,
1086,99400,4,3,,104234169,126941,Active,,,2.9999999999999997e-05,IC50,Inhibitory activity against the growth of Lactobacillus casei (ATCC 7469) was determined (glutamate residue 1),Confirmatory,2447278.0,
1087,99401,4,3,,104234169,126941,Active,,,9e-05,IC50,Inhibitory activity against the growth of Lactobacillus casei (ATCC 7469) was determined (glutamate residue 2),Confirmatory,2447278.0,
1088,99402,4,3,,104234169,126941,Active,,,0.0002,IC50,Inhibitory activity against the growth of Lactobacillus casei (ATCC 7469) was determined (glutamate residue 3),Confirmatory,2447278.0,
1089,99403,4,3,,104234169,126941,Active,,,0.0008,IC50,Inhibitory activity against the growth of Lactobacillus casei (ATCC 7469) was determined (glutamate residue 4),Confirmatory,2447278.0,
1090,99404,4,3,,104234169,126941,Active,,,0.0022,IC50,Inhibitory activity against the growth of Lactobacillus casei (ATCC 7469) was determined (glutamate residue 5),Confirmatory,2447278.0,
1091,99405,4,3,,104234169,126941,Active,,,0.027000000000000003,IC50,Inhibitory activity against the growth of Lactobacillus casei (ATCC 7469) was determined (glutamate residue 6),Confirmatory,2447278.0,
1092,99481,6,2,,104234169,126941,Unspecified,,,186.0,IC50,Inhibition of the growth of methotrexate resistant L1210 leukemia/R 81 cells in culture,Confirmatory,2704031.0,
1093,99482,6,2,,104234169,126941,Active,,,0.0044,IC50,Inhibition of the growth of methotrexate sensitive L1210 leukemia/S cells in culture,Confirmatory,2704031.0,
1094,99524,3,4,,104234169,126941,Unspecified,,,,,Concentration required for inhibition of murine leukemia L5178Y cells,Other,7057420.0,
1095,99534,4,3,,104234169,126941,Active,,,0.00085,IC50,Inhibitory activity against the growth of Streptococcus faecium (ATCC 8043) was determined (glutamate residue 1),Confirmatory,2447278.0,
1096,99535,4,3,,104234169,126941,Active,,,0.0034,IC50,Inhibitory activity against the growth of Streptococcus faecium (ATCC 8043) was determined (glutamate residue 2),Confirmatory,2447278.0,
1097,99536,4,3,,104234169,126941,Active,,,0.56,IC50,Inhibitory activity against the growth of Streptococcus faecium (ATCC 8043) was determined (glutamate residue 3),Confirmatory,2447278.0,
1098,99537,4,3,,104234169,126941,Active,,,2.6,IC50,Inhibitory activity against the growth of Streptococcus faecium (ATCC 8043) was determined (glutamate residue 4),Confirmatory,2447278.0,
1099,99538,4,3,,104234169,126941,Active,,,1.2,IC50,Inhibitory activity against the growth of Streptococcus faecium (ATCC 8043) was determined (glutamate residue 5),Confirmatory,2447278.0,
1100,99539,4,3,,104234169,126941,Unspecified,,,8.0,IC50,Inhibitory activity against the growth of Streptococcus faecium (ATCC 8043) was determined (glutamate residue 6),Confirmatory,2447278.0,
1101,99541,4,3,,104234169,126941,Active,,,0.1,IC50,Inhibitory activity against thymidylate synthase in Lactobacillus casei was determined (glutamate residue 1),Confirmatory,2447278.0,
1102,99542,4,3,,104234169,126941,Active,,,0.006,IC50,Inhibitory activity against thymidylate synthase in Lactobacillus casei was determined (glutamate residue 2),Confirmatory,2447278.0,
1103,99543,4,3,,104234169,126941,Active,,,0.0011,IC50,Inhibitory activity against thymidylate synthase in Lactobacillus casei was determined (glutamate residue 3),Confirmatory,2447278.0,
1104,99544,4,3,,104234169,126941,Active,,,0.00018,IC50,Inhibitory activity against thymidylate synthase in Lactobacillus casei was determined (glutamate residue 4),Confirmatory,2447278.0,
1105,99545,4,3,,104234169,126941,Active,,,0.00028,IC50,Inhibitory activity against thymidylate synthase in Lactobacillus casei was determined (glutamate residue 5),Confirmatory,2447278.0,
1106,99546,4,3,,104234169,126941,Active,,,0.00028,IC50,Inhibitory activity against thymidylate synthase in Lactobacillus casei was determined (glutamate residue 6),Confirmatory,2447278.0,
1107,99548,4,3,,104234169,126941,Active,,,5e-05,IC50,Tested for growth inhibition of Lactobacillus casei (ATCC 7649),Confirmatory,3121855.0,
1108,99549,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for 50% inhibition of the growth of Lactobacillus casei ATCC 7469 strain at folate concentration 1 ng/mL,Other,6699882.0,
1109,99550,4,2,,104234169,126941,Unspecified,,,,,Compound was evaluated for 50% inhibition of the growth of Lactobacillus casei MTX resistant strain at folate concentration 1 ng/mL,Other,6699882.0,
1110,99556,8,2,,104234169,126941,Unspecified,,,,,Compound was evaluated for inhibitory effect on growth of Lactobacillus casei ATCC 7469,Other,2423690.0,
1111,99557,8,2,,104234169,126941,Unspecified,,,,,Compound was evaluated for inhibitory effect on growth of Lactobacillus casei MTX resistant,Other,2423690.0,
1112,99654,3,4,,104234169,126941,Unspecified,,,,,Compound was tested in vitro for concentration required to decrease 50% growth rate of murine leukemia L5178Y/R cell culture,Other,7057421.0,
1113,99881,6,1,,104234169,126941,Unspecified,,,,,Mean survival of mice infected with L1210 leukemia after an intraperitoneal dose of 4 mg/kg for 9 days,Other,2898531.0,
1114,100184,3,5,,104234169,126941,Unspecified,,,,,Mean change in weight of mice infected with L1210 leukemia after 7 days after an intraperitoneal dose of 4 mg/kg,Other,2898531.0,
1115,100302,4,4,,104234169,126941,Unspecified,,,,,Compound was evaluated for transport properties against L1210 cells for efflux,Other,3712374.0,
1116,100304,3,4,,104234169,126941,Unspecified,,,,,Efflux characteristics in the L1210 cells was evaluated,Other,3184124.0,
1117,100305,3,4,,104234169,126941,Unspecified,,,,,k value for its transport after efflux through L1210 cells,Other,1732551.0,
1118,100308,3,4,,104234169,126941,Unspecified,,,,,Cross resistance to the compound expressed as as log of ratio of molar concentration of drug inducing 50% inhibition of growth in murine leukemia L1210/R71 and L1210/0 cells,Other,2362268.0,
1119,100337,6,2,,104234169,126941,Unspecified,,,220.0,IC50,Compound was tested for its inhibitory concentration to inhibit the growth of wild type L1210 cells and a subline (L1210 / R81).,Confirmatory,3462394.0,
1120,100447,6,2,,104234169,126941,Active,,,0.002,IC50,Compound was tested for its inhibitory concentration to inhibit the growth of wild type L1210 cells.,Confirmatory,3462394.0,
1121,100450,6,2,,104234169,126941,Active,,,0.03,IC50,Compound was tested for its inhibitory concentration to inhibit the growth of wild type L1210 cells; Range=0.01 to 0.03,Confirmatory,3462394.0,
1122,100470,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity against L1210 leukemia in 19 mice measured as Increased life span.,Other,6620303.0,
1123,100471,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity against L1210 leukemia in 23 mice measured as Increased life span.,Other,6620303.0,
1124,100478,3,4,,104234169,126941,Unspecified,,,,,In vivo anti tumor activity against L1210 leukemia in 19 mice measured as median survival range at 60 mg/kg; Value ranges from(9-28),Other,6620303.0,
1125,100479,3,4,,104234169,126941,Unspecified,,,,,In vivo anti tumor activity against L1210 leukemia in 23 mice measured as median survival range at 30 mg/kg; Value ranges from(14-23).,Other,6620303.0,
1126,100605,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity against L1210 leukemia in 17 mice measured as T/C values(days); T/C = 17/9,Other,6620303.0,
1127,100606,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity against L1210 leukemia in 18 mice measured as T/C values(days); T/C = 18/9,Other,6620303.0,
1128,100658,6,2,,104234169,126941,Active,,,0.009000000000000001,IC50,Inhibition of cell growth against L1210 murine leukemia cells,Confirmatory,2918496.0,
1129,100659,8,1,,104234169,126941,Active,,,0.012,ID50,Compound was evaluated for its cytotoxicity against the L1210 murine leukemia cell culture,Confirmatory,6546949.0,
1130,100663,3,4,,104234169,126941,Unspecified,,,,,Percent increase in life span was measured against L1210 murine leukemia cells at the dose of 1.3 mg/kg,Other,7057425.0,
1131,100698,4,4,,104234169,126941,Active,,,0.026000000000000002,IC50,The IC50 value was measured on LOX IMVI cell line in melanoma tumor ty,Confirmatory,9022795.0,
1132,101008,4,4,,104234169,126941,Active,,,0.026000000000000002,IC50,Compound was evaluated for in vitro activity against LOXIMV1 Melanoma cell lines (Human tumor cells ),Confirmatory,9857098.0,
1133,101020,5,2,,104234169,126941,Active,,,1.0,EC50,Growth inhibition against Leishmania major promastigotes in culture,Confirmatory,3599028.0,
1134,101084,6,2,,104234169,126941,Active,,,0.0039,IC50,Tested for growth inhibition of L1210 leukemia cells,Confirmatory,3121855.0,
1135,101709,6,2,,104234169,126941,Unspecified,,,,,Concentration (10 ug/mL) of hydrazone-linked conjugate of MTX and Dal K-20 recquires to reduces the colony formation of melanoma M21 cells,Other,2810330.0,
1136,101710,6,2,,104234169,126941,Unspecified,,,,,Concentration (10 ug/mL) of amide-linked conjugate of MTX and Dal K-20 requires to reduces the colony formation of melanoma M21 cells,Other,2810330.0,
1137,101711,6,2,,104234169,126941,Unspecified,,,,,Concentration (10 ug/mL) of amide-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells,Other,2810330.0,
1138,101712,6,2,,104234169,126941,Unspecified,,,,,Concentration (10 ug/mL) of hydrazone-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells,Other,2810330.0,
1139,101713,6,2,,104234169,126941,Unspecified,,,,,Concentration (15 ug/mL) of hydrazone-linked conjugate of MTX and Dal K-20 recquires to reduces the colony formation of melanoma M21 cells,Other,2810330.0,
1140,101714,6,2,,104234169,126941,Unspecified,,,,,Concentration (15 ug/mL) of amide-linked conjugate of MTX and Dal K-20 requires to reduces the colony formation of melanoma M21 cells,Other,2810330.0,
1141,101715,6,2,,104234169,126941,Unspecified,,,,,Concentration (15 ug/mL) of amide-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells,Other,2810330.0,
1142,101716,6,2,,104234169,126941,Unspecified,,,,,Concentration (15 ug/mL) of hydrazone-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells,Other,2810330.0,
1143,101717,6,2,,104234169,126941,Unspecified,,,,,Concentration (20 ug/mL) of hydrazone-linked conjugate of MTX and Dal K-20 recquires to reduces the colony formation of melanoma M21 cells,Other,2810330.0,
1144,101718,6,2,,104234169,126941,Unspecified,,,,,Concentration (20 ug/mL) of amide-linked conjugate of MTX and Dal K-20 requires to reduces the colony formation of melanoma M21 cells,Other,2810330.0,
1145,101719,6,2,,104234169,126941,Unspecified,,,,,Concentration (20 ug/mL) of amide-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells,Other,2810330.0,
1146,101720,6,2,,104234169,126941,Unspecified,,,,,Concentration (20 ug/mL) of hydrazone-linked conjugate (regiospecific coupling) of MTX and Dal K-20 required to reduce the colony formation of melanoma M21 cells,Other,2810330.0,
1147,102163,4,5,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against MDA-MB-435 breast cancer cell lines (Human tumor cells ),Confirmatory,9857098.0,
1148,102264,5,4,,104234169,126941,Unspecified,,,,,In vitro effect on 10-formyldihydrofolate (10-CHO-DHF) in MCF-7 cells at 1 uM(control= 0.2); Folate pools,Other,1375963.0,
1149,102265,5,4,,104234169,126941,Unspecified,,,,,In vitro effect on 10-formylfolic acid (10-CHO-FA) in MCF-7 cells at 1 uM(control= 0.1); Folate pools,Other,1375963.0,
1150,102266,5,4,,104234169,126941,Unspecified,,,,,In vitro effect on 10-formyltetrahydrofolate (10-CHO-THF) in MCF-7 cells at 1 uM(control= 1.7); Folate pools,Other,1375963.0,
1151,102267,5,4,,104234169,126941,Unspecified,,,,,In vitro effect on 5-formyltetrahydrofolate (5-CHO-THF) in MCF-7 cells at 1 uM(control= 0.1); Folate pools,Other,1375963.0,
1152,102268,5,4,,104234169,126941,Unspecified,,,,,In vitro effect on 5-methyltetrahydrofolate (5-CH3-THF) in MCF-7 cells at 1 uM(control= 0.7); Folate pools,Other,1375963.0,
1153,102269,5,4,,104234169,126941,Unspecified,,,,,In vitro effect on dihydrofolate (DHF) in MCF-7 cells at 1 uM(control= 0.2); Folate pools,Other,1375963.0,
1154,102270,5,4,,104234169,126941,Unspecified,,,,,In vitro effect on folic acid (FA) in MCF-7 cells at 1 uM(control= 0.0); Folate pools,Other,1375963.0,
1155,102271,5,4,,104234169,126941,Unspecified,,,,,In vitro effect on tetrahydrofolate (THF) in MCF-7 cells at 1 uM(control= 1.0); Folate pools,Other,1375963.0,
1156,102272,5,4,,104234169,126941,Unspecified,,,,,In vitro effect on total folates in MCF-7 cells at 1 uM(control= 4.0); Folate pools,Other,1375963.0,
1157,102548,4,4,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against MALME-3M Melanoma cell lines (Human tumor cells ),Confirmatory,9857098.0,
1158,102549,4,4,,104234169,126941,Unspecified,,,1.0,IC50,The IC50 value was measured on MALME-3M cell line in melanoma tumor type,Confirmatory,9022795.0,
1159,103413,4,4,,104234169,126941,Active,,,0.036000000000000004,IC50,Compound was evaluated for in vitro activity against MCF-7 breast cancer cell lines (Human tumor cells ),Confirmatory,9857098.0,
1160,103582,4,4,,104234169,126941,Active,,,0.036000000000000004,IC50,The IC50 value was measured on MCF-7 cell line in breast tumor type,Confirmatory,9022795.0,
1161,103763,4,5,,104234169,126941,Active,,,0.078,IC50,The IC50 value was measured on MCF7-ADR cell line in breast tumor type.,Confirmatory,9022795.0,
1162,104212,4,4,,104234169,126941,Active,,,0.032,IC50,Compound was evaluated for in vitro activity against M14 Melanoma cell lines (Human tumor cells ),Confirmatory,9857098.0,
1163,105115,6,1,,104234169,126941,Active,,,0.048,IC50,Compound was tested for its anticancer activity against human T-lymphocytic leukemia MOLT-4 cells.,Confirmatory,,
1164,105293,4,4,,104234169,126941,Active,,,0.027999999999999997,IC50,Compound was evaluated for in vitro activity against MOLT-4 leukemia cell lines (Human tumor cells ),Confirmatory,9857098.0,
1165,105505,6,2,,104234169,126941,Active,,,1.4,IC50,Compound was evaluated for inhibition of MTX influx into MOLT-4 cells,Confirmatory,1895294.0,
1166,105921,4,3,,104234169,126941,Active,,,0.675,EC50,Growth inhibition of MTX-resistant R1 sublines.,Confirmatory,10956221.0,
1167,105924,4,3,,104234169,126941,Active,,,1.6,EC50,Growth inhibition of MTX-resistant R2(Bos) sublines.,Confirmatory,10956221.0,
1168,105928,4,3,,104234169,126941,Active,,,0.013999999999999999,EC50,Growth inhibition of MTX-resistant R30dm sublines.,Confirmatory,10956221.0,
1169,108523,3,5,,104234169,126941,Unspecified,,,,,"Inoculation of 10 e5 L1210 cells, ip, on day 0, & treatment was started on day 1 with the administration of the compound, ip, in groups of five B6D2F1J male mice at dose 0.5 mg/kg",Other,6737432.0,
1170,108527,3,5,,104234169,126941,Unspecified,,,,,"Inoculation of 10 e5 L1210 cells, ip, on day 0, & treatment was started on day1 with the administration of the compound, ip, in groups of five B6D2F1J male mice at dose 1 mg/kg",Other,6737432.0,
1171,110838,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring percent increase in life span after intraperitoneal administration of compound at 0.5 mg/kg,Other,6546949.0,
1172,110839,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring percent increase in life span after intraperitoneal administration of compound at 0.75 mg/kg,Other,6546949.0,
1173,110842,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring percent increase in life span after intraperitoneal administration of compound at 1 mg/kg,Other,6546949.0,
1174,110893,3,3,,104234169,126941,Unspecified,,,,,Average weight of the mouse after treating with 15 mg/kg dose for 1 day.,Other,6620303.0,
1175,110901,3,3,,104234169,126941,Unspecified,,,,,Average weight of the mouse after treating with 30 mg/kg dose for 1 day.,Other,6620303.0,
1176,110908,3,3,,104234169,126941,Unspecified,,,,,Average weight of the mouse after treating with 60 mg/kg dose for 1 day.,Other,6620303.0,
1177,112601,3,3,,104234169,126941,Unspecified,,,,,1Percentage increase in life span after 12-15 days,Other,6139480.0,
1178,114602,6,3,,104234169,126941,Active,,,1.57,IC50,Inhibitory growth of EL4 thymoma cell line from C57BL/6 mice,Confirmatory,9379448.0,
1179,115261,4,3,,104234169,126941,Unspecified,,,,,secondary antibody response in mice at 0.625 mg/kg,Other,9379448.0,
1180,115262,4,3,,104234169,126941,Unspecified,,,,,secondary antibody response in mice at 1.25 mg/kg,Other,9379448.0,
1181,115645,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for antitumor activity against L1210 leukemia in mice and percent increase in life span was determined.,Other,6699882.0,
1182,116302,3,4,,104234169,126941,Unspecified,,,,,"Inoculation of 10 e5 L1210 cells, ip, on day 0, & treatment was started on day 1 with the administration of the compound, ip, in groups of five B6D2F1J male mice at dose 1.0 mg/kg",Other,6737432.0,
1183,116303,3,4,,104234169,126941,Unspecified,,,,,"Inoculation of 10 e5 L1210 cells, ip, on day 0, & treatment was started on day1 with the administration of the compound, ip, in groups of five B6D2F1J male mice at dose 0.5 mg/kg",Other,6737432.0,
1184,116572,6,1,,104234169,126941,Unspecified,,,,,Compound was evaluated for antitumor activity against L1210 leukemia in mice and median survival time was determined at ten animals per run.,Other,6699882.0,
1185,116708,3,4,,104234169,126941,Unspecified,,,,,Compound was evaluated for antitumor activity against L1210 leukemia in mice and LD10 was determined 24 hour after subcutaneous administration in 10 E 6 cells implanted intraperitoneally.,Other,6699882.0,
1186,117322,3,3,,104234169,126941,Unspecified,,,,,Percentage increase in life span after 11-22 days,Other,6139480.0,
1187,117324,3,3,,104234169,126941,Unspecified,,,,,Percentage increase in life span after 12-19 days,Other,6139480.0,
1188,117330,4,3,,104234169,126941,Unspecified,,,,,Percentage increase in life span after 14-18d ays,Other,6139480.0,
1189,117332,4,3,,104234169,126941,Unspecified,,,,,Percentage increase in life span after 15-17 days,Other,6139480.0,
1190,117336,3,3,,104234169,126941,Unspecified,,,,,Percentage increase in life span after 17-22 days,Other,6139480.0,
1191,118163,3,4,,104234169,126941,Unspecified,,,,,In vitro anti-folate activity and plasma clearance of folate analogue in mice was reported after 0.2 h,Other,7108907.0,
1192,118164,3,4,,104234169,126941,Unspecified,,,,,In vitro anti-folate activity and plasma clearance of folate analogue in mice was reported after 1.0 h,Other,7108907.0,
1193,118165,3,4,,104234169,126941,Unspecified,,,,,In vitro anti-folate activity and plasma clearance of folate analogue in mice was reported after 16 h,Other,7108907.0,
1194,118166,3,4,,104234169,126941,Unspecified,,,,,In vitro anti-folate activity and plasma clearance of folate analogue in mice was reported after 2 h,Other,7108907.0,
1195,118167,3,4,,104234169,126941,Unspecified,,,,,In vitro anti-folate activity and plasma clearance of folate analogue in mice was reported after 24 h,Other,7108907.0,
1196,118168,3,4,,104234169,126941,Unspecified,,,,,In vitro anti-folate activity and plasma clearance of folate analogue in mice was reported after 4 h,Other,7108907.0,
1197,118169,3,4,,104234169,126941,Unspecified,,,,,In vitro anti-folate activity and plasma clearance of folate analogue in mice was reported after 7 h,Other,7108907.0,
1198,119893,4,3,,104234169,126941,Unspecified,,,,,Compound dose suppressing antibody production by 75% in mice,Other,9379448.0,
1199,120315,3,5,,104234169,126941,Unspecified,,,,,Number of M5076 reticulum cell sarcoma bearing mice survived among the tested (5) on day 24 after treating with compound dose of 3.125 mg/Kg/day,Other,9301666.0,
1200,120896,3,3,,104234169,126941,Unspecified,,,,,Ratio of tumor volume of test(T) animals compared to control(C) animals x 100T/C(%)] at a dose of 3.125 mg/kg/day of compound,Other,2810335.0,
1201,120948,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring T/C median after intraperitoneal administration of compound at 0.5 mg/kg; T/C median=16/9,Other,6546949.0,
1202,120949,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring T/C median after intraperitoneal administration of compound at 0.75 mg/kg; T/C median=18/9,Other,6546949.0,
1203,120955,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring T/C median after intraperitoneal administration of compound at 1 mg/kg; T/C median=21/9,Other,6546949.0,
1204,121088,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring number of survival days after intraperitoneal administration of compound at 0.5 mg/kg; at a range of 15-18,Other,6546949.0,
1205,121089,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring number of survival days after intraperitoneal administration of compound at 0.75 mg/kg; at a range of 16-21,Other,6546949.0,
1206,121094,3,4,,104234169,126941,Unspecified,,,,,In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring number of survival days after intraperitoneal administration of compound at 1 mg/kg; at a range of 3-22,Other,6546949.0,
1207,121360,3,3,,104234169,126941,Unspecified,,,,,Toxicity in mice after 11-22 days at a dose of 6 mg/kg/day; value is 21/9,Other,6139480.0,
1208,121361,3,3,,104234169,126941,Unspecified,,,,,Toxicity in mice after 12-15 days at a dose of 0.25 mg/kg/day; value is 13/8,Other,6139480.0,
1209,121364,3,3,,104234169,126941,Unspecified,,,,,Toxicity in mice after 12-19 days at a dose of 4 mg/kg/day; value is 17/9,Other,6139480.0,
1210,121371,3,3,,104234169,126941,Unspecified,,,,,Toxicity in mice after 14-18 days at a dose of 10 mg/kg/day; value is 17/9,Other,6139480.0,
1211,121372,3,3,,104234169,126941,Unspecified,,,,,Toxicity in mice after 14-18 days at a dose of 2 mg/kg/day; value is 16/9,Other,6139480.0,
1212,121374,3,3,,104234169,126941,Unspecified,,,,,Toxicity in mice after 15-17 days at a dose of 0.5 mg/kg/day; value is 16/8,Other,6139480.0,
1213,121375,3,3,,104234169,126941,Unspecified,,,,,Toxicity in mice after 15-17 days at a dose of 0.75 mg/kg/day; value is 17/8,Other,6139480.0,
1214,121380,3,3,,104234169,126941,Unspecified,,,,,Toxicity in mice after 17-22 days at a dose of; value is 20/9,Other,6139480.0,
1215,122031,6,1,,104234169,126941,Unspecified,,,,,Tumor growth delay of subcutaneously implanted SCC-VII squamous cell carcinoma in mice at 0.75 mg/kg/day,Other,9022795.0,
1216,122087,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity expressed as a ratio of tumor volumes of test (T) animals compared to control (C) animals(100) at a dose of 3.125 mg/kg/day,Other,9301666.0,
1217,122344,3,6,,104234169,126941,Unspecified,,,,,"In vivo activity (survivors) at optimal dose of 4 mg/kg, by intraperitoneal administration in BDF1 mice against L1210 leukemia cells; survivors of rat given as 0/10",Other,4009615.0,
1218,122417,3,4,,104234169,126941,Unspecified,,,,,"Inoculation of 10 e5 L1210 cells, ip, on day 0, & treatment was started on day 1 with the administration of the compound, ip, in groups of five B6D2F1J male mice at dose 1.0 mg/kg; T=19; C=9",Other,6737432.0,
1219,122418,3,4,,104234169,126941,Unspecified,,,,,"Inoculation of 10 e5 L1210 cells, ip, on day 0, & treatment was started on day 1 with the administration of the compound, ip, in groups of five B6D2F1J male mice at dose 0.5 mg/kg; T =18; C=9",Other,6737432.0,
1220,122487,6,1,,104234169,126941,Unspecified,,,,,Time to reach 10 mm Tumor size of subcutaneously implanted SCC-VII squamous cell carcinoma in mice at 0.75 mg/kg/day,Other,9022795.0,
1221,122634,3,4,,104234169,126941,Unspecified,,,,,Weight change on day 7 in L1210 Lymphoid Leukemia in mice at a dose of 0.25 mg/kg/day (b.i.d. x10),Other,6139480.0,
1222,122635,3,4,,104234169,126941,Unspecified,,,,,Weight change on day 7 in L1210 Lymphoid Leukemia in mice at a dose of 0.5 mg/kg/day (b.i.d. x10),Other,6139480.0,
1223,122636,3,4,,104234169,126941,Unspecified,,,,,Weight change on day 7 in L1210 Lymphoid Leukemia in mice at a dose of 0.75 mg/kg/day (b.i.d. x10),Other,6139480.0,
1224,122637,3,4,,104234169,126941,Unspecified,,,,,Weight change on day 7 in L1210 Lymphoid Leukemia in mice at a dose of 10 mg/kg/day (qd x5),Other,6139480.0,
1225,122641,3,4,,104234169,126941,Unspecified,,,,,Weight change on day 7 in L1210 Lymphoid Leukemia in mice at a dose of 15 mg/kg/day (qd x5),Other,6139480.0,
1226,122647,3,4,,104234169,126941,Unspecified,,,,,Weight change on day 7 in L1210 Lymphoid Leukemia in mice at a dose of 2 mg/kg/day (qdx9),Other,6139480.0,
1227,122767,3,4,,104234169,126941,Unspecified,,,,,Weight change on day 7 in L1210 Lymphoid Leukemia in mice at a dose of 4 mg/kg/day (qdX9),Other,6139480.0,
1228,122770,3,4,,104234169,126941,Unspecified,,,,,Weight change on day 7 in L1210 Lymphoid Leukemia in mice at a dose of 6 mg/kg/day (qdX9),Other,6139480.0,
1229,123694,6,1,,104234169,126941,Unspecified,,,,,Tumor volume in 12 days after tumor implantation at a dose of 3.125 mg/kg/day of compound,Other,2810335.0,
1230,123696,6,1,,104234169,126941,Unspecified,,,,,Tumor volume in 12 days after tumor implantation at a dose of 6.25 mg/kg/day of compound,Other,2810335.0,
1231,123698,6,1,,104234169,126941,Unspecified,,,,,Tumor volume in 16 days after tumor implantation at a dose of 3.125 mg/kg/day of compound,Other,2810335.0,
1232,123700,6,1,,104234169,126941,Unspecified,,,,,Tumor volume in 16 days after tumor implantation at a dose of 6.25 mg/kg/day of compound,Other,2810335.0,
1233,123701,6,1,,104234169,126941,Unspecified,,,,,Tumor volume in 20 days after tumor implantation at a dose of 3.125 mg/kg/day of compound,Other,2810335.0,
1234,123703,5,2,,104234169,126941,Unspecified,,,,,Tumor volume in 20 days after tumor implantation at a dose of 6.25 mg/kg/day of compound; Found to be dead,Other,2810335.0,
1235,123704,6,1,,104234169,126941,Unspecified,,,,,Tumor volume in 24 days after tumor implantation at a dose of 3.125 mg/kg/day of compound,Other,2810335.0,
1236,123852,3,3,,104234169,126941,Unspecified,,,,,Tumor size of subcutaneously implanted SCC-VII squamous cell carcinoma in mice at 0.75 mg/kg/day on day 0,Other,9022795.0,
1237,123853,3,3,,104234169,126941,Unspecified,,,,,Tumor size of subcutaneously implanted SCC-VII squamous cell carcinoma in mice at 0.75 mg/kg/day on day 7,Other,9022795.0,
1238,124149,3,5,,104234169,126941,Unspecified,,,,,"Inoculation of 10 e5 L1210 cells, ip, on day 0, & treatment was started on day 1 with the administration of the compound, ip, in groups of five B6D2F1J male mice at dose 0.5 mg/kg; 14-20",Other,6737432.0,
1239,124150,3,5,,104234169,126941,Unspecified,,,,,"Inoculation of 10 e5 L1210 cells, ip, on day 0, & treatment was started on day 1 with the administration of the compound, ip, in groups of five B6D2F1J male mice at dose 1.0 mg/kg; 17-22",Other,6737432.0,
1240,124361,3,4,,104234169,126941,Unspecified,,,,,Average weight of the mouse after treating with 15 mg/kg dose for 7 days.,Other,6620303.0,
1241,124433,3,3,,104234169,126941,Unspecified,,,,,secondary antibody response in mice at 2.5 mg/kg,Other,9379448.0,
1242,124485,3,4,,104234169,126941,Unspecified,,,,,Average weight of the mouse after treating with 30 mg/kg dose for 7 days.,Other,6620303.0,
1243,124491,3,4,,104234169,126941,Unspecified,,,,,Average weight of the mouse after treating with 60 mg/kg dose for 7 days.,Other,6620303.0,
1244,124658,3,5,,104234169,126941,Unspecified,,,,,In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring 7-day weight change after intraperitoneal administration of compound at 0.5 mg/kg,Other,6546949.0,
1245,124659,3,5,,104234169,126941,Unspecified,,,,,In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring 7-day weight change after intraperitoneal administration of compound at 0.75 mg/kg,Other,6546949.0,
1246,124661,3,5,,104234169,126941,Unspecified,,,,,In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring 7-day weight change after intraperitoneal administration of compound at 1 mg/kg,Other,6546949.0,
1247,124665,3,4,,104234169,126941,Unspecified,,,,,Mean of weight gain from day 0 to day 24 at a dose of 3.125 mg/kg/day of compound,Other,2810335.0,
1248,125603,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 12 mg/kg out of 10 mice tested,Other,3712374.0,
1249,125608,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 18 mg/kg out of 10 mice tested,Other,3712374.0,
1250,125609,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 24 mg/kg out of 10 mice tested,Other,3712374.0,
1251,125614,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 9 mg/kg out of 10 mice tested,Other,3712374.0,
1252,125914,3,3,,104234169,126941,Unspecified,,,,,Antitumor effect (3 mg/kg) against EO771 mammary adenocarcinoma in mice measured as Average weight change on day 14.,Other,1732551.0,
1253,125915,3,3,,104234169,126941,Unspecified,,,,,Antitumor effect (3 mg/kg) against EO771 mammary adenocarcinoma in mice measured as Average weight change on day 7.,Other,1732551.0,
1254,129339,3,3,,104234169,126941,Unspecified,,,,,Incidence of disease (mouse type II collagen) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 23 at intraperitoneal dose of 9 mg/kg,Other,9022805.0,
1255,129496,3,3,,104234169,126941,Unspecified,,,,,Incidence of disease (mouse type II collagen) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 30 at intraperitoneal dose of 9 mg/kg,Other,9022805.0,
1256,129651,3,3,,104234169,126941,Unspecified,,,,,Incidence of disease (mouse type II collagen) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 37 at intraperitoneal dose of 9 mg/kg,Other,9022805.0,
1257,129828,3,3,,104234169,126941,Unspecified,,,,,Incidence of disease (mouse type II collagen) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 44 at intraperitoneal dose of 9 mg/kg,Other,9022805.0,
1258,129834,3,3,,104234169,126941,Unspecified,,,,,Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 23 at intraperitoneal dose of 12 mg/kg,Other,9022804.0,
1259,129842,3,3,,104234169,126941,Unspecified,,,,,Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 23 at intraperitoneal dose of 9 mg/kg,Other,9022804.0,
1260,129846,3,3,,104234169,126941,Unspecified,,,,,Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 30 at intraperitoneal of dose 12 mg/kg,Other,9022804.0,
1261,129988,3,3,,104234169,126941,Unspecified,,,,,Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 30 at intraperitoneal of dose 9 mg/kg,Other,9022804.0,
1262,129992,3,3,,104234169,126941,Unspecified,,,,,Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 37 at intraperitoneal of dose 12 mg/kg (1 animal died),Other,9022804.0,
1263,130000,3,3,,104234169,126941,Unspecified,,,,,Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 37 at intraperitoneal of dose 9 mg/kg,Other,9022804.0,
1264,130011,3,3,,104234169,126941,Unspecified,,,,,Incidence of disease(mouse type II collagen arthritis) was scored as the percentage of animals within each experimental group that exhibited joint or limb inflammation on day 44 at intraperitoneal of dose 9 mg/kg,Other,9022804.0,
1265,130012,3,3,,104234169,126941,Unspecified,,,,,Incidence of disease(mouse type II collagen arthritis)was scored as the % of animals within each experimental group that exhibited joint or limb inflammation on day 44 at intraperitoneal of dose 12 mg/kg,Other,9022804.0,
1266,130980,3,3,,104234169,126941,Unspecified,,,,,Antitumor activity in mice with L1210 Leukemia and percentage increase in life span was reported for 5 mice x 12 experiments at a dose of 15 mg/Kg,Other,4020824.0,
1267,130994,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 12 mg/kg,Other,3712374.0,
1268,130996,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 18 mg/kg,Other,3712374.0,
1269,131129,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 24 mg/kg,Other,3712374.0,
1270,131132,4,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 9 mg/kg,Other,3712374.0,
1271,132336,4,3,,104234169,126941,Active,,,0.00328,IC50,Antitumor activity against L1210 cell in mice,Confirmatory,4020824.0,
1272,132830,4,4,,104234169,126941,Active,,,0.031,IC50,Inhibitory concentration of compound was tested against Colon 26 tumor growth cell line,Confirmatory,8201595.0,
1273,133456,6,1,,104234169,126941,Unspecified,,,,,Antitumor activity in mice with L1210 Leukemia and maximal survival time (MST) in days was reported for 5 mice x 12 experiments at a dose of 15 mg/Kg.,Other,4020824.0,
1274,133574,6,1,,104234169,126941,Unspecified,,,,,Compound was evaluated for antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 12 mg/kg,Other,3712374.0,
1275,133575,6,1,,104234169,126941,Unspecified,,,,,Compound was evaluated for antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 18 mg/kg,Other,3712374.0,
1276,133577,6,1,,104234169,126941,Unspecified,,,,,Compound was evaluated for antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 24 mg/kg,Other,3712374.0,
1277,133578,7,1,,104234169,126941,Unspecified,,,,,Compound was evaluated for antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 9 mg/kg,Other,3712374.0,
1278,134195,4,1,,104234169,126941,Unspecified,,,,,Dissociation constant towards mouse DHFR mutant hF31S,Other,8627598.0,
1279,134198,4,2,,104234169,126941,Unspecified,,,,,Dissociation constant towards mouse wild type DHFR; no data,Other,8627598.0,
1280,134212,4,1,,104234169,126941,Unspecified,,,,,Binding affinity towards mouse DHFR mutant hF31S,Other,8627598.0,
1281,134213,4,1,,104234169,126941,Unspecified,,,,,Binding affinity towards mouse wild type DHFR,Other,8627598.0,
1282,134218,6,2,,104234169,126941,Active,,,4.2,Ki,Transport influx which is determined by competitive binding for the transport protein; expressed as Ki (uM),Confirmatory,8340923.0,
1283,134664,3,3,,104234169,126941,Unspecified,,,,,Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling of all animals in each group on day 23 at intraperitoneal dose of 9 mg/kg,Other,9022805.0,
1284,134814,3,3,,104234169,126941,Unspecified,,,,,Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling of all animals in each group on day 30 at intraperitoneal dose of 9 mg/kg,Other,9022805.0,
1285,134834,3,3,,104234169,126941,Unspecified,,,,,Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling of all animals in each group on day 37 at intraperitoneal dose of 9 mg/kg,Other,9022805.0,
1286,134992,3,3,,104234169,126941,Unspecified,,,,,Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling of all animals in each group on day 44 at intraperitoneal dose of 9 mg/kg,Other,9022805.0,
1287,134998,3,3,,104234169,126941,Unspecified,,,,,Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 23 at intraperitoneal dose of 12 mg/kg (1 animal died),Other,9022804.0,
1288,135008,3,3,,104234169,126941,Unspecified,,,,,Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 23 at intraperitoneal dose of 9 mg/kg,Other,9022804.0,
1289,135013,3,3,,104234169,126941,Unspecified,,,,,Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 30 at intraperitoneal dose of 12 mg/kg (1 animal died),Other,9022804.0,
1290,135154,3,3,,104234169,126941,Unspecified,,,,,Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 30 at intraperitoneal dose of 9 mg/kg,Other,9022804.0,
1291,135159,3,3,,104234169,126941,Unspecified,,,,,Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 37 at intraperitoneal dose of 12 mg/kg (1 animal died),Other,9022804.0,
1292,135169,3,3,,104234169,126941,Unspecified,,,,,Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 37 at intraperitoneal dose of 9 mg/kg,Other,9022804.0,
1293,135173,3,3,,104234169,126941,Unspecified,,,,,Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 44 at intraperitoneal dose of 12 mg/kg (1 animal died),Other,9022804.0,
1294,135321,3,3,,104234169,126941,Unspecified,,,,,Tested for antiinflammatory activity on mouse type II collagen arthritis as Paw swelling* of all animals in each group on day 44 at intraperitoneal dose of 9 mg/kg,Other,9022804.0,
1295,135697,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for the activity against Colon 26 Mouse colorectal carcinoma in mice by tumor weight assay at 10 (mg/kg) dose,Other,8201595.0,
1296,135699,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for the activity against Colon 26 Mouse colorectal carcinoma in mice by tumor weight assay at 20 (mg/kg) dose,Other,8201595.0,
1297,135701,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for the activity against Colon 26 Mouse colorectal carcinoma in mice by tumor weight assay at 50 (mg/kg) dose,Other,8201595.0,
1298,135703,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for the activity against LC-6 Non-Small cell lung carcinoma in mice by tumor weight assay at 10 (mg/kg) dose,Other,8201595.0,
1299,135708,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for the activity against LC-6 Non-Small cell lung carcinoma in mice by tumor weight assay at 20 (mg/kg) dose,Other,8201595.0,
1300,135849,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for the activity against LC-6 Non-Small cell lung carcinoma in mice by tumor weight assay at 40 (mg/kg) dose,Other,8201595.0,
1301,135868,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for the life span assay against P388 Leukemia in mice (Controls died in an average of 9.8 days) at 0.78 (mg/kg) dose,Other,8201595.0,
1302,135869,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for the life span assay against P388 Leukemia in mice (Controls died in an average of 9.8 days) at 1.56 (mg/kg) dose,Other,8201595.0,
1303,135870,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for the life span assay against P388 Leukemia in mice (Controls died in an average of 9.8 days) at 12.5 (mg/kg) dose,Other,8201595.0,
1304,135873,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for the life span assay against P388 Leukemia in mice (Controls died in an average of 9.8 days) at 6.25 (mg/kg) dose,Other,8201595.0,
1305,135874,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for the life span assay and the activity against P388 Leukemia in mice (Controls died in an average of 9.8 days) at 3.13 (mg/kg) dose,Other,8201595.0,
1306,136004,4,3,,104234169,126941,Unspecified,,,,,Number of survivors treated on day 24 at a dose of 3.125 mg/kg/day of compound expressed as ratio of (test/control); 5/5,Other,2810335.0,
1307,136005,4,3,,104234169,126941,Unspecified,,,,,Number of survivors treated on day 24 at a dose of 6.25 mg/kg/day of compound expressed as ratio of (test/control); 0/5,Other,2810335.0,
1308,137516,3,3,,104234169,126941,Unspecified,,,,,Antitumor effect (3 mg/kg) against EO771 mammary adenocarcinoma in mice measured as T/C(treated/control) on day 14.,Other,1732551.0,
1309,137517,3,3,,104234169,126941,Unspecified,,,,,Antitumor effect (3 mg/kg) against EO771 mammary adenocarcinoma in mice measured as T/C(treated/control) on day 7.,Other,1732551.0,
1310,137535,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity against E0771 mammary adenocarcinoma in mice at 100 mg/kg(5 days) was determined and mean survival of treated group to control at day 14 was reported,Other,8277497.0,
1311,137673,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity against E0771 mammary adenocarcinoma in mice at 3 mg/kg(5 days) was determined and mean survival of treated group to control at day 10 was reported,Other,8277497.0,
1312,137675,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity against E0771 mammary adenocarcinoma in mice at 3 mg/kg(5 days) was determined and mean survival of treated group to control at day 7 was reported,Other,8277497.0,
1313,137676,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity against E0771 mammary adenocarcinoma in mice at 30 mg/kg(5 days) was determined and mean survival of treated group to control at day 14 was reported,Other,8277497.0,
1314,137677,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity against E0771 mammary adenocarcinoma in mice at 6 mg/kg(5 days) was determined and mean survival of treated group to control at day 10 was reported,Other,8277497.0,
1315,137679,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity against E0771 mammary adenocarcinoma in mice at 6 mg/kg(5 days) was determined and mean survival of treated group to control at day 7 was reported,Other,8277497.0,
1316,137877,3,3,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 3 mg/kg at 10 day post treatment point; Expressed as % T/C,Other,8340923.0,
1317,137878,3,3,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 3 mg/kg at 14 day post treatment point; Expressed as % T/C,Other,8340923.0,
1318,137879,3,3,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 3 mg/kg at 21 day post treatment point; Expressed as % T/C,Other,8340923.0,
1319,138015,3,3,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 6 mg/kg at 10 day post treatment point; Expressed as % T/C,Other,8340923.0,
1320,138016,3,3,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 6 mg/kg at 14 day post treatment point; Expressed as % T/C,Other,8340923.0,
1321,138017,3,3,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 6 mg/kg at 21 day post treatment point; Expressed as % T/C,Other,8340923.0,
1322,138018,3,3,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 9 mg/kg at 10 day post treatment point; Expressed as % T/C,Other,8340923.0,
1323,138019,3,3,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 9 mg/kg at 14 day post treatment point; Expressed as % T/C,Other,8340923.0,
1324,138020,3,3,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 9 mg/kg at 21 day post treatment point; Expressed as % T/C,Other,8340923.0,
1325,138950,3,3,,104234169,126941,Unspecified,,,,,Antitumor effect (3 mg/kg) against EO771 mammary adenocarcinoma in mice measured as toxic deaths out of 10 mice tested,Other,1732551.0,
1326,138963,3,3,,104234169,126941,Unspecified,,,,,Antitumor effect (3 mg/kg) against EO771 mammary adenocarcinoma in mice measured as Tumor free/total on day 14,Other,1732551.0,
1327,138964,3,3,,104234169,126941,Unspecified,,,,,Antitumor effect (3 mg/kg) against EO771 mammary adenocarcinoma in mice measured as Tumor free/total on day 7.,Other,1732551.0,
1328,139438,6,1,,104234169,126941,Unspecified,,,,,"Compound is evaluated for activity against L1210 leukemia in mice, at dose 15 mg/kg expressed as T/C=15.5/9",Other,6787199.0,
1329,139443,6,1,,104234169,126941,Unspecified,,,,,"Compound is evaluated for activity against L1210 leukemia in mice, at dose 30 mg/kg expressed as T/C=16.5/9",Other,6787199.0,
1330,139447,6,1,,104234169,126941,Unspecified,,,,,"Compound is evaluated for activity against L1210 leukemia in mice, at dose 60 mg/kg expressed as T/C=18/9",Other,6787199.0,
1331,139874,3,3,,104234169,126941,Unspecified,,,,,Antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 12 mg/kg out of 10 mice tested,Other,3712374.0,
1332,139877,3,3,,104234169,126941,Unspecified,,,,,Antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 18 mg/kg out of 10 mice tested,Other,3712374.0,
1333,139879,3,3,,104234169,126941,Unspecified,,,,,Antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 24 mg/kg out of 10 mice tested,Other,3712374.0,
1334,139884,3,3,,104234169,126941,Unspecified,,,,,Antitumor activity against L1210 leukemia in mice after subcutaneous administration (Q2Dx5) at a dose 9 mg/kg out of 10 mice tested,Other,3712374.0,
1335,139891,6,1,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 3 mg/kg at 10 day post treatment point,Other,8340923.0,
1336,139892,6,1,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 3 mg/kg at 14 day post treatment point,Other,8340923.0,
1337,139893,6,1,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 3 mg/kg at 21 day post treatment point,Other,8340923.0,
1338,139897,6,1,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 6 mg/kg at 10 day post treatment point,Other,8340923.0,
1339,139898,6,1,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 6 mg/kg at 14 day post treatment point,Other,8340923.0,
1340,139899,6,1,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 6 mg/kg at 21 day post treatment point,Other,8340923.0,
1341,139900,6,1,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 9 mg/kg at 10 day post treatment point,Other,8340923.0,
1342,139901,6,1,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 9 mg/kg at 14 day post treatment point,Other,8340923.0,
1343,139902,6,1,,104234169,126941,Unspecified,,,,,Average E0771 solid murine mammary tumor volume in BDF1 female mice (n=5) at 9 mg/kg at 21 day post treatment point,Other,8340923.0,
1344,140224,3,3,,104234169,126941,Unspecified,,,,,Antitumor effect (3 mg/kg) against EO771 mammary adenocarcinoma in mice measured as Toxic deaths/total on day 14.,Other,1732551.0,
1345,140660,6,1,,104234169,126941,Unspecified,,,,,Antitumor activity against E0771 mammary adenocarcinoma in mice at 100 mg/kg(5 days) was determined and tumor volume at day 14 was reported,Other,8277497.0,
1346,140671,6,1,,104234169,126941,Unspecified,,,,,Antitumor activity against E0771 mammary adenocarcinoma in mice at 3 mg/kg(5 days) was determined and tumor volume at day 10 was reported,Other,8277497.0,
1347,140673,6,1,,104234169,126941,Unspecified,,,,,Antitumor activity against E0771 mammary adenocarcinoma in mice at 3 mg/kg(5 days) was determined and tumor volume at day 7 was reported,Other,8277497.0,
1348,140674,6,1,,104234169,126941,Unspecified,,,,,Antitumor activity against E0771 mammary adenocarcinoma in mice at 30 mg/kg(5 days) was determined and tumor volume at day 14 was reported,Other,8277497.0,
1349,140675,6,1,,104234169,126941,Unspecified,,,,,Antitumor activity against E0771 mammary adenocarcinoma in mice at 6 mg/kg(5 days) was determined and tumor volume at day 10 was reported,Other,8277497.0,
1350,140677,6,1,,104234169,126941,Unspecified,,,,,Antitumor activity against E0771 mammary adenocarcinoma in mice at 6 mg/kg(5 days) was determined and tumor volume at day 7 was reported,Other,8277497.0,
1351,140846,3,4,,104234169,126941,Unspecified,,,,,Antitumor activity in mice with L1210 Leukemia and weight at termination of the therapy was reported for 5 mice x 12 experiments at a dose of 15 mg/kg.,Other,4020824.0,
1352,142307,6,1,,104234169,126941,Unspecified,,,,,Compound at a optimum dose level of 0.5 mg/kg was evaluated in vivo against Murine P388/0 resistant cells (1 X 10E6 ip implant),Other,2423690.0,
1353,142308,3,4,,104234169,126941,Unspecified,,,,,Compound at a optimum dose level of 0.5 mg/kg was evaluated in vivo against Murine P388/0 resistant cells (1 X 10E6 ip implant),Other,2423690.0,
1354,142310,6,1,,104234169,126941,Unspecified,,,,,Compound at a optimum dose level of 2 mg/kg was evaluated in vivo against Murine P388/MTX resistant cells (1 X 10E6 ip implant),Other,2423690.0,
1355,142311,3,4,,104234169,126941,Unspecified,,,,,Compound at a optimum dose level of 0.5 mg/kg was evaluated in vivo against Murine P388/0 resistant cells (1 X 10E6 ip implant),Other,2423690.0,
1356,143035,4,5,,104234169,126941,Active,,,0.027999999999999997,IC50,Compound was evaluated for in vitro activity against NCI-H460 lung cancer cell lines (Human tumor cells ),Confirmatory,9857098.0,
1357,143342,4,5,,104234169,126941,Active,,,0.45,IC50,Compound was evaluated for in vitro activity against NCI-H522 lung cancer cell lines (Human tumor cells ),Confirmatory,9857098.0,
1358,143498,4,5,,104234169,126941,Active,,,0.078,IC50,Compound was evaluated for in vitro activity against NCI/ADR-RES breast cancer cell lines (Human tumor cells ),Confirmatory,9857098.0,
1359,143514,4,4,,104234169,126941,Active,,,0.043,IC50,The IC50 value was measured on NCl-H23 cell line in NSCL tumor type.,Confirmatory,9022795.0,
1360,143515,4,4,,104234169,126941,Active,,,0.027999999999999997,IC50,The IC50 value was measured on NCl-H460 cell line in NSCL tumor type,Confirmatory,9022795.0,
1361,143516,4,4,,104234169,126941,Active,,,0.22899999999999998,IC50,The IC50 value was measured on NCl-H522 cell line in NSCL tumor type.,Confirmatory,9022795.0,
1362,144931,4,5,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against NCI-H226 lung cancer cell lines (Human tumor cells ),Confirmatory,9857098.0,
1363,145052,4,4,,104234169,126941,Active,,,0.043,IC50,Compound was evaluated for in vitro activity against NCI-H23 lung cancer cell lines (Human tumor cells ),Confirmatory,9857098.0,
1364,145433,4,4,,104234169,126941,Active,,,0.4,IC50,Compound was evaluated for in vitro activity against OVCAR-3 Ovary cell lines (Human tumor cells ),Confirmatory,9857098.0,
1365,145447,4,4,,104234169,126941,Active,,,0.39799999999999996,IC50,The IC50 value was measured on OVCAR-3 cell line in ovarian tumor t,Confirmatory,9022795.0,
1366,145596,4,4,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against OVCAR-4 Ovary cell lines (Human tumor cells ),Confirmatory,9857098.0,
1367,145737,4,4,,104234169,126941,Active,,,0.98,IC50,Compound was evaluated for in vitro activity against OVCAR-5 Ovary cell lines (Human tumor cells ),Confirmatory,9857098.0,
1368,145738,4,4,,104234169,126941,Unspecified,,,1.0,IC50,The IC50 value was measured on OVCAR-5 cell line in ovarian tumor type.,Confirmatory,9022795.0,
1369,145765,4,4,,104234169,126941,Active,,,0.031,IC50,Compound was evaluated for in vitro activity against OVCAR-8 Ovary cell lines (Human tumor cells ),Confirmatory,9857098.0,
1370,145768,4,4,,104234169,126941,Active,,,0.031,IC50,The IC50 value was measured on OVCAR-8 cell line in ovarian tumor type.,Confirmatory,9022795.0,
1371,147186,6,2,,104234169,126941,Unspecified,,,339.0,Km,In vitro membrane transport activity in neoplastic epithelial cells of rodent gut,Confirmatory,7108907.0,
1372,150668,4,4,,104234169,126941,Active,,,0.023,IC50,Inhibitory concentration of compound was tested against P388 tumor growth cell line,Confirmatory,8201595.0,
1373,150669,4,4,,104234169,126941,Active,,,0.223,IC50,Inhibitory concentration of compound was tested against P388:Methotrexate resistant cells tumor growth cell line,Confirmatory,8201595.0,
1374,154143,4,4,,104234169,126941,Active,,,0.0048,IC50,Cytotoxic activity was evaluated against P388D1 tumor cells,Confirmatory,8632413.0,
1375,155305,4,3,,104234169,126941,Active,,,0.024,IC50,In vitro growth inhibition of human peripheral blood mononuclear cells (hPBMC),Confirmatory,9016334.0,
1376,155939,4,2,,104234169,126941,Unspecified,,,,,Compound was evaluated for 50% inhibition of the growth of Pediococcus cerevisiae at folate concentration 1 ng/mL,Other,6699882.0,
1377,156177,4,4,,104234169,126941,Active,,,0.002,IC50,The IC50 value was measured on PC-3 cell line in prostate tumor type.,Confirmatory,9022795.0,
1378,156341,4,4,,104234169,126941,Active,,,0.027000000000000003,IC50,Compound was evaluated for in vitro activity against PC-3 prostate cell lines (Human tumor cells ),Confirmatory,9857098.0,
1379,163325,4,4,,104234169,126941,Active,,,0.72,EC50,"the growth inhibition of, (during continuous exposure) methotrexate resistant human T-lymphoblastic leukemia cell subline R1 at resistance mechanism - increased DHFR",Confirmatory,8164259.0,
1380,163326,4,4,,104234169,126941,Active,,,0.985,EC50,Growth inhibition of MTX-resistant subline R1-CCRF-CEM Human Leukemia Cell was determined,Confirmatory,12570380.0,
1381,163331,4,4,,104234169,126941,Active,,,1.05,EC50,Inhibition of growth of R1 (n=2),Confirmatory,11960504.0,
1382,166042,4,4,,104234169,126941,Active,,,2.63,EC50,Growth inhibition of MTX-resistant subline R2-CCRF-CEM Human Leukemia Cell was determined,Confirmatory,12570380.0,
1383,166043,4,4,,104234169,126941,Active,,,2.6,EC50,Inhibition of growth of R2 (n=2),Confirmatory,11960504.0,
1384,166046,4,3,,104234169,126941,Active,,,0.015,EC50,Inhibition of growth of R30dm (n=2),Confirmatory,11960504.0,
1385,166049,4,4,,104234169,126941,Active,,,0.018000000000000002,EC50,"the growth inhibition of, (during continuous exposure) methotrexate resistant human T-lymphoblastic leukemia cell subline R30dm at resistance mechanism - decreased FPGS",Confirmatory,8164259.0,
1386,166054,4,5,,104234169,126941,Unspecified,,,,,Protection of human R30dm cells by hypoxanthine from growth inhibition induced by the compound,Other,11052789.0,
1387,166055,3,5,,104234169,126941,Unspecified,,,,,Protection of human R30dm cells by thymidine and hypoxanthine from growth inhibition induced by the compound,Other,11052789.0,
1388,166056,3,5,,104234169,126941,Unspecified,,,,,Protection of human R30dm cells by thymidine from growth inhibition induced by the compound,Other,11052789.0,
1389,166058,4,4,,104234169,126941,Active,,,0.0128,EC50,Growth inhibition of MTX-resistant subline R30dm-CCRF-CEM Human Leukemia Cell was determined,Confirmatory,12570380.0,
1390,166405,8,1,,104234169,126941,Active,,,0.003,ID50,Compound is tested for the inhibition of growth of rat basophilic leukemia (RBL)cells,Confirmatory,6787199.0,
1391,167057,4,4,,104234169,126941,Active,,,0.033,IC50,Compound was evaluated for in vitro activity against RPMI-8226 leukemia cell lines (Human tumor cells ),Confirmatory,9857098.0,
1392,167432,4,4,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against RXF-393 kidney cell lines (Human tumor cells ),Confirmatory,9857098.0,
1393,177304,7,2,,104234169,126941,Unspecified,,,,,Effect on RA model was examined using adjuvant arthritis in rats.,Other,9379448.0,
1394,191950,3,3,,104234169,126941,Unspecified,,,,,Effect on the development of adjuvant arthritis in the rats was evaluated as % suppression of arthritis at a dose of 0.1 mg/kg,Other,9016334.0,
1395,191951,3,3,,104234169,126941,Unspecified,,,,,Effect on the development of adjuvant arthritis in the rats was evaluated as % suppression of arthritis at a dose of 0.25 mg/kg,Other,9016334.0,
1396,198024,8,2,,104234169,126941,Unspecified,,,,,Compound was evaluated for growth inhibition against Streptococcus faecium ATCC 8043,Other,3712374.0,
1397,200581,4,4,,104234169,126941,Active,,,0.0075,IC50,Tested for inhibitory concentration against human SCC25 cell line,Confirmatory,8035423.0,
1398,200586,4,4,,104234169,126941,Active,,,0.0058,IC50,Tested for inhibitory concentration against SCC-VII murine squamous carcinoma cell line,Confirmatory,8035423.0,
1399,200587,6,2,,104234169,126941,Active,,,0.038,IC50,Inhibitory concentration against growth of SCC15 cell line,Confirmatory,3385730.0,
1400,200589,6,2,,104234169,126941,Active,,,0.58,IC50,Inhibitory concentration against growth of SCC15/R1 cell line,Confirmatory,3385730.0,
1401,200591,4,3,,104234169,126941,Active,,,0.015,IC50,"Compound was tested for in vitro antitumor activity, using SCC25 human head and neck squamous carcinoma cells",Confirmatory,9857098.0,
1402,200593,4,4,,104234169,126941,Active,,,0.027000000000000003,IC50,In vitro antitumor activity against SCC25 human head and neck squamous carcinoma cells containing 10% fetal bovine serum,Confirmatory,9022795.0,
1403,200595,6,2,,104234169,126941,Active,,,0.0075,IC50,Inhibitory concentration against growth of SCC25 cell line,Confirmatory,3385730.0,
1404,200596,6,2,,104234169,126941,Active,,,0.013999999999999999,IC50,Cell growth inhibition against human squamous cell carcinoma (SCC25) line,Confirmatory,3872941.0,
1405,200598,6,2,,104234169,126941,Active,,,0.15,IC50,Inhibitory concentration against growth of SCC25/R1 cell line,Confirmatory,3385730.0,
1406,200601,6,2,,104234169,126941,Active,,,0.15,IC50,Cell growth inhibition against human squamous cell carcinoma (SCC25/R1) line,Confirmatory,3872941.0,
1407,200603,6,2,,104234169,126941,Active,,,0.032,IC50,Cell growth inhibition against human squamous cell carcinoma (SCC68) line,Confirmatory,3872941.0,
1408,200605,6,2,,104234169,126941,Active,,,0.25,IC50,Cell growth inhibition against human squamous cell carcinoma (SCC68/R1) line,Confirmatory,3872941.0,
1409,200607,6,2,,104234169,126941,Active,,,0.013000000000000001,IC50,Cell growth inhibition against human squamous cell carcinoma (SCC78) line,Confirmatory,3872941.0,
1410,200609,6,2,,104234169,126941,Active,,,0.071,IC50,Cell growth inhibition against human squamous cell carcinoma (SCC78/R1) line,Confirmatory,3872941.0,
1411,200647,4,4,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against SNB-251 CNS cell lines (Human tumor cells ),Confirmatory,9857098.0,
1412,200663,4,4,,104234169,126941,Unspecified,,,1.0,IC50,The IC50 value was measured on SNB-75 cell line in CNS tumor type.,Confirmatory,9022795.0,
1413,200943,4,4,,104234169,126941,Active,,,0.052000000000000005,IC50,Compound was evaluated for in vitro activity against SF-268 CNS cell lines (Human tumor cells ),Confirmatory,9857098.0,
1414,200946,4,4,,104234169,126941,Active,,,0.052000000000000005,IC50,The IC50 value was measured on SF-268 cell line in CNS tumor type.,Confirmatory,9022795.0,
1415,201110,4,4,,104234169,126941,Active,,,0.036000000000000004,IC50,Compound was evaluated for in vitro activity against SF-295 CNS cell lines (Human tumor cells ),Confirmatory,9857098.0,
1416,201164,4,4,,104234169,126941,Active,,,0.033,IC50,Compound was evaluated for in vitro activity against SR leukemia cell lines (Human tumor cells ),Confirmatory,9857098.0,
1417,201285,4,4,,104234169,126941,Active,,,0.035,IC50,Compound was evaluated for in vitro activity against SF-539 CNS cell lines (Human tumor cells ),Confirmatory,9857098.0,
1418,201288,4,4,,104234169,126941,Active,,,0.035,IC50,The IC50 value was measured on SF-539 cell line in CNS tumor type.,Confirmatory,9022795.0,
1419,201578,7,2,,104234169,126941,Unspecified,,,,,Compound was measured for the 50% growth inhibition of Streptococcus faecium ATCC 8043 microorganism.,Other,6767031.0,
1420,201579,7,2,,104234169,126941,Unspecified,,,,,Compound was measured for the 50% growth inhibition of Streptococcus faecium MTX resistant microorganism.,Other,6767031.0,
1421,201581,6,2,,104234169,126941,Active,,,0.0009,IC50,Inhibition of the growth of Streptococcus faecium,Confirmatory,2498518.0,
1422,201582,4,3,,104234169,126941,Active,,,0.0008,IC50,Tested for growth inhibition of Streptococcus faecium (ATCC 8043),Confirmatory,3121855.0,
1423,201583,4,3,,104234169,126941,Active,,,8.0,IC50,Tested for growth inhibition of Streptococcus faecium (MTX resistant),Confirmatory,3121855.0,
1424,201822,4,4,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against SK-MEL-2 Melanoma cell lines (Human tumor cells ),Confirmatory,9857098.0,
1425,201845,4,4,,104234169,126941,Active,,,0.033,IC50,The IC50 value was measured on SW-620 cell line in colon tumor type.,Confirmatory,9022795.0,
1426,202039,6,2,,104234169,126941,Active,,,0.015,IC50,Inhibition of cell growth against SW480 human gastrointestinal adenocarcinoma cell lines in vitro,Confirmatory,3612694.0,
1427,202160,4,4,,104234169,126941,Active,,,0.087,IC50,Compound was evaluated for in vitro activity against SK-MEL-5 Melanoma cell lines (Human tumor cells ),Confirmatory,9857098.0,
1428,202163,4,4,,104234169,126941,Active,,,0.087,IC50,The IC50 value was measured on SK-MEL-5 cell line in melanoma tumor type.,Confirmatory,9022795.0,
1429,202212,6,2,,104234169,126941,Active,,,0.015,IC50,In vitro inhibition of growth of the human gastrointestinal adenocarcinoma cells SW480,Confirmatory,6694171.0,
1430,202325,4,4,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against SK-MEL28 Melanoma cell lines (Human tumor cells ),Confirmatory,9857098.0,
1431,202477,3,4,,104234169,126941,Unspecified,,,,,In vitro for antitumor activity against S180 Ascites tumor in mice at a dose of 15 mg/Kg (sc) was reported as percentage increase in life span,Other,7108907.0,
1432,202603,3,4,,104234169,126941,Unspecified,,,,,In vitro for antitumor activity against S180 Ascites tumor in mice at a dose of 6 mg/Kg (sc) was reported as percentage increase in life span,Other,7108907.0,
1433,202604,6,2,,104234169,126941,Active,,,11.4,Km,In vitro membrane transport activity in S180 ascites tumor in rodent,Confirmatory,7108907.0,
1434,202605,6,1,,104234169,126941,Unspecified,,,,,In vitro antitumor activity against S180 Ascites tumor in mice at a dose of 15 mg/Kg (sc) was reported as maximum survival time,Other,7108907.0,
1435,202608,6,1,,104234169,126941,Unspecified,,,,,In vitro antitumor activity against S180 Ascites tumor in mice at a dose of 6 mg/Kg (sc) was reported as maximum survival time,Other,7108907.0,
1436,202609,3,4,,104234169,126941,Unspecified,,,,,In vitro for antitumor activity against S180 Ascites tumor in mice at a dose of 15 mg/Kg (sc) was reported as weight at termination of the therapy,Other,7108907.0,
1437,202612,3,4,,104234169,126941,Unspecified,,,,,In vitro for antitumor activity against S180 Ascites tumor in mice at a dose of 6 mg/Kg (sc) was reported as weight at termination of the therapy,Other,7108907.0,
1438,202616,8,1,,104234169,126941,Active,,,0.016,ED50,Cytotoxic activity against the S180 cell cultures,Confirmatory,6928967.0,
1439,202621,4,5,,104234169,126941,Active,,,0.01,IC50,Tested for the ability to inhibit growth in vitro against S180 cells,Confirmatory,8277497.0,
1440,202623,7,1,,104234169,126941,Active,,,,,In vitro antitumor activity against S180 cell line.,Other,4020824.0,
1441,202626,6,2,,104234169,126941,Active,,,0.0054,IC50,Concentration required for 50% inhibition against S180 cells,Confirmatory,6403710.0,
1442,202825,4,4,,104234169,126941,Unspecified,,,1.0,IC50,The IC50 value was measured on SKMEL-28 cell line in melanoma tumor type.,Confirmatory,9022795.0,
1443,208716,8,1,,104234169,126941,Unspecified,,,8000.0,ID50,Evaluated for the concentration needed for 50% growth inhibition of mouse mammary adenocarcinoma cells (TA3) in culture,Confirmatory,7069721.0,
1444,209395,4,4,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against TK-10 kidney cell lines (Human tumor cells ),Confirmatory,9857098.0,
1445,209419,3,3,,104234169,126941,Unspecified,,,,,Concentration required for the 50% growth inhibition of Streptococcus faecium ATCC 8043 organism at 1 ng/mL folate concentration,Other,7143361.0,
1446,209420,3,3,,104234169,126941,Unspecified,,,,,Concentration required for the 50% growth inhibition of Streptococcus faecium MTX resist organism at 1 ng/mL folate concentration,Other,7143361.0,
1447,209426,8,2,,104234169,126941,Unspecified,,,,,Compound was evaluated for growth inhibition in Streptococcus faecium ATCC 8043,Other,3091834.0,
1448,209427,8,2,,104234169,126941,Unspecified,,,,,Compound was evaluated for growth inhibition in Streptococcus faecium MTX-resistant,Other,3091834.0,
1449,209429,8,2,,104234169,126941,Unspecified,,,,,Concentration required to inhibit growth of Streptococcus faecium by 50%,Other,6793726.0,
1450,209430,8,2,,104234169,126941,Unspecified,,,,,Concentration required for 50% inhibition against Streptococcus faecium (ATCC 8043),Other,6403710.0,
1451,209431,8,2,,104234169,126941,Unspecified,,,,,Concentration required for 50% inhibition against Streptococcus faecium MTX resistant,Other,6403710.0,
1452,209432,6,2,,104234169,126941,Unspecified,,,7200.0,IC50,In vitro antibacterial activity against MTX-resistant Streptococcus faecium,Confirmatory,7108907.0,
1453,209433,6,2,,104234169,126941,Active,,,0.09,IC50,In vitro antibacterial activity against Streptococcus faecium (ATCC 8043),Confirmatory,7108907.0,
1454,209434,8,2,,104234169,126941,Unspecified,,,,,Inhibitory activity against Streptococcus faecium ATCC 8043,Other,3100797.0,
1455,209435,8,2,,104234169,126941,Unspecified,,,,,Inhibitory activity against Streptococcus faecium MTX-resistant,Other,3100797.0,
1456,209436,4,3,,104234169,126941,Active,,,0.0003,IC50,Inhibitory activity against Streptococcus faecium ATCC 8043,Confirmatory,3091832.0,
1457,209437,4,3,,104234169,126941,Active,,,3.9,IC50,Inhibitory activity against Streptococcus faecium MTX-resistant,Confirmatory,3091832.0,
1458,209562,3,3,,104234169,126941,Unspecified,,,,,Compound was evaluated for 50% inhibition of the growth of Streptococcus faecium ATCC 8043 strain at folate concentration 1 ng/mL,Other,6699882.0,
1459,209563,4,2,,104234169,126941,Unspecified,,,,,Compound was evaluated for 50% inhibition of the growth of Streptococcus faecium MTX resistant strain at folate concentration 1 ng/mL,Other,6699882.0,
1460,209581,8,2,,104234169,126941,Unspecified,,,,,Compound was evaluated for inhibitory effect on growth of Streptococcus faecium ATCC 8043,Other,2423690.0,
1461,209585,8,2,,104234169,126941,Unspecified,,,,,Compound was evaluated for inhibitory effect on growth of Streptococcus faecium MTX resistant,Other,2423690.0,
1462,209809,8,2,,104234169,126941,Unspecified,,,,,Inhibitory activity against Con A-stimulated T cell proliferation.,Other,9379448.0,
1463,210110,4,4,,104234169,126941,Unspecified,,,1.0,IC50,Compound was evaluated for in vitro activity against T-47D breast cancer cell lines (Human tumor cells ),Confirmatory,9857098.0,
1464,210138,8,1,,104234169,126941,Active,,,0.03,ID50,Compound concentration required to reduce by 50% the number of T-C8166 lymphoblastoid cells after three cell cycles,Confirmatory,1548681.0,
1465,210141,8,1,,104234169,126941,Active,,,0.03,ID50,Compound concentration required to reduce by 50% the number of T-H9 lymphoblastoid cells after three cell cycles,Confirmatory,1548681.0,
1466,210264,8,1,,104234169,126941,Active,,,0.03,ID50,Compound concentration required to reduce by 50% the number of T-MT4 lymphoblastoid cells after three cell cycles,Confirmatory,1548681.0,
1467,211442,10,4,,104234169,126941,Active,,,1.8,IC50,Inhibitory activity against Escherichia coli thymidylate synthase,Confirmatory,11384244.0,
1468,211637,3,9,,104234169,126941,Unspecified,,,,,Inhibition of Escherichia coli thymidylate synthase (TS); ND means not determined,Other,11960504.0,
1469,211639,3,9,,104234169,126941,Inconclusive,,,,,Inhibitory concentration against Escherichia coli Thymidylate synthase (TS); ND means not determined,Other,10956221.0,
1470,211642,3,11,,104234169,126941,Unspecified,136612.0,,,,Concentration required for the 50% inhibition of Lactobacillus casei thymidylate synthase,Other,7143361.0,
1471,211643,9,5,,104234169,126941,Active,136612.0,,40.0,IC50,Ability to inhibit Lactobacillus casei thymidylate synthase in vitro was determined,Confirmatory,6772788.0,
1472,211783,9,6,,104234169,126941,Unspecified,136612.0,,,,Compound was evaluated for inhibitory effect on the thymidylate synthase (TS) of Lactobacillus casei,Other,2423690.0,
1473,211788,12,2,,104234169,126941,Unspecified,136612.0,,100.0,IC50,Compound was evaluated for the inhibition of thymidylate synthase (TS) derived from Lactobacillus casei,Confirmatory,3091834.0,
1474,211790,7,6,,104234169,126941,Unspecified,136612.0,,75.0,IC50,In vitro inhibition of activity against Lactobacillus casei enzyme thymidylate synthase,Confirmatory,7108907.0,
1475,211793,10,5,,104234169,126941,Unspecified,136612.0,,600.0,IC50,Inhibitory activity against thymidylate synthase derived from Lactobacillus casei,Confirmatory,3100797.0,
1476,211794,10,5,,104234169,126941,Unspecified,136612.0,,86.0,IC50,Inhibitory activity against thymidylate synthase of Lactobacillus casei,Confirmatory,3121855.0,
1477,211795,10,5,,104234169,126941,Unspecified,136612.0,,170.0,IC50,Inhibitory activity against thymidylate synthase of Lactobacillus casei,Confirmatory,3091832.0,
1478,211796,9,2,,104234169,126941,Unspecified,,,120.0,IC50,Inhibitory activity against thymidylate synthase of Streptococcus faecium,Confirmatory,3091832.0,
1479,211809,3,10,,104234169,126941,Unspecified,136612.0,,,,Compound was evaluated for 50% inhibition of the enzyme Thymidylate synthase (TS) from Lactobacillus casei,Other,6699882.0,
1480,211962,3,10,,104234169,126941,Unspecified,136612.0,,,,Inhibitory concentration against Lacto bacillus casei(L c) Thymidylate synthase (TS); ND means no data,Other,10956221.0,
1481,211977,9,5,,104234169,126941,Unspecified,136612.0,,120.0,IC50,Evaluated for inhibition of thymidylate synthase (TS) from Lactobacillus casei,Confirmatory,3184124.0,
1482,212019,4,3,,104234169,126941,Unspecified,,,,,Compound dose causing lethality in mice,Other,9379448.0,
1483,212131,3,7,,104234169,126941,Unspecified,,,,,Compound was evaluated for 50% inhibition of the enzyme Thymidylate synthase (TS) from Streptococcus faecium,Other,6699882.0,
1484,212297,9,5,,104234169,126941,Active,136611.0,7298.0,3.6,IC50,Inhibitory activity against human thymidylate synthase,Confirmatory,11384244.0,
1485,212304,9,2,,104234169,126941,Unspecified,,,170.0,IC50,Inhibitory concentration against recombinant human TS (Thymidylate synthase).,Confirmatory,7562910.0,
1486,212305,6,4,,104234169,126941,Unspecified,,,170.0,IC50,Inhibitory concentration for TS in human,Confirmatory,8164259.0,
1487,212467,3,7,,104234169,126941,Unspecified,,,,,Inhibition of recombinant human thymidylate synthase (TS); ND means not determined,Other,11960504.0,
1488,212468,3,7,,104234169,126941,Inconclusive,,,,,Inhibitory concentration against recombinant human (rh) Thymidylate synthase (TS); ND means no data,Other,10956221.0,
1489,212474,9,2,,104234169,126941,Active,,,20.0,IC50,Inhibition of L1210 leukemia thymidylate synthase (TS) enzyme,Confirmatory,2704031.0,
1490,212475,9,1,,104234169,126941,Active,,,20.0,IC50,Inhibitory activity against thymidylate synthase isolated from L1210 leukemia cells,Confirmatory,3339615.0,
1491,212533,7,2,,104234169,126941,Unspecified,,,,,Lethal dose in rats.,Other,9379448.0,
1492,212659,11,1,,104234169,126941,Active,,,45.0,Ki,Inhibitory activity against thymidylate synthase in murine tumor cells,Confirmatory,7086836.0,
1493,212675,11,1,,104234169,126941,Active,,,3.5,Ki,Affinity towards RFC measured by the inhibition of [3H]MTX uptake,Confirmatory,10821704.0,
1494,212812,3,7,,104234169,126941,Inconclusive,,,,,Inhibitory concentration against rat Thymidylate synthase (TS); ND means not determined,Other,10956221.0,
1495,212849,7,6,,104234169,126941,Unspecified,136612.0,,190.0,IC50,In vitro inhibitory concentration against Lactobacillus casei thymidylate synthetase,Confirmatory,4009615.0,
1496,213148,6,2,,104234169,126941,Unspecified,,,60.0,IC50,Concentration required for 50% inhibition against thymidylate synthase of Lactobacillus casei,Confirmatory,6403710.0,
1497,213149,6,2,,104234169,126941,Unspecified,,,150.0,IC50,Concentration required for 50% inhibition against thymidylate synthase of Streptococcus faecium,Confirmatory,6403710.0,
1498,214045,4,4,,104234169,126941,Active,,,0.022000000000000002,IC50,Cytotoxic activity was evaluated against U87MG tumor cells,Confirmatory,8632413.0,
1499,214233,4,4,,104234169,126941,Active,,,0.063,IC50,Compound was evaluated for in vitro activity against U251 CNS cell lines (Human tumor cells ),Confirmatory,9857098.0,
1500,214392,4,4,,104234169,126941,Active,,,0.012,IC50,Cytotoxic activity was evaluated against U373MG tumor cells,Confirmatory,8632413.0,
1501,214588,4,4,,104234169,126941,Active,,,0.79,IC50,Compound was evaluated for in vitro activity against UACC-257 Melanoma cell lines (Human tumor cells ),Confirmatory,9857098.0,
1502,214756,4,4,,104234169,126941,Active,,,0.027999999999999997,IC50,Compound was evaluated for in vitro activity against UACC-62 Melanoma cell lines (Human tumor cells ),Confirmatory,9857098.0,
1503,214757,4,4,,104234169,126941,Active,,,0.027999999999999997,IC50,The IC50 value was measured on UACC-62 cell line in melanoma tumor type.,Confirmatory,9022795.0,
1504,215121,4,4,,104234169,126941,Active,,,0.191,IC50,The IC50 value was measured on UO-31 cell line in renal tumor type.,Confirmatory,9022795.0,
1505,216019,4,4,,104234169,126941,Active,,,0.0092,IC50,Cytotoxic Activity was evaluated against Vero tumor cells,Confirmatory,8632413.0,
1506,216094,6,2,,104234169,126941,Active,,,0.013000000000000001,IC50,Ability to inhibit WI-L2 murine leukemia tumor cell growth in culture after 48 hr of its exposure.,Confirmatory,1992118.0,
1507,216095,6,2,,104234169,126941,Active,,,0.013000000000000001,IC50,Compound was evaluated for cell growth inhibition of human (WI-L2) leukemic cells.,Confirmatory,1992122.0,
1508,216096,6,3,,104234169,126941,Active,,,0.013000000000000001,IC50,Inhibition of cell growth against WI-L2 cells,Confirmatory,2918496.0,
1509,216115,6,2,,104234169,126941,Active,,,0.025,IC50,Inhibition of cell growth against WIDR human gastrointestinal adenocarcinoma cell lines in vitro,Confirmatory,3612694.0,
1510,216122,6,2,,104234169,126941,Active,,,0.025,IC50,In vitro inhibition of growth of the human gastrointestinal adenocarcinoma cells WIDR,Confirmatory,6694171.0,
1511,217943,8,1,,104234169,126941,Active,,,0.02,ED50,Cytotoxic activity against the Walker 256 carcinosarcoma in rats,Confirmatory,6928967.0,
1512,218438,4,3,,104234169,126941,Active,,,0.024,IC50,Compound was evaluated for the growth inhibition of WI-L2 cells,Confirmatory,1995880.0,
1513,218931,7,1,,104234169,126941,Unspecified,,,,,In vitro antitumor activity against epithelial cell line.,Other,4020824.0,
1514,219017,4,5,,104234169,126941,Active,,,0.0138,EC50,Tested for their inhibition of growth of CCRF-CEM human leukemia on carcinoma cell lines.,Confirmatory,11052789.0,
1515,219018,4,5,,104234169,126941,Active,,,0.0145,EC50,Tested for their inhibition of growth of FaDu head on carcinoma cell lines.,Confirmatory,11052789.0,
1516,219254,8,2,,104234169,126941,Active,,,1.2e-06,Ki,Inhibitory activity against Wild-type human DHFR,Confirmatory,7877140.0,
1517,220534,8,1,,104234169,126941,Active,7227951.0,,0.021,ID50,Compound is evaluated for binding to Lactobacillus casei dihydrofolate reductase using kinetic assay,Confirmatory,6787199.0,
1518,220535,8,1,,104234169,126941,Active,,,0.0068,ID50,Compound is evaluated for binding to L1210 mouse leukemia cells dihydrofolate reductase using kinetic assay,Confirmatory,6787199.0,
1519,220536,8,3,,104234169,126941,Active,,,1.0000000000000001e-11,Ki,Inhibitory activity against dihydrofolate reductase (DHFR) of L-1210 cells,Confirmatory,3373490.0,
1520,221756,6,3,,104234169,126941,Unspecified,,,116.0,Km,Michaelis-Menten constant for hog liver folyl-poly-glutamate synthetase (FPGS),Confirmatory,9990460.0,
1521,221757,5,7,,104234169,126941,Unspecified,,,,,Maximum rate of metabolism by hog liver folyl-poly-glutamate synthetase (FPGS) was determined,Other,9990460.0,
1522,221797,8,1,,104234169,126941,Active,,,0.02,ID50,Compound concentration required to reduce by 50% the number of human B (Raji)cells after three cell cycles,Confirmatory,1548681.0,
1523,226868,4,3,,104234169,126941,Active,,,0.0045,IC50,Inhibitory concentration towards wild type DHFR,Confirmatory,8627598.0,
1524,226869,4,3,,104234169,126941,Active,,,0.02,IC50,Inhibitory concentration towards wild type DHFR F31S,Confirmatory,8627598.0,
1525,226870,4,3,,104234169,126941,Active,,,0.03,IC50,Inhibitory concentration towards wild type DHFR F31W,Confirmatory,8627598.0,
1526,227718,7,1,,104234169,126941,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
1527,227872,4,3,,104234169,126941,Active,,,0.595,EC50,Concentration required to decrease cell growth by 50% in methotrexate-resistant CCRF-CEM human leukemia subline (R1),Confirmatory,12408727.0,
1528,227964,4,2,,104234169,126941,Unspecified,,,,,Dissociation constant towards DHFR mutant hF31S; no data,Other,8627598.0,
1529,227965,4,1,,104234169,126941,Unspecified,,,,,Dissociation constant towards wild type DHFR,Other,8627598.0,
1530,228015,4,3,,104234169,126941,Active,,,1.7,EC50,Concentration required to decrease cell growth by 50% in methotrexate-resistant CCRF-CEM human leukemia subline (R2),Confirmatory,12408727.0,
1531,228016,4,3,,104234169,126941,Active,,,0.016,EC50,Concentration required to decrease cell growth by 50% in methotrexate-resistant CCRF-CEM human leukemia subline (R30dm),Confirmatory,12408727.0,
1532,228117,4,1,,104234169,126941,Unspecified,,,,,Binding affinity towards DHFR mutant hF31S,Other,8627598.0,
1533,228118,4,1,,104234169,126941,Unspecified,,,,,Binding affinity towards wild type DHFR,Other,8627598.0,
1534,228545,6,2,,104234169,126941,Active,,,3.42,Km,Michaelis constant of compound was determined from affinity towards carrier component of transport mechanism,Confirmatory,7143361.0,
1535,228932,3,4,,104234169,126941,Unspecified,,,,,The compound was compared with MTX with respect to cytotoxicity toward H.Ep.-2 cells.,Other,7057425.0,
1536,229443,3,4,,104234169,126941,Unspecified,,,,,Selectivity ratio as the ratio of IC50 value against recombinant human (rh) DHFR to that of Escherichia coli (ec) DHFR.,Other,12408727.0,
1537,229444,3,3,,104234169,126941,Unspecified,,,,,Selectivity ratio as the ratio of IC50 value against recombinant human (rh) DHFR to that of pneumocystis carinii (pc ) DHFR.,Other,12408727.0,
1538,229445,3,4,,104234169,126941,Unspecified,,,,,Selectivity ratio as the ratio of IC50 value against recombinant human (rh) DHFR to that of Toxoplasma gondii (tg) DHFR.,Other,12408727.0,
1539,230504,3,3,,104234169,126941,Unspecified,,,,,Ratio of relative Vmax to Km was determined,Other,2308134.0,
1540,230505,3,3,,104234169,126941,Unspecified,,,,,Ratio of relative Vmax to that of Km values.,Other,1992148.0,
1541,230674,3,4,,104234169,126941,Unspecified,,,,,Ratio of Vmax/Km was evaluated.,Other,,
1542,231478,3,3,,104234169,126941,Unspecified,,,,,Ratio between IC50 values of CCRF-CEM and CEM/MTX,Other,8035423.0,
1543,231680,3,3,,104234169,126941,Unspecified,,,,,Ratio between Ki values of CCRF-CEM and CEM/MTX,Other,8035423.0,
1544,231772,3,4,,104234169,126941,Unspecified,,,,,Ratio of compound activity to that of MTX activity.,Other,1992121.0,
1545,232835,3,4,,104234169,126941,Unspecified,,,,,Ratio of Vmax and Km against CCRF-CEM Folyl-polyglutamate synthetase,Other,8277497.0,
1546,232845,3,4,,104234169,126941,Unspecified,,,,,Vmax/Km value was determined,Other,9990460.0,
1547,233114,3,5,,104234169,126941,Unspecified,,,,,Ratio of IC50 against rat liver DHFR and Pneumocystis carinii DHFR (IC50rl/IC50pc),Other,7783147.0,
1548,233115,3,5,,104234169,126941,Unspecified,,,,,Ratio of the IC50 against rat liver DHFR and Toxoplasma gondii DHFR (IC50rl/IC50tg),Other,7783147.0,
1549,233134,3,5,,104234169,126941,Unspecified,,,,,Selectivity for dihydrofolate reductase enzyme in rat liver Toxoplasma gondii,Other,9554874.0,
1550,233138,3,5,,104234169,126941,Unspecified,,,,,Selectivity for dihydrofolate reductase enzyme in rat liver and Pneumocystis carinii,Other,9554874.0,
1551,233285,3,5,,104234169,126941,Unspecified,,,,,Selectivity ratio is IC50 of rat liver DHFR to that of Pneumocystis carinii DHFR,Other,9301666.0,
1552,233287,3,5,,104234169,126941,Unspecified,,,,,Selectivity ratio is IC50 of rat liver DHFR to that of Toxoplasma gondii DHFR,Other,9301666.0,
1553,233296,3,3,,104234169,126941,Unspecified,,,,,Selectivity ratio is defined as IC50 human DHFR/IC50 ecDHFR,Other,8691474.0,
1554,233300,3,3,,104234169,126941,Unspecified,,,,,Selectivity ratio is defined as IC50 human DHFR/IC50 lcDHFR,Other,8691474.0,
1555,233304,3,3,,104234169,126941,Unspecified,,,,,Selectivity ratio is defined as IC50 human DHFR/IC50 sfDHFR,Other,8691474.0,
1556,233308,3,3,,104234169,126941,Unspecified,,,,,Selectivity ratio is defined as IC50 human DHFR/IC50 tgDHFR,Other,8691474.0,
1557,233406,3,5,,104234169,126941,Unspecified,,,,,Ratio for IC50 of mammalian DHFR to IC50 of Pneumocystis carinii DHFR,Other,7490723.0,
1558,233411,5,2,,104234169,126941,Unspecified,118998.0,,,,Selectivity ratio is defined as IC50 rlDHFR/IC50 pcDHFR,Other,8691474.0,
1559,233411,5,2,,104234169,126941,Unspecified,81871579.0,24312.0,,,Selectivity ratio is defined as IC50 rlDHFR/IC50 pcDHFR,Other,8691474.0,
1560,233412,5,2,,104234169,126941,Unspecified,729370.0,,,,Selectivity ratio is defined as IC50 rlDHFR/IC50 tgDHFR,Other,8691474.0,
1561,233412,5,2,,104234169,126941,Unspecified,81871579.0,24312.0,,,Selectivity ratio is defined as IC50 rlDHFR/IC50 tgDHFR,Other,8691474.0,
1562,234050,3,3,,104234169,126941,Unspecified,,,,,Selectivity for Trypanosoma cruzi dihydrofolate reductase compared to methotrexate,Other,10360757.0,
1563,234409,3,3,,104234169,126941,Unspecified,,,,,Influx with respect to the MTX.,Other,1732549.0,
1564,234718,3,4,,104234169,126941,Unspecified,,,,,Relative influx was determined by taking the ratio vs MTX in L1210 cell line,Other,2299633.0,
1565,234747,3,9,,104234169,126941,Unspecified,118992.0,1719.0,,,Selectivity ratio of Ki value against mutant DHFR and Wild-type DHFR,Other,7877140.0,
1566,234747,3,9,,104234169,126941,Unspecified,118992.0,573971.0,,,Selectivity ratio of Ki value against mutant DHFR and Wild-type DHFR,Other,7877140.0,
1567,235092,3,3,,104234169,126941,Unspecified,,,,,Fold resistance calculated by dividing the IC50(L1210/R81) by the IC50(L1210),Other,3112397.0,
1568,235828,3,3,,104234169,126941,Unspecified,,,,,Ratio of LD50 / ED50 value against adjuvant arthritis in rats.,Other,9379448.0,
1569,235830,4,3,,104234169,126941,Unspecified,,,,,Safety index = Ratio of lethal dose / suppressive dose value,Other,9379448.0,
1570,236268,3,4,,104234169,126941,Unspecified,,,,,Fraction absorbed in human intestine after oral administration compound was measured,Other,15658873.0,
1571,236912,6,1,,104234169,126941,Unspecified,,,,,Permeability Coefficient in 2/4/A1 cell model,Other,15658873.0,
1572,236913,6,1,,104234169,126941,Unspecified,,,,,Permeability Coefficient in Caco-2 cell culture model,Other,15658873.0,
1573,236914,6,1,,104234169,126941,Unspecified,,,,,Permeability Coefficient in hexadecane membranes model,Other,15658873.0,
1574,236916,6,1,,104234169,126941,Unspecified,,,,,Percentage of mass balance in hexadecane membranes model,Other,15658873.0,
1575,237416,3,4,,104234169,126941,Unspecified,,,,,Log D value against bovine serum albumin,Other,15267234.0,
1576,237474,3,3,,104234169,126941,Unspecified,,,,,Percentage of drug bound in bovine plasma albumin,Other,15267234.0,
1577,239884,4,2,,104234169,126941,Unspecified,,,,,pKa value of the compound,Other,15267234.0,
1578,241682,10,5,,104234169,126941,Active,165971782.0,,0.006999999999999999,IC50,Inhibition of Escherichia coli dihydrofolate reductase at 37 degree C pH 7.4,Confirmatory,16078850.0,
1579,241717,9,5,,104234169,126941,Active,118992.0,1719.0,0.022000000000000002,IC50,Inhibition of human dihydrofolate reductase at 37 degree C pH 7.4,Confirmatory,16078850.0,
1580,241717,9,5,,104234169,126941,Active,118992.0,573971.0,0.022000000000000002,IC50,Inhibition of human dihydrofolate reductase at 37 degree C pH 7.4,Confirmatory,16078850.0,
1581,241776,9,5,,104234169,126941,Active,7227951.0,,0.022000000000000002,IC50,Inhibition of Lactobacillus casei dihydrofolate reductase at 37 degree C pH 7.4,Confirmatory,16078850.0,
1582,242104,8,6,,104234169,126941,Inconclusive,,,,,Inhibition of Escherichia coli thymidylate synthetase at 37 degree C pH 7.4; Not determined,Other,16078850.0,
1583,242116,8,7,,104234169,126941,Inconclusive,136611.0,7298.0,,,Inhibition of human thymidylate synthetase at 37 degree C pH 7.4; Not determined,Other,16078850.0,
1584,242150,8,7,,104234169,126941,Inconclusive,136612.0,,,,Inhibition of Lactobacillus casei thymidylate synthetase at 37 degree C pH 7.4; Not determined,Other,16078850.0,
1585,244317,7,1,,104234169,126941,Active,,,,,Protection of CCRF-CEM human leukemia cells against the growth inhibitory effects of MTX by 5 uM thymidine,Other,16078850.0,
1586,246199,4,4,,104234169,126941,Active,,,0.013000000000000001,EC50,Growth inhibitory activity against CCRF-CEM human lymphoblastic leukemia cells,Confirmatory,16078850.0,
1587,246395,4,4,,104234169,126941,Active,,,0.62,EC50,Growth inhibitory activity against MTX resistant subline of CCRF-CEM human lymphoblastic leukemia cells,Confirmatory,16078850.0,
1588,246488,4,4,,104234169,126941,Active,,,1.5,EC50,Growth inhibitory activity against resistant CCRF-CEM human lymphoblastic leukemia cells with decreased uptake of MTX,Confirmatory,16078850.0,
1589,246563,4,4,,104234169,126941,Active,,,0.0145,EC50,Growth inhibitory activity against MTX resistant CCRF-CEM human lymphoblastic leukemia cells with decreased polyglutamylation,Confirmatory,16078850.0,
1590,247221,6,2,,104234169,126941,Active,,,0.07,GI50,Growth inhibitory activity against human HT-29 cell line,Confirmatory,15267250.0,
1591,247223,6,2,,104234169,126941,Active,,,0.01,GI50,Growth inhibitory activity against human HCT116 cell line,Confirmatory,15267250.0,
1592,247429,6,2,,104234169,126941,Unspecified,,,50.0,GI50,Growth inhibitory activity against human HT-29 cell line in presence of Hypoxanthine thymidine(HT),Confirmatory,15267250.0,
1593,247430,6,2,,104234169,126941,Unspecified,,,50.0,GI50,Growth inhibitory activity against human HCT116 cell line in presence of Hypoxanthine thymidine(HT),Confirmatory,15267250.0,
1594,247974,6,2,,104234169,126941,Unspecified,,,419.0,IC50,In vitro cytotoxic concentration measured against human myelogenous leukemia K562 cells,Confirmatory,15780632.0,
1595,252808,3,4,,104234169,126941,Unspecified,,,,,Protection of CCRF-CEM cells against the growth inhibitory effect of MTX by 5 uM of thymidine at 30 nM concentration of compound [Experiment 1],Other,16078850.0,
1596,252809,3,4,,104234169,126941,Unspecified,,,,,Protection of CCRF-CEM cells against the growth inhibitory effect of MTX by 5 uM of thymidine at 30 nM concentration of compound [Experiment 2],Other,16078850.0,
1597,252811,3,4,,104234169,126941,Unspecified,,,,,Protection of CCRF-CEM cells against the growth inhibitory effect of MTX by 10 uM of hypoxanthine at 30 nM concentration of compound [Experiment 1],Other,16078850.0,
1598,252812,3,4,,104234169,126941,Unspecified,,,,,Protection of CCRF-CEM cells against the growth inhibitory effect of MTX by 10 uM of hypoxanthine at 30 nM concentration of compound [Experiment 2],Other,16078850.0,
1599,252814,3,4,,104234169,126941,Unspecified,,,,,Protection of CCRF-CEM cells against the growth inhibitory effect of MTX by 10 uM of hypoxanthine and 5 uM of thymidine at 30 nM concentration of compound [Experiment 1],Other,16078850.0,
1600,252815,3,4,,104234169,126941,Unspecified,,,,,Protection of CCRF-CEM cells against the growth inhibitory effect of MTX by 10 uM of hypoxanthine and 5 uM of thymidine at 30 nM concentration of compound [Experiment 2],Other,16078850.0,
1601,260013,8,5,,104234169,126941,Inconclusive,136611.0,7298.0,,IC50,Inhibition of recombinant human TS,Confirmatory,16451071.0,
1602,260014,9,4,,104234169,126941,Inconclusive,,,,IC50,Inhibition of TS from Escherichia coli,Confirmatory,16451071.0,
1603,260023,4,4,,104234169,126941,Active,,,0.013999999999999999,EC50,Inhibition of growth in CCRF-CEM cells,Confirmatory,16451071.0,
1604,260024,4,4,,104234169,126941,Active,,,0.565,EC50,"Inhibition of growth in MTX-resistant CCRF-CEM cell line, R1 cells",Confirmatory,16451071.0,
1605,260025,4,4,,104234169,126941,Active,,,1.7,EC50,"Inhibition of growth in MTX-resistant CCRF-CEM cell line, R2 cells",Confirmatory,16451071.0,
1606,260026,4,4,,104234169,126941,Active,,,0.017,EC50,"Inhibition of growth in MTX-resistant CCRF-CEM cell line, R30dm cells",Confirmatory,16451071.0,
1607,260027,3,4,,104234169,126941,Unspecified,,,,,Protection against growth inhibition of CCRF-CEM cells in presence of 0.1 uM of Leucovorin at concentrations that inhibited the growth by 95%,Other,16451071.0,
1608,260029,3,4,,104234169,126941,Unspecified,,,,,"Protection against growth of CCRF-CEM cells in presence of 10 uM Hypoxanthine and 10 uM Deoxycytidine, relative to control",Other,16451071.0,
1609,260030,3,4,,104234169,126941,Unspecified,,,,,"Protection against growth of CCRF-CEM cells in presence of 5 uM Thymidine and 10 uM Deoxycytidine, relative to control",Other,16451071.0,
1610,260031,3,4,,104234169,126941,Unspecified,,,,,"Protection against growth of CCRF-CEM cells in presence of 5 uM Thymidine, 10 uM Deoxycytidine and 10 uM Hypoxanthine, relative to control",Other,16451071.0,
1611,260032,3,4,,104234169,126941,Unspecified,,,,,"Protection against growth of CCRF-CEM cells in presence of 10 uM Hypoxanthine, relative to control",Other,16451071.0,
1612,260033,3,4,,104234169,126941,Unspecified,,,,,"Protection against growth of CCRF-CEM cells in presence of 10 uM Deoxycytidine, relative to control",Other,16451071.0,
1613,260034,3,4,,104234169,126941,Unspecified,,,,,"Protection against growth of CCRF-CEM cells in presence of 5 uM Thymidine, relative to control",Other,16451071.0,
1614,260039,9,5,,104234169,126941,Active,118992.0,1719.0,0.022000000000000002,IC50,Inhibition of recombinant human DHFR,Confirmatory,16451071.0,
1615,260039,9,5,,104234169,126941,Active,118992.0,573971.0,0.022000000000000002,IC50,Inhibition of recombinant human DHFR,Confirmatory,16451071.0,
1616,260046,8,2,,104234169,126941,Active,,,0.0066,IC50,Inhibition of DHFR from Escherichia coli,Confirmatory,16451071.0,
1617,261687,4,1,,104234169,126941,Unspecified,,,,,Antiproliferative activity against NCI60 cell line,Other,16539384.0,
1618,261688,3,3,,104234169,126941,Unspecified,,,,,Activity against NCI60 cell line xenograft in nude mouse by HF assay,Other,16539384.0,
1619,272613,9,6,,104234169,126941,Active,165971782.0,,0.003,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,17125251.0,
1620,275284,6,2,,104234169,126941,Inconclusive,,,,EC50,Reduction of PrPSC accumulation in ScN2a cells,Confirmatory,17201410.0,
1621,275285,8,1,,104234169,126941,Inconclusive,,,,LD50,Cytotoxicity against ScN2a cells,Confirmatory,17201410.0,
1622,275286,6,2,,104234169,126941,Unspecified,,,,,Solubility in phosphate buffer at pH 6.5 at 500 uM,Other,17201410.0,
1623,275287,3,4,,104234169,126941,Unspecified,,,,,Permeability across DOPC lipid membrane by PAMPA,Other,17201410.0,
1624,279961,6,2,,104234169,126941,Active,,,23.0,IC50,Inhibition of Cryptosporidium hominis DHFR-TS expressed in Escherichia coli,Confirmatory,17269758.0,
1625,279962,10,5,,104234169,126941,Active,729370.0,,14.0,IC50,Inhibition of Toxoplasma gondii DHFR-TS,Confirmatory,17269758.0,
1626,279963,3,3,,104234169,126941,Unspecified,,,,,Ligand efficiency at Cryptosporidium hominis DHFR-TS,Other,17269758.0,
1627,279964,3,9,,104234169,126941,Unspecified,729370.0,,,,Ligand efficiency at Toxoplasma gondii DHFR-TS,Other,17269758.0,
1628,282386,8,5,,104234169,126941,Inconclusive,136611.0,7298.0,,IC50,Inhibition of human thymidylate synthase,Confirmatory,15615522.0,
1629,282387,8,4,,104234169,126941,Inconclusive,,,,IC50,Inhibition of Escherichia coli thymidylate synthase,Confirmatory,15615522.0,
1630,282388,9,5,,104234169,126941,Active,118992.0,1719.0,0.009000000000000001,IC50,Inhibition of human DHFR,Confirmatory,15615522.0,
1631,282388,9,5,,104234169,126941,Active,118992.0,573971.0,0.009000000000000001,IC50,Inhibition of human DHFR,Confirmatory,15615522.0,
1632,282389,6,2,,104234169,126941,Active,,,0.032,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,15615522.0,
1633,282390,4,4,,104234169,126941,Active,,,0.0175,EC50,Growth inhibition of human CCRF-CEM cells,Confirmatory,15615522.0,
1634,282391,4,4,,104234169,126941,Active,,,0.68,EC50,Growth inhibition of MTX-resistant human CCRF-CEM R1 cells overexpressing DHFR,Confirmatory,15615522.0,
1635,282392,4,4,,104234169,126941,Active,,,2.1,EC50,Growth inhibition of MTX-resistant human CCRF-CEM R2 cells,Confirmatory,15615522.0,
1636,282393,4,4,,104234169,126941,Active,,,0.0165,EC50,Growth inhibition of MTX-resistant human CCRF-CEM R30dm cells,Confirmatory,15615522.0,
1637,282394,3,4,,104234169,126941,Unspecified,,,,,Growth inhibition of human CCRF-CEM cells at 40 nM relative to leucovorin,Other,15615522.0,
1638,282571,9,5,,104234169,126941,Active,118992.0,1719.0,0.022000000000000002,IC50,Inhibition of human recombinant DHFR,Confirmatory,15615538.0,
1639,282571,9,5,,104234169,126941,Active,118992.0,573971.0,0.022000000000000002,IC50,Inhibition of human recombinant DHFR,Confirmatory,15615538.0,
1640,282572,10,5,,104234169,126941,Active,165971782.0,,0.006999999999999999,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,15615538.0,
1641,282573,9,5,,104234169,126941,Active,7227951.0,,0.022000000000000002,IC50,Inhibition of Lactobacillus casei DHFR,Confirmatory,15615538.0,
1642,282574,9,5,,104234169,126941,Inconclusive,136611.0,7298.0,,IC50,Inhibition of human recombinant thymidylate synthase,Confirmatory,15615538.0,
1643,282575,10,4,,104234169,126941,Inconclusive,,,,IC50,Inhibition of Escherichia coli thymidylate synthase,Confirmatory,15615538.0,
1644,282576,9,5,,104234169,126941,Inconclusive,136612.0,,,IC50,Inhibition of Lactobacillus casei thymidylate synthase,Confirmatory,15615538.0,
1645,282580,4,4,,104234169,126941,Active,,,0.0082,EC50,Growth inhibition of human CCRF-CEM cells,Confirmatory,15615538.0,
1646,282582,4,4,,104234169,126941,Active,,,0.66,EC50,Growth inhibition of methotrexate-resistant human CCRF-CEM R1 cells overproducing DHFR after 120 hrs,Confirmatory,15615538.0,
1647,282583,4,4,,104234169,126941,Active,,,1.5,EC50,Growth inhibition of methotrexate-transport-resistant human CCRF-CEM R2 cells after 120 hrs,Confirmatory,15615538.0,
1648,282584,4,5,,104234169,126941,Active,,,0.0079,EC50,Growth inhibition of methotrexate-resistant human CCRF-CEM R30dm cells expressing low levels of folyl-poly-glutamate synthetase after 120 hrs,Confirmatory,15615538.0,
1649,282585,3,4,,104234169,126941,Unspecified,,,,,Cell growth in human CCRF-CEM cells at 30 nM relative to control,Other,15615538.0,
1650,282586,3,4,,104234169,126941,Unspecified,,,,,Cell growth in human CCRF-CEM cells relative to control,Other,15615538.0,
1651,282587,3,4,,104234169,126941,Unspecified,,,,,Cell growth in human CCRF-CEM cells at 30 nM in presence of 5 uM thymidine and 10 uM deoxycytidine relative to control,Other,15615538.0,
1652,282588,3,4,,104234169,126941,Unspecified,,,,,Cell growth in human CCRF-CEM cells at 30 nM in presence of 10 uM hypoxanthine and 10 uM deoxycytidine,Other,15615538.0,
1653,282589,3,4,,104234169,126941,Unspecified,,,,,"Cell growth in human CCRF-CEM cells at 30 nM in presence of thymidine, hypoxanthine and 10 uM deoxycytidine",Other,15615538.0,
1654,282590,3,4,,104234169,126941,Unspecified,,,,,Cell growth in human CCRF-CEM cells in presence of 5 uM thymidine and 10 uM deoxycytidine relative to control,Other,15615538.0,
1655,282591,3,4,,104234169,126941,Unspecified,,,,,Cell growth in human CCRF-CEM cells in presence of 10 uM hypoxanthine and 10 uM deoxycytidine relative to control,Other,15615538.0,
1656,282592,3,4,,104234169,126941,Unspecified,,,,,Cell growth in human CCRF-CEM cells in presence of thymidine and hypoxanthine and 10 uM deoxycytidine relative to control,Other,15615538.0,
1657,282785,9,5,,104234169,126941,Active,118992.0,1719.0,0.022000000000000002,IC50,Inhibition of human DHFR,Confirmatory,16279780.0,
1658,282785,9,5,,104234169,126941,Active,118992.0,573971.0,0.022000000000000002,IC50,Inhibition of human DHFR,Confirmatory,16279780.0,
1659,282786,10,5,,104234169,126941,Active,165971782.0,,0.0066,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,16279780.0,
1660,282787,10,5,,104234169,126941,Active,729370.0,,0.011000000000000001,IC50,Inhibition of Toxoplasma gondii DHFR,Confirmatory,16279780.0,
1661,282788,9,5,,104234169,126941,Active,136611.0,7298.0,29.0,IC50,Inhibition of human thymidylate synthase,Confirmatory,16279780.0,
1662,282789,10,4,,104234169,126941,Unspecified,,,90.0,IC50,Inhibition of Escherichia coli thymidylate synthase,Confirmatory,16279780.0,
1663,282790,10,5,,104234169,126941,Active,729370.0,,18.0,IC50,Inhibition of Toxoplasma gondii thymidylate synthase,Confirmatory,16279780.0,
1664,282791,4,4,,104234169,126941,Active,,,0.0125,EC50,Growth inhibition of human CCRF-CEM cells,Confirmatory,16279780.0,
1665,282793,4,4,,104234169,126941,Active,,,0.615,EC50,Growth inhibition of methotrexate-resistant human CCRF-CEM R1 cells overproducing DHFR after 120 hrs,Confirmatory,16279780.0,
1666,282794,4,4,,104234169,126941,Active,,,1.5,EC50,Growth inhibition of methotrexate-transport-resistant human CCRF-CEM R2 cells after 120 hrs,Confirmatory,16279780.0,
1667,282795,4,5,,104234169,126941,Active,,,0.0145,EC50,Growth inhibition of methotrexate-resistant human CCRF-CEM R30dm cells expressing low levels of folyl-poly-glutamate synthetase after 120 hrs,Confirmatory,16279780.0,
1668,282800,3,4,,104234169,126941,Unspecified,,,,,Protection of drug-induced growth inhibition by 0.1 uM leucovorin in human CCRF-CEM cells assessed as growth at 20 nM relative to control,Other,16279780.0,
1669,282802,3,4,,104234169,126941,Unspecified,,,,,Protection of drug-induced growth inhibition by 1 uM leucovorin in human CCRF-CEM cells assessed as growth at 20 nM relative to control,Other,16279780.0,
1670,282804,3,4,,104234169,126941,Unspecified,,,,,Protection of drug-induced growth inhibition by 10 uM leucovorin in human CCRF-CEM cells assessed as growth at 20 nM relative to control,Other,16279780.0,
1671,282806,3,4,,104234169,126941,Unspecified,,,,,Cell growth in human CCRF-CEM cells at 20 nM relative to control,Other,16279780.0,
1672,282812,3,4,,104234169,126941,Unspecified,,,,,Cell growth in human CCRF-CEM cells at 40 nM relative to control,Other,16279780.0,
1673,288649,8,1,,104234169,126941,Active,,,0.00692,IC50,Antiproliferative activity against human HL60 cells after 48 hrs by trypan blue exclusion test,Confirmatory,17497807.0,
1674,291229,9,1,,104234169,126941,Active,,,0.0066,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,17552508.0,
1675,291230,9,5,,104234169,126941,Active,118992.0,1719.0,0.022000000000000002,IC50,Inhibition of human DHFR,Confirmatory,17552508.0,
1676,291230,9,5,,104234169,126941,Active,118992.0,573971.0,0.022000000000000002,IC50,Inhibition of human DHFR,Confirmatory,17552508.0,
1677,291231,3,3,,104234169,126941,Unspecified,,,,,Selectivity ratio of IC50 for human DHFR to IC50 for Escherichia coli DHFR,Other,17552508.0,
1678,291241,4,4,,104234169,126941,Active,,,0.0133,EC50,Growth inhibition of human CCRF-CEM cells,Confirmatory,17552508.0,
1679,291242,4,4,,104234169,126941,Active,,,0.41,EC50,Growth inhibition of methotrexate-resistant human CCRF-CEM R1 cells overexpressing DHFR,Confirmatory,17552508.0,
1680,291243,4,4,,104234169,126941,Active,,,1.95,EC50,Growth inhibition of human CCRF-CEM R2 cells with low methotrexate uptake,Confirmatory,17552508.0,
1681,291244,4,4,,104234169,126941,Active,,,0.0157,EC50,Growth inhibition of of methotrexate-resistant human CCRF-CEM R30dm cells expressing low levels of FPGS,Confirmatory,17552508.0,
1682,291245,3,4,,104234169,126941,Unspecified,,,,,Effect on growth of human CCRF-CEM cells at 40 nM in presence of 10 uM deoxycytidine relative to control,Other,17552508.0,
1683,291246,3,4,,104234169,126941,Unspecified,,,,,"Effect on growth of human CCRF-CEM cells at 40 nM in presence of 10 uM deoxycytidine, 5 uM thymidine relative to control",Other,17552508.0,
1684,291247,3,4,,104234169,126941,Unspecified,,,,,"Effect on growth of human CCRF-CEM cells at 40 nM in presence of 10 uM deoxycytidine, 10 uM hypoxanthine relative to control",Other,17552508.0,
1685,291248,3,4,,104234169,126941,Unspecified,,,,,"Effect on growth of human CCRF-CEM cells at 40 nM in presence of 10 uM deoxycytidine, 5 uM thymidine and 10 uM hypoxanthine relative to control",Other,17552508.0,
1686,291523,11,2,,104234169,126941,Active,118992.0,1719.0,0.02,IC50,Inhibition of human recombinant DHFR,Confirmatory,17569517.0,
1687,291523,11,2,,104234169,126941,Active,118992.0,573971.0,0.02,IC50,Inhibition of human recombinant DHFR,Confirmatory,17569517.0,
1688,291528,11,2,,104234169,126941,Active,7227951.0,,0.006,IC50,Inhibition of Lactobacillus casei DHFR,Confirmatory,17569517.0,
1689,291529,6,3,,104234169,126941,Unspecified,,,,,Growth inhibition of human SNB7 cells after 72 hrs,Other,17569517.0,
1690,291530,6,2,,104234169,126941,Unspecified,,,,,Growth inhibition of human DLD1 cells after 72 hrs,Other,17569517.0,
1691,291531,6,2,,104234169,126941,Unspecified,,,,,Growth inhibition of human NCI-H23 cells after 72 hrs,Other,17569517.0,
1692,291532,6,2,,104234169,126941,Unspecified,,,,,Growth inhibition of human ZR-75-1 cells after 72 hrs,Other,17569517.0,
1693,291533,6,2,,104234169,126941,Unspecified,,,,,Growth inhibition of human LOX IMVI cells after 72 hrs,Other,17569517.0,
1694,291534,6,2,,104234169,126941,Unspecified,,,,,Growth inhibition of human PC3 cells after 72 hrs,Other,17569517.0,
1695,291535,6,2,,104234169,126941,Unspecified,,,,,Growth inhibition of human CAKI1 cells after 72 hrs,Other,17569517.0,
1696,293066,6,2,,104234169,126941,Active,,,0.1,IC50,Antiproliferative activity against A549 cells after 72 hrs by MTT assay,Confirmatory,17127067.0,
1697,293067,6,3,,104234169,126941,Active,,,0.1,IC50,Antiproliferative activity against PPC1 cells after 72 hrs by MTT assay,Confirmatory,17127067.0,
1698,293068,6,3,,104234169,126941,Active,,,0.1,IC50,Antiproliferative activity against Tsu-Pr1 cells after 72 hrs by MTT assay,Confirmatory,17127067.0,
1699,293069,7,2,,104234169,126941,Active,,,0.035,IC50,Inhibition of DHFR using folic acid substrate,Confirmatory,17127067.0,
1700,293070,7,2,,104234169,126941,Active,,,0.009000000000000001,IC50,Inhibition of DHFR using dihydrofolic acid substrate,Confirmatory,17127067.0,
1701,293071,6,2,,104234169,126941,Active,,,0.02,IC50,Antiproliferative activity against A549 cells after 72 hrs in folate depleted media,Confirmatory,17127067.0,
1702,293072,6,3,,104234169,126941,Active,,,0.01,IC50,Antiproliferative activity against PPC1 cells after 72 hrs in folate depleted media,Confirmatory,17127067.0,
1703,293073,6,3,,104234169,126941,Active,,,0.008,IC50,Antiproliferative activity against Tsu-Pr1 cells after 72 hrs in folate depleted media,Confirmatory,17127067.0,
1704,295406,4,4,,104234169,126941,Active,,,0.12,IC50,Cytotoxicity against FKBP deficient MEF cells by MTT assay,Confirmatory,17383876.0,
1705,295407,4,4,,104234169,126941,Active,,,0.18,IC50,Cytotoxicity against mouse wild type fibroblast cells by MTT assay,Confirmatory,17383876.0,
1706,311524,4,3,,104234169,126941,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
1707,312253,9,5,,104234169,126941,Inconclusive,136611.0,7298.0,,IC50,Inhibition of human thymidylate synthase,Confirmatory,18072727.0,
1708,312254,10,4,,104234169,126941,Inconclusive,,,,IC50,Inhibition of Escherichia coli thymidylate synthase,Confirmatory,18072727.0,
1709,312255,6,2,,104234169,126941,Inconclusive,,,,IC50,Inhibition of Toxoplasma gondii thymidylate synthase,Confirmatory,18072727.0,
1710,312256,9,5,,104234169,126941,Active,118992.0,1719.0,0.02,IC50,Inhibition of human recombinant DHFR,Confirmatory,18072727.0,
1711,312256,9,5,,104234169,126941,Active,118992.0,573971.0,0.02,IC50,Inhibition of human recombinant DHFR,Confirmatory,18072727.0,
1712,312257,8,2,,104234169,126941,Active,,,0.0088,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,18072727.0,
1713,312258,6,2,,104234169,126941,Active,,,0.033,IC50,Inhibition of Toxoplasma gondii DHFR,Confirmatory,18072727.0,
1714,312259,3,3,,104234169,126941,Unspecified,,,,,Selectivity ratio of IC50 for Toxoplasma gondii DHFR over IC50 for human recombinant DHFR,Other,18072727.0,
1715,313040,11,2,,104234169,126941,Active,118992.0,1719.0,0.001,IC50,Inhibition of human recombinant DHFR,Confirmatory,18205293.0,
1716,313040,11,2,,104234169,126941,Active,118992.0,573971.0,0.001,IC50,Inhibition of human recombinant DHFR,Confirmatory,18205293.0,
1717,313041,3,3,,104234169,126941,Inactive,,,,,Activation of SMN2 promoter in human NSC34 cells assessed as induction of beta-lactamase activity at 30 uM,Other,18205293.0,
1718,320706,9,3,,104234169,126941,Unspecified,,,10000.0,IC50,Inhibition of PAD4 by ABPP-based assay,Confirmatory,17964793.0,
1719,341427,6,2,,104234169,126941,Active,,,0.0125,EC50,Cytotoxicity against human CCRF-CEM cells,Confirmatory,18605720.0,
1720,341428,9,5,,104234169,126941,Active,136611.0,7298.0,29.0,IC50,Inhibition of human thymidylate synthase,Confirmatory,18605720.0,
1721,341439,10,4,,104234169,126941,Unspecified,,,90.0,IC50,Inhibition of Escherichia coli thymidylate synthase,Confirmatory,18605720.0,
1722,341451,10,5,,104234169,126941,Active,729370.0,,18.0,IC50,Inhibition of Toxoplasma gondii thymidylate synthase,Confirmatory,18605720.0,
1723,341462,9,5,,104234169,126941,Active,118992.0,1719.0,0.022000000000000002,IC50,Inhibition of human dihydrofolate reductase,Confirmatory,18605720.0,
1724,341462,9,5,,104234169,126941,Active,118992.0,573971.0,0.022000000000000002,IC50,Inhibition of human dihydrofolate reductase,Confirmatory,18605720.0,
1725,341469,6,2,,104234169,126941,Active,,,0.0066,IC50,Inhibition of Escherichia coli dihydrofolate reductase,Confirmatory,18605720.0,
1726,341470,10,5,,104234169,126941,Active,729370.0,,0.011000000000000001,IC50,Inhibition of Toxoplasma gondii dihydrofolate reductase,Confirmatory,18605720.0,
1727,341471,3,3,,104234169,126941,Unspecified,,,,,Selectivity for Escherichia coli dihydrofolate reductase over human dihydrofolate reductase,Other,18605720.0,
1728,341472,3,3,,104234169,126941,Unspecified,,,,,Selectivity for sToxoplasma gondii dihydrofolate reductase over human dihydrofolate reductase,Other,18605720.0,
1729,349807,3,4,,104234169,126941,Inactive,,,,,Antitumor activity against human KB cells expressing human folate receptor alpha at 1 to 1000 nM after 10 days by colony-forming inhibition assay,Other,19371039.0,
1730,349812,3,9,,104234169,126941,Unspecified,544337.0,2348.0,,,Displacement of [3H]folic acid from human folate receptor alpha in chinese hamster RT16 cells assessed as relative binding affinity relative to folic acid,Other,19371039.0,
1731,349813,3,9,,104234169,126941,Unspecified,116241366.0,2350.0,,,Displacement of [3H]folic acid from human folate receptor beta in chinese hamster D4 cells assessed as relative binding affinity relative to folic acid,Other,19371039.0,
1732,355578,9,1,,104234169,126941,Active,,,4.4,IC50,Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay,Confirmatory,2778449.0,
1733,355579,3,5,,104234169,126941,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 10 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1734,355580,3,5,,104234169,126941,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1735,355581,3,5,,104234169,126941,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1736,355582,3,5,,104234169,126941,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1737,355583,9,1,,104234169,126941,Active,,,0.066,IC50,Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay,Confirmatory,2778449.0,
1738,355584,3,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1739,355585,3,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1740,355586,3,5,,104234169,126941,Inactive,,,,,Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1741,358555,7,2,,104234169,126941,Active,,,0.012,IC50,Cytotoxicity against human HL60 cells after 72 hrs by MTT assay,Confirmatory,11170674.0,
1742,360149,11,2,,104234169,126941,Unspecified,56404586.0,381203.0,602.56,Ki,Inhibition of mouse Oat6-mediated [3H]ES uptake in Xenopus oocytes after 1 hr,Confirmatory,17553798.0,
1743,360150,11,2,,104234169,126941,Unspecified,81901833.0,18399.0,891.2510000000001,Ki,Inhibition of mouse Oat1-mediated [3H]PAH uptake in Xenopus oocytes after 1 hr,Confirmatory,17553798.0,
1744,360151,3,4,,104234169,126941,Unspecified,,,,,Ratio of pKi for mouse Oat1 expressed in Xenopus oocytes to pKi for mouse Oat6 expressed in Xenopus oocytes,Other,17553798.0,
1745,360152,8,1,,104234169,126941,Inconclusive,56404586.0,381203.0,,,Activity of mouse Oat6 expressed in Xenopus oocytes assessed as drug uptake,Other,17553798.0,
1746,360153,7,1,,104234169,126941,Unspecified,81901833.0,18399.0,,,Activity of mouse Oat1 expressed in Xenopus oocytes assessed as drug uptake,Other,17553798.0,
1747,362421,4,3,,104234169,126941,Active,,,0.012,IC50,Antiproliferative activity against human RFC expressing Chinese hamster PC43-10 cells,Confirmatory,18680275.0,
1748,362422,4,4,,104234169,126941,Active,,,0.21600000000000003,IC50,Antiproliferative activity against human RFC expressing Chinese hamster R2 cells,Confirmatory,18680275.0,
1749,362423,4,3,,104234169,126941,Active,,,0.114,IC50,Antiproliferative activity against human FRalpha expressing Chinese hamster RT16 cells,Confirmatory,18680275.0,
1750,362424,4,3,,104234169,126941,Active,,,0.461,IC50,Antiproliferative activity against human FRalpha expressing Chinese hamster RT16 cells in presence of folic acid,Confirmatory,18680275.0,
1751,362425,4,3,,104234169,126941,Active,,,0.106,IC50,Antiproliferative activity against human FRbeta expressing Chinese hamster D4 cells,Confirmatory,18680275.0,
1752,362426,4,3,,104234169,126941,Active,,,0.21100000000000002,IC50,Antiproliferative activity against human FRbeta expressing Chinese hamster D4 cells in presence of folic acid,Confirmatory,18680275.0,
1753,362427,4,4,,104234169,126941,Active,,,0.006,IC50,Antiproliferative activity against human RFC and FRalpha expressing human KB cells,Confirmatory,18680275.0,
1754,362428,4,4,,104234169,126941,Active,,,0.02,IC50,Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid,Confirmatory,18680275.0,
1755,362429,4,4,,104234169,126941,Active,,,0.021,IC50,Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells,Confirmatory,18680275.0,
1756,362430,4,4,,104234169,126941,Active,,,0.022000000000000002,IC50,Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid,Confirmatory,18680275.0,
1757,362433,3,11,,104234169,126941,Unspecified,12643280.0,6573.0,,,Inhibition of human RFC-mediated [3H]MTX transport in Chinese hamster PC43-10 cells at 10 uM,Other,18680275.0,
1758,376373,6,2,,104234169,126941,Unspecified,,,,,Antitumor activity against mouse P388 cells,Other,10579858.0,
1759,376374,6,2,,104234169,126941,Unspecified,,,,,Antitumor activity against human A549 cells,Other,10579858.0,
1760,376375,6,2,,104234169,126941,Unspecified,,,,,Antitumor activity against human HT-29 cells,Other,10579858.0,
1761,376376,6,3,,104234169,126941,Unspecified,,,,,Antitumor activity against human SK MEL28 cells,Other,10579858.0,
1762,382739,5,2,,104234169,126941,Active,,,0.039810000000000005,GI50,Growth inhibition of human CCRF-CEM cells after 48 hrs by SRB staining method,Confirmatory,17532099.0,
1763,382774,5,2,,104234169,126941,Active,,,0.00251,GI50,Growth inhibition of human OVCAR4 cells after 48 hrs by SRB staining method,Confirmatory,17532099.0,
1764,382800,9,5,,104234169,126941,Active,118992.0,1719.0,4.42,Ki,Inhibition of human dihydrofolate reductase,Confirmatory,17532099.0,
1765,382800,9,5,,104234169,126941,Active,118992.0,573971.0,4.42,Ki,Inhibition of human dihydrofolate reductase,Confirmatory,17532099.0,
1766,386623,4,8,,104234169,126941,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
1767,391732,9,5,,104234169,126941,Inconclusive,136611.0,7298.0,,IC50,Inhibition of human thymidylate synthase,Confirmatory,18800768.0,
1768,391733,10,4,,104234169,126941,Inconclusive,,,,IC50,Inhibition of Escherichia coli thymidylate synthase,Confirmatory,18800768.0,
1769,391734,9,5,,104234169,126941,Active,118992.0,1719.0,0.02,IC50,Inhibition of human recombinant DHFR,Confirmatory,18800768.0,
1770,391734,9,5,,104234169,126941,Active,118992.0,573971.0,0.02,IC50,Inhibition of human recombinant DHFR,Confirmatory,18800768.0,
1771,391735,10,5,,104234169,126941,Inconclusive,729370.0,,,IC50,Inhibition of Toxoplasma gondii thymidylate synthase,Confirmatory,18800768.0,
1772,391736,9,5,,104234169,126941,Active,165971782.0,,0.0088,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,18800768.0,
1773,391737,10,5,,104234169,126941,Active,729370.0,,0.033,IC50,Inhibition of Toxoplasma gondii DHFR,Confirmatory,18800768.0,
1774,391738,6,2,,104234169,126941,Active,,,0.6,IC50,Selectivity ratio of IC50 for human recombinant DHFR to IC50 for Toxoplasma gondii DHFR,Confirmatory,18800768.0,
1775,404304,3,10,,104234169,126941,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
1776,406728,6,2,,104234169,126941,Active,,,0.04,IC50,Cytotoxicity against human Raji cells after 96 hrs by MTT assay,Confirmatory,18513976.0,
1777,409947,3,9,,104234169,126941,Inactive,113980.0,4129.0,,,Inhibition of human recombinant MAOB at 1 mM by fluorimetric method,Other,18834112.0,
1778,409952,3,9,,104234169,126941,Inactive,113980.0,4129.0,,,Inhibition of human brain MAOB,Other,18834112.0,
1779,412213,3,3,,104234169,126941,Unspecified,,,,,"Effect on oxazolone-induced delayed type hypersensitivity in mouse assessed as ear thickness at 50 mg/kg, iv after 7 days challenged with oxazolone on day 3",Other,19010675.0,
1780,412214,3,3,,104234169,126941,Unspecified,,,,,"Effect on oxazolone-induced delayed type hypersensitivity in mouse assessed as ear thickness at 50 mg/kg, iv after 14 days challenged with oxazolone on day 10",Other,19010675.0,
1781,412217,3,3,,104234169,126941,Unspecified,,,,,"Reduction in synovitis damage in Freund's adjuvant-induced arthritis Lewis rat model at 25 mg/kg, iv after 21 days relative to control",Other,19010675.0,
1782,416461,9,5,,104234169,126941,Active,118992.0,1719.0,0.03294,IC50,Inhibition of human recombinant DHFR by spectrophotometry,Confirmatory,18555562.0,
1783,416461,9,5,,104234169,126941,Active,118992.0,573971.0,0.03294,IC50,Inhibition of human recombinant DHFR by spectrophotometry,Confirmatory,18555562.0,
1784,416462,6,2,,104234169,126941,Active,,,0.1,IC50,Cytotoxicity against human HeLa cells after 48 hrs,Confirmatory,18555562.0,
1785,416463,6,3,,104234169,126941,Unspecified,,,82.3,IC50,Cytotoxicity against human Bel7402 cells after 48 hrs,Confirmatory,18555562.0,
1786,416464,6,2,,104234169,126941,Active,,,0.21,IC50,Cytotoxicity against human HL60 cells after 48 hrs,Confirmatory,18555562.0,
1787,416465,6,3,,104234169,126941,Active,,,0.11,IC50,Cytotoxicity against human BGC823 cells after 48 hrs,Confirmatory,18555562.0,
1788,418674,6,2,,104234169,126941,Active,,,0.016,IC50,Cytotoxicity against human 5637 cells after 96 hrs by crystal violet staining,Confirmatory,19243173.0,
1789,418675,6,3,,104234169,126941,Active,,,0.04,IC50,Cytotoxicity against human RT4 cells after 96 hrs by crystal violet staining,Confirmatory,19243173.0,
1790,418676,6,2,,104234169,126941,Active,,,5.52,IC50,Cytotoxicity against human A427 cells after 96 hrs by crystal violet staining,Confirmatory,19243173.0,
1791,418677,6,3,,104234169,126941,Active,,,0.025,IC50,Cytotoxicity against human LCLC-103H cells after 96 hrs by crystal violet staining,Confirmatory,19243173.0,
1792,418678,6,2,,104234169,126941,Active,,,0.077,IC50,Cytotoxicity against human DAN-G cells after 96 hrs by crystal violet staining,Confirmatory,19243173.0,
1793,418679,6,2,,104234169,126941,Active,,,0.05,IC50,Cytotoxicity against human MCF7 cells after 96 hrs by crystal violet staining,Confirmatory,19243173.0,
1794,422632,9,5,,104234169,126941,Inconclusive,136611.0,7298.0,,IC50,Inhibition of human thymidylate synthase,Confirmatory,19719239.0,
1795,422633,9,4,,104234169,126941,Inconclusive,,,,IC50,Inhibition of Escherichia coli thymidylate synthase,Confirmatory,19719239.0,
1796,422634,10,5,,104234169,126941,Inconclusive,729370.0,,,IC50,Inhibition of Toxoplasma gondii thymidylate synthase,Confirmatory,19719239.0,
1797,422635,9,5,,104234169,126941,Active,118992.0,1719.0,0.02,IC50,Inhibition of human recombinant dihydrofolate reductase,Confirmatory,19719239.0,
1798,422635,9,5,,104234169,126941,Active,118992.0,573971.0,0.02,IC50,Inhibition of human recombinant dihydrofolate reductase,Confirmatory,19719239.0,
1799,422636,6,2,,104234169,126941,Active,,,0.0088,IC50,Inhibition of Escherichia coli dihydrofolate reductase,Confirmatory,19719239.0,
1800,422637,10,5,,104234169,126941,Active,729370.0,,0.033,IC50,Inhibition of Toxoplasma gondii dihydrofolate reductase,Confirmatory,19719239.0,
1801,422638,3,4,,104234169,126941,Unspecified,,,,,Ratio of IC50 for human recombinant dihydrofolate reductase to IC50 for Toxoplasma gondii dihydrofolate reductase,Other,19719239.0,
1802,425652,7,2,,104234169,126941,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
1803,425653,7,2,,104234169,126941,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
1804,434955,1,2,,56463665,126941,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1805,434962,1,2,,56463665,126941,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1806,434973,1,3,,56463665,126941,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
1807,434989,1,1,,56463665,126941,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1808,435003,1,3,,56463665,126941,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1809,435005,1,1,,56463665,126941,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
1810,435022,2,2,,56463665,126941,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1811,435030,1,2,,56463665,126941,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1812,435030,1,2,,56463665,126941,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1813,444050,7,1,,104234169,126941,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
1814,444051,6,2,,104234169,126941,Unspecified,,,,,Total clearance in human,Other,20070106.0,
1815,444052,6,2,,104234169,126941,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
1816,444053,6,2,,104234169,126941,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
1817,444054,6,1,,104234169,126941,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
1818,444055,3,3,,104234169,126941,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
1819,444056,3,3,,104234169,126941,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
1820,444057,3,3,,104234169,126941,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
1821,444058,6,2,,104234169,126941,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
1822,444877,9,2,,104234169,126941,Active,21264503.0,,0.039,Ki,Inhibition of Leishmania major recombinant PTR1,Confirmatory,19916554.0,
1823,444878,5,2,,104234169,126941,Active,,,0.152,Ki,Inhibition of Trypanosoma brucei recombinant PTR1,Confirmatory,19916554.0,
1824,444880,3,3,,104234169,126941,Unspecified,,,,,Ratio of ED50 for Trypanosoma brucei brucei Lister 427 to Ki for Trypanosoma PTR1,Other,19916554.0,
1825,444881,3,3,,104234169,126941,Unspecified,,,,,Ratio of ED50 for Trypanosoma brucei brucei Lister 427 to Ki for Trypanosoma DHFR,Other,19916554.0,
1826,449728,1,2,,56463665,126941,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1827,449748,1,2,,56463665,126941,Inconclusive,,,,AC50_uM,Luminescence Cell-Based Dose Retest to Confirm Inhibitors of Cancer Stem Cells,Confirmatory,,
1828,449762,1,2,,56463665,126941,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1829,449763,1,3,,56463665,126941,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1830,452315,8,5,,104234169,126941,Active,1706542.0,13361.0,3e-06,Ki,Competitive inhibition of mouse DHFR by enzyme kinetics assay in presence of variable DHFA level,Confirmatory,19748785.0,
1831,452316,8,5,,104234169,126941,Active,118992.0,1719.0,7.7e-05,Ki,Inhibition of human DHFR in presence of variable DHFA level by enzyme kinetics assay,Confirmatory,19748785.0,
1832,452316,8,5,,104234169,126941,Active,118992.0,573971.0,7.7e-05,Ki,Inhibition of human DHFR in presence of variable DHFA level by enzyme kinetics assay,Confirmatory,19748785.0,
1833,452317,8,5,,104234169,126941,Active,81871579.0,24312.0,7.3e-05,Ki,Inhibition of rat liver DHFR by enzyme kinetics assay in presence of variable DHFA level,Confirmatory,19748785.0,
1834,452612,3,4,,104234169,126941,Inactive,,,,,Antivascular activity in HUVEC cells assessed as change in cell shape at 1 uM after 1 hr by fluorescent-labeled high molecular weight F-dextran permeability assay,Other,19837593.0,
1835,455986,3,5,,104234169,126941,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
1836,457192,10,2,,104234169,126941,Active,136611.0,7298.0,29.0,IC50,Inhibition of human thymidylate synthase at 30 degC under pH 7.4 by spectrophotometry,Confirmatory,20056546.0,
1837,457193,7,1,,104234169,126941,Unspecified,,,90.0,IC50,Inhibition of Escherichia coli TS at 30 degC under pH 7.4 by spectrophotometry,Confirmatory,20056546.0,
1838,457194,9,5,,104234169,126941,Active,729370.0,,18.0,IC50,Inhibition of Toxoplasma gondii TS at 30 degC under pH 7.4 by spectrophotometry,Confirmatory,20056546.0,
1839,457195,10,2,,104234169,126941,Active,118992.0,1719.0,0.022000000000000002,IC50,Inhibition of human DHFR at 30 degC under pH 7.4 by spectrophotometry,Confirmatory,20056546.0,
1840,457195,10,2,,104234169,126941,Active,118992.0,573971.0,0.022000000000000002,IC50,Inhibition of human DHFR at 30 degC under pH 7.4 by spectrophotometry,Confirmatory,20056546.0,
1841,457196,7,1,,104234169,126941,Active,,,0.0066,IC50,Inhibition of Escherichia coli DHFR at 30 degC under pH 7.4 by spectrophotometry,Confirmatory,20056546.0,
1842,457197,9,5,,104234169,126941,Active,729370.0,,0.011000000000000001,IC50,Inhibition of Toxoplasma gondii DHFR at 30 degC under pH 7.4 by spectrophotometry,Confirmatory,20056546.0,
1843,459863,3,9,,104234169,126941,Inactive,544337.0,2348.0,,,Displacement of [3H]folic acid from human FRalpha expressed in Chinese hamster RT16 cells relative to unlabeled folic acid,Other,20085328.0,
1844,459864,3,9,,104234169,126941,Inactive,116241366.0,2350.0,,,Displacement of [3H]folic acid from human FRbeta expressed in Chinese hamster D4 cells relative to unlabeled folic acid,Other,20085328.0,
1845,463074,1,3,,56463665,126941,Active,,,0.16,AC50_uM,Dose Response HTS Screen to Identify Cytotoxic Compounds of HMLE_sh_eGFP,Confirmatory,,
1846,463079,1,2,,56463665,126941,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1847,463082,1,1,,56463665,126941,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1848,463096,1,1,,50104777,126941,Inconclusive,,,0.1413,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
1849,463097,1,1,,50104777,126941,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
1850,463104,1,2,,56463665,126941,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1851,463106,1,2,,90340825,126941,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1852,463141,1,2,,56463665,126941,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1853,463189,1,1,,53777126,126941,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1854,463190,1,2,,56463665,126941,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1855,463195,1,2,,56463665,126941,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1856,463210,1,2,,56463665,126941,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1857,463212,1,1,,56463665,126941,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1858,472619,8,5,,104234169,126941,Active,109940075.0,508809.0,0.08,IC50,Inhibition of bovine DHFR after 2 mins,Confirmatory,20350811.0,
1859,472620,8,5,,104234169,126941,Active,118992.0,1719.0,0.08,IC50,Inhibition of human DHFR after 2 mins,Confirmatory,20350811.0,
1860,472620,8,5,,104234169,126941,Active,118992.0,573971.0,0.08,IC50,Inhibition of human DHFR after 2 mins,Confirmatory,20350811.0,
1861,476565,10,2,,104234169,126941,Active,118992.0,1719.0,0.022000000000000002,IC50,Inhibition of human DHFR,Confirmatory,20092323.0,
1862,476565,10,2,,104234169,126941,Active,118992.0,573971.0,0.022000000000000002,IC50,Inhibition of human DHFR,Confirmatory,20092323.0,
1863,476566,5,2,,104234169,126941,Active,,,0.0066,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,20092323.0,
1864,476741,5,2,,104234169,126941,Active,,,0.019,IC50,Inhibition of Toxoplasma gondii DHFR,Confirmatory,20092323.0,
1865,476929,3,3,,104234169,126941,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
1866,477295,3,3,,104234169,126941,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20106561.0,
1867,485270,1,1,,56463665,126941,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1868,485272,1,1,,56463665,126941,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1869,485273,2,1,,56463665,126941,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1870,485275,1,3,,56463665,126941,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1871,485281,1,1,,26752121,126941,Inactive,254220970.0,,31.6228,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1872,485290,1,1,,11113978,126941,Inconclusive,20150581.0,,63.0957,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1873,485290,1,1,,26752120,126941,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1874,485290,1,1,,26752121,126941,Inconclusive,20150581.0,,89.1251,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1875,485290,1,1,,50104777,126941,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1876,485295,1,2,,90340825,126941,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
1877,485297,1,1,,90340825,126941,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1878,485298,1,1,,90340825,126941,Inactive,,,7.3078,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1879,485313,1,2,,90340825,126941,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1880,485314,1,1,,50104777,126941,Active,4505931.0,5423.0,39.8107,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1881,485317,1,2,,56463665,126941,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
1882,485342,1,2,,90340825,126941,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1883,485345,1,2,,90340825,126941,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1884,485346,1,1,,56463665,126941,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1885,485346,1,1,,56463665,126941,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1886,485350,1,2,,92125176,126941,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1887,485366,1,2,,90340825,126941,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1888,485368,1,2,,90340825,126941,Active,72386991.0,3656265.0,37.933,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1889,488745,1,4,,50104777,126941,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1890,488752,1,4,,50104777,126941,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1891,488772,1,1,,90340825,126941,Inactive,8659577.0,58819.0,18.8876,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1892,488773,1,2,,90340825,126941,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1893,488816,1,1,,90340825,126941,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
1894,488837,1,1,,90340825,126941,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1895,488839,1,1,,56463665,126941,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1896,488839,1,1,,56463665,126941,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1897,488847,1,3,,56463665,126941,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1898,488862,1,1,,56463665,126941,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1899,488890,1,2,,56463665,126941,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1900,488895,1,2,,56463665,126941,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1901,488896,1,1,,56463665,126941,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1902,488899,1,1,,56463665,126941,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1903,488949,1,2,,50104777,126941,Active,41055989.0,54737.0,79.4328,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1904,488949,1,2,,90340825,126941,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1905,488953,1,1,,90340825,126941,Inconclusive,187960037.0,10951.0,56.2341,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1906,488965,1,2,,56463665,126941,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1907,488966,1,1,,56463665,126941,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1908,488975,1,2,,56463665,126941,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1909,488977,1,2,,56463665,126941,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1910,488978,1,1,,90340825,126941,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
1911,488979,1,1,,50104777,126941,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
1912,488980,1,1,,50104777,126941,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
1913,488981,1,1,,90340825,126941,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
1914,488982,1,1,,90340825,126941,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
1915,488983,1,1,,90340825,126941,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
1916,489028,1,2,,56463665,126941,Active,88702791.0,4194.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1917,489028,1,2,,56463665,126941,Active,89993689.0,4193.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1918,489030,2,1,,56463665,126941,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1919,489031,2,1,,56463665,126941,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1920,492953,1,1,,56463665,126941,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1921,492956,1,1,,56463665,126941,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1922,492961,1,1,,26752120,126941,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
1923,492967,1,2,,92125176,126941,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1924,492967,1,2,,99301202,126941,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1925,492972,1,1,,56463665,126941,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1926,493005,1,1,,56463665,126941,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1927,493008,1,1,,56463665,126941,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1928,493008,1,1,,56463665,126941,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1929,493008,1,1,,56463665,126941,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1930,493008,1,1,,56463665,126941,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1931,493011,1,1,,56463665,126941,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1932,493012,1,1,,56463665,126941,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1933,493033,1,2,,92125176,126941,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1934,493036,1,2,,56463665,126941,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1935,493087,1,1,,56463665,126941,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1936,493091,1,1,,56463665,126941,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1937,493098,1,1,,56463665,126941,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1938,493106,1,1,,90340825,126941,Inactive,116283940.0,79915.0,0.2592,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1939,493107,1,1,,90340825,126941,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1940,493127,1,1,,50104777,126941,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
1941,493131,1,1,,56463665,126941,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1942,493140,1,1,,103913884,126941,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
1943,493153,1,1,,90340825,126941,Active,,4780.0,0.5805,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1944,493153,1,1,,90340825,126941,Active,224028257.0,4780.0,0.5805,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1945,493160,1,1,,56463665,126941,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1946,493162,1,2,,99301202,126941,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1947,493164,1,2,,90340825,126941,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1948,493164,1,2,,90340825,126941,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1949,493164,1,2,,90340825,126941,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1950,493187,1,2,,56463665,126941,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1951,493189,1,1,,50104777,126941,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
1952,493244,1,1,,56463665,126941,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1953,493244,1,1,,56463665,126941,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1954,493244,1,1,,56463665,126941,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1955,493244,1,1,,56463665,126941,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1956,501899,4,2,,104234169,126941,Active,,,1.1,EC50,Cytotoxicity again human Caco-2 cells assessed as cell viability by XTT assay,Confirmatory,20674353.0,
1957,501900,4,2,,104234169,126941,Active,,,0.9,EC50,Cytotoxicity again human MCF7 cells assessed as cell viability by XTT assay,Confirmatory,20674353.0,
1958,501901,4,2,,104234169,126941,Unspecified,,,80.0,EC50,Cytotoxicity again human MDA-MB-231 cells assessed as cell viability by XTT assay,Confirmatory,20674353.0,
1959,504326,1,2,,56463665,126941,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1960,504326,1,2,,56463665,126941,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1961,504327,1,1,,11113978,126941,Inconclusive,153791535.0,2648.0,35.4813,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1962,504327,1,1,,26752120,126941,Inconclusive,153791535.0,2648.0,31.6228,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1963,504327,1,1,,26752121,126941,Inconclusive,153791535.0,2648.0,14.1254,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1964,504327,1,1,,90340825,126941,Inconclusive,153791535.0,2648.0,22.3872,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1965,504329,1,1,,56463665,126941,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1966,504332,1,1,,26752120,126941,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1967,504332,1,1,,26752121,126941,Inconclusive,168985070.0,,12.5893,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1968,504332,1,1,,50104777,126941,Active,168985070.0,,7.9433,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1969,504332,1,1,,90340825,126941,Active,168985070.0,,7.5193,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1970,504339,1,1,,56463665,126941,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1971,504357,1,1,,56463665,126941,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1972,504357,1,1,,56463665,126941,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1973,504364,1,1,,50104777,126941,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
1974,504406,1,1,,56463665,126941,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1975,504411,1,1,,56463665,126941,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1976,504414,1,1,,56463665,126941,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1977,504414,1,1,,56463665,126941,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1978,504423,1,1,,56463665,126941,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1979,504441,1,1,,56463665,126941,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1980,504444,1,1,,56463665,126941,Active,224028257.0,4780.0,1.4581,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1981,504454,1,3,,56463665,126941,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1982,504462,1,1,,56463665,126941,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1983,504490,1,2,,56463665,126941,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1984,504523,1,1,,56463665,126941,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1985,504523,1,1,,56463665,126941,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1986,504536,1,1,,90340825,126941,Inconclusive,5453898.0,5300.0,23.9341,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
1987,504547,1,1,,90340825,126941,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1988,504548,1,2,,90340825,126941,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
1989,504558,1,1,,56463665,126941,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1990,504577,2,2,,56463665,126941,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1991,504582,2,1,,56463665,126941,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1992,504607,1,1,,56463665,126941,Inactive,,,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Full-Length Luciferase Counterscreen assay,Screening,,
1993,504621,1,1,,56463665,126941,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1994,504634,1,1,,56463665,126941,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1995,504648,1,1,,56463665,126941,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1996,504668,1,1,,56463665,126941,Active,728984.0,672.0,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,Screening,,
1997,504668,1,1,,56463665,126941,Active,116241265.0,580.0,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,Screening,,
1998,504690,1,3,,56463665,126941,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1999,504692,2,2,,56463665,126941,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
2000,504700,1,1,,56463665,126941,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
2001,504700,1,1,,56463665,126941,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
2002,504707,1,1,,56463665,126941,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
2003,504707,1,1,,56463665,126941,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
2004,504720,1,1,,56463665,126941,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
2005,504734,1,1,,56463665,126941,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
2006,504749,1,3,,26752120,126941,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2007,504749,1,3,1.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2008,504749,1,3,2.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2009,504749,1,3,3.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2010,504749,1,3,4.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2011,504749,1,3,5.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2012,504749,1,3,6.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2013,504749,1,3,7.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2014,504749,1,3,8.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2015,504749,1,3,9.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2016,504749,1,3,10.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2017,504749,1,3,11.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2018,504749,1,3,12.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2019,504749,1,3,13.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2020,504749,1,3,14.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2021,504749,1,3,15.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2022,504749,1,3,16.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2023,504749,1,3,17.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2024,504749,1,3,18.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2025,504749,1,3,19.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2026,504749,1,3,20.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2027,504749,1,3,21.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2028,504749,1,3,22.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2029,504749,1,3,23.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2030,504749,1,3,24.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2031,504749,1,3,25.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2032,504749,1,3,26.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2033,504749,1,3,27.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2034,504749,1,3,28.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2035,504749,1,3,29.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2036,504749,1,3,30.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2037,504749,1,3,31.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2038,504749,1,3,32.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2039,504749,1,3,33.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2040,504749,1,3,34.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2041,504749,1,3,35.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2042,504749,1,3,36.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2043,504749,1,3,37.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2044,504749,1,3,38.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2045,504749,1,3,39.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2046,504749,1,3,40.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2047,504749,1,3,41.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2048,504749,1,3,42.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2049,504749,1,3,43.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2050,504749,1,3,44.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2051,504749,1,3,45.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2052,504749,1,3,46.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2053,504749,1,3,47.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2054,504749,1,3,48.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2055,504749,1,3,49.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2056,504749,1,3,50.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2057,504749,1,3,51.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2058,504749,1,3,52.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2059,504749,1,3,53.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2060,504749,1,3,54.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2061,504749,1,3,55.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2062,504749,1,3,56.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2063,504749,1,3,57.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2064,504749,1,3,58.0,26752120,126941,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2065,504749,1,3,59.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2066,504749,1,3,60.0,26752120,126941,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2067,504749,1,3,61.0,26752120,126941,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2068,504766,2,1,,56463665,126941,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
2069,504775,1,1,,56463665,126941,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
2070,504803,1,1,,56463665,126941,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
2071,504810,1,2,,90340825,126941,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2072,504812,1,2,,90340825,126941,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2073,504821,1,1,,50104777,126941,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
2074,504832,1,1,,26752120,126941,Active,,,0.0426,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2075,504834,1,1,,26752120,126941,Active,,,1.6944,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2076,504836,1,2,,90340825,126941,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
2077,504845,1,1,,11113978,126941,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2078,504845,1,1,,26752121,126941,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2079,504845,1,1,,56463665,126941,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2080,504845,1,1,,90340825,126941,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2081,504847,1,1,,11113978,126941,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2082,504847,1,1,,26752120,126941,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2083,504847,1,1,,26752121,126941,Active,63054845.0,7421.0,39.8107,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2084,504847,1,1,,56463665,126941,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2085,504847,1,1,,90340825,126941,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2086,504865,1,1,,11113978,126941,Inconclusive,118600387.0,7398.0,56.2341,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2087,504865,1,1,,26752120,126941,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2088,504865,1,1,,90340825,126941,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2089,504884,1,2,,56463665,126941,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2090,504891,1,1,,56463665,126941,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
2091,504894,1,1,,56463665,126941,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
2092,504937,1,2,,56463665,126941,Inactive,179095.0,6609.0,31.6228,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
2093,514214,6,5,,104234169,126941,Active,7227951.0,,0.005,IC50,Inhibition of Lactobacillus casei DHFR by spectrophotometric analysis,Confirmatory,20580561.0,
2094,514216,6,1,,104234169,126941,Active,,,0.005,IC50,Antiproliferative activity against human A549 cells after 72 hrs by MTT assay,Confirmatory,20580561.0,
2095,514217,6,1,,104234169,126941,Active,,,0.001,IC50,Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,20580561.0,
2096,521220,3,3,,104234169,126941,Active,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
2097,524790,7,2,,104234169,126941,Active,,,7e-05,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2098,524791,7,2,,104234169,126941,Active,,,0.00011,IC50,Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2099,524792,7,2,,104234169,126941,Active,,,4e-05,IC50,Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2100,524793,7,2,,104234169,126941,Active,,,9e-05,IC50,Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2101,524794,7,1,,104234169,126941,Active,,,4e-05,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2102,524795,7,2,,104234169,126941,Active,,,7e-05,IC50,Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2103,524796,7,1,,104234169,126941,Active,,,4e-05,IC50,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2104,536795,4,2,,104234169,126941,Unspecified,,,,,Cytotoxicity against human Caco-2 cells after 48 hrs by MTT assay,Other,20846760.0,
2105,536796,4,2,,104234169,126941,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay,Other,20846760.0,
2106,536797,4,2,,104234169,126941,Unspecified,,,,,Cytotoxicity against human T47D cells after 48 hrs by MTT assay,Other,20846760.0,
2107,537733,2,3,,104234169,126941,Inactive,,,,,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Other,20739103.0,
2108,537734,5,2,,104234169,126941,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay,Other,20739103.0,
2109,537735,2,3,,104234169,126941,Active,,,,,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Other,20739103.0,
2110,537736,5,2,,104234169,126941,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay,Other,20739103.0,
2111,540209,4,3,,104234169,126941,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
2112,540210,4,3,,104234169,126941,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
2113,540211,2,5,,104234169,126941,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
2114,540212,4,3,,104234169,126941,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
2115,540213,4,3,,104234169,126941,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
2116,540214,4,3,,104234169,126941,Unspecified,,,,,Clearance in rat after iv administration,Other,15920768.0,
2117,540215,3,2,,104234169,126941,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,15920768.0,
2118,540216,4,3,,104234169,126941,Unspecified,,,,,Clearance in dog after iv administration,Other,15920768.0,
2119,540217,4,3,,104234169,126941,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,15920768.0,
2120,540218,4,3,,104234169,126941,Unspecified,,,,,Clearance in monkey after iv administration,Other,15920768.0,
2121,540219,4,3,,104234169,126941,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,15920768.0,
2122,540220,4,3,,104234169,126941,Unspecified,,,,,Clearance in human after iv administration,Other,15920768.0,
2123,540221,4,3,,104234169,126941,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,15920768.0,
2124,540235,1,3,,104234169,126941,Inactive,,,,,Phospholipidosis-negative literature compound,Other,17428028.0,
2125,540253,1,1,,56463665,126941,Inconclusive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2126,540253,1,1,,56463665,126941,Inconclusive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2127,540253,1,1,,56463665,126941,Inconclusive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2128,540256,1,2,,50104777,126941,Inconclusive,,,0.1413,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2129,540256,1,2,,90340825,126941,Inconclusive,,,0.231,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2130,540263,1,1,,56463665,126941,Inconclusive,5031833.0,10073.0,112.20200000000001,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2131,540263,1,1,,56463665,126941,Inconclusive,19923142.0,3837.0,112.20200000000001,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2132,540267,1,1,,56463665,126941,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
2133,540276,1,2,,11113978,126941,Active,420597.0,,0.0398,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2134,540276,1,2,,26752120,126941,Active,420597.0,,0.0398,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2135,540276,1,2,,26752121,126941,Active,420597.0,,0.0398,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2136,540276,1,2,,26752122,126941,Active,420597.0,,0.0398,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2137,540276,1,2,,50104777,126941,Active,420597.0,,0.0398,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2138,540276,1,2,,50104778,126941,Active,420597.0,,0.0398,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2139,540276,1,2,,56463665,126941,Active,420597.0,,0.0398,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2140,540276,1,2,,90340825,126941,Inconclusive,420597.0,,0.1458,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2141,540295,1,1,,56463665,126941,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
2142,540299,1,2,,92125176,126941,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2143,540303,1,1,,56463665,126941,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2144,540303,1,1,,56463665,126941,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2145,540303,1,1,,56463665,126941,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2146,540308,1,1,,56463665,126941,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
2147,540317,1,1,,56463665,126941,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2148,540336,1,1,,56463665,126941,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2149,540336,1,1,,56463665,126941,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2150,540364,1,2,,56463665,126941,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
2151,559547,3,2,,104234169,126941,Active,,,0.04,IC50,"Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum V1S expressing DHFR quadruple mutant with point mutations at codons 108, 51, 59 and 164 gene by [3H]hypoxanthine incorporation assay",Confirmatory,19528269.0,
2152,559548,2,4,,104234169,126941,Active,,,0.0499,IC50,Antimalarial activity against pyrimethamine-sensitive Plasmodium falciparum 3D7 expressing wild type DHFR by [3H]hypoxanthine incorporation assay,Confirmatory,19528269.0,
2153,559549,2,3,,104234169,126941,Active,,,0.0836,IC50,Antimalarial activity against Plasmodium falciparum Kenyan isolates by [3H]hypoxanthine incorporation assay,Confirmatory,19528269.0,
2154,560256,2,3,,104234169,126941,Active,,,0.08489,IC50,Antimalarial activity against Plasmodium falciparum Kenyan isolates expressing DHFR Ser108Asn and Cys59Arg or Ser108Asn and Asn51Ile double mutant by [3H]hypoxanthine incorporation assay,Confirmatory,19528269.0,
2155,560257,2,3,,104234169,126941,Active,,,0.08359,IC50,"Antimalarial activity against Plasmodium falciparum Kenyan isolates expressing DHFR Ser108Asn, Asn51Ile and Cys59Arg triple mutant by [3H]hypoxanthine incorporation assay",Confirmatory,19528269.0,
2156,560258,3,2,,104234169,126941,Active,,,0.05662999999999999,IC50,"Antimalarial activity against Plasmodium falciparum isolate Kil-164 expressing DHFR Ser108Asn, Asn51Ile, Cys59Arg and Ile164Leu quadruple mutant by [3H]hypoxanthine incorporation assay",Confirmatory,19528269.0,
2157,561835,9,2,,104234169,126941,Active,81715208.0,,0.015,IC50,Inhibition of Bacillus anthracis DHFR,Confirmatory,19364848.0,
2158,562110,2,4,,104234169,126941,Active,,,0.063,IC50,Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay,Confirmatory,19364853.0,
2159,567387,7,1,,104234169,126941,Unspecified,,,,GI50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
2160,567388,7,1,,104234169,126941,Unspecified,,,,GI50,Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
2161,567389,4,2,,104234169,126941,Active,,,0.03,GI50,Cytotoxicity against human K562 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
2162,567390,4,2,,104234169,126941,Inconclusive,,,,GI50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
2163,567391,4,2,,104234169,126941,Active,,,0.1,GI50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
2164,567392,4,3,,104234169,126941,Inconclusive,,,,GI50,Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay,Confirmatory,21115210.0,
2165,571507,3,3,,104234169,126941,Active,,,0.0686,IC50,Inhibition of Babesia gibsoni Dihydrofolate reductase-thymidylate synthase expressed in Escherichia coli BL21,Confirmatory,18794380.0,
2166,571508,3,3,,104234169,126941,Active,,,,,Antiparasitic activity against Babesia gibsoni infected in dog erythrocytes assessed as growth inhibition at 50 nM by Giemsa staining based microscopy,Other,18794380.0,
2167,571509,3,3,,104234169,126941,Active,,,,,Antiparasitic activity against Babesia gibsoni infected in dog erythrocytes assessed as growth inhibition at 150 nM by Giemsa staining based microscopy,Other,18794380.0,
2168,588208,2,3,,104234169,126941,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
2169,588209,2,3,,104234169,126941,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
2170,588210,2,4,,104234169,126941,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
2171,588211,2,3,,104234169,126941,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
2172,588212,2,3,,104234169,126941,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
2173,588213,2,3,,104234169,126941,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
2174,588214,2,3,,104234169,126941,Active,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
2175,588215,2,3,,104234169,126941,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
2176,588216,2,3,,104234169,126941,Active,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
2177,588217,2,3,,104234169,126941,Active,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
2178,588218,2,3,,104234169,126941,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
2179,588219,2,3,,104234169,126941,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
2180,588334,1,1,,56463665,126941,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
2181,588335,1,1,,56463665,126941,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
2182,588349,1,1,,90340825,126941,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
2183,588352,1,2,,56463665,126941,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
2184,588354,1,1,,56463665,126941,Active,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
2185,588358,1,2,,56463665,126941,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
2186,588378,1,1,,90340825,126941,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
2187,588379,1,2,,11113978,126941,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
2188,588391,1,1,,56463665,126941,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2189,588405,1,1,,56463665,126941,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
2190,588413,1,2,,56463665,126941,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
2191,588436,1,1,,56463665,126941,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2192,588453,1,1,,50104777,126941,Inactive,8659577.0,58819.0,56.2341,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2193,588453,1,1,,56463665,126941,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2194,588453,1,1,,90340825,126941,Inactive,8659577.0,58819.0,17.7828,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2195,588453,1,1,,124886991,126941,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2196,588456,1,1,,56463665,126941,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2197,588456,1,1,,90340825,126941,Inactive,8659577.0,58819.0,25.1189,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2198,588456,1,1,,124886991,126941,Inactive,8659577.0,58819.0,56.2341,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2199,588458,1,1,,56463665,126941,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
2200,588473,1,1,,56463665,126941,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2201,588473,1,1,,56463665,126941,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2202,588475,1,2,,56463665,126941,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2203,588475,1,2,,56463665,126941,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2204,588478,1,2,,124800664,126941,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
2205,588489,1,1,,56463665,126941,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
2206,588492,1,1,,56463665,126941,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
2207,588493,1,2,,56463665,126941,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
2208,588497,1,2,,56463665,126941,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
2209,588497,1,2,,56463665,126941,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
2210,588497,1,2,,56463665,126941,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
2211,588499,1,3,,56463665,126941,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
2212,588499,1,3,,56463665,126941,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
2213,588499,1,3,,56463665,126941,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
2214,588501,1,2,,56463665,126941,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
2215,588501,1,2,,56463665,126941,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
2216,588501,1,2,,56463665,126941,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
2217,588511,1,2,,56463665,126941,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
2218,588513,1,1,,26752122,126941,Inconclusive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
2219,588514,1,1,,26752122,126941,Inconclusive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
2220,588515,1,1,,26752122,126941,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
2221,588516,1,1,,26752122,126941,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
2222,588519,1,2,,92125176,126941,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2223,588526,1,1,,26752122,126941,Inconclusive,325495553.0,9971.0,0.1585,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
2224,588527,1,1,,26752122,126941,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
2225,588532,1,1,,26752122,126941,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
2226,588533,1,1,,26752122,126941,Inconclusive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
2227,588534,1,1,,26752122,126941,Inconclusive,216409690.0,5467.0,1.4125,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2228,588535,1,1,,26752122,126941,Inconclusive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2229,588536,1,1,,26752122,126941,Inconclusive,216409692.0,5468.0,0.2818,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2230,588537,1,1,,26752122,126941,Active,216409692.0,5468.0,0.4467,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2231,588541,1,1,,26752122,126941,Inconclusive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
2232,588543,1,1,,26752122,126941,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
2233,588544,1,1,,26752122,126941,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
2234,588545,1,1,,26752122,126941,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
2235,588546,1,1,,26752122,126941,Inconclusive,325495497.0,6256.0,0.1122,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
2236,588547,1,1,,26752122,126941,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
2237,588549,1,1,,56463665,126941,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2238,588579,1,1,,11113978,126941,Inconclusive,7705344.0,51426.0,14.1254,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2239,588579,1,1,,26752120,126941,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2240,588579,1,1,,26752121,126941,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2241,588579,1,1,,56463665,126941,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2242,588579,1,1,,90340825,126941,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2243,588579,1,1,,124886991,126941,Inconclusive,7705344.0,51426.0,79.4328,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2244,588590,1,1,,50104777,126941,Active,154350220.0,11201.0,31.6228,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2245,588590,1,1,,56463665,126941,Inactive,154350220.0,11201.0,100.0,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2246,588590,1,1,,124886991,126941,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2247,588591,1,1,,50104777,126941,Active,5729982.0,5429.0,31.6228,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2248,588591,1,1,,56463665,126941,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2249,588621,1,1,,56463665,126941,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
2250,588627,1,1,,56463665,126941,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
2251,588664,1,2,,56463665,126941,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2252,588664,1,2,,56463665,126941,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2253,588674,1,2,,56463665,126941,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2254,588675,1,1,,56463665,126941,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
2255,588676,1,1,,56463665,126941,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
2256,588689,1,1,,56463665,126941,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
2257,588692,2,1,,56463665,126941,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2258,588726,1,2,,56463665,126941,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
2259,588727,1,1,,56463665,126941,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
2260,588792,1,1,,56463665,126941,Active,32307126.0,8202.0,,,Luminescence-based cell-based high throughput confirmation assay for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
2261,588794,1,1,,56463665,126941,Inactive,9629429.0,,,,Counterscreen for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),Screening,,
2262,588795,1,1,,56463665,126941,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2263,588795,1,1,,90340825,126941,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2264,588795,1,1,,124886991,126941,Inconclusive,4758356.0,2237.0,50.1187,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2265,588814,1,3,,56463665,126941,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
2266,588819,1,4,,56463665,126941,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
2267,588820,1,1,,56463665,126941,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based high throughput confirmation assay for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1).,Screening,,
2268,588824,1,1,,56463665,126941,Inactive,9629429.0,,,,Counterscreen for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16).,Screening,,
2269,588834,2,1,,50104777,126941,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2270,588834,2,1,,144204495,126941,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2271,588850,1,1,,56463665,126941,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
2272,588852,1,3,,56463665,126941,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
2273,588855,1,1,,56463665,126941,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2274,588855,1,1,,124886991,126941,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2275,588856,1,1,,56463665,126941,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2276,588856,1,1,,124886991,126941,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2277,588964,1,10,,104234169,126941,Unspecified,74762955.0,9356.0,,,"Substrates of transporters of clinical importance in the absorption and disposition of drugs, OAT1",Other,20190787.0,
2278,588967,1,10,,104234169,126941,Unspecified,1171882.0,6579.0,,,"Substrates of transporters of clinical importance in the absorption and disposition of drugs, OATP1A2",Other,20190787.0,
2279,588975,1,10,,104234169,126941,Unspecified,67462103.0,9429.0,,,"Substrates of transporters of clinical importance in the absorption and disposition of drugs, BCRP",Other,20190787.0,
2280,588977,1,10,,104234169,126941,Unspecified,308153583.0,1244.0,,,"Substrates of transporters of clinical importance in the absorption and disposition of drugs, MRP2",Other,20190787.0,
2281,588978,1,10,,104234169,126941,Unspecified,6920069.0,8714.0,,,"Substrates of transporters of clinical importance in the absorption and disposition of drugs, MPR3",Other,20190787.0,
2282,588979,1,9,,104234169,126941,Unspecified,206729914.0,10257.0,,,"Substrates of transporters of clinical importance in the absorption and disposition of drugs, MRP4",Other,20190787.0,
2283,592681,1,4,,104234169,126941,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
2284,602123,1,1,,56463665,126941,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
2285,602141,1,1,,56463665,126941,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
2286,602162,1,1,,56463665,126941,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
2287,602163,1,1,,56463665,126941,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
2288,602166,1,1,,56463665,126941,Inactive,32307126.0,8202.0,35.879,IC50,Luminescence-based cell-based high throughput dose response assay for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Confirmatory,,
2289,602167,1,1,,56463665,126941,Inactive,9629429.0,,35.879,IC50,Counterscreen for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3): Luminescence-based cell-based high throughput dose response assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),Confirmatory,,
2290,602168,1,1,,56463665,126941,Inactive,22538455.0,8648.0,35.879,IC50,Counterscreen for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3): Luminescence-based cell-based high throughput dose response assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Confirmatory,,
2291,602179,1,2,,56463665,126941,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
2292,602229,1,1,,56463665,126941,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
2293,602233,1,1,,56463665,126941,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2294,602234,1,1,,56463665,126941,Active,32307126.0,8202.0,0.21097,IC50,Counterscreen for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1): Luminescence-based cell-based high throughput dose response assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Confirmatory,,
2295,602235,1,1,,56463665,126941,Inactive,22538455.0,8648.0,35.879,IC50,Luminescence-based cell-based high throughput dose response assay for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Confirmatory,,
2296,602236,1,1,,56463665,126941,Inactive,9629429.0,,35.879,IC50,Counterscreen for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1): Luminescence-based cell-based high throughput dose response assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),Confirmatory,,
2297,602244,1,2,,56463665,126941,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
2298,602247,1,2,,56463665,126941,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2299,602248,1,2,,56463665,126941,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2300,602250,1,2,,56463665,126941,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
2301,602252,1,1,,56463665,126941,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2302,602252,1,1,,56463665,126941,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2303,602261,1,1,,56463665,126941,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
2304,602274,1,2,,56463665,126941,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
2305,602281,1,1,,56463665,126941,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2306,602281,1,1,,56463665,126941,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2307,602310,1,2,,56463665,126941,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2308,602310,1,2,,124886991,126941,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2309,602313,1,1,,56463665,126941,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
2310,602314,1,2,,92125176,126941,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2311,602329,1,1,,56463665,126941,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2312,602332,1,1,,11113978,126941,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2313,602332,1,1,,26752120,126941,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2314,602332,1,1,,26752121,126941,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2315,602332,1,1,,56463665,126941,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2316,602332,1,1,,90340825,126941,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2317,602332,1,1,,124886991,126941,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2318,602340,1,2,,56463665,126941,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
2319,602342,2,1,,56463665,126941,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2320,602346,1,1,,56463665,126941,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2321,602363,1,1,,56463665,126941,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2322,602393,1,1,,56463665,126941,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2323,602396,1,2,,56463665,126941,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
2324,602399,1,2,,56463665,126941,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
2325,602405,1,1,,56463665,126941,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2326,602410,1,1,,56463665,126941,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
2327,602429,1,1,,56463665,126941,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
2328,602438,1,1,,56463665,126941,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
2329,602440,1,1,,56463665,126941,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
2330,602449,1,2,,56463665,126941,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
2331,602481,1,1,,56463665,126941,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2332,604020,1,4,,104234169,126941,Active,,,,,Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
2333,604021,3,1,,104234169,126941,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
2334,604022,1,4,,104234169,126941,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
2335,604023,1,3,,104234169,126941,Unspecified,,,,,Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
2336,604024,1,3,,104234169,126941,Unspecified,,,,,Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr,Other,19764786.0,
2337,604025,1,4,,104234169,126941,Unspecified,,,,,Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
2338,604026,1,4,,104234169,126941,Unspecified,,,,,Unbound CSF to plasma concentration ratio in human,Other,19764786.0,
2339,605421,5,5,,104234169,126941,Active,109940075.0,508809.0,0.0034,IC50,Inhibition of bovine liver DHFR using dihydrofolic acid substrate by UV-visible spectrophotometry,Confirmatory,20036565.0,
2340,605422,1,4,,104234169,126941,Active,,,0.0374,IC50,Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion method,Confirmatory,20036565.0,
2341,605426,1,4,,104234169,126941,Unspecified,,,,,Growth inhibition of human A549 cells assessed as cell growth at 370 nM after 72 hrs by fluorometric microculture cytotoxicity assay in presence of 100 uM hypoxanthine relative to untreated control,Other,20036565.0,
2342,605427,1,4,,104234169,126941,Unspecified,,,,,Growth inhibition of human A549 cells assessed as cell growth at 370 nM after 72 hrs by fluorometric microculture cytotoxicity assay in presence of 20 uM thymidine relative to untreated control,Other,20036565.0,
2343,605428,1,4,,104234169,126941,Unspecified,,,,,Growth inhibition of human A549 cells assessed as cell growth at 370 nM after 72 hrs by fluorometric microculture cytotoxicity assay in presence of 100 uM hypoxanthine and 20 uM thymidine relative to untreated control,Other,20036565.0,
2344,605433,1,4,,104234169,126941,Unspecified,,,,,Growth inhibition of human A549 cells assessed as cell growth at 370 nM after 72 hrs by fluorometric microculture cytotoxicity assay relative to untreated control,Other,20036565.0,
2345,613093,6,5,,104234169,126941,Unspecified,136611.0,7298.0,18.0,IC50,Inhibition of human TS assessed as oxidation of tetrahydrofolate to dihydrofolate after 2 to 12 mins by spectrophotometry,Confirmatory,21550809.0,
2346,613094,6,5,,104234169,126941,Unspecified,220980066.0,7547161.0,18.0,IC50,Inhibition of Escherichia coli TS assessed as oxidation of tetrahydrofolate to dihydrofolate after 2 to 12 mins by spectrophotometry,Confirmatory,21550809.0,
2347,613095,7,5,,104234169,126941,Unspecified,729370.0,,18.0,IC50,Inhibition of Toxoplasma gondii TS assessed as oxidation of tetrahydrofolate to dihydrofolate after 2 to 12 mins by spectrophotometry,Confirmatory,21550809.0,
2348,613096,6,5,,104234169,126941,Active,118992.0,1719.0,0.022000000000000002,IC50,Inhibition of human DHFR by spectrophotometry,Confirmatory,21550809.0,
2349,613096,6,5,,104234169,126941,Active,118992.0,573971.0,0.022000000000000002,IC50,Inhibition of human DHFR by spectrophotometry,Confirmatory,21550809.0,
2350,613097,3,2,,104234169,126941,Active,,,0.0044,IC50,Inhibition of Escherichia coli DHFR by spectrophotometry,Confirmatory,21550809.0,
2351,613098,7,5,,104234169,126941,Active,729370.0,,0.022000000000000002,IC50,Inhibition of Toxoplasma gondii DHFR by spectrophotometry,Confirmatory,21550809.0,
2352,613101,1,4,,104234169,126941,Unspecified,,,,,"Selectivity index, ratio of IC50 for human DHFR to IC50 for Escherichia coli DHFR",Other,21550809.0,
2353,616653,3,2,,104234169,126941,Active,,,10.25,GI50,Growth inhibition of human NCI-H226 cells after 72 hrs by MTT assay,Confirmatory,21802949.0,
2354,616654,3,2,,104234169,126941,Active,,,0.1,GI50,Growth inhibition of human NPC-TW01 cells after 72 hrs by MTT assay,Confirmatory,21802949.0,
2355,616655,3,2,,104234169,126941,Active,,,1.25,GI50,Growth inhibition of human Jurkat cells after 72 hrs by MTT assay,Confirmatory,21802949.0,
2356,621122,1,4,,104234169,126941,Active,,,0.012,IC50,Antiproliferative activity against chinese hamster PC43-10 expressing human RFC assessed as reduction of viable cells after 96 hrs,Confirmatory,21879757.0,
2357,621123,1,4,,104234169,126941,Active,,,0.21600000000000003,IC50,Antiproliferative activity against chinese hamster R2 cells assessed as reduction of viable cells after 96 hrs,Confirmatory,21879757.0,
2358,621124,1,5,,104234169,126941,Active,,,0.114,IC50,Antiproliferative activity against chinese hamster RT16 cells expressing human FRalpha assessed as reduction of viable cells after 96 hrs,Confirmatory,21879757.0,
2359,621125,1,5,,104234169,126941,Active,,,0.461,IC50,Antiproliferative activity against chinese hamster RT16 cells expressing human FRalpha assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid,Confirmatory,21879757.0,
2360,621126,1,5,,104234169,126941,Active,,,0.106,IC50,Antiproliferative activity against chinese hamster D4 cells expressing human FRbeta assessed as reduction of viable cells after 96 hrs,Confirmatory,21879757.0,
2361,621127,1,5,,104234169,126941,Active,,,0.21100000000000002,IC50,Antiproliferative activity against chinese hamster D4 cells expressing human FRbeta assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid,Confirmatory,21879757.0,
2362,621128,1,4,,104234169,126941,Active,,,0.121,IC50,Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as reduction of viable cells after 96 hrs,Confirmatory,21879757.0,
2363,621129,1,4,,104234169,126941,Unspecified,,,1.0,IC50,Antiproliferative activity against chinese hamster R2(VC) cells expressing human PCFT assessed as reduction of viable cells after 96 hrs,Confirmatory,21879757.0,
2364,621130,1,4,,104234169,126941,Active,,,0.006,IC50,"Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs",Confirmatory,21879757.0,
2365,621131,1,4,,104234169,126941,Active,,,0.02,IC50,"Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid",Confirmatory,21879757.0,
2366,621132,1,4,,104234169,126941,Active,,,0.021,IC50,"Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs",Confirmatory,21879757.0,
2367,621133,1,4,,104234169,126941,Active,,,0.022000000000000002,IC50,"Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid",Confirmatory,21879757.0,
2368,623870,1,1,,56463665,126941,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2369,623870,1,1,,56463665,126941,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2370,623877,1,1,,56463665,126941,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
2371,623901,1,1,,56463665,126941,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
2372,624030,1,2,,26752120,126941,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
2373,624031,1,2,,26752120,126941,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
2374,624032,1,2,,26752120,126941,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
2375,624037,1,3,,56463665,126941,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2376,624038,1,3,,56463665,126941,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2377,624040,1,3,,56463665,126941,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2378,624044,1,2,,26752120,126941,Inconclusive,8393992.0,24660.0,0.0999,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
2379,624125,1,4,,56463665,126941,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2380,624126,1,3,,56463665,126941,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2381,624127,1,2,,56463665,126941,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2382,624146,1,1,,90340825,126941,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
2383,624147,1,1,,90340825,126941,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
2384,624148,1,2,,90340825,126941,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
2385,624149,1,1,,90340825,126941,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
2386,624168,1,1,,56463665,126941,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
2387,624169,1,1,,56463665,126941,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
2388,624170,1,1,,26752120,126941,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2389,624170,1,1,,56463665,126941,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2390,624171,1,1,,56463665,126941,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
2391,624172,1,1,,26752120,126941,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2392,624172,1,1,,56463665,126941,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2393,624173,1,3,,26752120,126941,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2394,624173,1,3,,56463665,126941,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2395,624178,1,1,,56463665,126941,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2396,624178,1,1,,124886991,126941,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2397,624202,1,1,,56463665,126941,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2398,624202,1,1,,124886991,126941,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2399,624204,1,2,,56463665,126941,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
2400,624246,1,1,,56463665,126941,Inactive,343478176.0,2078.0,39.8107,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
2401,624256,1,2,,56463665,126941,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
2402,624263,1,1,,56463665,126941,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2403,624263,1,1,,56463665,126941,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2404,624263,1,1,,124886991,126941,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2405,624263,1,1,,124886991,126941,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2406,624267,1,2,,56463665,126941,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2407,624267,1,2,,56463665,126941,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2408,624268,1,3,,56463665,126941,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
2409,624288,1,1,,56463665,126941,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
2410,624296,1,1,,26752120,126941,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2411,624296,1,1,,56463665,126941,Inactive,7705682.0,51053.0,0.92,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2412,624297,1,1,,26752120,126941,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2413,624297,1,1,,56463665,126941,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2414,624304,1,2,,56463665,126941,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
2415,624330,1,2,,56463665,126941,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
2416,624349,1,2,,92125176,126941,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2417,624349,1,2,,121362847,126941,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2418,624352,1,1,,56463665,126941,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
2419,624354,1,1,,56463665,126941,Active,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
2420,624377,1,1,,56463665,126941,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
2421,624414,1,1,,56463665,126941,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2422,624414,1,1,,124886991,126941,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2423,624415,1,2,,56463665,126941,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2424,624416,1,1,,56463665,126941,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
2425,624417,1,1,,56463665,126941,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
2426,624418,1,1,,56463665,126941,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
2427,624455,1,1,,90340825,126941,Inconclusive,299681.0,1812.0,4.6109,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
2428,624463,1,1,,56463665,126941,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
2429,624464,1,1,,56463665,126941,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
2430,624465,1,1,,56463665,126941,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
2431,624466,1,3,,56463665,126941,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2432,624467,1,1,,56463665,126941,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2433,624483,1,1,,56463665,126941,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
2434,624622,3,1,,104234169,126941,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
2435,624623,3,1,,104234169,126941,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells,Other,11602674.0,
2436,624626,1,9,,104234169,126941,Unspecified,238054374.0,5243.0,,,Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
2437,624628,1,9,,104234169,126941,Unspecified,238054374.0,5243.0,,,Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM,Other,11602674.0,
2438,624629,1,9,,104234169,126941,Unspecified,238054374.0,5243.0,,,Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay,Other,11602674.0,
2439,625144,5,5,,104234169,126941,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
2440,625145,4,7,,104234169,126941,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
2441,625146,5,5,,104234169,126941,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
2442,625147,4,7,,104234169,126941,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2443,625148,4,7,,104234169,126941,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2444,625149,4,7,,104234169,126941,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2445,625150,5,5,,104234169,126941,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
2446,625151,4,7,,104234169,126941,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2447,625152,4,7,,104234169,126941,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2448,625153,4,7,,104234169,126941,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2449,625154,4,7,,104234169,126941,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2450,625155,4,7,,104234169,126941,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2451,625156,1,9,,104234169,126941,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
2452,625157,6,2,,104234169,126941,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
2453,625158,3,4,,104234169,126941,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
2454,625159,5,5,,104234169,126941,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
2455,625160,1,9,,104234169,126941,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
2456,625161,4,7,,104234169,126941,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
2457,625162,4,7,,104234169,126941,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2458,625163,4,7,,104234169,126941,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2459,625164,1,6,,104234169,126941,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
2460,625165,3,4,,104234169,126941,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2461,625166,3,4,,104234169,126941,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2462,625167,5,5,,104234169,126941,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
2463,625168,4,7,,104234169,126941,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
2464,625169,1,6,,104234169,126941,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
2465,625170,3,4,,104234169,126941,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
2466,625171,4,7,,104234169,126941,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
2467,625172,4,7,,104234169,126941,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
2468,625173,5,5,,104234169,126941,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
2469,625174,5,5,,104234169,126941,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
2470,625175,5,5,,104234169,126941,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
2471,625176,1,9,,104234169,126941,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
2472,625177,5,5,,104234169,126941,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2473,625178,5,5,,104234169,126941,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2474,625179,1,9,,104234169,126941,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
2475,625180,5,5,,104234169,126941,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2476,625181,5,5,,104234169,126941,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2477,625182,5,5,,104234169,126941,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2478,625183,5,5,,104234169,126941,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
2479,625184,5,5,,104234169,126941,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2480,625185,5,5,,104234169,126941,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2481,625186,5,5,,104234169,126941,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2482,625187,5,5,,104234169,126941,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2483,625188,1,9,,104234169,126941,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
2484,625189,1,7,,104234169,126941,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
2485,625190,4,5,,104234169,126941,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
2486,625191,4,7,,104234169,126941,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2487,625192,4,7,,104234169,126941,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
2488,625193,5,5,,104234169,126941,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
2489,625194,4,7,,104234169,126941,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
2490,625195,4,7,,104234169,126941,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
2491,625196,5,6,,104234169,126941,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
2492,625197,3,4,,104234169,126941,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
2493,625198,4,7,,104234169,126941,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2494,625199,4,7,,104234169,126941,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2495,625200,4,7,,104234169,126941,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2496,625201,4,7,,104234169,126941,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
2497,625202,4,7,,104234169,126941,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
2498,625203,4,7,,104234169,126941,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
2499,625204,4,7,,104234169,126941,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2500,625205,4,7,,104234169,126941,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
2501,625206,4,7,,104234169,126941,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2502,625207,4,7,,104234169,126941,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2503,625208,5,5,,104234169,126941,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
2504,625209,4,7,,104234169,126941,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
2505,625210,3,4,,104234169,126941,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
2506,625211,1,6,,104234169,126941,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
2507,625212,3,4,,104234169,126941,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
2508,625213,4,7,,104234169,126941,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
2509,625214,1,9,,104234169,126941,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
2510,625215,3,4,,104234169,126941,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
2511,625216,3,4,,104234169,126941,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
2512,625217,4,7,,104234169,126941,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2513,625218,4,7,,104234169,126941,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
2514,625219,3,4,,104234169,126941,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
2515,625220,4,7,,104234169,126941,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
2516,625221,4,7,,104234169,126941,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2517,625222,4,7,,104234169,126941,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
2518,625223,4,7,,104234169,126941,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
2519,625224,3,4,,104234169,126941,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
2520,625225,3,4,,104234169,126941,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
2521,625226,4,7,,104234169,126941,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
2522,625227,4,7,,104234169,126941,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
2523,625228,4,7,,104234169,126941,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
2524,625229,5,5,,104234169,126941,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
2525,625230,1,6,,104234169,126941,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
2526,625231,4,7,,104234169,126941,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
2527,625232,1,9,,104234169,126941,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
2528,625233,4,7,,104234169,126941,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
2529,625234,3,4,,104234169,126941,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
2530,625235,4,7,,104234169,126941,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
2531,625236,5,5,,104234169,126941,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
2532,625237,4,7,,104234169,126941,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
2533,625238,4,7,,104234169,126941,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
2534,625239,4,7,,104234169,126941,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
2535,625240,1,9,,104234169,126941,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
2536,625241,4,7,,104234169,126941,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
2537,625242,4,7,,104234169,126941,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
2538,625243,5,5,,104234169,126941,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2539,625244,5,5,,104234169,126941,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2540,625245,5,5,,104234169,126941,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2541,625246,1,9,,104234169,126941,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
2542,625247,5,5,,104234169,126941,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2543,625248,5,5,,104234169,126941,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2544,625249,5,5,,104234169,126941,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2545,625250,5,5,,104234169,126941,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2546,625251,5,5,,104234169,126941,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
2547,625252,4,7,,104234169,126941,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
2548,625253,4,7,,104234169,126941,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2549,625254,4,7,,104234169,126941,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2550,625255,4,7,,104234169,126941,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2551,625256,4,7,,104234169,126941,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2552,625257,4,7,,104234169,126941,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
2553,625258,4,7,,104234169,126941,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2554,625259,4,7,,104234169,126941,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2555,625260,3,4,,104234169,126941,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
2556,625261,3,4,,104234169,126941,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
2557,625262,3,4,,104234169,126941,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
2558,625263,4,7,,104234169,126941,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
2559,625264,3,4,,104234169,126941,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
2560,625265,1,6,,104234169,126941,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
2561,625266,3,4,,104234169,126941,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
2562,625267,3,4,,104234169,126941,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
2563,625268,4,2,,104234169,126941,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2564,625268,4,2,,104234169,126941,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2565,625268,4,2,,104234169,126941,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2566,625268,4,2,,104234169,126941,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2567,625269,4,7,,104234169,126941,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
2568,625270,4,7,,104234169,126941,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
2569,625271,5,5,,104234169,126941,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
2570,625272,3,4,,104234169,126941,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
2571,625273,4,6,,104234169,126941,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
2572,625274,1,6,,104234169,126941,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
2573,625275,3,4,,104234169,126941,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
2574,625276,1,3,,104234169,126941,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI,Other,21624500.0,
2575,625279,1,3,,104234169,126941,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
2576,625280,1,3,,104234169,126941,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
2577,625281,1,3,,104234169,126941,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
2578,625282,1,3,,104234169,126941,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
2579,625283,1,3,,104234169,126941,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
2580,625284,1,3,,104234169,126941,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
2581,625285,1,3,,104234169,126941,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
2582,625286,1,3,,104234169,126941,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
2583,625287,1,3,,104234169,126941,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
2584,625288,1,3,,104234169,126941,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
2585,625289,1,3,,104234169,126941,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
2586,625290,1,3,,104234169,126941,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
2587,625291,1,3,,104234169,126941,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
2588,625292,1,3,,104234169,126941,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
2589,651550,1,1,,56463665,126941,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
2590,651560,1,1,,56463665,126941,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
2591,651572,1,2,,56463665,126941,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
2592,651582,1,1,,56463665,126941,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
2593,651602,1,1,,56463665,126941,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2594,651602,1,1,,56463665,126941,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2595,651602,1,1,,56463665,126941,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2596,651610,2,1,,56463665,126941,Active,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2597,651611,1,1,,56463665,126941,Active,,,,,Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based cell-based high throughput assay to identify nonselective inhibitors of the Steroidogenic acute regulatory protein (StAR) promoter or luminescence assay artifacts,Screening,,
2598,651613,1,1,,56463665,126941,Active,4504343.0,2494.0,,,Luminescence-based cell-based high throughput confirmation assay for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
2599,651614,1,1,,56463665,126941,Active,20070193.0,2516.0,,,Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based cell-based high throughput assay to identify inverse agonists of the Steroidogenic Factor 1 Nuclear Receptor (SF1; NR5A1),Screening,,
2600,651615,1,1,,56463665,126941,Inactive,9629429.0,,,,Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),Screening,,
2601,651631,4,1,,144204495,126941,Active,269849759.0,7157.0,0.1333,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2602,651631,4,1,,144210589,126941,Active,269849759.0,7157.0,0.1087,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2603,651632,4,1,,144204495,126941,Inactive,296439460.0,79915.0,0.1333,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2604,651632,4,1,,144210589,126941,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2605,651633,4,1,,144204495,126941,Active,,,0.1679,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2606,651633,4,1,,144210589,126941,Active,,,0.0486,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2607,651634,4,1,,144204495,126941,Inactive,,,26.6032,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2608,651634,4,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2609,651635,1,3,,56463665,126941,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2610,651635,1,3,,90340825,126941,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2611,651636,1,1,,56463665,126941,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
2612,651640,1,1,,56463665,126941,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
2613,651644,1,1,,56463665,126941,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
2614,651647,1,1,,56463665,126941,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
2615,651654,1,1,,56463665,126941,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2616,651658,1,1,,56463665,126941,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2617,651661,2,1,,56463665,126941,Active,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2618,651687,1,1,,56463665,126941,Active,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2619,651699,1,1,,56463665,126941,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2620,651699,1,1,,56463665,126941,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2621,651702,1,2,,56463665,126941,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
2622,651704,2,1,,56463665,126941,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2623,651710,1,1,,56463665,126941,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2624,651711,2,1,,56463665,126941,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2625,651718,1,2,,56463665,126941,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
2626,651719,1,2,,56463665,126941,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
2627,651723,1,1,,56463665,126941,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
2628,651724,1,1,,56463665,126941,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
2629,651725,1,1,,56463665,126941,Inconclusive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
2630,651741,1,1,,26752122,126941,Active,20149576.0,4780.0,0.1536,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2631,651743,1,1,,26752122,126941,Active,269849759.0,7157.0,0.3162,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2632,651749,1,1,,26752122,126941,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2633,651751,1,1,,26752122,126941,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2634,651768,1,2,,56463665,126941,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
2635,651777,1,1,,26752122,126941,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
2636,651778,1,1,,26752122,126941,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
2637,651800,1,1,,56463665,126941,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
2638,651819,1,1,,56463665,126941,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
2639,651820,1,1,,56463665,126941,Inconclusive,,,11.2202,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2640,651821,2,4,,56463665,126941,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
2641,651828,1,2,,121360865,126941,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2642,651838,1,1,,26752122,126941,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2643,651838,1,1,1.0,26752122,126941,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2644,651838,1,1,2.0,26752122,126941,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2645,651838,1,1,3.0,26752122,126941,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2646,651838,1,1,4.0,26752122,126941,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2647,651838,1,1,5.0,26752122,126941,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2648,651838,1,1,6.0,26752122,126941,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2649,651838,1,1,7.0,26752122,126941,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2650,651838,1,1,8.0,26752122,126941,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2651,651957,1,1,,56463665,126941,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
2652,651958,1,1,,56463665,126941,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
2653,651965,1,1,,56463665,126941,Inconclusive,2668494.0,,31.6228,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2654,651965,1,1,,124886991,126941,Inconclusive,2668494.0,,15.8489,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2655,651999,1,1,,56463665,126941,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
2656,652010,1,1,,56463665,126941,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
2657,652017,1,1,,56463665,126941,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
2658,652025,1,1,,56463665,126941,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
2659,652039,1,1,,56463665,126941,Active,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2660,652048,1,2,,56463665,126941,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2661,652048,1,2,,144204495,126941,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2662,652051,1,1,,56463665,126941,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2663,652051,1,1,,144204495,126941,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2664,652054,1,1,,56463665,126941,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2665,652067,1,4,,56463665,126941,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2666,652104,1,1,,56463665,126941,Inconclusive,20140568.0,23435.0,1.2589,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2667,652105,1,1,,56463665,126941,Inconclusive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2668,652106,1,1,,56463665,126941,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2669,652106,1,1,,90340825,126941,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2670,652106,1,1,,124886991,126941,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2671,652115,1,1,,56463665,126941,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2672,652126,1,3,,56463665,126941,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2673,652154,1,1,,56463665,126941,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2674,652162,2,1,,56463665,126941,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2675,652163,1,1,,56463665,126941,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2676,652197,1,1,,56463665,126941,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2677,652257,1,1,,56463665,126941,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2678,659913,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-9 M after 24 hrs by cell counting method,Other,22480495.0,
2679,659914,2,2,,104234169,126941,Inconclusive,,,,IC50,Cytostatic activity against human MCF7 cells after 4 days by MTT assay,Confirmatory,22480495.0,
2680,659915,2,2,,104234169,126941,Active,,,0.3,IC50,Cytostatic activity against human LNCAP cells after 4 days by MTT assay,Confirmatory,22480495.0,
2681,659916,2,2,,104234169,126941,Active,,,1.4,IC50,Cytostatic activity against human HT-29 cells after 4 days by MTT assay,Confirmatory,22480495.0,
2682,659917,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-9 M after 48 hrs by cell counting method,Other,22480495.0,
2683,659918,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-9 M after 72 hrs by cell counting method,Other,22480495.0,
2684,659919,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-8 M after 24 hrs by cell counting method,Other,22480495.0,
2685,659920,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-8 M after 48 hrs by cell counting method,Other,22480495.0,
2686,659921,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-8 M after 72 hrs by cell counting method,Other,22480495.0,
2687,659922,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-7 M after 24 hrs by cell counting method,Other,22480495.0,
2688,659923,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-7 M after 48 hrs by cell counting method,Other,22480495.0,
2689,659924,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-7 M after 72 hrs by cell counting method,Other,22480495.0,
2690,659925,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-6 M after 24 hrs by cell counting method,Other,22480495.0,
2691,659926,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-6 M after 48 hrs by cell counting method,Other,22480495.0,
2692,659927,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-6 M after 72 hrs by cell counting method,Other,22480495.0,
2693,659928,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as cell viability at 10'-6 M after 24 hrs by cell counting method relative to untreated control,Other,22480495.0,
2694,659930,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as cell viability at 10'-7 to 10'-6 M after 48 hrs by cell counting method relative to untreated control,Other,22480495.0,
2695,659931,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as cell viability at 10'-6 M after 72 hrs by cell counting method relative to untreated control,Other,22480495.0,
2696,659933,1,5,,104234169,126941,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as cell viability at 10'-7 to 10'-6 M after 72 hrs by cell counting method relative to untreated control,Other,22480495.0,
2697,659937,1,5,,104234169,126941,Unspecified,,,,,Induction of adhesion in human MONO-MAC-6 cells at 10'-9 to 10'-6 M after 24 hrs by electrical impedence method relative to control,Other,22480495.0,
2698,659938,1,5,,104234169,126941,Active,,,,,Induction of adhesion in human MONO-MAC-6 cells at 10'-11 to 10'-12 M after 24 hrs by electrical impedence method relative to control,Other,22480495.0,
2699,660264,1,3,,104234169,126941,Unspecified,,,,,Ratio of MIC for wild type Escherichia coli HS414 to MIC for acrB-deficient Escherichia coli HS832 by agar dilution method,Other,22483632.0,
2700,660265,2,2,,104234169,126941,Unspecified,,,,,Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump,Other,22483632.0,
2701,671160,7,2,,104234169,126941,Active,118992.0,1719.0,0.02,IC50,Inhibition of human DHFR,Confirmatory,22739090.0,
2702,671160,7,2,,104234169,126941,Active,118992.0,573971.0,0.02,IC50,Inhibition of human DHFR,Confirmatory,22739090.0,
2703,671161,4,1,,104234169,126941,Active,,,0.0088,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,22739090.0,
2704,671162,7,2,,104234169,126941,Active,729370.0,,0.033,IC50,Inhibition of Toxoplasma gondii DHFR,Confirmatory,22739090.0,
2705,671370,1,3,,104234169,126941,Active,,,,,"Immunosuppressant activity in collagen-induced Lewis rat arthritis model assessed as reduction in joint inflammation at 0.075 mg/kg, po qd",Other,22633692.0,
2706,678712,1,8,,104234169,126941,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
2707,678713,1,8,,104234169,126941,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
2708,678714,1,8,,104234169,126941,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2709,678715,1,8,,104234169,126941,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
2710,678716,1,8,,104234169,126941,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
2711,678717,1,8,,104234169,126941,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
2712,678721,1,5,,104234169,126941,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
2713,678722,1,5,,104234169,126941,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
2714,678788,2,7,,104234169,126941,Unspecified,3914190.0,170698.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,9294213.0,
2715,678798,2,7,,104234169,126941,Unspecified,67462103.0,9429.0,1300.0,Km,TP_TRANSPORTER: uptake (vesicle) in membrane vesicle from ABCG2-R482-expressing HEK293 cells,Confirmatory,12874005.0,
2716,678809,2,7,,104234169,126941,Unspecified,27734563.0,28234.0,24.7,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,11375950.0,
2717,678812,2,7,,104234169,126941,Unspecified,74761045.0,,776.0,Km,TP_TRANSPORTER: uptake in membrane vesicles from MRP3-expressing HEK293 cells,Confirmatory,10987286.0,
2718,678961,1,8,,104234169,126941,Unspecified,74753520.0,10864.0,,,TP_TRANSPORTER: uptake in OAT2-expressing EcR293 cells,Other,11327718.0,
2719,678977,3,6,,104234169,126941,Unspecified,74761045.0,,1200.0,Ki,TP_TRANSPORTER: inhibition of E217betaG uptake in membrane vesicle from MRP3-expressing Sf9 cells,Confirmatory,11837698.0,
2720,679035,3,6,,104234169,126941,Unspecified,3219824.0,25303.0,236.0,Ki,TP_TRANSPORTER: inhibition of DNP-SG uptake in bile canalicular membrane vesicles from SD rat,Confirmatory,9270020.0,
2721,679228,1,8,,104234169,126941,Unspecified,74756298.0,89845.0,,,"TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 1 uM, MTX:100uM) in membrane vesicles from MRP7-expressing HEK293 cells",Other,12527806.0,
2722,679285,1,8,,104234169,126941,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: intracellular accumulation in CEM/MTX R cells,Other,8598312.0,
2723,679299,2,7,,104234169,126941,Unspecified,74761045.0,,620.0,Km,TP_TRANSPORTER: uptake in membrane vesicles from MRP3-expressing HEK293 cells,Confirmatory,11585759.0,
2724,679329,1,8,,104234169,126941,Unspecified,1171883.0,50572.0,,,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Other,11713643.0,
2725,679377,2,7,,104234169,126941,Unspecified,74762955.0,9356.0,553.8,Km,TP_TRANSPORTER: uptake in OAT1-expressing S2 cells,Confirmatory,12130730.0,
2726,679478,2,7,,104234169,126941,Unspecified,6016599.0,140668.0,,Km,TP_TRANSPORTER: uptake in membrane vesicle from Mrp3-expressing LLC-PK1 cells,Confirmatory,10329726.0,
2727,679479,3,6,,104234169,126941,Unspecified,6016599.0,140668.0,90.0,Ki,TP_TRANSPORTER: inhibition of E217betaG uptake in membrane vesicles from Mrp3-expressing Sf9 cells,Confirmatory,11837698.0,
2728,679488,1,7,,104234169,126941,Unspecified,81886651.0,29509.0,,,TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes,Other,9827570.0,
2729,679528,1,8,,104234169,126941,Unspecified,74762955.0,9356.0,,,TP_TRANSPORTER: inhibition of PAH uptake (MTX: 200 uM) in OAT1-expressing HeLa cells,Other,9950961.0,
2730,679651,1,7,,104234169,126941,Unspecified,74761045.0,,,,TP_TRANSPORTER: uptake in membrane vesicles from HEK293T cells,Other,12388190.0,
2731,679653,2,7,,104234169,126941,Unspecified,74761045.0,,910.0,Km,TP_TRANSPORTER: uptake in MRP3-expressing MCF7 cells,Confirmatory,12731885.0,
2732,679660,1,8,,104234169,126941,Unspecified,308153583.0,1244.0,,,TP_TRANSPORTER: uptake in membrane vesicles from MRP2-expressing Sf9 cells,Other,10727523.0,
2733,679693,2,7,,104234169,126941,Unspecified,27735248.0,80899.0,2.1,Km,TP_TRANSPORTER: uptake in OAT-K1-expressing MDCK cells,Confirmatory,10508931.0,
2734,679694,2,7,,104234169,126941,Unspecified,27735248.0,80899.0,1.0,Km,TP_TRANSPORTER: uptake in OAT-K1-expressing LLC-PK1 cells,Confirmatory,8702823.0,
2735,679699,1,8,,104234169,126941,Unspecified,27735248.0,80899.0,,,"TP_TRANSPORTER: inhibition of T3 uptake (T3: 0.43nM, MTX: 2500 uM) in OAT-K2-expressing MDCK cells",Other,11561088.0,
2736,679700,1,8,,104234169,126941,Unspecified,27735248.0,80899.0,,,"TP_TRANSPORTER: inhibition of T3 uptake (T3: 0.43nM, MTX: 2500 uM) in OAT-K1-expressing MDCK cells",Other,11561088.0,
2737,679720,1,7,,104234169,126941,Unspecified,1709076.0,25027.0,,,TP_TRANSPORTER: uptake of Methotrexate at a concentration of 0.03uM in MCT1-expressing MDA-MB231 cells,Other,10579682.0,
2738,679802,2,7,,104234169,126941,Unspecified,3219824.0,25303.0,296.0,Km,TP_TRANSPORTER: uptake in bile canalicular membrane vesicles from SD rat,Confirmatory,9270020.0,
2739,679809,3,6,,104234169,126941,Unspecified,3219824.0,25303.0,326.0,Ki,TP_TRANSPORTER: inhibition of L-MTX uptake in bile canalicular membrane vesicles from SD rat,Confirmatory,9270020.0,
2740,679821,1,8,,104234169,126941,Unspecified,3219824.0,25303.0,,,TP_TRANSPORTER: In vivo biliary excretion of SDR rat,Other,12608533.0,
2741,680165,2,7,,104234169,126941,Unspecified,74734337.0,55867.0,17.8,Km,TP_TRANSPORTER: uptake in OAT1-expressing S2 cells,Confirmatory,12130730.0,
2742,680551,1,8,,104234169,126941,Unspecified,12643959.0,10599.0,,,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Other,11375950.0,
2743,680592,1,7,,104234169,126941,Unspecified,74761045.0,,,,"TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.40 uM, MTX: 1000 uM) in membrane vesicles from HEK293T cells",Other,12388190.0,
2744,680777,1,8,,104234169,126941,Unspecified,308153583.0,1244.0,,,TP_TRANSPORTER: uptake in membrane vesicle from MRP2-expressing 2008 cells,Other,10363967.0,
2745,680969,1,8,,104234169,126941,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: uptake in membrane vesicle from BCRP-expressing Sf9 cells,Other,15313923.0,
2746,680976,2,7,,104234169,126941,Unspecified,67462103.0,9429.0,5700.0,Km,TP_TRANSPORTER: uptake (vesicle) in membrane vesicle from ABCG2-expressing HEK-293 cells,Confirmatory,12741957.0,
2747,681022,1,8,,104234169,126941,Unspecified,81901833.0,18399.0,,,"TP_TRANSPORTER: inhibition of PAH uptake (PAH: 20 uM, MTX: 300 uM) in OAT-expressing COS-7 cells",Other,9880528.0,
2748,681034,2,7,,104234169,126941,Unspecified,74730587.0,9376.0,21.1,Km,TP_TRANSPORTER: uptake in OAT1-expressing S2 cells,Confirmatory,12130730.0,
2749,681075,2,7,,104234169,126941,Unspecified,296439301.0,4363.0,2150.0,Km,TP_TRANSPORTER: uptake in membrane vesicle from MRP1-expressing NIH3T3 cells,Confirmatory,11585759.0,
2750,681129,3,6,,104234169,126941,Unspecified,3219824.0,25303.0,462.0,Ki,TP_TRANSPORTER: inhibition of DNP-SG uptake in bile canalicular membrane vesicles from SD rat,Confirmatory,11465411.0,
2751,681135,2,7,,104234169,126941,Unspecified,27734564.0,53919.0,,Km,TP_TRANSPORTER: uptake in OATP-F-expressing CHO cells,Confirmatory,12351693.0,
2752,681141,2,7,,104234169,126941,Unspecified,74730587.0,9376.0,10.9,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,11306713.0,
2753,681149,2,7,,104234169,126941,Unspecified,27735247.0,80900.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,11713643.0,
2754,681150,2,7,,104234169,126941,Unspecified,317373278.0,58978.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,11713643.0,
2755,681168,2,7,,104234169,126941,Unspecified,124015184.0,19879.0,,Km,TP_TRANSPORTER: uptake in Oat3-expressing oocyte cells,Confirmatory,14762099.0,
2756,681172,2,7,,104234169,126941,Unspecified,67462103.0,9429.0,,Km,TP_TRANSPORTER: uptake (vesicle) in membrane vesicles from ABCG2-expressing P388 cells,Confirmatory,12682043.0,
2757,681287,1,8,,104234169,126941,Unspecified,296439301.0,4363.0,,,"TP_TRANSPORTER: inhibition of DNP-SG uptake (DNP-SG: 0.01 uM, MTX: 10 uM) in membrane vesicles from GLC4/ADR cells",Other,9188796.0,
2758,681346,2,7,,104234169,126941,Unspecified,74762666.0,85320.0,957.0,Km,TP_TRANSPORTER: ATP-dependent uptake in membrane vesicle from MRP8-expressing LLC-PK1 cells,Confirmatory,15537867.0,
2759,681362,2,7,,104234169,126941,Unspecified,81886651.0,29509.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,9228014.0,
2760,681367,2,7,,104234169,126941,Unspecified,296452954.0,28232.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,14631946.0,
2761,681429,1,7,,104234169,126941,Unspecified,81872813.0,83500.0,,,"TP_TRANSPORTER: inhibition of E1S uptake (E1S: 40 uM, MTX: 1000 uM) in Xenopus laevis oocytes",Other,10224140.0,
2762,681575,2,7,,104234169,126941,Unspecified,81871841.0,89776.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,9650585.0,
2763,681577,2,7,,104234169,126941,Unspecified,27735248.0,80899.0,1.8,Km,TP_TRANSPORTER: uptake in OAT-K2-expressing MDCK cells,Confirmatory,11561088.0,
2764,681603,1,8,,104234169,126941,Unspecified,27735248.0,80899.0,,,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Other,10101033.0,
2765,681876,2,7,,104234169,126941,Unspecified,206729914.0,10257.0,1300.0,Km,TP_TRANSPORTER: uptake in membrane vesicles from MRP4-expressing Sf9 cells,Confirmatory,11856762.0,
2766,681881,1,7,,104234169,126941,Unspecified,206729914.0,10257.0,,,TP_TRANSPORTER: inhibition of bimane-GS efflux in the presence of Methotrexate at a concentration of 100uM in MRP4-expressing HepG2 cells,Other,14643890.0,
2767,681892,1,7,,104234169,126941,Unspecified,206729914.0,10257.0,,,TP_TRANSPORTER: inhibition of Taurocholate uptake in the presence of Methotrexate at a concentration of 20uM in membrane vesicles from MRP4-expressing V79 cells,Other,12883481.0,
2768,681924,1,7,,104234169,126941,Unspecified,206729914.0,10257.0,,,"TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 1 uM, MTX: 300 uM) in membrane vesicles from MRP4-expressing Sf9 cells",Other,11447229.0,
2769,682046,2,7,,104234169,126941,Unspecified,67462103.0,9429.0,680.0,Km,TP_TRANSPORTER: uptake (vesicle) in membrane vesicles from BCRP-expressing MCF7 cells,Confirmatory,14500392.0,
2770,682073,1,8,,104234169,126941,Unspecified,3219824.0,25303.0,,,"TP_TRANSPORTER: In vivo biliary excretion in vivo, biliary excretion of SDR and EHBR rat",Other,12608533.0,
2771,682078,2,7,,104234169,126941,Unspecified,296439301.0,4363.0,930.0,Km,TP_TRANSPORTER: uptake in MRP1-expressing MCF7 cells,Confirmatory,12731885.0,
2772,682163,1,8,,104234169,126941,Unspecified,6016599.0,140668.0,,,"TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.1 uM, MTX: 1000 uM) in membrane vesicles from MRP3-expressing HeLa cells",Other,10329726.0,
2773,682170,1,8,,104234169,126941,Unspecified,124015184.0,19879.0,,,TP_TRANSPORTER: inhibition of benzylpenicillin uptake by Methotrexate at a concentration of 1000uM in Oat3-expressing oocyte cells,Other,14762099.0,
2774,682182,2,7,,104234169,126941,Unspecified,6016599.0,140668.0,4.5,Km,TP_TRANSPORTER: uptake in membrane vesicles from Mrp3-Sf9 cells,Confirmatory,12909565.0,
2775,682183,2,7,,104234169,126941,Unspecified,6016599.0,140668.0,11.7,Km,TP_TRANSPORTER: uptake in membrane vesicles from IEC-6 cells,Confirmatory,12909565.0,
2776,682203,1,8,,104234169,126941,Unspecified,6016599.0,140668.0,,,"TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.1 uM, MTX: 1000 uM) in membrane vesicles from MRP3-expressing LLC-PK1 cells",Other,10329726.0,
2777,686920,1,1,,56463665,126941,Inconclusive,,,,AbsAC35_uM,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2778,686940,1,1,,56463665,126941,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2779,686949,1,1,,56463665,126941,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput confirmation assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2780,686952,1,2,,56463665,126941,Inactive,,,,,Counterscreen for activators of kallikrein-7 (K7) zymogen: Fluorescence intensity-based biochemical high throughput counterscreen assay for activators that optically interfere with measurement of EDANS-DABCYL fluorescence,Screening,,
2781,686964,1,1,,56463665,126941,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2782,686970,1,2,,56463665,126941,Active,49168486.0,3417.0,0.0052,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2783,686971,1,2,,56463665,126941,Active,,,0.0461,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2784,686978,1,1,,11113978,126941,Active,79154014.0,55775.0,0.0106,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2785,686978,1,1,,56463665,126941,Active,79154014.0,55775.0,0.0103,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2786,686978,1,1,,124886991,126941,Inconclusive,79154014.0,55775.0,0.0224,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2787,686978,1,1,,144204495,126941,Inconclusive,79154014.0,55775.0,0.0596,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2788,686979,1,1,,11113978,126941,Active,79154014.0,55775.0,0.0211,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2789,686979,1,1,,56463665,126941,Active,79154014.0,55775.0,0.0411,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2790,686979,1,1,,124886991,126941,Active,79154014.0,55775.0,0.1259,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2791,686979,1,1,,144204495,126941,Active,79154014.0,55775.0,0.0211,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2792,686992,2,1,,56463665,126941,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
2793,686996,1,1,,56463665,126941,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2794,687014,1,1,,56463665,126941,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
2795,687016,1,1,,56463665,126941,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
2796,687035,1,1,,163563974,126941,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2797,687037,1,3,,163563974,126941,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
2798,693371,2,2,,104234169,126941,Active,,,0.06,IC50,Antiproliferative activity against human SKOV3 cells after 48 hrs,Confirmatory,23124219.0,
2799,693372,2,2,,104234169,126941,Active,,,20.9,IC50,Antiproliferative activity against human KB cells after 48 hrs,Confirmatory,23124219.0,
2800,695089,1,2,,104234169,126941,Active,,,0.0085,IC50,Inhibition of colony formation of human KB cells endogenously expressing RFC/FRalpha/PCFT incubated for 14 days by methylene blue staining based clonogenicty assay,Confirmatory,22243528.0,
2801,695097,1,7,,104234169,126941,Inactive,544337.0,2348.0,,,Inhibition of [3H]folic acid binding to human FRalpha expressed in CHO cells relative to folic acid,Other,22243528.0,
2802,698893,2,4,,104234169,126941,Active,,,,,Inhibition of DHFR reduction in conversion of DHF to THF in presence of NADPH by DHFR assay,Other,22734697.0,
2803,699539,1,7,,104234169,126941,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
2804,699540,1,7,,104234169,126941,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2805,699541,1,7,,104234169,126941,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2806,700317,1,2,,104234169,126941,Unspecified,,,,,Resistance ratio of IC50 for human methotrexate-resistant DOGUM cells to IC50 for human DOGUM cells,Other,23031590.0,
2807,700319,2,3,,104234169,126941,Active,,,0.084,IC50,Cytotoxicity against human DOGUM cells after 72 hrs by MTT assay,Confirmatory,23031590.0,
2808,700320,2,3,,104234169,126941,Active,,,0.34,IC50,Cytotoxicity against human methotrexate-resistant DOGUM cells after 72 hrs by MTT assay,Confirmatory,23031590.0,
2809,700321,2,3,,104234169,126941,Active,,,0.534,IC50,Cytotoxicity against human methotrexate-resistant GUMBUS cells after 72 hrs by MTT assay,Confirmatory,23031590.0,
2810,700322,1,2,,104234169,126941,Unspecified,,,,,Resistance ratio of IC50 for human methotrexate-resistant GUMBUS cells to IC50 for human GUMBUS cells,Other,23031590.0,
2811,700323,2,3,,104234169,126941,Active,,,0.024,IC50,Cytotoxicity against human GUMBUS cells after 72 hrs by MTT assay,Confirmatory,23031590.0,
2812,708417,1,2,,104234169,126941,Unspecified,,,,,"Selectivity index, ratio of Ki for human TS to Ki for Leishmania major PTR1",Other,22946585.0,
2813,708418,1,2,,104234169,126941,Unspecified,,,,,"Selectivity index, ratio of Ki for human DHFR to Ki for Leishmania major PTR1",Other,22946585.0,
2814,708419,3,5,,104234169,126941,Active,136611.0,7298.0,0.6,Ki,Inhibition of human TS by spectrophotometric analysis,Confirmatory,22946585.0,
2815,708604,3,5,,104234169,126941,Active,118992.0,1719.0,3.4e-07,Ki,Inhibition of human DHFR by spectrophotometric analysis,Confirmatory,22946585.0,
2816,708604,3,5,,104234169,126941,Active,118992.0,573971.0,3.4e-07,Ki,Inhibition of human DHFR by spectrophotometric analysis,Confirmatory,22946585.0,
2817,708605,2,2,,104234169,126941,Active,,,0.18,Ki,Inhibition of Leishmania major PTR1 by spectrophotometric assay,Confirmatory,22946585.0,
2818,720504,1,1,,56463665,126941,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2819,720508,1,1,,56463665,126941,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2820,720509,1,1,,56463665,126941,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2821,720511,1,1,,56463665,126941,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
2822,720513,1,1,,56463665,126941,Inactive,,,,AbsAC40_uM,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_Dose_CherryPick_Activity_Set6,Confirmatory,,
2823,720514,1,1,,56463665,126941,Inactive,,,,AC50_uM,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2824,720516,2,1,,144204495,126941,Inconclusive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2825,720516,2,1,,144210589,126941,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2826,720532,1,1,,11113978,126941,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2827,720532,1,1,,26752121,126941,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2828,720532,1,1,,144204495,126941,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2829,720533,1,1,,11113978,126941,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2830,720533,1,1,,26752121,126941,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2831,720533,1,1,,144204495,126941,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2832,720538,1,2,,90340825,126941,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
2833,720542,1,2,,56463665,126941,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2834,720543,1,1,,56463665,126941,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
2835,720551,1,2,,56463665,126941,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2836,720552,2,1,,144204495,126941,Active,269849759.0,7157.0,0.266032,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2837,720552,2,1,,144210589,126941,Active,269849759.0,7157.0,0.136854,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2838,720553,1,2,,56463665,126941,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2839,720559,1,2,,90340825,126941,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
2840,720570,1,1,,56463665,126941,Active,,,26.0,Max_Activity_Conc_uM,Luminescence cell-based Retest at Dose assay to determine EWS/Fli1 dependent TC71 mammalian cell cytotoxity  Measured in Cell-Based System Using Plate Reader - 7014-04_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2841,720572,1,2,,90340825,126941,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
2842,720573,1,2,,90340825,126941,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
2843,720579,2,1,,56463665,126941,Inconclusive,222762.0,3707576.0,1.0,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2844,720579,2,1,,124886991,126941,Active,222762.0,3707576.0,0.8913,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2845,720580,1,1,,56463665,126941,Inconclusive,222762.0,3707576.0,0.8913,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2846,720580,1,1,,124886991,126941,Active,222762.0,3707576.0,3.1623,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2847,720582,1,1,,56463665,126941,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
2848,720586,1,1,,56463665,126941,Inactive,169655958.0,,,AbsAC35_uM,Fluorescence polarization acridine orange assay to identify DNA binding small molcules Measured in Biochemical System Using Plate Reader - 7014-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2849,720587,1,1,,56463665,126941,Active,,,0.018000000000000002,AbsAC35_uM,Luminescence cell-based Retest at Dose assay to determine EWS/Fli1 dependent A673 mammalian cell cytotoxity  Measured in Cell-Based System Using Plate Reader - 7014-03_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
2850,720588,1,1,,56463665,126941,Active,,,0.0275,AbsAC35_uM,HEK293 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-01_Inhibitor_Dose_CherryPick_Activity_Set3,Confirmatory,,
2851,720589,1,1,,56463665,126941,Active,,,0.0224,AbsAC35_uM,HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_CherryPick_Activity_Set3,Confirmatory,,
2852,720596,1,1,,56463665,126941,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
2853,720634,2,1,,144204495,126941,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2854,720634,2,1,,144210589,126941,Inconclusive,,,0.0015,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2855,720635,2,1,,144204495,126941,Inconclusive,,,7.4978,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2856,720635,2,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2857,720636,1,1,,26752122,126941,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2858,720637,2,1,,144204495,126941,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2859,720637,2,1,,144210589,126941,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2860,720647,1,2,,56463665,126941,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
2861,720648,1,1,,56463665,126941,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
2862,720653,1,1,,26752122,126941,Active,,,0.0447,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2863,720659,1,1,,26752122,126941,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2864,720674,2,2,,144204495,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2865,720674,2,2,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2866,720675,2,2,,144204495,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2867,720675,2,2,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2868,720678,2,1,,144204495,126941,Inconclusive,,,14.1254,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2869,720678,2,1,,144210589,126941,Inconclusive,,,44.6684,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2870,720679,2,1,,144204495,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2871,720679,2,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2872,720680,2,1,,144204495,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2873,720680,2,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2874,720681,2,1,,144204495,126941,Inconclusive,,,15.8489,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2875,720681,2,1,,144210589,126941,Active,,,39.8107,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2876,720682,2,1,,144204495,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2877,720682,2,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2878,720683,2,1,,144204495,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2879,720683,2,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2880,720684,2,1,,144204495,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2881,720684,2,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2882,720685,2,1,,144204495,126941,Inconclusive,,,15.8489,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2883,720685,2,1,,144210589,126941,Active,,,35.4813,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2884,720686,2,1,,144204495,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2885,720686,2,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2886,720687,2,2,,144204495,126941,Inconclusive,,,15.8489,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2887,720687,2,2,,144210589,126941,Active,,,35.4813,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2888,720691,4,1,,144204495,126941,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2889,720691,4,1,,144210589,126941,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2890,720692,3,1,,144204495,126941,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2891,720692,3,1,,144210589,126941,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2892,720693,3,1,,144204495,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2893,720693,3,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2894,720700,1,4,,56463665,126941,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2895,720702,1,1,,56463665,126941,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2896,720704,1,4,,56463665,126941,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2897,720707,1,2,,56463665,126941,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2898,720708,1,2,,56463665,126941,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2899,720709,1,2,,56463665,126941,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2900,720711,1,2,,56463665,126941,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2901,720717,1,3,,92125176,126941,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2902,720719,2,1,,144204495,126941,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2903,720719,2,1,,144210589,126941,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2904,720725,2,1,,144204495,126941,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2905,720725,2,1,,144210589,126941,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2906,734121,1,3,,104234169,126941,Active,,,,,"Antimetastatic activity against GFP-tagged mouse B16F10 cells isografted into syngeneic athymic Ncr nu/nu mouse assessed as decrease in in number of B16F10 lung metastases at 10 mg/kg, ip administered twice weekly starting from day 8 post-tumor inoculation by hematoxylin-eosin staining",Other,23375090.0,
2907,734123,1,3,,104234169,126941,Active,,,,,"Antiangiogenic activity against GFP-tagged mouse B16F10 cells isografted into syngeneic athymic Ncr nu/nu mouse assessed as decrease in vascular density at 10 mg/kg, ip administered twice weekly starting from day 8 post-tumor inoculation",Other,23375090.0,
2908,734125,1,3,,104234169,126941,Active,,,,,"Antitumor activity against GFP-tagged mouse B16F10 cells isografted into syngeneic athymic Ncr nu/nu mouse assessed as decrease in tumor volume at 10 mg/kg, ip administered twice weekly starting from day 8 post-tumor inoculation",Other,23375090.0,
2909,734127,1,3,,104234169,126941,Active,,,,,"Antitumor activity against GFP-tagged mouse B16F10 cells isografted into syngeneic athymic Ncr nu/nu mouse assessed as decrease in tumor growth rate at 10 mg/kg, ip administered twice weekly starting from day 8 post-tumor inoculation",Other,23375090.0,
2910,741697,1,3,,104234169,126941,Active,,,1.4336799999999998,IC50,SANGER: Inhibition of human NCI-H1563 cell growth in a cell viability assay.,Confirmatory,,
2911,741698,1,3,,104234169,126941,Active,,,13.2177,IC50,SANGER: Inhibition of human NCI-H1573 cell growth in a cell viability assay.,Confirmatory,,
2912,741699,1,3,,104234169,126941,Active,,,8.690380000000001,IC50,SANGER: Inhibition of human NCI-H1581 cell growth in a cell viability assay.,Confirmatory,,
2913,741701,1,3,,104234169,126941,Active,,,13.1175,IC50,SANGER: Inhibition of human NCI-H1623 cell growth in a cell viability assay.,Confirmatory,,
2914,741702,1,3,,104234169,126941,Active,,,14.8041,IC50,SANGER: Inhibition of human NCI-H1648 cell growth in a cell viability assay.,Confirmatory,,
2915,741703,1,3,,104234169,126941,Active,,,1.62866,IC50,SANGER: Inhibition of human NCI-H1650 cell growth in a cell viability assay.,Confirmatory,,
2916,741704,1,3,,104234169,126941,Active,,,7.80243,IC50,SANGER: Inhibition of human NCI-H1651 cell growth in a cell viability assay.,Confirmatory,,
2917,741705,1,3,,104234169,126941,Active,,,0.44878999999999997,IC50,SANGER: Inhibition of human NCI-H1666 cell growth in a cell viability assay.,Confirmatory,,
2918,741706,1,3,,104234169,126941,Active,,,6.680280000000001,IC50,SANGER: Inhibition of human NCI-H1693 cell growth in a cell viability assay.,Confirmatory,,
2919,741708,1,3,,104234169,126941,Active,,,20.3088,IC50,SANGER: Inhibition of human NCI-H1703 cell growth in a cell viability assay.,Confirmatory,,
2920,741710,1,3,,104234169,126941,Active,,,0.28720999999999997,IC50,SANGER: Inhibition of human NCI-H1755 cell growth in a cell viability assay.,Confirmatory,,
2921,741711,1,3,,104234169,126941,Active,,,0.00198,IC50,SANGER: Inhibition of human NCI-H1770 cell growth in a cell viability assay.,Confirmatory,,
2922,741712,1,3,,104234169,126941,Active,,,0.11424000000000001,IC50,SANGER: Inhibition of human NCI-H1792 cell growth in a cell viability assay.,Confirmatory,,
2923,741713,1,3,,104234169,126941,Active,,,2.3404,IC50,SANGER: Inhibition of human NCI-H1793 cell growth in a cell viability assay.,Confirmatory,,
2924,741714,1,3,,104234169,126941,Active,,,2.7114599999999998,IC50,SANGER: Inhibition of human NCI-H1838 cell growth in a cell viability assay.,Confirmatory,,
2925,741719,1,3,,104234169,126941,Active,,,23.1884,IC50,SANGER: Inhibition of human NCI-H1993 cell growth in a cell viability assay.,Confirmatory,,
2926,741721,1,3,,104234169,126941,Active,,,25.7967,IC50,SANGER: Inhibition of human NCI-H2029 cell growth in a cell viability assay.,Confirmatory,,
2927,741722,1,3,,104234169,126941,Active,,,9.18352,IC50,SANGER: Inhibition of human NCI-H2030 cell growth in a cell viability assay.,Confirmatory,,
2928,741723,1,3,,104234169,126941,Active,,,2.50968,IC50,SANGER: Inhibition of human NCI-H2052 cell growth in a cell viability assay.,Confirmatory,,
2929,741725,1,3,,104234169,126941,Active,,,10.1667,IC50,SANGER: Inhibition of human NCI-H2087 cell growth in a cell viability assay.,Confirmatory,,
2930,741726,1,3,,104234169,126941,Active,,,0.36582,IC50,SANGER: Inhibition of human NCI-H209 cell growth in a cell viability assay.,Confirmatory,,
2931,741728,1,3,,104234169,126941,Active,,,0.15143,IC50,SANGER: Inhibition of human NCI-H2122 cell growth in a cell viability assay.,Confirmatory,,
2932,741729,1,3,,104234169,126941,Active,,,13.7158,IC50,SANGER: Inhibition of human NCI-H2126 cell growth in a cell viability assay.,Confirmatory,,
2933,741731,1,3,,104234169,126941,Active,,,7.8596699999999995,IC50,SANGER: Inhibition of human NCI-H2170 cell growth in a cell viability assay.,Confirmatory,,
2934,741735,1,3,,104234169,126941,Active,,,7.687119999999999,IC50,SANGER: Inhibition of human NCI-H2228 cell growth in a cell viability assay.,Confirmatory,,
2935,741736,1,3,,104234169,126941,Active,,,5.355169999999999,IC50,SANGER: Inhibition of human NCI-H226 cell growth in a cell viability assay.,Confirmatory,,
2936,741737,1,3,,104234169,126941,Active,,,4.34085,IC50,SANGER: Inhibition of human NCI-H2291 cell growth in a cell viability assay.,Confirmatory,,
2937,741738,1,3,,104234169,126941,Active,,,0.29320999999999997,IC50,SANGER: Inhibition of human NCI-H23 cell growth in a cell viability assay.,Confirmatory,,
2938,741739,1,3,,104234169,126941,Active,,,21.6185,IC50,SANGER: Inhibition of human NCI-H2342 cell growth in a cell viability assay.,Confirmatory,,
2939,741740,1,3,,104234169,126941,Active,,,9.71696,IC50,SANGER: Inhibition of human NCI-H2347 cell growth in a cell viability assay.,Confirmatory,,
2940,741741,1,3,,104234169,126941,Active,,,29.0895,IC50,SANGER: Inhibition of human NCI-H2405 cell growth in a cell viability assay.,Confirmatory,,
2941,741742,1,3,,104234169,126941,Active,,,0.65063,IC50,SANGER: Inhibition of human NCI-H2452 cell growth in a cell viability assay.,Confirmatory,,
2942,741744,1,3,,104234169,126941,Active,,,0.29905,IC50,SANGER: Inhibition of human NCI-H28 cell growth in a cell viability assay.,Confirmatory,,
2943,741745,1,3,,104234169,126941,Active,,,6.47748,IC50,SANGER: Inhibition of human NCI-H292 cell growth in a cell viability assay.,Confirmatory,,
2944,741748,1,3,,104234169,126941,Active,,,0.25058,IC50,SANGER: Inhibition of human NCI-H358 cell growth in a cell viability assay.,Confirmatory,,
2945,741750,1,3,,104234169,126941,Active,,,0.67292,IC50,SANGER: Inhibition of human NCI-H441 cell growth in a cell viability assay.,Confirmatory,,
2946,741751,1,3,,104234169,126941,Active,,,11.1658,IC50,SANGER: Inhibition of human NCI-H446 cell growth in a cell viability assay.,Confirmatory,,
2947,741753,1,3,,104234169,126941,Active,,,4.79154,IC50,SANGER: Inhibition of human NCI-H510A cell growth in a cell viability assay.,Confirmatory,,
2948,741754,1,3,,104234169,126941,Active,,,1.38932,IC50,SANGER: Inhibition of human NCI-H520 cell growth in a cell viability assay.,Confirmatory,,
2949,741757,1,3,,104234169,126941,Active,,,0.000691,IC50,SANGER: Inhibition of human NCI-H526 cell growth in a cell viability assay.,Confirmatory,,
2950,741758,1,3,,104234169,126941,Active,,,0.83344,IC50,SANGER: Inhibition of human NCI-H596 cell growth in a cell viability assay.,Confirmatory,,
2951,741759,1,3,,104234169,126941,Active,,,6.51861,IC50,SANGER: Inhibition of human NCI-H630 cell growth in a cell viability assay.,Confirmatory,,
2952,741761,1,3,,104234169,126941,Active,,,0.80779,IC50,SANGER: Inhibition of human NCI-H650 cell growth in a cell viability assay.,Confirmatory,,
2953,741762,1,3,,104234169,126941,Active,,,3.5628699999999998,IC50,SANGER: Inhibition of human NCI-H661 cell growth in a cell viability assay.,Confirmatory,,
2954,741767,1,3,,104234169,126941,Active,,,1.12799,IC50,SANGER: Inhibition of human NCI-H727 cell growth in a cell viability assay.,Confirmatory,,
2955,741768,1,3,,104234169,126941,Active,,,13.0773,IC50,SANGER: Inhibition of human NCI-H747 cell growth in a cell viability assay.,Confirmatory,,
2956,741770,1,3,,104234169,126941,Active,,,14.3159,IC50,SANGER: Inhibition of human NCI-H810 cell growth in a cell viability assay.,Confirmatory,,
2957,741771,1,3,,104234169,126941,Active,,,0.78992,IC50,SANGER: Inhibition of human NCI-H82 cell growth in a cell viability assay.,Confirmatory,,
2958,741774,1,3,,104234169,126941,Active,,,6.03226,IC50,SANGER: Inhibition of human NCI-N87 cell growth in a cell viability assay.,Confirmatory,,
2959,741775,1,3,,104234169,126941,Active,,,0.007509999999999999,IC50,SANGER: Inhibition of human NCI-SNU-1 cell growth in a cell viability assay.,Confirmatory,,
2960,741777,1,3,,104234169,126941,Active,,,1.49968,IC50,SANGER: Inhibition of human NCI-SNU-5 cell growth in a cell viability assay.,Confirmatory,,
2961,741778,1,3,,104234169,126941,Active,,,0.28976,IC50,SANGER: Inhibition of human NEC8 cell growth in a cell viability assay.,Confirmatory,,
2962,741779,1,3,,104234169,126941,Active,,,3.5065,IC50,SANGER: Inhibition of human NH-12 cell growth in a cell viability assay.,Confirmatory,,
2963,741780,1,3,,104234169,126941,Active,,,0.0077,IC50,SANGER: Inhibition of human NKM-1 cell growth in a cell viability assay.,Confirmatory,,
2964,741781,1,3,,104234169,126941,Active,,,11.3482,IC50,SANGER: Inhibition of human NMC-G1 cell growth in a cell viability assay.,Confirmatory,,
2965,741782,1,3,,104234169,126941,Active,,,0.01625,IC50,SANGER: Inhibition of human NOMO-1 cell growth in a cell viability assay.,Confirmatory,,
2966,741783,1,3,,104234169,126941,Active,,,4.55551,IC50,SANGER: Inhibition of human NOS-1 cell growth in a cell viability assay.,Confirmatory,,
2967,741784,1,4,,104234169,126941,Active,,,3.14874,IC50,SANGER: Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay.,Confirmatory,,
2968,741785,1,3,,104234169,126941,Active,,,6.1225,IC50,SANGER: Inhibition of human NUGC-3 cell growth in a cell viability assay.,Confirmatory,,
2969,741786,1,3,,104234169,126941,Active,,,0.7229899999999999,IC50,SANGER: Inhibition of human NY cell growth in a cell viability assay.,Confirmatory,,
2970,741787,1,3,,104234169,126941,Active,,,13.8525,IC50,SANGER: Inhibition of human OAW-28 cell growth in a cell viability assay.,Confirmatory,,
2971,741788,1,3,,104234169,126941,Active,,,8.41744,IC50,SANGER: Inhibition of human OAW-42 cell growth in a cell viability assay.,Confirmatory,,
2972,741789,1,3,,104234169,126941,Active,,,0.68605,IC50,SANGER: Inhibition of human OC-314 cell growth in a cell viability assay.,Confirmatory,,
2973,741790,1,3,,104234169,126941,Active,,,0.26563000000000003,IC50,SANGER: Inhibition of human OCI-AML2 cell growth in a cell viability assay.,Confirmatory,,
2974,741791,1,3,,104234169,126941,Active,,,22.2462,IC50,SANGER: Inhibition of human OCUB-M cell growth in a cell viability assay.,Confirmatory,,
2975,741792,1,3,,104234169,126941,Active,,,1.5446,IC50,SANGER: Inhibition of human OE19 cell growth in a cell viability assay.,Confirmatory,,
2976,741793,1,3,,104234169,126941,Active,,,0.28167,IC50,SANGER: Inhibition of human OE33 cell growth in a cell viability assay.,Confirmatory,,
2977,741794,1,3,,104234169,126941,Active,,,24.6212,IC50,SANGER: Inhibition of human OMC-1 cell growth in a cell viability assay.,Confirmatory,,
2978,741795,1,3,,104234169,126941,Active,,,0.06377000000000001,IC50,SANGER: Inhibition of human ONS-76 cell growth in a cell viability assay.,Confirmatory,,
2979,741797,1,3,,104234169,126941,Active,,,5.32083,IC50,SANGER: Inhibition of human OS-RC-2 cell growth in a cell viability assay.,Confirmatory,,
2980,741798,1,3,,104234169,126941,Active,,,0.81002,IC50,SANGER: Inhibition of human OVCAR-3 cell growth in a cell viability assay.,Confirmatory,,
2981,741799,1,3,,104234169,126941,Active,,,4.41418,IC50,SANGER: Inhibition of human OVCAR-4 cell growth in a cell viability assay.,Confirmatory,,
2982,741800,1,3,,104234169,126941,Active,,,14.6687,IC50,SANGER: Inhibition of human OVCAR-5 cell growth in a cell viability assay.,Confirmatory,,
2983,741801,1,3,,104234169,126941,Active,,,9.99071,IC50,SANGER: Inhibition of human OVCAR-8 cell growth in a cell viability assay.,Confirmatory,,
2984,741802,1,3,,104234169,126941,Active,,,0.0413,IC50,SANGER: Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay.,Confirmatory,,
2985,741803,1,3,,104234169,126941,Active,,,0.04355,IC50,SANGER: Inhibition of human P30-OHK cell growth in a cell viability assay.,Confirmatory,,
2986,741805,1,3,,104234169,126941,Active,,,9.897780000000001,IC50,SANGER: Inhibition of human PA-1 cell growth in a cell viability assay.,Confirmatory,,
2987,741806,1,3,,104234169,126941,Active,,,7.92715,IC50,SANGER: Inhibition of human PANC-03-27 cell growth in a cell viability assay.,Confirmatory,,
2988,741807,1,3,,104234169,126941,Active,,,3.88613,IC50,SANGER: Inhibition of human PANC-08-13 cell growth in a cell viability assay.,Confirmatory,,
2989,741808,1,3,,104234169,126941,Active,,,4.31758,IC50,SANGER: Inhibition of human PANC-10-05 cell growth in a cell viability assay.,Confirmatory,,
2990,741809,1,3,,104234169,126941,Active,,,0.57286,IC50,SANGER: Inhibition of human PC-14 cell growth in a cell viability assay.,Confirmatory,,
2991,741810,1,3,,104234169,126941,Active,,,2.63741,IC50,SANGER: Inhibition of human PC-3 cell growth in a cell viability assay.,Confirmatory,,
2992,741812,1,3,,104234169,126941,Active,,,1.20631,IC50,SANGER: Inhibition of human PFSK-1 cell growth in a cell viability assay.,Confirmatory,,
2993,741814,1,3,,104234169,126941,Active,,,1.58664,IC50,SANGER: Inhibition of human PSN1 cell growth in a cell viability assay.,Confirmatory,,
2994,741815,1,3,,104234169,126941,Active,,,0.13940999999999998,IC50,SANGER: Inhibition of human QIMR-WIL cell growth in a cell viability assay.,Confirmatory,,
2995,741816,1,3,,104234169,126941,Active,,,20.2102,IC50,SANGER: Inhibition of human RCC10RGB cell growth in a cell viability assay.,Confirmatory,,
2996,741817,1,3,,104234169,126941,Active,,,1.46139,IC50,SANGER: Inhibition of human RCM-1 cell growth in a cell viability assay.,Confirmatory,,
2997,741818,1,3,,104234169,126941,Active,,,8.43719,IC50,SANGER: Inhibition of human RD cell growth in a cell viability assay.,Confirmatory,,
2998,741820,1,3,,104234169,126941,Active,,,1.1107,IC50,SANGER: Inhibition of human RERF-LC-MS cell growth in a cell viability assay.,Confirmatory,,
2999,741821,1,3,,104234169,126941,Active,,,0.36182,IC50,SANGER: Inhibition of human RH-1 cell growth in a cell viability assay.,Confirmatory,,
3000,741822,1,3,,104234169,126941,Active,,,15.8004,IC50,SANGER: Inhibition of human RH-18 cell growth in a cell viability assay.,Confirmatory,,
3001,741823,1,3,,104234169,126941,Active,,,4.7628900000000005,IC50,SANGER: Inhibition of human RKO cell growth in a cell viability assay.,Confirmatory,,
3002,741826,1,3,,104234169,126941,Active,,,10.693,IC50,SANGER: Inhibition of human RMG-I cell growth in a cell viability assay.,Confirmatory,,
3003,741827,1,3,,104234169,126941,Active,,,7.240889999999999,IC50,SANGER: Inhibition of human RO82-W-1 cell growth in a cell viability assay.,Confirmatory,,
3004,741828,1,3,,104234169,126941,Active,,,6.187819999999999,IC50,SANGER: Inhibition of human RPMI-2650 cell growth in a cell viability assay.,Confirmatory,,
3005,741830,1,3,,104234169,126941,Active,,,1.95297,IC50,SANGER: Inhibition of human RPMI-7951 cell growth in a cell viability assay.,Confirmatory,,
3006,741831,1,3,,104234169,126941,Active,,,0.1012,IC50,SANGER: Inhibition of human RPMI-8226 cell growth in a cell viability assay.,Confirmatory,,
3007,741833,1,3,,104234169,126941,Active,,,0.01999,IC50,SANGER: Inhibition of human RPMI-8866 cell growth in a cell viability assay.,Confirmatory,,
3008,741834,1,3,,104234169,126941,Active,,,0.00705,IC50,SANGER: Inhibition of human RS4-11 cell growth in a cell viability assay.,Confirmatory,,
3009,741835,1,3,,104234169,126941,Active,,,0.14231,IC50,SANGER: Inhibition of human RT-112 cell growth in a cell viability assay.,Confirmatory,,
3010,741837,1,3,,104234169,126941,Active,,,23.0443,IC50,SANGER: Inhibition of human RVH-421 cell growth in a cell viability assay.,Confirmatory,,
3011,741838,1,3,,104234169,126941,Active,,,13.8527,IC50,SANGER: Inhibition of human RXF393 cell growth in a cell viability assay.,Confirmatory,,
3012,741840,1,3,,104234169,126941,Active,,,0.026860000000000002,IC50,SANGER: Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay.,Confirmatory,,
3013,741841,1,3,,104234169,126941,Active,,,10.8166,IC50,SANGER: Inhibition of human S-117 cell growth in a cell viability assay.,Confirmatory,,
3014,741842,1,3,,104234169,126941,Active,,,3.93781,IC50,SANGER: Inhibition of human SAS cell growth in a cell viability assay.,Confirmatory,,
3015,741843,1,3,,104234169,126941,Active,,,0.56379,IC50,SANGER: Inhibition of human SBC-1 cell growth in a cell viability assay.,Confirmatory,,
3016,741844,1,3,,104234169,126941,Active,,,0.06936,IC50,SANGER: Inhibition of human SBC-5 cell growth in a cell viability assay.,Confirmatory,,
3017,741845,1,3,,104234169,126941,Active,,,0.80509,IC50,SANGER: Inhibition of human SCC-15 cell growth in a cell viability assay.,Confirmatory,,
3018,741846,1,3,,104234169,126941,Active,,,6.59415,IC50,SANGER: Inhibition of human SCC-25 cell growth in a cell viability assay.,Confirmatory,,
3019,741848,1,3,,104234169,126941,Active,,,7.60907,IC50,SANGER: Inhibition of human SCC-4 cell growth in a cell viability assay.,Confirmatory,,
3020,741849,1,3,,104234169,126941,Active,,,7.433439999999999,IC50,SANGER: Inhibition of human SCC-9 cell growth in a cell viability assay.,Confirmatory,,
3021,741850,1,3,,104234169,126941,Active,,,0.9844700000000001,IC50,SANGER: Inhibition of human SCH cell growth in a cell viability assay.,Confirmatory,,
3022,741852,1,3,,104234169,126941,Active,,,17.9625,IC50,SANGER: Inhibition of human SF126 cell growth in a cell viability assay.,Confirmatory,,
3023,741853,1,3,,104234169,126941,Active,,,0.42796999999999996,IC50,SANGER: Inhibition of human SF268 cell growth in a cell viability assay.,Confirmatory,,
3024,741854,1,3,,104234169,126941,Active,,,12.4198,IC50,SANGER: Inhibition of human SF295 cell growth in a cell viability assay.,Confirmatory,,
3025,741855,1,3,,104234169,126941,Active,,,19.0902,IC50,SANGER: Inhibition of human SF539 cell growth in a cell viability assay.,Confirmatory,,
3026,741856,1,3,,104234169,126941,Active,,,6.94267,IC50,SANGER: Inhibition of human SH-4 cell growth in a cell viability assay.,Confirmatory,,
3027,741857,1,3,,104234169,126941,Active,,,1.9145900000000002,IC50,SANGER: Inhibition of human SHP-77 cell growth in a cell viability assay.,Confirmatory,,
3028,741861,1,3,,104234169,126941,Active,,,15.6585,IC50,SANGER: Inhibition of human SJSA-1 cell growth in a cell viability assay.,Confirmatory,,
3029,741863,1,3,,104234169,126941,Active,,,1.05335,IC50,SANGER: Inhibition of human SK-HEP-1 cell growth in a cell viability assay.,Confirmatory,,
3030,741865,1,3,,104234169,126941,Active,,,7.598389999999999,IC50,SANGER: Inhibition of human SK-LU-1 cell growth in a cell viability assay.,Confirmatory,,
3031,741866,1,3,,104234169,126941,Active,,,0.50044,IC50,SANGER: Inhibition of human SK-MEL-1 cell growth in a cell viability assay.,Confirmatory,,
3032,741867,1,3,,104234169,126941,Active,,,17.0576,IC50,SANGER: Inhibition of human SK-MEL-2 cell growth in a cell viability assay.,Confirmatory,,
3033,741868,1,3,,104234169,126941,Active,,,1.05605,IC50,SANGER: Inhibition of human SK-MEL-24 cell growth in a cell viability assay.,Confirmatory,,
3034,741869,1,3,,104234169,126941,Active,,,7.394010000000001,IC50,SANGER: Inhibition of human SK-MEL-28 cell growth in a cell viability assay.,Confirmatory,,
3035,741870,1,3,,104234169,126941,Active,,,1.05593,IC50,SANGER: Inhibition of human SK-MEL-3 cell growth in a cell viability assay.,Confirmatory,,
3036,741871,1,3,,104234169,126941,Active,,,3.85121,IC50,SANGER: Inhibition of human SK-MEL-30 cell growth in a cell viability assay.,Confirmatory,,
3037,741873,1,3,,104234169,126941,Active,,,5.06911,IC50,SANGER: Inhibition of human SK-MES-1 cell growth in a cell viability assay.,Confirmatory,,
3038,741876,1,3,,104234169,126941,Active,,,1.41783,IC50,SANGER: Inhibition of human SK-N-AS cell growth in a cell viability assay.,Confirmatory,,
3039,741877,1,3,,104234169,126941,Active,,,0.74308,IC50,SANGER: Inhibition of human SK-N-DZ cell growth in a cell viability assay.,Confirmatory,,
3040,741878,1,3,,104234169,126941,Active,,,13.1842,IC50,SANGER: Inhibition of human SK-N-FI cell growth in a cell viability assay.,Confirmatory,,
3041,741879,1,3,,104234169,126941,Active,,,0.0048200000000000005,IC50,SANGER: Inhibition of human SK-NEP-1 cell growth in a cell viability assay.,Confirmatory,,
3042,741881,1,3,,104234169,126941,Active,,,8.35661,IC50,SANGER: Inhibition of human SK-PN-DW cell growth in a cell viability assay.,Confirmatory,,
3043,741882,1,3,,104234169,126941,Active,,,12.1697,IC50,SANGER: Inhibition of human SK-UT-1 cell growth in a cell viability assay.,Confirmatory,,
3044,741883,1,3,,104234169,126941,Active,,,6.78683,IC50,SANGER: Inhibition of human SKG-IIIa cell growth in a cell viability assay.,Confirmatory,,
3045,741885,1,3,,104234169,126941,Active,,,5.55432,IC50,SANGER: Inhibition of human SN12C cell growth in a cell viability assay.,Confirmatory,,
3046,741886,1,3,,104234169,126941,Active,,,24.775,IC50,SANGER: Inhibition of human SNB75 cell growth in a cell viability assay.,Confirmatory,,
3047,741888,1,3,,104234169,126941,Active,,,12.3426,IC50,SANGER: Inhibition of human SNU-387 cell growth in a cell viability assay.,Confirmatory,,
3048,741889,1,3,,104234169,126941,Active,,,16.347,IC50,SANGER: Inhibition of human SNU-423 cell growth in a cell viability assay.,Confirmatory,,
3049,741890,1,3,,104234169,126941,Active,,,0.82735,IC50,SANGER: Inhibition of human SNU-449 cell growth in a cell viability assay.,Confirmatory,,
3050,741893,1,3,,104234169,126941,Active,,,0.14474,IC50,SANGER: Inhibition of human SNU-C2B cell growth in a cell viability assay.,Confirmatory,,
3051,741898,1,3,,104234169,126941,Active,,,6.443969999999999,IC50,SANGER: Inhibition of human SW1088 cell growth in a cell viability assay.,Confirmatory,,
3052,741899,1,3,,104234169,126941,Active,,,12.8841,IC50,SANGER: Inhibition of human SW1116 cell growth in a cell viability assay.,Confirmatory,,
3053,741900,1,3,,104234169,126941,Active,,,8.0437,IC50,SANGER: Inhibition of human SW13 cell growth in a cell viability assay.,Confirmatory,,
3054,741901,1,3,,104234169,126941,Active,,,1.91334,IC50,SANGER: Inhibition of human SW1417 cell growth in a cell viability assay.,Confirmatory,,
3055,741902,1,3,,104234169,126941,Active,,,11.3769,IC50,SANGER: Inhibition of human SW1463 cell growth in a cell viability assay.,Confirmatory,,
3056,741903,1,3,,104234169,126941,Active,,,11.5198,IC50,SANGER: Inhibition of human SW1573 cell growth in a cell viability assay.,Confirmatory,,
3057,741904,1,3,,104234169,126941,Active,,,5.961880000000001,IC50,SANGER: Inhibition of human SW1710 cell growth in a cell viability assay.,Confirmatory,,
3058,741905,1,3,,104234169,126941,Active,,,15.7647,IC50,SANGER: Inhibition of human SW1783 cell growth in a cell viability assay.,Confirmatory,,
3059,741906,1,3,,104234169,126941,Active,,,18.0631,IC50,SANGER: Inhibition of human SW1990 cell growth in a cell viability assay.,Confirmatory,,
3060,741907,1,3,,104234169,126941,Active,,,12.9524,IC50,SANGER: Inhibition of human SW48 cell growth in a cell viability assay.,Confirmatory,,
3061,741908,1,3,,104234169,126941,Active,,,0.54193,IC50,SANGER: Inhibition of human SW620 cell growth in a cell viability assay.,Confirmatory,,
3062,741909,1,3,,104234169,126941,Active,,,16.4693,IC50,SANGER: Inhibition of human SW626 cell growth in a cell viability assay.,Confirmatory,,
3063,741910,1,3,,104234169,126941,Active,,,9.28187,IC50,SANGER: Inhibition of human SW684 cell growth in a cell viability assay.,Confirmatory,,
3064,741911,1,3,,104234169,126941,Active,,,13.8609,IC50,SANGER: Inhibition of human SW756 cell growth in a cell viability assay.,Confirmatory,,
3065,741912,1,3,,104234169,126941,Active,,,0.11629,IC50,SANGER: Inhibition of human SW780 cell growth in a cell viability assay.,Confirmatory,,
3066,741913,1,3,,104234169,126941,Active,,,4.59068,IC50,SANGER: Inhibition of human SW837 cell growth in a cell viability assay.,Confirmatory,,
3067,741914,1,3,,104234169,126941,Active,,,4.6002,IC50,SANGER: Inhibition of human SW872 cell growth in a cell viability assay.,Confirmatory,,
3068,741915,1,3,,104234169,126941,Active,,,11.2399,IC50,SANGER: Inhibition of human SW900 cell growth in a cell viability assay.,Confirmatory,,
3069,741916,1,3,,104234169,126941,Active,,,18.6269,IC50,SANGER: Inhibition of human SW948 cell growth in a cell viability assay.,Confirmatory,,
3070,741917,1,3,,104234169,126941,Active,,,0.21315,IC50,SANGER: Inhibition of human SW954 cell growth in a cell viability assay.,Confirmatory,,
3071,741918,1,3,,104234169,126941,Active,,,12.9963,IC50,SANGER: Inhibition of human SW962 cell growth in a cell viability assay.,Confirmatory,,
3072,741919,1,3,,104234169,126941,Active,,,11.0169,IC50,SANGER: Inhibition of human SW982 cell growth in a cell viability assay.,Confirmatory,,
3073,741920,1,3,,104234169,126941,Active,,,2.9636,IC50,SANGER: Inhibition of human Saos-2 cell growth in a cell viability assay.,Confirmatory,,
3074,741921,1,3,,104234169,126941,Active,,,8.50233,IC50,SANGER: Inhibition of human SiHa cell growth in a cell viability assay.,Confirmatory,,
3075,741922,1,3,,104234169,126941,Active,,,13.9548,IC50,SANGER: Inhibition of human T-24 cell growth in a cell viability assay.,Confirmatory,,
3076,741923,1,3,,104234169,126941,Active,,,24.8783,IC50,SANGER: Inhibition of human T47D cell growth in a cell viability assay.,Confirmatory,,
3077,741924,1,3,,104234169,126941,Active,,,17.5368,IC50,SANGER: Inhibition of human T84 cell growth in a cell viability assay.,Confirmatory,,
3078,741925,1,3,,104234169,126941,Active,,,12.8459,IC50,SANGER: Inhibition of human T98G cell growth in a cell viability assay.,Confirmatory,,
3079,741928,1,3,,104234169,126941,Active,,,8.56961,IC50,SANGER: Inhibition of human TCCSUP cell growth in a cell viability assay.,Confirmatory,,
3080,741929,1,3,,104234169,126941,Active,,,0.38824000000000003,IC50,SANGER: Inhibition of human TE-1 cell growth in a cell viability assay.,Confirmatory,,
3081,741930,1,3,,104234169,126941,Active,,,0.53688,IC50,SANGER: Inhibition of human 22RV1 cell growth in a cell viability assay.,Confirmatory,,
3082,741932,1,3,,104234169,126941,Active,,,0.29334,IC50,SANGER: Inhibition of human 5637 cell growth in a cell viability assay.,Confirmatory,,
3083,741933,1,3,,104234169,126941,Active,,,6.32379,IC50,SANGER: Inhibition of human 639-V cell growth in a cell viability assay.,Confirmatory,,
3084,741934,1,3,,104234169,126941,Active,,,9.30722,IC50,SANGER: Inhibition of human 647-V cell growth in a cell viability assay.,Confirmatory,,
3085,741935,1,3,,104234169,126941,Active,,,0.01257,IC50,SANGER: Inhibition of human 697 cell growth in a cell viability assay.,Confirmatory,,
3086,741936,1,3,,104234169,126941,Active,,,0.04526,IC50,SANGER: Inhibition of human 769-P cell growth in a cell viability assay.,Confirmatory,,
3087,741937,1,3,,104234169,126941,Active,,,0.6433,IC50,SANGER: Inhibition of human 786-0 cell growth in a cell viability assay.,Confirmatory,,
3088,741938,1,3,,104234169,126941,Active,,,21.8057,IC50,SANGER: Inhibition of human 8-MG-BA cell growth in a cell viability assay.,Confirmatory,,
3089,741939,1,3,,104234169,126941,Active,,,0.19634000000000001,IC50,SANGER: Inhibition of human 8305C cell growth in a cell viability assay.,Confirmatory,,
3090,741940,1,3,,104234169,126941,Active,,,12.2121,IC50,SANGER: Inhibition of human 8505C cell growth in a cell viability assay.,Confirmatory,,
3091,741941,1,3,,104234169,126941,Active,,,14.9363,IC50,SANGER: Inhibition of human A101D cell growth in a cell viability assay.,Confirmatory,,
3092,741942,1,3,,104234169,126941,Active,,,1.89589,IC50,SANGER: Inhibition of human A172 cell growth in a cell viability assay.,Confirmatory,,
3093,741943,1,3,,104234169,126941,Active,,,1.08408,IC50,SANGER: Inhibition of human A204 cell growth in a cell viability assay.,Confirmatory,,
3094,741944,1,3,,104234169,126941,Active,,,1.98773,IC50,SANGER: Inhibition of human A2058 cell growth in a cell viability assay.,Confirmatory,,
3095,741946,1,3,,104234169,126941,Active,,,0.05454,IC50,SANGER: Inhibition of human A2780 cell growth in a cell viability assay.,Confirmatory,,
3096,741947,1,3,,104234169,126941,Active,,,0.00892,IC50,SANGER: Inhibition of human A3-KAW cell growth in a cell viability assay.,Confirmatory,,
3097,741948,1,3,,104234169,126941,Active,,,9.816460000000001,IC50,SANGER: Inhibition of human A375 cell growth in a cell viability assay.,Confirmatory,,
3098,741949,1,3,,104234169,126941,Active,,,1.605,IC50,SANGER: Inhibition of human A388 cell growth in a cell viability assay.,Confirmatory,,
3099,741950,1,3,,104234169,126941,Active,,,0.03823,IC50,SANGER: Inhibition of human A4-Fuk cell growth in a cell viability assay.,Confirmatory,,
3100,741951,1,3,,104234169,126941,Active,,,16.1842,IC50,SANGER: Inhibition of human A427 cell growth in a cell viability assay.,Confirmatory,,
3101,741952,1,3,,104234169,126941,Active,,,2.1971,IC50,SANGER: Inhibition of human A431 cell growth in a cell viability assay.,Confirmatory,,
3102,741953,1,3,,104234169,126941,Active,,,9.373669999999999,IC50,SANGER: Inhibition of human A498 cell growth in a cell viability assay.,Confirmatory,,
3103,741954,1,3,,104234169,126941,Active,,,11.5899,IC50,SANGER: Inhibition of human A549 cell growth in a cell viability assay.,Confirmatory,,
3104,741955,1,3,,104234169,126941,Active,,,1.6053,IC50,SANGER: Inhibition of human A673 cell growth in a cell viability assay.,Confirmatory,,
3105,741956,1,3,,104234169,126941,Active,,,22.8145,IC50,SANGER: Inhibition of human A704 cell growth in a cell viability assay.,Confirmatory,,
3106,741957,1,3,,104234169,126941,Active,,,21.1496,IC50,SANGER: Inhibition of human ABC-1 cell growth in a cell viability assay.,Confirmatory,,
3107,741958,1,3,,104234169,126941,Active,,,0.08526,IC50,SANGER: Inhibition of human ACHN cell growth in a cell viability assay.,Confirmatory,,
3108,741959,1,3,,104234169,126941,Active,,,16.3789,IC50,SANGER: Inhibition of human ACN cell growth in a cell viability assay.,Confirmatory,,
3109,741961,1,3,,104234169,126941,Active,,,0.00586,IC50,SANGER: Inhibition of human ALL-PO cell growth in a cell viability assay.,Confirmatory,,
3110,741962,1,3,,104234169,126941,Active,,,0.60387,IC50,SANGER: Inhibition of human AM-38 cell growth in a cell viability assay.,Confirmatory,,
3111,741963,1,3,,104234169,126941,Active,,,9.488999999999999,IC50,SANGER: Inhibition of human AN3-CA cell growth in a cell viability assay.,Confirmatory,,
3112,741965,1,3,,104234169,126941,Active,,,0.00392,IC50,SANGER: Inhibition of human ATN-1 cell growth in a cell viability assay.,Confirmatory,,
3113,741966,1,3,,104234169,126941,Active,,,0.06134,IC50,SANGER: Inhibition of human AU565 cell growth in a cell viability assay.,Confirmatory,,
3114,741967,1,3,,104234169,126941,Active,,,0.26621999999999996,IC50,SANGER: Inhibition of human AsPC-1 cell growth in a cell viability assay.,Confirmatory,,
3115,741968,1,3,,104234169,126941,Active,,,1.18696,IC50,SANGER: Inhibition of human BALL-1 cell growth in a cell viability assay.,Confirmatory,,
3116,741969,1,3,,104234169,126941,Active,,,0.09427999999999999,IC50,SANGER: Inhibition of human BB30-HNC cell growth in a cell viability assay.,Confirmatory,,
3117,741970,1,3,,104234169,126941,Active,,,10.1864,IC50,SANGER: Inhibition of human BB49-HNC cell growth in a cell viability assay.,Confirmatory,,
3118,741971,1,3,,104234169,126941,Active,,,7.08595,IC50,SANGER: Inhibition of human BB65-RCC cell growth in a cell viability assay.,Confirmatory,,
3119,741974,1,3,,104234169,126941,Active,,,0.0431,IC50,SANGER: Inhibition of human BCPAP cell growth in a cell viability assay.,Confirmatory,,
3120,741975,1,3,,104234169,126941,Active,,,0.03875,IC50,SANGER: Inhibition of human BE-13 cell growth in a cell viability assay.,Confirmatory,,
3121,741976,1,3,,104234169,126941,Active,,,9.70411,IC50,SANGER: Inhibition of human BEN cell growth in a cell viability assay.,Confirmatory,,
3122,741977,1,3,,104234169,126941,Active,,,9.016060000000001,IC50,SANGER: Inhibition of human BFTC-905 cell growth in a cell viability assay.,Confirmatory,,
3123,741978,1,3,,104234169,126941,Active,,,9.208639999999999,IC50,SANGER: Inhibition of human BFTC-909 cell growth in a cell viability assay.,Confirmatory,,
3124,741979,1,3,,104234169,126941,Active,,,26.6443,IC50,SANGER: Inhibition of human BHT-101 cell growth in a cell viability assay.,Confirmatory,,
3125,741980,1,3,,104234169,126941,Active,,,5.7258,IC50,SANGER: Inhibition of human BHY cell growth in a cell viability assay.,Confirmatory,,
3126,741984,1,3,,104234169,126941,Active,,,0.77241,IC50,SANGER: Inhibition of human BPH-1 cell growth in a cell viability assay.,Confirmatory,,
3127,741985,1,3,,104234169,126941,Active,,,1.35019,IC50,SANGER: Inhibition of human BT-20 cell growth in a cell viability assay.,Confirmatory,,
3128,741986,1,3,,104234169,126941,Active,,,12.5418,IC50,SANGER: Inhibition of human BT-474 cell growth in a cell viability assay.,Confirmatory,,
3129,741988,1,3,,104234169,126941,Active,,,0.00635,IC50,SANGER: Inhibition of human BV-173 cell growth in a cell viability assay.,Confirmatory,,
3130,741989,1,3,,104234169,126941,Active,,,12.7926,IC50,SANGER: Inhibition of human Becker cell growth in a cell viability assay.,Confirmatory,,
3131,741990,1,3,,104234169,126941,Active,,,4.40682,IC50,SANGER: Inhibition of human BxPC-3 cell growth in a cell viability assay.,Confirmatory,,
3132,741991,1,3,,104234169,126941,Active,,,10.6854,IC50,SANGER: Inhibition of human C-33-A cell growth in a cell viability assay.,Confirmatory,,
3133,741993,1,3,,104234169,126941,Active,,,0.99616,IC50,SANGER: Inhibition of human C2BBe1 cell growth in a cell viability assay.,Confirmatory,,
3134,741994,1,3,,104234169,126941,Active,,,2.9247,IC50,SANGER: Inhibition of human C32 cell growth in a cell viability assay.,Confirmatory,,
3135,741995,1,3,,104234169,126941,Active,,,2.98832,IC50,SANGER: Inhibition of human C3A cell growth in a cell viability assay.,Confirmatory,,
3136,741996,1,3,,104234169,126941,Active,,,0.22411999999999999,IC50,SANGER: Inhibition of human C8166 cell growth in a cell viability assay.,Confirmatory,,
3137,741998,1,3,,104234169,126941,Active,,,0.6714899999999999,IC50,SANGER: Inhibition of human CAKI-1 cell growth in a cell viability assay.,Confirmatory,,
3138,741999,1,3,,104234169,126941,Active,,,10.8389,IC50,SANGER: Inhibition of human CAL-120 cell growth in a cell viability assay.,Confirmatory,,
3139,742000,1,3,,104234169,126941,Active,,,8.43014,IC50,SANGER: Inhibition of human CAL-12T cell growth in a cell viability assay.,Confirmatory,,
3140,742002,1,3,,104234169,126941,Active,,,9.6443,IC50,SANGER: Inhibition of human CAL-27 cell growth in a cell viability assay.,Confirmatory,,
3141,742003,1,3,,104234169,126941,Active,,,7.6771199999999995,IC50,SANGER: Inhibition of human CAL-33 cell growth in a cell viability assay.,Confirmatory,,
3142,742004,1,3,,104234169,126941,Active,,,17.4072,IC50,SANGER: Inhibition of human CAL-39 cell growth in a cell viability assay.,Confirmatory,,
3143,742005,1,3,,104234169,126941,Active,,,4.53264,IC50,SANGER: Inhibition of human CAL-51 cell growth in a cell viability assay.,Confirmatory,,
3144,742006,1,3,,104234169,126941,Active,,,2.79173,IC50,SANGER: Inhibition of human CAL-54 cell growth in a cell viability assay.,Confirmatory,,
3145,742007,1,3,,104234169,126941,Active,,,3.17541,IC50,SANGER: Inhibition of human CAL-62 cell growth in a cell viability assay.,Confirmatory,,
3146,742008,1,3,,104234169,126941,Active,,,0.41594,IC50,SANGER: Inhibition of human CAL-72 cell growth in a cell viability assay.,Confirmatory,,
3147,742009,1,3,,104234169,126941,Active,,,10.9405,IC50,SANGER: Inhibition of human CAL-85-1 cell growth in a cell viability assay.,Confirmatory,,
3148,742010,1,3,,104234169,126941,Active,,,12.6585,IC50,SANGER: Inhibition of human TE-10 cell growth in a cell viability assay.,Confirmatory,,
3149,742011,1,3,,104234169,126941,Active,,,0.7732100000000001,IC50,SANGER: Inhibition of human TE-11 cell growth in a cell viability assay.,Confirmatory,,
3150,742012,1,3,,104234169,126941,Active,,,0.51068,IC50,SANGER: Inhibition of human TE-12 cell growth in a cell viability assay.,Confirmatory,,
3151,742015,1,3,,104234169,126941,Active,,,11.9923,IC50,SANGER: Inhibition of human TE-5 cell growth in a cell viability assay.,Confirmatory,,
3152,742016,1,3,,104234169,126941,Active,,,11.0327,IC50,SANGER: Inhibition of human TE-6 cell growth in a cell viability assay.,Confirmatory,,
3153,742017,1,3,,104234169,126941,Active,,,8.75699,IC50,SANGER: Inhibition of human TE-8 cell growth in a cell viability assay.,Confirmatory,,
3154,742018,1,3,,104234169,126941,Active,,,3.47042,IC50,SANGER: Inhibition of human TE-9 cell growth in a cell viability assay.,Confirmatory,,
3155,742019,1,3,,104234169,126941,Active,,,18.2546,IC50,SANGER: Inhibition of human TGBC11TKB cell growth in a cell viability assay.,Confirmatory,,
3156,742020,1,3,,104234169,126941,Active,,,7.6174100000000005,IC50,SANGER: Inhibition of human TGBC1TKB cell growth in a cell viability assay.,Confirmatory,,
3157,742021,1,3,,104234169,126941,Active,,,4.5853,IC50,SANGER: Inhibition of human TGBC24TKB cell growth in a cell viability assay.,Confirmatory,,
3158,742024,1,3,,104234169,126941,Active,,,11.6051,IC50,SANGER: Inhibition of human TI-73 cell growth in a cell viability assay.,Confirmatory,,
3159,742025,1,3,,104234169,126941,Active,,,26.8495,IC50,SANGER: Inhibition of human TK10 cell growth in a cell viability assay.,Confirmatory,,
3160,742028,1,3,,104234169,126941,Active,,,0.19727,IC50,SANGER: Inhibition of human TYK-nu cell growth in a cell viability assay.,Confirmatory,,
3161,742029,1,3,,104234169,126941,Active,,,4.67136,IC50,SANGER: Inhibition of human U-118-MG cell growth in a cell viability assay.,Confirmatory,,
3162,742030,1,3,,104234169,126941,Active,,,0.18232,IC50,SANGER: Inhibition of human U-2-OS cell growth in a cell viability assay.,Confirmatory,,
3163,742031,1,3,,104234169,126941,Active,,,5.528569999999999,IC50,SANGER: Inhibition of human U-266 cell growth in a cell viability assay.,Confirmatory,,
3164,742033,1,3,,104234169,126941,Active,,,18.5606,IC50,SANGER: Inhibition of human U-87-MG cell growth in a cell viability assay.,Confirmatory,,
3165,742034,1,4,,104234169,126941,Active,,,3.6434,IC50,SANGER: Inhibition of human U031 cell growth in a cell viability assay.,Confirmatory,,
3166,742035,1,3,,104234169,126941,Active,,,12.1928,IC50,SANGER: Inhibition of human U251 cell growth in a cell viability assay.,Confirmatory,,
3167,742036,1,3,,104234169,126941,Active,,,19.2295,IC50,SANGER: Inhibition of human UACC-257 cell growth in a cell viability assay.,Confirmatory,,
3168,742037,1,3,,104234169,126941,Active,,,17.9158,IC50,SANGER: Inhibition of human UACC-62 cell growth in a cell viability assay.,Confirmatory,,
3169,742039,1,3,,104234169,126941,Active,,,1.09512,IC50,SANGER: Inhibition of human UACC-893 cell growth in a cell viability assay.,Confirmatory,,
3170,742040,1,3,,104234169,126941,Active,,,7.035189999999999,IC50,SANGER: Inhibition of human UM-UC-3 cell growth in a cell viability assay.,Confirmatory,,
3171,742041,1,3,,104234169,126941,Active,,,9.58354,IC50,SANGER: Inhibition of human UMC-11 cell growth in a cell viability assay.,Confirmatory,,
3172,742042,1,3,,104234169,126941,Active,,,5.05884,IC50,SANGER: Inhibition of human VA-ES-BJ cell growth in a cell viability assay.,Confirmatory,,
3173,742043,1,3,,104234169,126941,Active,,,0.37442,IC50,SANGER: Inhibition of human VM-CUB-1 cell growth in a cell viability assay.,Confirmatory,,
3174,742044,1,3,,104234169,126941,Active,,,5.07977,IC50,SANGER: Inhibition of human VMRC-RCZ cell growth in a cell viability assay.,Confirmatory,,
3175,742045,1,3,,104234169,126941,Active,,,1.82733,IC50,SANGER: Inhibition of human WM-115 cell growth in a cell viability assay.,Confirmatory,,
3176,742047,1,3,,104234169,126941,Active,,,0.66575,IC50,SANGER: Inhibition of human YAPC cell growth in a cell viability assay.,Confirmatory,,
3177,742048,1,3,,104234169,126941,Active,,,21.4065,IC50,SANGER: Inhibition of human YH-13 cell growth in a cell viability assay.,Confirmatory,,
3178,742049,1,3,,104234169,126941,Active,,,23.243000000000002,IC50,SANGER: Inhibition of human YKG-1 cell growth in a cell viability assay.,Confirmatory,,
3179,742051,1,3,,104234169,126941,Active,,,2.23294,IC50,SANGER: Inhibition of human ZR-75-30 cell growth in a cell viability assay.,Confirmatory,,
3180,742052,1,3,,104234169,126941,Active,,,7.30721,IC50,SANGER: Inhibition of human no-10 cell growth in a cell viability assay.,Confirmatory,,
3181,742053,1,3,,104234169,126941,Active,,,11.1956,IC50,SANGER: Inhibition of human no-11 cell growth in a cell viability assay.,Confirmatory,,
3182,742054,1,3,,104234169,126941,Active,,,3.9373400000000003,IC50,SANGER: Inhibition of human CAMA-1 cell growth in a cell viability assay.,Confirmatory,,
3183,742055,1,3,,104234169,126941,Active,,,6.09615,IC50,SANGER: Inhibition of human CAPAN-1 cell growth in a cell viability assay.,Confirmatory,,
3184,742056,1,3,,104234169,126941,Active,,,16.5667,IC50,SANGER: Inhibition of human CAS-1 cell growth in a cell viability assay.,Confirmatory,,
3185,742058,1,3,,104234169,126941,Active,,,0.69581,IC50,SANGER: Inhibition of human CCRF-CEM cell growth in a cell viability assay.,Confirmatory,,
3186,742060,1,3,,104234169,126941,Active,,,0.68955,IC50,SANGER: Inhibition of human CFPAC-1 cell growth in a cell viability assay.,Confirmatory,,
3187,742061,1,3,,104234169,126941,Active,,,0.03121,IC50,SANGER: Inhibition of human CGTH-W-1 cell growth in a cell viability assay.,Confirmatory,,
3188,742062,1,3,,104234169,126941,Active,,,0.20951,IC50,SANGER: Inhibition of human CHL-1 cell growth in a cell viability assay.,Confirmatory,,
3189,742065,1,3,,104234169,126941,Active,,,7.847410000000001,IC50,SANGER: Inhibition of human CHP-212 cell growth in a cell viability assay.,Confirmatory,,
3190,742068,1,3,,104234169,126941,Active,,,0.052379999999999996,IC50,SANGER: Inhibition of human COLO-320-HSR cell growth in a cell viability assay.,Confirmatory,,
3191,742069,1,3,,104234169,126941,Active,,,0.49856000000000006,IC50,SANGER: Inhibition of human COLO-668 cell growth in a cell viability assay.,Confirmatory,,
3192,742070,1,3,,104234169,126941,Active,,,11.98,IC50,SANGER: Inhibition of human COLO-678 cell growth in a cell viability assay.,Confirmatory,,
3193,742071,1,3,,104234169,126941,Active,,,18.5837,IC50,SANGER: Inhibition of human COLO-679 cell growth in a cell viability assay.,Confirmatory,,
3194,742072,1,3,,104234169,126941,Active,,,19.5982,IC50,SANGER: Inhibition of human COLO-680N cell growth in a cell viability assay.,Confirmatory,,
3195,742073,1,3,,104234169,126941,Active,,,0.03755,IC50,SANGER: Inhibition of human COLO-684 cell growth in a cell viability assay.,Confirmatory,,
3196,742074,1,3,,104234169,126941,Active,,,0.16212000000000001,IC50,SANGER: Inhibition of human COLO-741 cell growth in a cell viability assay.,Confirmatory,,
3197,742075,1,3,,104234169,126941,Active,,,16.9659,IC50,SANGER: Inhibition of human COLO-792 cell growth in a cell viability assay.,Confirmatory,,
3198,742076,1,3,,104234169,126941,Active,,,0.12372000000000001,IC50,SANGER: Inhibition of human COLO-800 cell growth in a cell viability assay.,Confirmatory,,
3199,742077,1,3,,104234169,126941,Active,,,14.2897,IC50,SANGER: Inhibition of human COLO-824 cell growth in a cell viability assay.,Confirmatory,,
3200,742078,1,3,,104234169,126941,Active,,,1.42979,IC50,SANGER: Inhibition of human COLO-829 cell growth in a cell viability assay.,Confirmatory,,
3201,742079,1,3,,104234169,126941,Active,,,16.8635,IC50,SANGER: Inhibition of human COR-L105 cell growth in a cell viability assay.,Confirmatory,,
3202,742080,1,3,,104234169,126941,Active,,,0.12192,IC50,SANGER: Inhibition of human COR-L23 cell growth in a cell viability assay.,Confirmatory,,
3203,742083,1,3,,104234169,126941,Active,,,12.2925,IC50,SANGER: Inhibition of human CP50-MEL-B cell growth in a cell viability assay.,Confirmatory,,
3204,742088,1,3,,104234169,126941,Active,,,0.01623,IC50,SANGER: Inhibition of human CTB-1 cell growth in a cell viability assay.,Confirmatory,,
3205,742089,1,3,,104234169,126941,Active,,,0.0771,IC50,SANGER: Inhibition of human CTV-1 cell growth in a cell viability assay.,Confirmatory,,
3206,742090,1,3,,104234169,126941,Active,,,15.7772,IC50,SANGER: Inhibition of human CW-2 cell growth in a cell viability assay.,Confirmatory,,
3207,742091,1,3,,104234169,126941,Active,,,0.37319,IC50,SANGER: Inhibition of human Ca-Ski cell growth in a cell viability assay.,Confirmatory,,
3208,742092,1,3,,104234169,126941,Active,,,3.4049400000000003,IC50,SANGER: Inhibition of human Ca9-22 cell growth in a cell viability assay.,Confirmatory,,
3209,742093,1,3,,104234169,126941,Active,,,13.2168,IC50,SANGER: Inhibition of human CaR-1 cell growth in a cell viability assay.,Confirmatory,,
3210,742095,1,3,,104234169,126941,Active,,,15.2992,IC50,SANGER: Inhibition of human Calu-3 cell growth in a cell viability assay.,Confirmatory,,
3211,742096,1,3,,104234169,126941,Active,,,0.55272,IC50,SANGER: Inhibition of human Calu-6 cell growth in a cell viability assay.,Confirmatory,,
3212,742099,1,3,,104234169,126941,Active,,,2.28226,IC50,SANGER: Inhibition of human Capan-2 cell growth in a cell viability assay.,Confirmatory,,
3213,742100,1,3,,104234169,126941,Active,,,7.73826,IC50,SANGER: Inhibition of human ChaGo-K-1 cell growth in a cell viability assay.,Confirmatory,,
3214,742101,1,3,,104234169,126941,Active,,,15.5928,IC50,SANGER: Inhibition of human D-247MG cell growth in a cell viability assay.,Confirmatory,,
3215,742102,1,3,,104234169,126941,Active,,,3.9839900000000004,IC50,SANGER: Inhibition of human D-263MG cell growth in a cell viability assay.,Confirmatory,,
3216,742103,1,4,,104234169,126941,Active,,,7.7046,IC50,SANGER: Inhibition of human D-283MED cell growth in a cell viability assay.,Confirmatory,,
3217,742104,1,3,,104234169,126941,Active,,,11.8898,IC50,SANGER: Inhibition of human D-336MG cell growth in a cell viability assay.,Confirmatory,,
3218,742105,1,3,,104234169,126941,Active,,,0.15809,IC50,SANGER: Inhibition of human D-392MG cell growth in a cell viability assay.,Confirmatory,,
3219,742106,1,3,,104234169,126941,Active,,,23.8285,IC50,SANGER: Inhibition of human D-423MG cell growth in a cell viability assay.,Confirmatory,,
3220,742107,1,3,,104234169,126941,Active,,,22.9461,IC50,SANGER: Inhibition of human D-502MG cell growth in a cell viability assay.,Confirmatory,,
3221,742109,1,3,,104234169,126941,Active,,,21.869,IC50,SANGER: Inhibition of human D-566MG cell growth in a cell viability assay.,Confirmatory,,
3222,742110,1,3,,104234169,126941,Active,,,0.02128,IC50,SANGER: Inhibition of human DB cell growth in a cell viability assay.,Confirmatory,,
3223,742111,1,3,,104234169,126941,Active,,,0.17118,IC50,SANGER: Inhibition of human DBTRG-05MG cell growth in a cell viability assay.,Confirmatory,,
3224,742112,1,3,,104234169,126941,Active,,,0.00312,IC50,SANGER: Inhibition of human DEL cell growth in a cell viability assay.,Confirmatory,,
3225,742114,1,3,,104234169,126941,Active,,,20.25,IC50,SANGER: Inhibition of human DJM-1 cell growth in a cell viability assay.,Confirmatory,,
3226,742115,1,3,,104234169,126941,Active,,,17.3929,IC50,SANGER: Inhibition of human DK-MG cell growth in a cell viability assay.,Confirmatory,,
3227,742116,1,3,,104234169,126941,Active,,,9.647039999999999,IC50,SANGER: Inhibition of human DMS-114 cell growth in a cell viability assay.,Confirmatory,,
3228,742118,1,3,,104234169,126941,Active,,,3.70551,IC50,SANGER: Inhibition of human DMS-273 cell growth in a cell viability assay.,Confirmatory,,
3229,742120,1,3,,104234169,126941,Active,,,0.62813,IC50,SANGER: Inhibition of human DMS-79 cell growth in a cell viability assay.,Confirmatory,,
3230,742121,1,3,,104234169,126941,Active,,,0.02156,IC50,SANGER: Inhibition of human DOHH-2 cell growth in a cell viability assay.,Confirmatory,,
3231,742122,1,3,,104234169,126941,Active,,,7.58205,IC50,SANGER: Inhibition of human DOK cell growth in a cell viability assay.,Confirmatory,,
3232,742123,1,3,,104234169,126941,Active,,,0.53272,IC50,SANGER: Inhibition of human DSH1 cell growth in a cell viability assay.,Confirmatory,,
3233,742124,1,3,,104234169,126941,Active,,,1.01074,IC50,SANGER: Inhibition of human DU-145 cell growth in a cell viability assay.,Confirmatory,,
3234,742127,1,3,,104234169,126941,Active,,,12.6833,IC50,SANGER: Inhibition of human Daoy cell growth in a cell viability assay.,Confirmatory,,
3235,742129,1,3,,104234169,126941,Active,,,6.924739999999999,IC50,SANGER: Inhibition of human Detroit562 cell growth in a cell viability assay.,Confirmatory,,
3236,742130,1,3,,104234169,126941,Active,,,7.058210000000001,IC50,SANGER: Inhibition of human DoTc2-4510 cell growth in a cell viability assay.,Confirmatory,,
3237,742133,1,3,,104234169,126941,Active,,,10.6256,IC50,SANGER: Inhibition of human EC-GI-10 cell growth in a cell viability assay.,Confirmatory,,
3238,742138,1,3,,104234169,126941,Active,,,10.5923,IC50,SANGER: Inhibition of human EFM-19 cell growth in a cell viability assay.,Confirmatory,,
3239,742139,1,3,,104234169,126941,Active,,,3.01666,IC50,SANGER: Inhibition of human EFO-21 cell growth in a cell viability assay.,Confirmatory,,
3240,742140,1,3,,104234169,126941,Active,,,0.5674100000000001,IC50,SANGER: Inhibition of human EFO-27 cell growth in a cell viability assay.,Confirmatory,,
3241,742141,1,3,,104234169,126941,Active,,,19.9713,IC50,SANGER: Inhibition of human EGI-1 cell growth in a cell viability assay.,Confirmatory,,
3242,742143,1,3,,104234169,126941,Active,,,9.12941,IC50,SANGER: Inhibition of human EKVX cell growth in a cell viability assay.,Confirmatory,,
3243,742144,1,3,,104234169,126941,Active,,,0.05712999999999999,IC50,SANGER: Inhibition of human EM-2 cell growth in a cell viability assay.,Confirmatory,,
3244,742145,1,3,,104234169,126941,Active,,,5.19957,IC50,SANGER: Inhibition of human EPLC-272H cell growth in a cell viability assay.,Confirmatory,,
3245,742146,1,3,,104234169,126941,Active,,,0.016390000000000002,IC50,SANGER: Inhibition of human ES1 cell growth in a cell viability assay.,Confirmatory,,
3246,742147,1,3,,104234169,126941,Active,,,0.24258000000000002,IC50,SANGER: Inhibition of human ES3 cell growth in a cell viability assay.,Confirmatory,,
3247,742148,1,3,,104234169,126941,Active,,,0.07951,IC50,SANGER: Inhibition of human ES4 cell growth in a cell viability assay.,Confirmatory,,
3248,742149,1,3,,104234169,126941,Active,,,0.43531000000000003,IC50,SANGER: Inhibition of human ES5 cell growth in a cell viability assay.,Confirmatory,,
3249,742150,1,3,,104234169,126941,Active,,,0.42837,IC50,SANGER: Inhibition of human ES6 cell growth in a cell viability assay.,Confirmatory,,
3250,742151,1,3,,104234169,126941,Active,,,0.14836,IC50,SANGER: Inhibition of human ES7 cell growth in a cell viability assay.,Confirmatory,,
3251,742152,1,3,,104234169,126941,Active,,,0.52199,IC50,SANGER: Inhibition of human ES8 cell growth in a cell viability assay.,Confirmatory,,
3252,742153,1,3,,104234169,126941,Active,,,1.02691,IC50,SANGER: Inhibition of human ESS-1 cell growth in a cell viability assay.,Confirmatory,,
3253,742154,1,3,,104234169,126941,Active,,,1.39588,IC50,SANGER: Inhibition of human ETK-1 cell growth in a cell viability assay.,Confirmatory,,
3254,742156,1,3,,104234169,126941,Active,,,0.16835,IC50,SANGER: Inhibition of human EW-1 cell growth in a cell viability assay.,Confirmatory,,
3255,742157,1,3,,104234169,126941,Active,,,0.59737,IC50,SANGER: Inhibition of human EW-11 cell growth in a cell viability assay.,Confirmatory,,
3256,742159,1,3,,104234169,126941,Active,,,0.0723,IC50,SANGER: Inhibition of human EW-13 cell growth in a cell viability assay.,Confirmatory,,
3257,742160,1,3,,104234169,126941,Active,,,0.89475,IC50,SANGER: Inhibition of human EW-16 cell growth in a cell viability assay.,Confirmatory,,
3258,742161,1,3,,104234169,126941,Active,,,0.49993999999999994,IC50,SANGER: Inhibition of human EW-18 cell growth in a cell viability assay.,Confirmatory,,
3259,742162,1,3,,104234169,126941,Active,,,0.21795,IC50,SANGER: Inhibition of human EW-22 cell growth in a cell viability assay.,Confirmatory,,
3260,742163,1,3,,104234169,126941,Active,,,0.49654,IC50,SANGER: Inhibition of human EW-24 cell growth in a cell viability assay.,Confirmatory,,
3261,742167,1,3,,104234169,126941,Active,,,6.28916,IC50,SANGER: Inhibition of human FADU cell growth in a cell viability assay.,Confirmatory,,
3262,742168,1,3,,104234169,126941,Active,,,2.51395,IC50,SANGER: Inhibition of human FTC-133 cell growth in a cell viability assay.,Confirmatory,,
3263,742170,1,3,,104234169,126941,Active,,,0.6390100000000001,IC50,SANGER: Inhibition of human G-401 cell growth in a cell viability assay.,Confirmatory,,
3264,742171,1,3,,104234169,126941,Active,,,21.5781,IC50,SANGER: Inhibition of human G-402 cell growth in a cell viability assay.,Confirmatory,,
3265,742172,1,3,,104234169,126941,Active,,,8.80609,IC50,SANGER: Inhibition of human GAK cell growth in a cell viability assay.,Confirmatory,,
3266,742173,1,3,,104234169,126941,Active,,,0.80497,IC50,SANGER: Inhibition of human GAMG cell growth in a cell viability assay.,Confirmatory,,
3267,742174,1,3,,104234169,126941,Active,,,15.3998,IC50,SANGER: Inhibition of human GB-1 cell growth in a cell viability assay.,Confirmatory,,
3268,742175,1,3,,104234169,126941,Active,,,12.3853,IC50,SANGER: Inhibition of human GCIY cell growth in a cell viability assay.,Confirmatory,,
3269,742176,1,3,,104234169,126941,Active,,,16.5942,IC50,SANGER: Inhibition of human GCT cell growth in a cell viability assay.,Confirmatory,,
3270,742178,1,3,,104234169,126941,Active,,,19.4924,IC50,SANGER: Inhibition of human GI-1 cell growth in a cell viability assay.,Confirmatory,,
3271,742179,1,3,,104234169,126941,Active,,,0.14715999999999999,IC50,SANGER: Inhibition of human GI-ME-N cell growth in a cell viability assay.,Confirmatory,,
3272,742180,1,3,,104234169,126941,Active,,,21.8427,IC50,SANGER: Inhibition of human GMS-10 cell growth in a cell viability assay.,Confirmatory,,
3273,742181,1,3,,104234169,126941,Active,,,2.0535200000000002,IC50,SANGER: Inhibition of human GOTO cell growth in a cell viability assay.,Confirmatory,,
3274,742182,1,3,,104234169,126941,Active,,,9.61403,IC50,SANGER: Inhibition of human GP5d cell growth in a cell viability assay.,Confirmatory,,
3275,742183,1,3,,104234169,126941,Active,,,0.03628,IC50,SANGER: Inhibition of human GR-ST cell growth in a cell viability assay.,Confirmatory,,
3276,742184,1,3,,104234169,126941,Active,,,10.7147,IC50,SANGER: Inhibition of human GT3TKB cell growth in a cell viability assay.,Confirmatory,,
3277,742185,1,3,,104234169,126941,Active,,,20.775,IC50,SANGER: Inhibition of human H-EMC-SS cell growth in a cell viability assay.,Confirmatory,,
3278,742186,1,3,,104234169,126941,Active,,,11.4757,IC50,SANGER: Inhibition of human H4 cell growth in a cell viability assay.,Confirmatory,,
3279,742188,1,3,,104234169,126941,Active,,,0.022269999999999998,IC50,SANGER: Inhibition of human HAL-01 cell growth in a cell viability assay.,Confirmatory,,
3280,742189,1,3,,104234169,126941,Active,,,0.06957,IC50,SANGER: Inhibition of human HC-1 cell growth in a cell viability assay.,Confirmatory,,
3281,742192,1,3,,104234169,126941,Active,,,23.2308,IC50,SANGER: Inhibition of human HCC1395 cell growth in a cell viability assay.,Confirmatory,,
3282,742193,1,3,,104234169,126941,Active,,,13.8122,IC50,SANGER: Inhibition of human HCC1419 cell growth in a cell viability assay.,Confirmatory,,
3283,742194,1,3,,104234169,126941,Active,,,6.37095,IC50,SANGER: Inhibition of human HCC1569 cell growth in a cell viability assay.,Confirmatory,,
3284,742196,1,3,,104234169,126941,Active,,,5.25467,IC50,SANGER: Inhibition of human HCC1806 cell growth in a cell viability assay.,Confirmatory,,
3285,742197,1,3,,104234169,126941,Active,,,8.17918,IC50,SANGER: Inhibition of human HCC1937 cell growth in a cell viability assay.,Confirmatory,,
3286,742198,1,3,,104234169,126941,Active,,,11.9911,IC50,SANGER: Inhibition of human HCC1954 cell growth in a cell viability assay.,Confirmatory,,
3287,742201,1,3,,104234169,126941,Active,,,0.21156999999999998,IC50,SANGER: Inhibition of human HCC2998 cell growth in a cell viability assay.,Confirmatory,,
3288,742202,1,3,,104234169,126941,Active,,,17.5671,IC50,SANGER: Inhibition of human HCC38 cell growth in a cell viability assay.,Confirmatory,,
3289,742203,1,3,,104234169,126941,Active,,,0.38918,IC50,SANGER: Inhibition of human HCC70 cell growth in a cell viability assay.,Confirmatory,,
3290,742204,1,3,,104234169,126941,Active,,,0.77872,IC50,SANGER: Inhibition of human HCE-4 cell growth in a cell viability assay.,Confirmatory,,
3291,742205,1,3,,104234169,126941,Active,,,0.87584,IC50,SANGER: Inhibition of human HCE-T cell growth in a cell viability assay.,Confirmatory,,
3292,742206,1,3,,104234169,126941,Active,,,0.78769,IC50,SANGER: Inhibition of human HCT-116 cell growth in a cell viability assay.,Confirmatory,,
3293,742208,1,3,,104234169,126941,Active,,,0.30951,IC50,SANGER: Inhibition of human HD-MY-Z cell growth in a cell viability assay.,Confirmatory,,
3294,742209,1,3,,104234169,126941,Active,,,0.01004,IC50,SANGER: Inhibition of human HDLM-2 cell growth in a cell viability assay.,Confirmatory,,
3295,742210,1,3,,104234169,126941,Active,,,8.07574,IC50,SANGER: Inhibition of human HEC-1 cell growth in a cell viability assay.,Confirmatory,,
3296,742211,1,3,,104234169,126941,Active,,,0.01145,IC50,SANGER: Inhibition of human HEL cell growth in a cell viability assay.,Confirmatory,,
3297,742212,1,3,,104234169,126941,Active,,,3.79874,IC50,SANGER: Inhibition of human HGC-27 cell growth in a cell viability assay.,Confirmatory,,
3298,742213,1,3,,104234169,126941,Active,,,0.0316,IC50,SANGER: Inhibition of human HH cell growth in a cell viability assay.,Confirmatory,,
3299,742214,1,3,,104234169,126941,Active,,,0.02478,IC50,SANGER: Inhibition of human HL-60 cell growth in a cell viability assay.,Confirmatory,,
3300,742215,1,3,,104234169,126941,Active,,,7.0854,IC50,SANGER: Inhibition of human HLE cell growth in a cell viability assay.,Confirmatory,,
3301,742216,1,3,,104234169,126941,Active,,,1.87858,IC50,SANGER: Inhibition of human HMV-II cell growth in a cell viability assay.,Confirmatory,,
3302,742217,1,3,,104234169,126941,Active,,,6.88448,IC50,SANGER: Inhibition of human HN cell growth in a cell viability assay.,Confirmatory,,
3303,742218,1,3,,104234169,126941,Active,,,6.17442,IC50,SANGER: Inhibition of human HO-1-N-1 cell growth in a cell viability assay.,Confirmatory,,
3304,742220,1,3,,104234169,126941,Active,,,16.6539,IC50,SANGER: Inhibition of human HOP-92 cell growth in a cell viability assay.,Confirmatory,,
3305,742221,1,3,,104234169,126941,Active,,,11.0071,IC50,SANGER: Inhibition of human HOS cell growth in a cell viability assay.,Confirmatory,,
3306,742222,1,3,,104234169,126941,Active,,,6.11846,IC50,SANGER: Inhibition of human HPAF-II cell growth in a cell viability assay.,Confirmatory,,
3307,742223,1,3,,104234169,126941,Active,,,0.3987,IC50,SANGER: Inhibition of human HSC-2 cell growth in a cell viability assay.,Confirmatory,,
3308,742224,1,3,,104234169,126941,Active,,,10.2833,IC50,SANGER: Inhibition of human HSC-3 cell growth in a cell viability assay.,Confirmatory,,
3309,742225,1,3,,104234169,126941,Active,,,6.47278,IC50,SANGER: Inhibition of human HSC-4 cell growth in a cell viability assay.,Confirmatory,,
3310,742226,1,3,,104234169,126941,Active,,,0.13369,IC50,SANGER: Inhibition of human HT cell growth in a cell viability assay.,Confirmatory,,
3311,742227,1,3,,104234169,126941,Active,,,12.9922,IC50,SANGER: Inhibition of human HT-1080 cell growth in a cell viability assay.,Confirmatory,,
3312,742228,1,3,,104234169,126941,Active,,,2.61232,IC50,SANGER: Inhibition of human HT-1197 cell growth in a cell viability assay.,Confirmatory,,
3313,742229,1,3,,104234169,126941,Active,,,14.9943,IC50,SANGER: Inhibition of human HT-1376 cell growth in a cell viability assay.,Confirmatory,,
3314,742230,1,3,,104234169,126941,Active,,,8.20687,IC50,SANGER: Inhibition of human HT-144 cell growth in a cell viability assay.,Confirmatory,,
3315,742231,1,3,,104234169,126941,Active,,,0.15337,IC50,SANGER: Inhibition of human HT-29 cell growth in a cell viability assay.,Confirmatory,,
3316,742232,1,3,,104234169,126941,Active,,,0.06937,IC50,SANGER: Inhibition of human HT-3 cell growth in a cell viability assay.,Confirmatory,,
3317,742233,1,3,,104234169,126941,Active,,,2.40807,IC50,SANGER: Inhibition of human HT55 cell growth in a cell viability assay.,Confirmatory,,
3318,742234,1,3,,104234169,126941,Active,,,3.44245,IC50,SANGER: Inhibition of human HTC-C3 cell growth in a cell viability assay.,Confirmatory,,
3319,742236,1,3,,104234169,126941,Active,,,24.7097,IC50,SANGER: Inhibition of human Hs-578-T cell growth in a cell viability assay.,Confirmatory,,
3320,742237,1,3,,104234169,126941,Active,,,16.3275,IC50,SANGER: Inhibition of human HuCCT1 cell growth in a cell viability assay.,Confirmatory,,
3321,742238,1,3,,104234169,126941,Active,,,3.1888900000000002,IC50,SANGER: Inhibition of human HuH-7 cell growth in a cell viability assay.,Confirmatory,,
3322,742239,1,3,,104234169,126941,Active,,,0.08909,IC50,SANGER: Inhibition of human HuO-3N1 cell growth in a cell viability assay.,Confirmatory,,
3323,742240,1,3,,104234169,126941,Active,,,1.32794,IC50,SANGER: Inhibition of human HuO9 cell growth in a cell viability assay.,Confirmatory,,
3324,742241,1,3,,104234169,126941,Active,,,4.61839,IC50,SANGER: Inhibition of human HuP-T3 cell growth in a cell viability assay.,Confirmatory,,
3325,742242,1,3,,104234169,126941,Active,,,8.84849,IC50,SANGER: Inhibition of human HuP-T4 cell growth in a cell viability assay.,Confirmatory,,
3326,742243,1,3,,104234169,126941,Active,,,13.722999999999999,IC50,SANGER: Inhibition of human IA-LM cell growth in a cell viability assay.,Confirmatory,,
3327,742244,1,3,,104234169,126941,Active,,,2.73874,IC50,SANGER: Inhibition of human IGR-1 cell growth in a cell viability assay.,Confirmatory,,
3328,742249,1,3,,104234169,126941,Active,,,0.12638,IC50,SANGER: Inhibition of human IST-MEL1 cell growth in a cell viability assay.,Confirmatory,,
3329,742250,1,3,,104234169,126941,Active,,,20.6658,IC50,SANGER: Inhibition of human IST-MES1 cell growth in a cell viability assay.,Confirmatory,,
3330,742251,1,3,,104234169,126941,Active,,,0.3901,IC50,SANGER: Inhibition of human IST-SL1 cell growth in a cell viability assay.,Confirmatory,,
3331,742253,1,3,,104234169,126941,Active,,,0.01942,IC50,SANGER: Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay.,Confirmatory,,
3332,742254,1,3,,104234169,126941,Active,,,4.099419999999999,IC50,SANGER: Inhibition of human J82 cell growth in a cell viability assay.,Confirmatory,,
3333,742255,1,3,,104234169,126941,Active,,,0.18836,IC50,SANGER: Inhibition of human JAR cell growth in a cell viability assay.,Confirmatory,,
3334,742256,1,3,,104234169,126941,Active,,,7.0319199999999995,IC50,SANGER: Inhibition of human JEG-3 cell growth in a cell viability assay.,Confirmatory,,
3335,742257,1,3,,104234169,126941,Active,,,2.1806400000000004,IC50,SANGER: Inhibition of human JVM-2 cell growth in a cell viability assay.,Confirmatory,,
3336,742258,1,3,,104234169,126941,Active,,,0.016040000000000002,IC50,SANGER: Inhibition of human JVM-3 cell growth in a cell viability assay.,Confirmatory,,
3337,742260,1,3,,104234169,126941,Active,,,4.8750599999999995,IC50,SANGER: Inhibition of human K-562 cell growth in a cell viability assay.,Confirmatory,,
3338,742262,1,3,,104234169,126941,Active,,,0.0598,IC50,SANGER: Inhibition of human K5 cell growth in a cell viability assay.,Confirmatory,,
3339,742263,1,3,,104234169,126941,Active,,,9.08399,IC50,SANGER: Inhibition of human KALS-1 cell growth in a cell viability assay.,Confirmatory,,
3340,742264,1,3,,104234169,126941,Active,,,0.4935,IC50,SANGER: Inhibition of human KARPAS-299 cell growth in a cell viability assay.,Confirmatory,,
3341,742266,1,3,,104234169,126941,Active,,,0.12389000000000001,IC50,SANGER: Inhibition of human KARPAS-45 cell growth in a cell viability assay.,Confirmatory,,
3342,742268,1,3,,104234169,126941,Active,,,0.01553,IC50,SANGER: Inhibition of human KE-37 cell growth in a cell viability assay.,Confirmatory,,
3343,742269,1,3,,104234169,126941,Active,,,0.50853,IC50,SANGER: Inhibition of human KG-1 cell growth in a cell viability assay.,Confirmatory,,
3344,742270,1,3,,104234169,126941,Active,,,0.15012,IC50,SANGER: Inhibition of human KGN cell growth in a cell viability assay.,Confirmatory,,
3345,742271,1,3,,104234169,126941,Active,,,0.61454,IC50,SANGER: Inhibition of human KINGS-1 cell growth in a cell viability assay.,Confirmatory,,
3346,742272,1,3,,104234169,126941,Active,,,6.15907,IC50,SANGER: Inhibition of human KLE cell growth in a cell viability assay.,Confirmatory,,
3347,742273,1,3,,104234169,126941,Active,,,0.3694,IC50,SANGER: Inhibition of human KM-H2 cell growth in a cell viability assay.,Confirmatory,,
3348,742274,1,3,,104234169,126941,Active,,,0.16444,IC50,SANGER: Inhibition of human KM12 cell growth in a cell viability assay.,Confirmatory,,
3349,742275,1,3,,104234169,126941,Active,,,0.09742,IC50,SANGER: Inhibition of human KMOE-2 cell growth in a cell viability assay.,Confirmatory,,
3350,742277,1,3,,104234169,126941,Active,,,22.9791,IC50,SANGER: Inhibition of human KNS-42 cell growth in a cell viability assay.,Confirmatory,,
3351,742278,1,3,,104234169,126941,Active,,,5.91216,IC50,SANGER: Inhibition of human KNS-62 cell growth in a cell viability assay.,Confirmatory,,
3352,742279,1,3,,104234169,126941,Active,,,9.632430000000001,IC50,SANGER: Inhibition of human KNS-81-FD cell growth in a cell viability assay.,Confirmatory,,
3353,742280,1,3,,104234169,126941,Active,,,2.34293,IC50,SANGER: Inhibition of human KOSC-2 cell growth in a cell viability assay.,Confirmatory,,
3354,742281,1,3,,104234169,126941,Active,,,3.15403,IC50,SANGER: Inhibition of human KP-4 cell growth in a cell viability assay.,Confirmatory,,
3355,742283,1,3,,104234169,126941,Active,,,18.8494,IC50,SANGER: Inhibition of human KP-N-YN cell growth in a cell viability assay.,Confirmatory,,
3356,742284,1,3,,104234169,126941,Active,,,3.3961,IC50,SANGER: Inhibition of human KP-N-YS cell growth in a cell viability assay.,Confirmatory,,
3357,742285,1,3,,104234169,126941,Active,,,10.7687,IC50,SANGER: Inhibition of human KS-1 cell growth in a cell viability assay.,Confirmatory,,
3358,742286,1,3,,104234169,126941,Active,,,1.07752,IC50,SANGER: Inhibition of human KU-19-19 cell growth in a cell viability assay.,Confirmatory,,
3359,742288,1,3,,104234169,126941,Active,,,1.88694,IC50,SANGER: Inhibition of human KURAMOCHI cell growth in a cell viability assay.,Confirmatory,,
3360,742290,1,3,,104234169,126941,Active,,,1.24529,IC50,SANGER: Inhibition of human KYSE-140 cell growth in a cell viability assay.,Confirmatory,,
3361,742291,1,3,,104234169,126941,Active,,,0.11506,IC50,SANGER: Inhibition of human KYSE-150 cell growth in a cell viability assay.,Confirmatory,,
3362,742292,1,3,,104234169,126941,Active,,,1.21205,IC50,SANGER: Inhibition of human KYSE-180 cell growth in a cell viability assay.,Confirmatory,,
3363,742293,1,3,,104234169,126941,Active,,,0.052110000000000004,IC50,SANGER: Inhibition of human KYSE-270 cell growth in a cell viability assay.,Confirmatory,,
3364,742294,1,3,,104234169,126941,Active,,,3.6392599999999997,IC50,SANGER: Inhibition of human KYSE-410 cell growth in a cell viability assay.,Confirmatory,,
3365,742295,1,3,,104234169,126941,Active,,,0.33447,IC50,SANGER: Inhibition of human KYSE-450 cell growth in a cell viability assay.,Confirmatory,,
3366,742296,1,3,,104234169,126941,Active,,,0.09172000000000001,IC50,SANGER: Inhibition of human KYSE-510 cell growth in a cell viability assay.,Confirmatory,,
3367,742297,1,3,,104234169,126941,Active,,,4.45456,IC50,SANGER: Inhibition of human KYSE-520 cell growth in a cell viability assay.,Confirmatory,,
3368,742298,1,3,,104234169,126941,Active,,,6.165830000000001,IC50,SANGER: Inhibition of human KYSE-70 cell growth in a cell viability assay.,Confirmatory,,
3369,742299,1,3,,104234169,126941,Active,,,0.01426,IC50,SANGER: Inhibition of human L-363 cell growth in a cell viability assay.,Confirmatory,,
3370,742300,1,3,,104234169,126941,Active,,,1.2567,IC50,SANGER: Inhibition of human L-428 cell growth in a cell viability assay.,Confirmatory,,
3371,742302,1,3,,104234169,126941,Active,,,0.01239,IC50,SANGER: Inhibition of human LAMA-84 cell growth in a cell viability assay.,Confirmatory,,
3372,742303,1,3,,104234169,126941,Active,,,1.7456200000000002,IC50,SANGER: Inhibition of human LAN-6 cell growth in a cell viability assay.,Confirmatory,,
3373,742304,1,3,,104234169,126941,Active,,,15.2239,IC50,SANGER: Inhibition of human LB1047-RCC cell growth in a cell viability assay.,Confirmatory,,
3374,742305,1,3,,104234169,126941,Active,,,13.7984,IC50,SANGER: Inhibition of human LB2241-RCC cell growth in a cell viability assay.,Confirmatory,,
3375,742306,1,3,,104234169,126941,Active,,,6.82267,IC50,SANGER: Inhibition of human LB2518-MEL cell growth in a cell viability assay.,Confirmatory,,
3376,742309,1,3,,104234169,126941,Active,,,17.7199,IC50,SANGER: Inhibition of human LB771-HNC cell growth in a cell viability assay.,Confirmatory,,
3377,742310,1,3,,104234169,126941,Active,,,1.7115099999999999,IC50,SANGER: Inhibition of human LB831-BLC cell growth in a cell viability assay.,Confirmatory,,
3378,742313,1,3,,104234169,126941,Active,,,2.1627,IC50,SANGER: Inhibition of human LC-2-ad cell growth in a cell viability assay.,Confirmatory,,
3379,742315,1,3,,104234169,126941,Active,,,0.17389000000000002,IC50,SANGER: Inhibition of human LCLC-103H cell growth in a cell viability assay.,Confirmatory,,
3380,742316,1,3,,104234169,126941,Active,,,0.4222,IC50,SANGER: Inhibition of human LCLC-97TM1 cell growth in a cell viability assay.,Confirmatory,,
3381,742317,1,3,,104234169,126941,Active,,,0.31751,IC50,SANGER: Inhibition of human LK-2 cell growth in a cell viability assay.,Confirmatory,,
3382,742318,1,3,,104234169,126941,Active,,,3.36325,IC50,SANGER: Inhibition of human LN-405 cell growth in a cell viability assay.,Confirmatory,,
3383,742319,1,3,,104234169,126941,Active,,,9.57798,IC50,SANGER: Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay.,Confirmatory,,
3384,742321,1,3,,104234169,126941,Active,,,0.20185999999999998,IC50,SANGER: Inhibition of human LOXIMVI cell growth in a cell viability assay.,Confirmatory,,
3385,742323,1,3,,104234169,126941,Active,,,6.86775,IC50,SANGER: Inhibition of human LS-1034 cell growth in a cell viability assay.,Confirmatory,,
3386,742324,1,3,,104234169,126941,Active,,,10.2892,IC50,SANGER: Inhibition of human LS-123 cell growth in a cell viability assay.,Confirmatory,,
3387,742325,1,3,,104234169,126941,Active,,,0.11759000000000001,IC50,SANGER: Inhibition of human LS-411N cell growth in a cell viability assay.,Confirmatory,,
3388,742326,1,3,,104234169,126941,Active,,,4.35308,IC50,SANGER: Inhibition of human LS-513 cell growth in a cell viability assay.,Confirmatory,,
3389,742327,1,3,,104234169,126941,Active,,,0.08865,IC50,SANGER: Inhibition of human LU-134-A cell growth in a cell viability assay.,Confirmatory,,
3390,742328,1,3,,104234169,126941,Active,,,2.23007,IC50,SANGER: Inhibition of human LU-135 cell growth in a cell viability assay.,Confirmatory,,
3391,742329,1,3,,104234169,126941,Active,,,0.23540999999999998,IC50,SANGER: Inhibition of human LU-139 cell growth in a cell viability assay.,Confirmatory,,
3392,742331,1,4,,104234169,126941,Active,,,4.07799,IC50,SANGER: Inhibition of human LU-65 cell growth in a cell viability assay.,Confirmatory,,
3393,742332,1,3,,104234169,126941,Active,,,0.27384000000000003,IC50,SANGER: Inhibition of human LU-99A cell growth in a cell viability assay.,Confirmatory,,
3394,742333,1,3,,104234169,126941,Active,,,6.56265,IC50,SANGER: Inhibition of human LXF-289 cell growth in a cell viability assay.,Confirmatory,,
3395,742334,1,3,,104234169,126941,Active,,,13.7444,IC50,SANGER: Inhibition of human LoVo cell growth in a cell viability assay.,Confirmatory,,
3396,742335,1,3,,104234169,126941,Active,,,15.1239,IC50,SANGER: Inhibition of human M059J cell growth in a cell viability assay.,Confirmatory,,
3397,742336,1,3,,104234169,126941,Active,,,1.94298,IC50,SANGER: Inhibition of human M14 cell growth in a cell viability assay.,Confirmatory,,
3398,742338,1,3,,104234169,126941,Active,,,9.512889999999999,IC50,SANGER: Inhibition of human MC-IXC cell growth in a cell viability assay.,Confirmatory,,
3399,742339,1,3,,104234169,126941,Active,,,0.060610000000000004,IC50,SANGER: Inhibition of human MC116 cell growth in a cell viability assay.,Confirmatory,,
3400,742340,1,3,,104234169,126941,Active,,,16.1989,IC50,SANGER: Inhibition of human MCF7 cell growth in a cell viability assay.,Confirmatory,,
3401,742342,1,3,,104234169,126941,Active,,,3.24593,IC50,SANGER: Inhibition of human MDA-MB-157 cell growth in a cell viability assay.,Confirmatory,,
3402,742343,1,3,,104234169,126941,Active,,,17.4296,IC50,SANGER: Inhibition of human MDA-MB-175-VII cell growth in a cell viability assay.,Confirmatory,,
3403,742344,1,3,,104234169,126941,Active,,,22.898000000000003,IC50,SANGER: Inhibition of human MDA-MB-231 cell growth in a cell viability assay.,Confirmatory,,
3404,742345,1,3,,104234169,126941,Active,,,12.2938,IC50,SANGER: Inhibition of human MDA-MB-361 cell growth in a cell viability assay.,Confirmatory,,
3405,742346,1,3,,104234169,126941,Active,,,8.42465,IC50,SANGER: Inhibition of human MDA-MB-415 cell growth in a cell viability assay.,Confirmatory,,
3406,742347,1,3,,104234169,126941,Active,,,5.89794,IC50,SANGER: Inhibition of human MDA-MB-453 cell growth in a cell viability assay.,Confirmatory,,
3407,742349,1,3,,104234169,126941,Active,,,0.5877399999999999,IC50,SANGER: Inhibition of human ME-180 cell growth in a cell viability assay.,Confirmatory,,
3408,742350,1,3,,104234169,126941,Active,,,0.09944,IC50,SANGER: Inhibition of human MEG-01 cell growth in a cell viability assay.,Confirmatory,,
3409,742351,1,3,,104234169,126941,Active,,,2.92893,IC50,SANGER: Inhibition of human MEL-HO cell growth in a cell viability assay.,Confirmatory,,
3410,742352,1,3,,104234169,126941,Active,,,4.74418,IC50,SANGER: Inhibition of human MEL-JUSO cell growth in a cell viability assay.,Confirmatory,,
3411,742354,1,3,,104234169,126941,Active,,,13.7611,IC50,SANGER: Inhibition of human MFE-280 cell growth in a cell viability assay.,Confirmatory,,
3412,742357,1,3,,104234169,126941,Active,,,6.06013,IC50,SANGER: Inhibition of human MFM-223 cell growth in a cell viability assay.,Confirmatory,,
3413,742358,1,3,,104234169,126941,Active,,,0.1971,IC50,SANGER: Inhibition of human MG-63 cell growth in a cell viability assay.,Confirmatory,,
3414,742360,1,3,,104234169,126941,Active,,,0.10701,IC50,SANGER: Inhibition of human MHH-ES-1 cell growth in a cell viability assay.,Confirmatory,,
3415,742361,1,3,,104234169,126941,Active,,,0.40951,IC50,SANGER: Inhibition of human MHH-NB-11 cell growth in a cell viability assay.,Confirmatory,,
3416,742362,1,3,,104234169,126941,Active,,,0.01323,IC50,SANGER: Inhibition of human MHH-PREB-1 cell growth in a cell viability assay.,Confirmatory,,
3417,742363,1,3,,104234169,126941,Active,,,9.12528,IC50,SANGER: Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay.,Confirmatory,,
3418,742364,1,3,,104234169,126941,Active,,,2.24641,IC50,SANGER: Inhibition of human MKN1 cell growth in a cell viability assay.,Confirmatory,,
3419,742365,1,3,,104234169,126941,Active,,,1.33391,IC50,SANGER: Inhibition of human MKN28 cell growth in a cell viability assay.,Confirmatory,,
3420,742366,1,3,,104234169,126941,Active,,,0.87229,IC50,SANGER: Inhibition of human MKN45 cell growth in a cell viability assay.,Confirmatory,,
3421,742367,1,3,,104234169,126941,Active,,,12.0639,IC50,SANGER: Inhibition of human MKN7 cell growth in a cell viability assay.,Confirmatory,,
3422,742368,1,3,,104234169,126941,Active,,,0.0049700000000000005,IC50,SANGER: Inhibition of human ML-2 cell growth in a cell viability assay.,Confirmatory,,
3423,742369,1,3,,104234169,126941,Active,,,0.09654,IC50,SANGER: Inhibition of human MLMA cell growth in a cell viability assay.,Confirmatory,,
3424,742370,1,3,,104234169,126941,Active,,,19.5532,IC50,SANGER: Inhibition of human MMAC-SF cell growth in a cell viability assay.,Confirmatory,,
3425,742371,1,3,,104234169,126941,Active,,,0.06573,IC50,SANGER: Inhibition of human MN-60 cell growth in a cell viability assay.,Confirmatory,,
3426,742373,1,3,,104234169,126941,Active,,,0.0116,IC50,SANGER: Inhibition of human MOLT-16 cell growth in a cell viability assay.,Confirmatory,,
3427,742374,1,3,,104234169,126941,Active,,,0.021169999999999998,IC50,SANGER: Inhibition of human MOLT-4 cell growth in a cell viability assay.,Confirmatory,,
3428,742376,1,3,,104234169,126941,Active,,,11.2566,IC50,SANGER: Inhibition of human MPP-89 cell growth in a cell viability assay.,Confirmatory,,
3429,742378,1,3,,104234169,126941,Active,,,0.04526,IC50,SANGER: Inhibition of human MS-1 cell growth in a cell viability assay.,Confirmatory,,
3430,742379,1,3,,104234169,126941,Active,,,0.51865,IC50,SANGER: Inhibition of human MSTO-211H cell growth in a cell viability assay.,Confirmatory,,
3431,742380,1,3,,104234169,126941,Active,,,0.01935,IC50,SANGER: Inhibition of human MV-4-11 cell growth in a cell viability assay.,Confirmatory,,
3432,742381,1,3,,104234169,126941,Active,,,8.83346,IC50,SANGER: Inhibition of human MZ1-PC cell growth in a cell viability assay.,Confirmatory,,
3433,742382,1,3,,104234169,126941,Active,,,9.82677,IC50,SANGER: Inhibition of human MZ2-MEL cell growth in a cell viability assay.,Confirmatory,,
3434,742383,1,3,,104234169,126941,Active,,,11.1829,IC50,SANGER: Inhibition of human MZ7-mel cell growth in a cell viability assay.,Confirmatory,,
3435,742384,1,3,,104234169,126941,Active,,,3.7352199999999995,IC50,SANGER: Inhibition of human Mewo cell growth in a cell viability assay.,Confirmatory,,
3436,742385,1,4,,104234169,126941,Active,,,5.49103,IC50,SANGER: Inhibition of human Mo-T cell growth in a cell viability assay.,Confirmatory,,
3437,742388,1,3,,104234169,126941,Active,,,5.51218,IC50,SANGER: Inhibition of human NB10 cell growth in a cell viability assay.,Confirmatory,,
3438,742389,1,3,,104234169,126941,Active,,,19.6531,IC50,SANGER: Inhibition of human NB12 cell growth in a cell viability assay.,Confirmatory,,
3439,742390,1,3,,104234169,126941,Active,,,5.260730000000001,IC50,SANGER: Inhibition of human NB13 cell growth in a cell viability assay.,Confirmatory,,
3440,742391,1,3,,104234169,126941,Active,,,0.07501000000000001,IC50,SANGER: Inhibition of human NB14 cell growth in a cell viability assay.,Confirmatory,,
3441,742392,1,3,,104234169,126941,Active,,,16.8323,IC50,SANGER: Inhibition of human NB17 cell growth in a cell viability assay.,Confirmatory,,
3442,742393,1,3,,104234169,126941,Active,,,14.2275,IC50,SANGER: Inhibition of human NB5 cell growth in a cell viability assay.,Confirmatory,,
3443,742394,1,3,,104234169,126941,Active,,,25.8767,IC50,SANGER: Inhibition of human NB6 cell growth in a cell viability assay.,Confirmatory,,
3444,742395,1,3,,104234169,126941,Active,,,14.7321,IC50,SANGER: Inhibition of human NB69 cell growth in a cell viability assay.,Confirmatory,,
3445,742396,1,3,,104234169,126941,Active,,,0.4476,IC50,SANGER: Inhibition of human NB7 cell growth in a cell viability assay.,Confirmatory,,
3446,742397,1,3,,104234169,126941,Active,,,0.029580000000000002,IC50,SANGER: Inhibition of human NBsusSR cell growth in a cell viability assay.,Confirmatory,,
3447,742399,1,3,,104234169,126941,Active,,,0.32842,IC50,SANGER: Inhibition of human NCI-H1048 cell growth in a cell viability assay.,Confirmatory,,
3448,742400,1,3,,104234169,126941,Active,,,0.92204,IC50,SANGER: Inhibition of human NCI-H1092 cell growth in a cell viability assay.,Confirmatory,,
3449,742401,1,3,,104234169,126941,Active,,,0.26618,IC50,SANGER: Inhibition of human NCI-H1155 cell growth in a cell viability assay.,Confirmatory,,
3450,742403,1,3,,104234169,126941,Active,,,0.25003000000000003,IC50,SANGER: Inhibition of human NCI-H1299 cell growth in a cell viability assay.,Confirmatory,,
3451,742404,1,3,,104234169,126941,Active,,,2.4089400000000003,IC50,SANGER: Inhibition of human NCI-H1304 cell growth in a cell viability assay.,Confirmatory,,
3452,742405,1,3,,104234169,126941,Active,,,10.878,IC50,SANGER: Inhibition of human NCI-H1355 cell growth in a cell viability assay.,Confirmatory,,
3453,742406,1,3,,104234169,126941,Active,,,7.279889999999999,IC50,SANGER: Inhibition of human NCI-H1395 cell growth in a cell viability assay.,Confirmatory,,
3454,742409,1,3,,104234169,126941,Active,,,1.67736,IC50,SANGER: Inhibition of human NCI-H1437 cell growth in a cell viability assay.,Confirmatory,,
3455,743012,3,1,,144204495,126941,Active,,,0.0094,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3456,743012,3,1,,144210589,126941,Active,,,0.0017,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3457,743014,3,1,,144204495,126941,Active,,,0.0119,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3458,743014,3,1,,144210589,126941,Active,,,0.0017,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3459,743015,3,1,,144204495,126941,Active,,,0.0133,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3460,743015,3,1,,144210589,126941,Active,,,0.0017,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3461,743033,3,1,,144204495,126941,Active,,,0.0756,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3462,743033,3,1,,144210589,126941,Inconclusive,,,0.0195,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3463,743035,2,1,,144204495,126941,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3464,743035,2,1,,144210589,126941,Inconclusive,124375976.0,367.0,27.5357,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3465,743036,2,1,,144204495,126941,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3466,743036,2,1,,144210589,126941,Inconclusive,124375976.0,367.0,54.941,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3467,743040,3,1,,144204495,126941,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3468,743040,3,1,,144210589,126941,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3469,743041,3,1,,144204495,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3470,743041,3,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3471,743042,3,1,,144204495,126941,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3472,743042,3,1,,144210589,126941,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3473,743053,2,1,,144204495,126941,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3474,743053,2,1,,144210589,126941,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3475,743054,2,1,,144204495,126941,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3476,743054,2,1,,144210589,126941,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3477,743063,2,1,,144204495,126941,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3478,743063,2,1,,144210589,126941,Inconclusive,124375976.0,367.0,27.5357,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3479,743064,3,1,,144204495,126941,Inconclusive,,,0.7498,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3480,743064,3,1,,144210589,126941,Inconclusive,,,0.2169,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3481,743065,3,1,,144204495,126941,Active,399498506.0,24831.0,0.3349,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3482,743065,3,1,,144210589,126941,Active,399498506.0,24831.0,0.0545,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3483,743066,3,1,,144204495,126941,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3484,743066,3,1,,144210589,126941,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3485,743067,2,1,,144204495,126941,Inconclusive,399498506.0,24831.0,0.27644,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3486,743067,2,1,,144210589,126941,Inconclusive,399498506.0,24831.0,0.071273,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3487,743069,2,1,,144204495,126941,Inconclusive,348019627.0,2099.0,0.8485,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3488,743069,2,1,,144210589,126941,Inconclusive,348019627.0,2099.0,3.8895,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3489,743074,2,1,,144204495,126941,Active,,,0.2391,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3490,743074,2,1,,144210589,126941,Inconclusive,,,0.138,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3491,743075,2,1,,144204495,126941,Inactive,348019627.0,2099.0,2.3891,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3492,743075,2,1,,144210589,126941,Inactive,348019627.0,2099.0,0.1949,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3493,743077,2,1,,144204495,126941,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3494,743077,2,1,,144210589,126941,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3495,743078,2,1,,144204495,126941,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3496,743078,2,1,,144210589,126941,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3497,743079,3,1,,144204495,126941,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3498,743079,3,1,,144210589,126941,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3499,743080,3,1,,144204495,126941,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3500,743080,3,1,,144210589,126941,Inconclusive,348019627.0,2099.0,0.0545,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3501,743081,3,1,,144204495,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3502,743081,3,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3503,743083,3,1,,144204495,126941,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3504,743083,3,1,,144210589,126941,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3505,743084,3,1,,144204495,126941,Inconclusive,,,0.5956,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3506,743084,3,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3507,743085,3,1,,144204495,126941,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3508,743085,3,1,,144210589,126941,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3509,743086,3,1,,144204495,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3510,743086,3,1,,144210589,126941,Inconclusive,,,13.6854,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3511,743091,2,1,,144204495,126941,Inconclusive,348019627.0,2099.0,0.298493,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3512,743091,2,1,,144210589,126941,Inconclusive,348019627.0,2099.0,0.27305999999999997,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3513,743094,3,1,,144204495,126941,Inconclusive,216409692.0,5468.0,0.8485,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3514,743094,3,1,,144210589,126941,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3515,743122,2,1,,144204495,126941,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3516,743122,2,1,,144210589,126941,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3517,743126,1,1,,56463665,126941,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
3518,743139,2,1,,144204495,126941,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3519,743139,2,1,,144210589,126941,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3520,743140,2,1,,144204495,126941,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3521,743140,2,1,,144210589,126941,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3522,743191,3,1,,144210589,126941,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3523,743191,3,1,,170464688,126941,Inconclusive,216409692.0,5468.0,0.7497,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3524,743194,3,1,,144210589,126941,Inconclusive,,,0.0014,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3525,743194,3,1,,170464688,126941,Inconclusive,,,0.2985,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3526,743199,2,1,,144210589,126941,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3527,743199,2,1,,170464688,126941,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3528,743202,4,1,,144210589,126941,Active,20149576.0,4780.0,0.0097,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3529,743202,4,1,,170464688,126941,Active,20149576.0,4780.0,0.0596,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3530,743203,3,1,,144210589,126941,Active,,,0.0061,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3531,743203,3,1,,170464688,126941,Active,,,0.0473,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3532,743205,1,1,,90340825,126941,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3533,743205,1,1,,90340825,126941,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3534,743206,1,1,,90340825,126941,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3535,743206,1,1,,90340825,126941,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3536,743207,1,1,,90340825,126941,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3537,743207,1,1,,90340825,126941,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3538,743209,3,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3539,743209,3,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3540,743210,4,1,,144210589,126941,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3541,743210,4,1,,170464688,126941,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3542,743211,3,1,,144210589,126941,Inconclusive,,,0.0389,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3543,743211,3,1,,170464688,126941,Inconclusive,,,0.3758,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3544,743212,3,1,,144210589,126941,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3545,743212,3,1,,170464688,126941,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3546,743213,3,1,,144210589,126941,Inconclusive,,,0.0347,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3547,743213,3,1,,170464688,126941,Inconclusive,,,0.266,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3548,743215,3,1,,144210589,126941,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3549,743215,3,1,,170464688,126941,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3550,743217,3,1,,144210589,126941,Inconclusive,325495553.0,9971.0,0.0977,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3551,743217,3,1,,170464688,126941,Active,325495553.0,9971.0,0.3758,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3552,743218,3,1,,144210589,126941,Inconclusive,,,0.0389,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3553,743218,3,1,,170464688,126941,Inconclusive,,,0.1059,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3554,743219,3,1,,144210589,126941,Inconclusive,20149576.0,4780.0,0.00863492,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3555,743219,3,1,,170464688,126941,Inconclusive,20149576.0,4780.0,0.0446581,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3556,743220,3,1,,144210589,126941,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3557,743220,3,1,,170464688,126941,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3558,743221,3,1,,144210589,126941,Inconclusive,,,0.0245,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3559,743221,3,1,,170464688,126941,Inconclusive,,,0.2985,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3560,743222,3,1,,144210589,126941,Inconclusive,216409708.0,7421.0,43.6412,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3561,743222,3,1,,170464688,126941,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3562,743223,3,1,,144210589,126941,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3563,743223,3,1,,170464688,126941,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3564,743224,3,1,,144210589,126941,Active,,,0.0309,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3565,743224,3,1,,170464688,126941,Active,,,0.1883,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3566,743225,3,1,,144210589,126941,Inconclusive,,,0.0309,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3567,743225,3,1,,170464688,126941,Active,,,0.2131,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3568,743226,2,1,,144210589,126941,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3569,743226,2,1,,170464688,126941,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3570,743227,2,1,,144210589,126941,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3571,743227,2,1,,170464688,126941,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3572,743228,3,1,,144210589,126941,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3573,743228,3,1,,170464688,126941,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3574,743238,1,1,,56463665,126941,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
3575,743239,2,1,,144210589,126941,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3576,743239,2,1,,170464688,126941,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3577,743240,2,1,,144210589,126941,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3578,743240,2,1,,170464688,126941,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3579,743241,2,1,,144210589,126941,Inconclusive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3580,743241,2,1,,170464688,126941,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3581,743242,2,1,,144210589,126941,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3582,743242,2,1,,170464688,126941,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3583,743244,1,1,,90340825,126941,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3584,743244,1,1,,144204495,126941,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3585,743247,1,2,,56463665,126941,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3586,743255,1,1,,56463665,126941,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
3587,743266,1,2,,56463665,126941,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
3588,743269,1,1,,56463665,126941,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3589,743269,1,1,,56463665,126941,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3590,743279,1,2,,56463665,126941,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
3591,743287,1,1,,56463665,126941,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
3592,743288,1,1,,26752122,126941,Inconclusive,,,0.0501,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
3593,743292,1,1,,26752122,126941,Active,,,0.2818,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
3594,743344,1,1,,174006964,126941,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
3595,743345,1,1,,174006964,126941,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
3596,743346,1,1,,174006964,126941,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
3597,743347,1,1,,174006964,126941,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
3598,743364,1,2,,174006964,126941,Inactive,,,,Potency,qHTS profiling of inhibitors of Plasmodium falciparum (3D7) proliferation (acoustic dispense),Confirmatory,,
3599,743365,1,2,,174006964,126941,Inactive,,,,Potency,qHTS profiling of inhibitors of Plasmodium falciparum (DD2) proliferation (acoustic dispense),Confirmatory,,
3600,743366,1,2,,174006964,126941,Inactive,,,,Potency,qHTS profiling of inhibitors of Plasmodium falciparum (HB3) proliferation (acoustic dispense),Confirmatory,,
3601,743397,1,1,,56463665,126941,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3602,743398,1,1,,56463665,126941,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
3603,743586,2,3,,104234169,126941,Active,109940075.0,508809.0,0.08,IC50,Inhibition of bovine DHFR after 2 mins by spectrophotometry,Confirmatory,23454532.0,
3604,747607,1,1,,104234169,126941,Unspecified,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR,Other,23627352.0,
3605,747608,1,1,,104234169,126941,Active,,,0.00022,IC50,Inhibition of Mycobacterium avium DHFR,Confirmatory,23627352.0,
3606,747609,1,1,,104234169,126941,Unspecified,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Mycobacterium avium DHFR,Other,23627352.0,
3607,747610,2,3,,104234169,126941,Active,118998.0,,0.0013,IC50,Inhibition of Pneumocystis carinii DHFR,Confirmatory,23627352.0,
3608,747611,2,3,,104234169,126941,Active,81871579.0,24312.0,0.0025,IC50,Inhibition of rat liver DHFR,Confirmatory,23627352.0,
3609,747612,1,1,,104234169,126941,Unspecified,,,,,Selectivity ratio of IC50 for human recombinant DHFR to IC50 for Pneumocystis jirovecii recombinant DHFR,Other,23627352.0,
3610,747613,1,1,,104234169,126941,Active,,,0.0051,IC50,Inhibition of Pneumocystis jirovecii recombinant DHFR,Confirmatory,23627352.0,
3611,747614,2,3,,104234169,126941,Active,118992.0,1719.0,0.0017,IC50,Inhibition of human recombinant DHFR,Confirmatory,,
3612,747614,2,3,,104234169,126941,Active,118992.0,573971.0,0.0017,IC50,Inhibition of human recombinant DHFR,Confirmatory,,
3613,750525,2,3,,104234169,126941,Active,118992.0,1719.0,0.0021,IC50,Inhibition of human dihydrofolate reductase by spectrophotometric analysis,Confirmatory,23665106.0,
3614,750525,2,3,,104234169,126941,Active,118992.0,573971.0,0.0021,IC50,Inhibition of human dihydrofolate reductase by spectrophotometric analysis,Confirmatory,23665106.0,
3615,750526,1,5,,104234169,126941,Unspecified,118992.0,1719.0,,,Inhibition of human dihydrofolate reductase at 5 nM by spectrophotometric analysis relative to control,Other,23665106.0,
3616,750526,1,5,,104234169,126941,Unspecified,118992.0,573971.0,,,Inhibition of human dihydrofolate reductase at 5 nM by spectrophotometric analysis relative to control,Other,23665106.0,
3617,762391,3,1,,104234169,126941,Unspecified,,,,GI50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,23831811.0,
3618,762392,3,1,,104234169,126941,Unspecified,,,,GI50,Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay,Confirmatory,23831811.0,
3619,763669,1,1,,104234169,126941,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa at 200 ug/disc after 24 hrs by agar disc-diffusion method,Other,23792351.0,
3620,763670,1,1,,104234169,126941,Unspecified,,,,,Antifungal activity against Candida albicans at 200 ug/disc after 48 hrs by agar disc-diffusion method,Other,23792351.0,
3621,763671,1,1,,104234169,126941,Unspecified,,,,,Antibacterial activity against Escherichia coli at 200 ug/disc after 24 hrs by agar disc-diffusion method,Other,23792351.0,
3622,763672,1,1,,104234169,126941,Unspecified,,,,,Antibacterial activity against Bacillus subtilis at 200 ug/disc after 24 hrs by agar disc-diffusion method,Other,23792351.0,
3623,763673,1,1,,104234169,126941,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus at 200 ug/disc after 24 hrs by agar disc-diffusion method,Other,23792351.0,
3624,763675,2,3,,104234169,126941,Active,109940075.0,508809.0,0.08,IC50,Inhibition of bovine liver DHFR measured every 1 min for 10 mins,Confirmatory,23792351.0,
3625,770684,1,2,,104234169,126941,Active,,,5.25,IC50,Cytotoxicity against human COLO320DM cells after 48 hrs by MTT assay,Confirmatory,23968824.0,
3626,770685,1,1,,104234169,126941,Active,,,3.45,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,23968824.0,
3627,770695,1,3,,104234169,126941,Active,,,3.27,IC50,Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay,Confirmatory,23968824.0,
3628,771864,1,5,,104234169,126941,Unspecified,,,,,Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by MTT assay,Other,,
3629,771865,1,3,,104234169,126941,Unspecified,,,,,Cytotoxicity against human T47D cells after 48 hrs by MTT assay,Other,,
3630,771866,1,3,,104234169,126941,Unspecified,,,,,Cytotoxicity against human Caco2 cells after 48 hrs by MTT assay,Other,,
3631,771867,1,3,,104234169,126941,Unspecified,,,,,Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay,Other,,
3632,929833,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011023,Other,,
3633,929834,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011023,Other,,
3634,929835,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011023,Other,,
3635,929923,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011023,Other,,
3636,929924,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011023,Other,,
3637,932565,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011023,Other,,
3638,932566,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011023,Other,,
3639,932567,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011023,Other,,
3640,932568,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011023,Other,,
3641,932569,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011023,Other,,
3642,932570,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011023,Other,,
3643,932571,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011023,Other,,
3644,932572,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011023,Other,,
3645,932573,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011023,Other,,
3646,932574,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011023,Other,,
3647,932575,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011023,Other,,
3648,932576,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011023",Other,,
3649,932577,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011023,Other,,
3650,932578,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011023,Other,,
3651,932579,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011023,Other,,
3652,932580,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011023,Other,,
3653,932581,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011023,Other,,
3654,932885,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011127,Other,,
3655,932886,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011127,Other,,
3656,932887,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011127,Other,,
3657,932888,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011127,Other,,
3658,934903,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011127,Other,,
3659,934904,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011127,Other,,
3660,935534,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011127,Other,,
3661,935535,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011127,Other,,
3662,935536,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011127,Other,,
3663,935537,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011127,Other,,
3664,935538,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011127,Other,,
3665,935539,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011127,Other,,
3666,935540,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011127,Other,,
3667,935541,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011127,Other,,
3668,935542,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011127",Other,,
3669,935543,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011127,Other,,
3670,935544,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011127,Other,,
3671,935545,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011127,Other,,
3672,935546,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011127,Other,,
3673,947712,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011023,Other,,
3674,947713,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011023,Other,,
3675,947714,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011023,Other,,
3676,947715,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011023,Other,,
3677,947716,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011023,Other,,
3678,947717,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011023,Other,,
3679,947718,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011023,Other,,
3680,947719,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011023,Other,,
3681,947720,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011023,Other,,
3682,947721,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011023,Other,,
3683,947722,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011023,Other,,
3684,947723,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011023,Other,,
3685,947724,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011023",Other,,
3686,947725,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011023,Other,,
3687,947726,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011023,Other,,
3688,947727,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011023,Other,,
3689,960378,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011023,Other,,
3690,960379,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011023,Other,,
3691,960380,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011023,Other,,
3692,960381,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011023,Other,,
3693,960382,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011023,Other,,
3694,960383,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011023,Other,,
3695,960384,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011023,Other,,
3696,960818,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011023,Other,,
3697,960819,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011023,Other,,
3698,960820,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011023,Other,,
3699,960821,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011023,Other,,
3700,960822,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011023,Other,,
3701,960823,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011023,Other,,
3702,960824,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011023,Other,,
3703,960825,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011023,Other,,
3704,960826,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011023,Other,,
3705,960827,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011023,Other,,
3706,960828,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011023,Other,,
3707,960829,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011023,Other,,
3708,968931,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011023,Other,,
3709,968932,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011023,Other,,
3710,968933,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011023,Other,,
3711,968934,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011023,Other,,
3712,968935,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011023,Other,,
3713,968936,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011023,Other,,
3714,970960,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011023,Other,,
3715,970961,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011023,Other,,
3716,971591,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011023,Other,,
3717,971592,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011023,Other,,
3718,971593,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011023,Other,,
3719,971594,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011023,Other,,
3720,971595,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011023,Other,,
3721,971596,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011023,Other,,
3722,971597,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011023,Other,,
3723,971598,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011023,Other,,
3724,971599,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011023,Other,,
3725,971600,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011023,Other,,
3726,971601,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011023,Other,,
3727,976602,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011127,Other,,
3728,976603,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011127,Other,,
3729,976604,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011127,Other,,
3730,976605,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011127,Other,,
3731,976606,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011127,Other,,
3732,976607,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011127,Other,,
3733,976608,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011127,Other,,
3734,976609,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011127,Other,,
3735,976610,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011127,Other,,
3736,976611,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011127,Other,,
3737,976612,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011127,Other,,
3738,976613,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011127,Other,,
3739,976614,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011127,Other,,
3740,976615,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011127,Other,,
3741,976616,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011127,Other,,
3742,976617,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011127,Other,,
3743,976618,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011127,Other,,
3744,976619,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011127,Other,,
3745,976620,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011127,Other,,
3746,977611,3,1,,46391726,126941,Active,493971.0,,0.055,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,8265622.0,
3747,977611,3,1,,46391727,126941,Active,493973.0,,0.281,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,8265622.0,
3748,977611,3,1,,46394046,126941,Active,494770.0,,0.00013000000000000002,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,1932031.0,
3749,977611,3,1,,208013677,126941,Active,,,0.04,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,23934049.0,
3750,977611,3,1,,310263289,126941,Active,,,3.6000000000000003e-06,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,24832237.0,
3751,1001936,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011127",Other,,
3752,1001937,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011127",Other,,
3753,1001938,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011127",Other,,
3754,1001939,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011127",Other,,
3755,1001940,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011127",Other,,
3756,1001941,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011127",Other,,
3757,1001942,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011127,Other,,
3758,1001943,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011127",Other,,
3759,1001944,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011127,Other,,
3760,1001945,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011127",Other,,
3761,1001946,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011127",Other,,
3762,1001947,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011127",Other,,
3763,1001948,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011127",Other,,
3764,1001949,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011127",Other,,
3765,1001950,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011127",Other,,
3766,1001951,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011127",Other,,
3767,1001952,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011127",Other,,
3768,1001953,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011127",Other,,
3769,1001954,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
3770,1001955,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011127",Other,,
3771,1001956,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011127",Other,,
3772,1001957,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
3773,1001958,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
3774,1001959,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011127",Other,,
3775,1003829,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011127",Other,,
3776,1003830,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
3777,1003831,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011127",Other,,
3778,1003832,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011127",Other,,
3779,1003833,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
3780,1003834,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011127,Other,,
3781,1003835,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011127,Other,,
3782,1003836,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011127",Other,,
3783,1003837,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
3784,1003838,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
3785,1004422,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011127",Other,,
3786,1004423,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011127,Other,,
3787,1004424,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
3788,1004425,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
3789,1004426,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011127",Other,,
3790,1004427,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011127",Other,,
3791,1004428,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011127,Other,,
3792,1004429,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
3793,1004430,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011127",Other,,
3794,1004431,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011127",Other,,
3795,1004432,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
3796,1004433,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011127",Other,,
3797,1004434,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011127",Other,,
3798,1004435,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011127",Other,,
3799,1004436,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011127,Other,,
3800,1004437,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011127",Other,,
3801,1004438,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011127",Other,,
3802,1004439,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011127",Other,,
3803,1004440,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011127,Other,,
3804,1004441,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011127",Other,,
3805,1004442,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011127",Other,,
3806,1004443,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
3807,1004444,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011127",Other,,
3808,1004445,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011127",Other,,
3809,1004446,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011127",Other,,
3810,1015227,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
3811,1015228,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011127,Other,,
3812,1015229,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011127,Other,,
3813,1015230,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011127",Other,,
3814,1015231,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
3815,1015232,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
3816,1015233,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011127",Other,,
3817,1015234,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011127,Other,,
3818,1015235,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
3819,1015236,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
3820,1015237,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011127",Other,,
3821,1015238,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011127",Other,,
3822,1015239,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011127",Other,,
3823,1015240,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011127,Other,,
3824,1015241,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
3825,1015825,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011127",Other,,
3826,1015826,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011127",Other,,
3827,1015827,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
3828,1015828,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011127",Other,,
3829,1015829,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011127",Other,,
3830,1015830,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011127",Other,,
3831,1015831,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011127",Other,,
3832,1015832,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011127,Other,,
3833,1015833,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011127",Other,,
3834,1015834,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011127",Other,,
3835,1015835,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011127,Other,,
3836,1015836,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011127",Other,,
3837,1015837,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011127",Other,,
3838,1015838,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
3839,1015839,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011127",Other,,
3840,1015840,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011127",Other,,
3841,1015841,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011127",Other,,
3842,1015842,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011023",Other,,
3843,1015843,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011023",Other,,
3844,1015844,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011023",Other,,
3845,1015845,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011023",Other,,
3846,1015846,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011023",Other,,
3847,1015847,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011023",Other,,
3848,1015848,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011023",Other,,
3849,1015849,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011023,Other,,
3850,1017720,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011023",Other,,
3851,1017721,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011023,Other,,
3852,1017722,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011023",Other,,
3853,1017723,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011023",Other,,
3854,1017724,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011023",Other,,
3855,1017725,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011023",Other,,
3856,1017726,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011023",Other,,
3857,1017727,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011023",Other,,
3858,1017728,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011023",Other,,
3859,1017729,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011023",Other,,
3860,1017730,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011023",Other,,
3861,1018314,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011023",Other,,
3862,1018315,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011023",Other,,
3863,1018316,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011023",Other,,
3864,1018317,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011023",Other,,
3865,1018318,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011023",Other,,
3866,1018319,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011023",Other,,
3867,1018320,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011023",Other,,
3868,1018321,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011023",Other,,
3869,1018322,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011023",Other,,
3870,1018323,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011023",Other,,
3871,1018324,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011023,Other,,
3872,1018325,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011023,Other,,
3873,1018326,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011023",Other,,
3874,1018327,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011023",Other,,
3875,1018328,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011023",Other,,
3876,1018329,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011023",Other,,
3877,1018330,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011023,Other,,
3878,1018331,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011023",Other,,
3879,1018332,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011023",Other,,
3880,1018333,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011023",Other,,
3881,1018334,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011023",Other,,
3882,1018335,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011023",Other,,
3883,1018336,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011023,Other,,
3884,1018337,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011023",Other,,
3885,1018338,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011023",Other,,
3886,1018339,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011023",Other,,
3887,1018340,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011023",Other,,
3888,1018341,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011023",Other,,
3889,1020212,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011023",Other,,
3890,1020213,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011023",Other,,
3891,1020214,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011023,Other,,
3892,1020215,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011023",Other,,
3893,1020216,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011023",Other,,
3894,1020217,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011023,Other,,
3895,1020218,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011023",Other,,
3896,1020801,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011023",Other,,
3897,1020802,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011023",Other,,
3898,1020803,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011023",Other,,
3899,1020804,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011023",Other,,
3900,1020805,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011023",Other,,
3901,1023281,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011127",Other,,
3902,1023282,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011127",Other,,
3903,1023283,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011127",Other,,
3904,1023284,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011127",Other,,
3905,1023285,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011127",Other,,
3906,1023286,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011127,Other,,
3907,1023867,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011127",Other,,
3908,1023868,1,3,,104234169,126941,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011127,Other,,
3909,1023869,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011127",Other,,
3910,1023870,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011127",Other,,
3911,1023871,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011127",Other,,
3912,1023872,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011127",Other,,
3913,1023873,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011127",Other,,
3914,1023874,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011127",Other,,
3915,1023875,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011127",Other,,
3916,1023876,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011127",Other,,
3917,1023877,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011127",Other,,
3918,1023878,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011127",Other,,
3919,1023879,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011127",Other,,
3920,1023880,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011127",Other,,
3921,1023881,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011127",Other,,
3922,1023882,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
3923,1023883,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011127",Other,,
3924,1023884,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011127",Other,,
3925,1023885,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011127",Other,,
3926,1023886,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011127",Other,,
3927,1023887,1,3,,104234169,126941,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011127",Other,,
3928,1053197,1,1,,56463665,126941,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
3929,1053446,1,1,,104234169,126941,Active,,,0.02,IC50,Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay in presence of folic acid,Confirmatory,24111942.0,
3930,1053447,1,1,,104234169,126941,Active,,,0.006,IC50,Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay,Confirmatory,24111942.0,
3931,1053448,1,1,,104234169,126941,Unspecified,,,1.0,IC50,Growth inhibition of Chinese hamster R2(VC) cells after 96 hrs by CellTiter-blue assay,Confirmatory,24111942.0,
3932,1053449,1,1,,104234169,126941,Active,,,0.121,IC50,Growth inhibition of Chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTiter-blue assay,Confirmatory,24111942.0,
3933,1053450,1,1,,104234169,126941,Active,,,0.21100000000000002,IC50,Growth inhibition of Chinese hamster D4 cells after 96 hrs by CellTiter-blue assay in presence of folic acid,Confirmatory,24111942.0,
3934,1053451,1,1,,104234169,126941,Active,,,0.106,IC50,Growth inhibition of Chinese hamster D4 cells after 96 hrs by CellTiter-blue assay,Confirmatory,24111942.0,
3935,1053452,1,1,,104234169,126941,Active,,,0.461,IC50,Growth inhibition of Chinese hamster RT16 cells after 96 hrs by CellTiter-blue assay in presence of folic acid,Confirmatory,24111942.0,
3936,1053453,1,1,,104234169,126941,Active,,,0.114,IC50,Growth inhibition of Chinese hamster RT16 cells after 96 hrs by CellTiter-blue assay,Confirmatory,24111942.0,
3937,1053454,1,1,,104234169,126941,Active,,,0.21600000000000003,IC50,Growth inhibition of Chinese hamster MTXRII-OuaR2-4 cells after 96 hrs by CellTiter-blue assay,Confirmatory,24111942.0,
3938,1053455,1,1,,104234169,126941,Active,,,0.012,IC50,Growth inhibition of Chinese hamster PC43-10 cells after 96 hrs by CellTiter-blue assay,Confirmatory,24111942.0,
3939,1062549,1,4,,104234169,126941,Inactive,544337.0,2348.0,,,Displacement of [3H]folic acid from human FRalpha expressed in chinese hamster RT16 cells after 15 mins by scintillation counting analysis,Other,24256410.0,
3940,1062553,1,1,,104234169,126941,Unspecified,,,1.0,IC50,Cytotoxicity against chinese hamster R2(VC) cells after 96 hrs by CellTitre-Blue fluorescence assay,Confirmatory,24256410.0,
3941,1062554,1,1,,104234169,126941,Active,,,0.1205,IC50,Cytotoxicity against chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTitre-Blue fluorescence assay,Confirmatory,24256410.0,
3942,1070349,2,3,,104234169,126941,Active,109940075.0,508809.0,0.08,IC50,Inhibition of bovine liver DHFR measured for every 1 min of 10 mins,Confirmatory,24469112.0,
3943,1074584,1,1,,104234169,126941,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 13709 after 18 to 24 hrs by alamar Blue assay,Other,24428639.0,
3944,1074586,2,3,,104234169,126941,Unspecified,118992.0,1719.0,4e-06,Ki,Inhibition of human DHFR using dihydrofolate as substrate preincubated for 10 mins followed by substrate addition by spectrophotometric analysis in presence of NADPH,Confirmatory,24428639.0,
3945,1074586,2,3,,104234169,126941,Unspecified,118992.0,573971.0,4e-06,Ki,Inhibition of human DHFR using dihydrofolate as substrate preincubated for 10 mins followed by substrate addition by spectrophotometric analysis in presence of NADPH,Confirmatory,24428639.0,
3946,1074587,2,3,,104234169,126941,Unspecified,60392215.0,28380994.0,4e-06,Ki,Inhibition of Staphylococcus aureus DHFR using dihydrofolate as substrate preincubated for 10 mins followed by substrate addition by spectrophotometric analysis in presence of NADPH,Confirmatory,24428639.0,
3947,1077634,1,4,,104234169,126941,Active,,,,,Stabilization of Cryptosporidium hominis thymidylate synthase-dihydrofolate reductase assessed as resistance to enzyme sensitivity to trypsin proteolysis at 100 uM by SDS-PAGE mthod,Other,24324854.0,
3948,1079931,1,1,,104234169,126941,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
3949,1079932,1,1,,104234169,126941,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
3950,1079933,1,1,,104234169,126941,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
3951,1079934,1,1,,104234169,126941,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
3952,1079935,1,1,,104234169,126941,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
3953,1079936,1,1,,104234169,126941,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
3954,1079937,1,1,,104234169,126941,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
3955,1079938,1,1,,104234169,126941,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
3956,1079939,1,1,,104234169,126941,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
3957,1079940,1,1,,104234169,126941,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
3958,1079941,1,1,,104234169,126941,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
3959,1079942,1,1,,104234169,126941,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
3960,1079943,1,1,,104234169,126941,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
3961,1079944,1,1,,104234169,126941,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
3962,1079945,1,1,,104234169,126941,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
3963,1079946,1,1,,104234169,126941,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
3964,1079947,1,1,,104234169,126941,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
3965,1079948,1,1,,104234169,126941,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
3966,1079949,1,1,,104234169,126941,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
3967,1097363,1,2,,104234169,126941,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) PN-5C-12 at 100 ug after 72 hr by MTT assay,Other,,
3968,1097364,1,2,,104234169,126941,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HL60-P58 at 100 ug after 72 hr by MTT assay,Other,,
3969,1097365,1,2,,104234169,126941,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) HeLa-B75 at 100 ug after 72 hr by MTT assay,Other,,
3970,1097366,1,2,,104234169,126941,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) Hep-3BPN7 at 100 ug after 72 hr by MTT assay,Other,,
3971,1114392,1,2,,104234169,126941,Active,,,1.27,IC50,Cytotoxicity against Homo sapiens (human) HEK293 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay,Confirmatory,,
3972,1114393,1,2,,104234169,126941,Active,,,2.26,IC50,Anticancer activity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay,Confirmatory,,
3973,1114394,1,2,,104234169,126941,Active,,,2.2,IC50,Anticancer activity against Homo sapiens (human) NCI lung cancer cell assessed as inhibition of cell proliferation after 24 hr by MTT assay,Confirmatory,,
3974,1114518,1,2,,104234169,126941,Inconclusive,,,,IC50,Anticancer activity against Homo sapiens (human) HL60 cells after 48 hr by CC108 microcell counter analysis,Confirmatory,,
3975,1114520,1,2,,104234169,126941,Active,,,0.04,IC50,Anticancer activity against Homo sapiens (human) HBL100 cells after 72 hr by MTT assay,Confirmatory,,
3976,1117298,1,2,,170464688,126941,Inactive,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
3977,1117301,1,2,,170464688,126941,Inactive,,,31.6228,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
3978,1117302,1,2,,170464688,126941,Inactive,,,8.9125,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
3979,1117303,1,2,,170464688,126941,Inactive,,,0.29,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
3980,1117304,1,2,,170464688,126941,Inactive,,,14.1254,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
3981,1117305,1,2,,170464688,126941,Inactive,,,8.9125,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
3982,1117310,1,1,,170464688,126941,Inactive,,,39.8107,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
3983,1117311,1,1,,170464688,126941,Inactive,,,31.6228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
3984,1117312,1,1,,170464688,126941,Inactive,,,8.912510000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
3985,1117314,1,1,,170464688,126941,Inactive,,,14.1254,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
3986,1117315,1,1,,170464688,126941,Inactive,,,8.912510000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
3987,1117318,1,1,,170464688,126941,Inactive,,,0.28183800000000003,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
3988,1117322,1,1,,170464688,126941,Active,,,0.001,IC50,RKO viability from Cell TiterGlo-IC50,Confirmatory,,
3989,1117323,1,1,,170464688,126941,Inactive,,,20.0,IC50,SNU-C1 viability from Cell TiterGlo-IC50,Confirmatory,,
3990,1117324,1,1,,170464688,126941,Inactive,,,10.0,IC50,VEGF stimulated ADSC/ECFC co-culture nuclear area decrease (viability)-IC50,Confirmatory,,
3991,1117325,1,1,,170464688,126941,Active,,,0.0265,IC50,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-IC50,Confirmatory,,
3992,1117326,1,1,,170464688,126941,Active,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
3993,1117327,1,1,,170464688,126941,Active,,,0.0116,IC50,alkaline phosphatase stimulation in WNT3A conditioned C2C12 cells-IC50,Confirmatory,,
3994,1117329,1,1,,170464688,126941,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
3995,1117330,1,1,,170464688,126941,Active,,,0.001,IC50,HT-29 viability from Cell TiterGlo-IC50,Confirmatory,,
3996,1117332,1,1,,170464688,126941,Active,,,0.001,IC50,HCT116 viability from Cell TiterGlo-IC50,Confirmatory,,
3997,1117334,1,1,,170464688,126941,Active,,,0.001,IC50,Colo320 viability from Cell TiterGlo-IC50,Confirmatory,,
3998,1117336,1,1,,170464688,126941,Active,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
3999,1117337,1,1,,170464688,126941,Inactive,,,10.0,IC50,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-IC50,Confirmatory,,
4000,1117338,1,1,,170464688,126941,Active,,,0.001,IC50,SW480 viability from Cell TiterGlo-IC50,Confirmatory,,
4001,1117339,1,1,,170464688,126941,Active,,,0.001,IC50,GSK3B-pretreated HCT116 viability from Cell TiterGlo-IC50,Confirmatory,,
4002,1117340,1,1,,170464688,126941,Active,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
4003,1117341,1,1,,170464688,126941,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
4004,1117342,1,1,,170464688,126941,Active,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
4005,1117343,1,1,,170464688,126941,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
4006,1117346,1,1,,170464688,126941,Active,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
4007,1117347,1,1,,170464688,126941,Inactive,,,10.0,IC50,Decreased HeLa cell count-IC50,Confirmatory,,
4008,1117348,1,1,,170464688,126941,Inactive,,,10.0,IC50,Increased HeLa cells in S-phase-IC50,Confirmatory,,
4009,1117349,1,1,,170464688,126941,Inactive,,,10.0,IC50,Increased HeLa cells with 2N DNA content-IC50,Confirmatory,,
4010,1117350,1,1,,170464688,126941,Inactive,,,10.0,IC50,Increased chromatin condensation in HeLa cells-IC50,Confirmatory,,
4011,1117351,1,1,,170464688,126941,Inactive,,,10.0,IC50,Increased HeLa cells with 4N DNA content-IC50,Confirmatory,,
4012,1121442,2,2,,104234169,126941,Active,118992.0,1719.0,0.003,IC50,Inhibition of human DHFR assessed as depletion of NADPH after 30 secs shaking by spectrophotometry,Confirmatory,,
4013,1121442,2,2,,104234169,126941,Active,118992.0,573971.0,0.003,IC50,Inhibition of human DHFR assessed as depletion of NADPH after 30 secs shaking by spectrophotometry,Confirmatory,,
4014,1123073,1,1,,104234169,126941,Unspecified,,,,,Cytotoxicity against human CCRF-CEM cells,Other,109617.0,
4015,1123074,1,1,,104234169,126941,Unspecified,,,,,Antimicrobial activity against Lactobacillus casei ATCC 7469,Other,109617.0,
4016,1123132,3,2,,104234169,126941,Active,118992.0,1719.0,0.0015,IC50,Inhibition of dihydrofolate reductase (unknown origin) using dihydrofolic acid as substrate by spectrophotometry,Confirmatory,110934.0,
4017,1123132,3,2,,104234169,126941,Active,118992.0,573971.0,0.0015,IC50,Inhibition of dihydrofolate reductase (unknown origin) using dihydrofolic acid as substrate by spectrophotometry,Confirmatory,110934.0,
4018,1123134,1,1,,104234169,126941,Unspecified,,,,,Antibacterial activity against Streptococcus faecalis ATCC 8043 at 1 ug/ml,Other,110934.0,
4019,1130120,1,1,,104234169,126941,Active,,,0.026000000000000002,IC50,Inhibition of pigeon liver dihydrofolate reductase,Confirmatory,448685.0,
4020,1130121,1,2,,104234169,126941,Unspecified,,,,,Cytotoxicity against human KB cells,Other,448685.0,
4021,1130131,1,1,,104234169,126941,Unspecified,,,,,"Antitumor activity against mouse L1210 cells transfected in mouse assessed as increase in life span at 1.5 mg/kg, ip qd from day 1 to day 9 relative to control",Other,448685.0,
4022,1130136,1,1,,104234169,126941,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,448685.0,
4023,1130137,1,1,,104234169,126941,Unspecified,,,,,"Potency index, ratio of I50 for MTX to I50 for compound against pigeon liver dihydrofolate reductase",Other,448685.0,
4024,1130138,1,1,,104234169,126941,Unspecified,,,,,"Potency index, ratio of ED50 for MTX to ED50 for compound against human KB cells",Other,448685.0,
4025,1130590,1,1,,104234169,126941,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as minimum effective dose administered as single dose,Other,490545.0,
4026,1130627,1,1,,104234169,126941,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as minimum effective dose administered as once each 4 days for 3 total injection,Other,490545.0,
4027,1130628,1,1,,104234169,126941,Unspecified,,,,,Toxicity in mouse P388 cells allografted ip dosed mouse assessed as maximum tolerated dose administered as single dose,Other,490545.0,
4028,1130629,1,1,,104234169,126941,Unspecified,,,,,Toxicity in mouse P388 cells allografted ip dosed mouse assessed as maximum tolerated dose administered as once each 4 days for 3 total injection,Other,490545.0,
4029,1130630,1,1,,104234169,126941,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as dose providing 40% increase in life span administered as single dose,Other,490545.0,
4030,1130631,1,1,,104234169,126941,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as dose providing 40% increase in life span administered as once each 4 days for 3 total injection,Other,490545.0,
4031,1130632,1,1,,104234169,126941,Unspecified,,,,,"Therapeutic index, ratio of MTD for mouse P388 cells allografted ip dosed mouse to MED for mouse P388 cells allografted in ip dosed mouse administered as single dose",Other,490545.0,
4032,1130633,1,1,,104234169,126941,Unspecified,,,,,"Therapeutic index, ratio of MTD for mouse P388 cells allografted ip dosed mouse to MED for mouse P388 cells allografted in ip dosed mouse administered as once each 4 days for 3 total injection",Other,490545.0,
4033,1131716,1,1,,104234169,126941,Unspecified,,,,,Growth inhibition of human CCRF-CEM cells,Other,565818.0,
4034,1131717,3,1,,104234169,126941,Unspecified,,,,,Inhibition of rabbit liver dihydrofolate reductase using [3H]-folic acid after 10 mins by scintillation counting,Other,565818.0,
4035,1131769,1,2,,104234169,126941,Unspecified,,,,,Retention time in human serum at 150 mg after 72 hrs by HPLC analysis,Other,565818.0,
4036,1134001,1,3,,104234169,126941,Active,81871579.0,24312.0,0.001,IC50,Inhibition of rat liver dihydrofolate reductase using dihydrofolate as substrate,Confirmatory,850245.0,
4037,1134002,1,3,,104234169,126941,Active,118987.0,,0.0014,IC50,Inhibition of Streptococcus faecium dihydrofolate reductase using dihydrofolate as substrate,Confirmatory,850245.0,
4038,1134709,1,1,,104234169,126941,Unspecified,,,,,"Antitumor activity against mouse L1210 cells allografted in mouse assessed as increase in host survival at 25 mg/kg, ip administered as single dose on day 1 following tumor implantation",Other,915899.0,
4039,1134710,1,1,,104234169,126941,Unspecified,,,,,"Antitumor activity against mouse L1210 cells allografted in mouse assessed as increase in host survival at 50 mg/kg, ip administered as single dose on day 1 following tumor implantation",Other,915899.0,
4040,1134711,1,1,,104234169,126941,Unspecified,,,,,"Antitumor activity against mouse L1210 cells allografted in mouse assessed as increase in host survival at 75 mg/kg, ip administered as single dose on day 1 following tumor implantation",Other,915899.0,
4041,1134712,1,1,,104234169,126941,Unspecified,,,,,"Antitumor activity against mouse L1210 cells allografted in mouse assessed as increase in host survival at 100 mg/kg, ip administered as single dose on day 1 following tumor implantation",Other,915899.0,
4042,1134883,1,1,,104234169,126941,Unspecified,,,,,Antitumor activity against human CCRF-CEM assessed as growth inhibition,Other,109616.0,
4043,1134884,2,2,,104234169,126941,Active,7227951.0,,0.003,IC50,Inhibition of Lactobacillus casei ATCC 7469 dihydrofolate reductase,Confirmatory,109616.0,
4044,1134885,1,1,,104234169,126941,Unspecified,,,,,Antimicrobial activity against folate-dependent Lactobacillus casei ATCC 7469 assessed as growth inhibition,Other,109616.0,
4045,1134886,2,2,,104234169,126941,Unspecified,136612.0,,100.0,IC50,Inhibition of Lactobacillus casei ATCC 7469 thymidylate synthase,Confirmatory,109616.0,
4046,1134890,1,1,,104234169,126941,Unspecified,,,,,"Antitumor activity against mouse L1210 cells allografted in BDF/1 hybrid mouse assessed as increase in life span at 30 mg/kg, ip first dose treated 24 hrs after tumor implantation and on day 4 and 7",Other,109616.0,
4047,1136109,1,1,,104234169,126941,Unspecified,,,,,Growth inhibition of human CCRF-CEM cells,Other,271739.0,
4048,1137066,1,1,,104234169,126941,Unspecified,,,,,Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition,Other,406398.0,
4049,1137067,1,1,,104234169,126941,Unspecified,,,,,Cytotoxicity against RBL cells assessed as growth inhibition,Other,406398.0,
4050,1137091,1,2,,104234169,126941,Unspecified,,,,,"Drug level in mouse plasma treated with methotrexate bis(benzylamide) at 100 mg/kg, ip measured after 6 to 24 hrs by TLC analysis",Other,406398.0,
4051,1137093,1,1,,104234169,126941,Unspecified,,,,,"Drug level in mouse liver treated with methotrexate bis(benzylamide) at 100 mg/kg, ip measured after 6 to 24 hrs by TLC analysis",Other,406398.0,
4052,1137095,1,2,,104234169,126941,Unspecified,,,,,Drug level in rat whole serum treated with methotrexate di-n-butyl ester measured after 1 hr by TLC analysis,Other,406398.0,
4053,1145671,1,1,,104234169,126941,Active,,,0.002,IC50,Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth,Confirmatory,137981.0,
4054,1145672,1,1,,104234169,126941,Active,,,0.01,IC50,Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth,Confirmatory,137981.0,
4055,1145673,1,1,,104234169,126941,Unspecified,,,,,"Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 to IC50 for sensitive Streptococcus faecium ATCC 8043",Other,137981.0,
4056,1145674,1,1,,104234169,126941,Active,,,5.9999999999999995e-05,IC50,Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction,Confirmatory,137981.0,
4057,1145675,1,1,,104234169,126941,Active,,,1e-05,IC50,Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth,Confirmatory,137981.0,
4058,1145676,1,1,,104234169,126941,Unspecified,,,,,"Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 to IC50 for sensitive Lactobacillus casei ATCC 7469",Other,137981.0,
4059,1145677,1,1,,104234169,126941,Active,,,0.4,IC50,Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction,Confirmatory,137981.0,
4060,1145678,1,1,,104234169,126941,Active,,,1.5,IC50,Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth,Confirmatory,137981.0,
4061,1145679,1,1,,104234169,126941,Unspecified,,,,,"Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 to IC50 for sensitive Pediococcus cerevisiae ATCC 808",Other,137981.0,
4062,1145680,1,1,,104234169,126941,Unspecified,,,143.0,IC50,Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth,Confirmatory,137981.0,
4063,1145681,1,1,,104234169,126941,Active,,,,,Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth in presence of 0.002 ug/ml folic acid,Other,137981.0,
4064,1145682,1,1,,104234169,126941,Active,,,,,Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth in presence of 0.002 ug/ml folic acid,Other,137981.0,
4065,1145683,1,1,,104234169,126941,Active,,,,,Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction in growth in presence of 0.001 ug/ml folic acid,Other,137981.0,
4066,1145684,1,1,,104234169,126941,Active,,,,,Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth in presence of 0.001 ug/ml folic acid,Other,137981.0,
4067,1145685,1,1,,104234169,126941,Inactive,,,,,Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction in growth in presence of 0.001 ug/ml folinic acid,Other,137981.0,
4068,1145686,1,1,,104234169,126941,Inactive,,,,,Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth in presence of 0.001 ug/ml folinic acid,Other,137981.0,
4069,1145687,1,1,,104234169,126941,Active,,,,,Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth in presence of p-aminobenzoic acid,Other,137981.0,
4070,1145688,1,1,,104234169,126941,Unspecified,,,,,Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as active dose required to increase of 100% in mean survival time,Other,137981.0,
4071,1145689,1,1,,104234169,126941,Unspecified,,,,,Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as dose required to survivors for period of 60 days,Other,137981.0,
4072,1147566,1,1,,104234169,126941,Active,,,4e-05,GI50,Antimicrobial activity against Lactobacillus casei ATCC 7469 assessed as growth inhibition,Confirmatory,409842.0,
4073,1147567,2,2,,104234169,126941,Active,7227951.0,,0.003,IC50,Inhibition of MTX-resistant Lactobacillus casei dihydrofolate reductase,Confirmatory,409842.0,
4074,1147568,2,2,,104234169,126941,Unspecified,136612.0,,100.0,IC50,Inhibition of MTX-resistant Lactobacillus casei thymidylate synthetase,Confirmatory,409842.0,
4075,1147569,1,1,,104234169,126941,Unspecified,,,,,Cytotoxicity against human CCRF-CEM cells,Other,409842.0,
4076,1147570,1,1,,104234169,126941,Unspecified,,,,,"Toxicity in BDF/1 hybrid mouse xenografted with mouse L1210 cells assessed as optimal nontoxic dose administered q3d on day 1, 4 and 7",Other,409842.0,
4077,1147571,1,1,,104234169,126941,Unspecified,,,,,Antitumor activity against mouse L1210 cells allografted in BDF/1 hybrid mouse assessed as increase in life span relative to control,Other,409842.0,
4078,1149272,2,2,,104234169,126941,Active,7227951.0,,0.0045,IC50,Inhibition of DCM-resistant Lactobacillus casei DHFR,Confirmatory,820858.0,
4079,1159389,1,2,,104234169,126941,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
4080,1159509,1,1,,144210589,126941,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4081,1159509,1,1,,170464688,126941,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4082,1159515,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4083,1159515,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4084,1159516,1,1,,144210589,126941,Inconclusive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4085,1159516,1,1,,170464688,126941,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4086,1159517,1,1,,144210589,126941,Inconclusive,,,0.4364,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4087,1159517,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4088,1159518,1,1,,144210589,126941,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4089,1159518,1,1,,170464688,126941,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4090,1159519,1,1,,144210589,126941,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4091,1159519,1,1,,170464688,126941,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4092,1159520,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4093,1159520,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4094,1159521,1,1,,144210589,126941,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4095,1159521,1,1,,170464688,126941,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4096,1159523,1,1,,144210589,126941,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4097,1159523,1,1,,170464688,126941,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4098,1159524,1,1,,11113978,126941,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4099,1159524,1,1,,56463665,126941,Inconclusive,,,0.631,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4100,1159525,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4101,1159525,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4102,1159526,1,1,,144210589,126941,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4103,1159526,1,1,,170464688,126941,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4104,1159527,1,1,,144210589,126941,Inconclusive,325495497.0,6256.0,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4105,1159527,1,1,,170464688,126941,Inconclusive,325495497.0,6256.0,0.4772,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4106,1159528,1,1,,144210589,126941,Inconclusive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4107,1159528,1,1,,170464688,126941,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4108,1159529,1,1,,144210589,126941,Inconclusive,,,0.2454,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4109,1159529,1,1,,170464688,126941,Inconclusive,,,0.3011,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4110,1159531,1,1,,144210589,126941,Inconclusive,325495497.0,6256.0,0.275357,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4111,1159531,1,1,,170464688,126941,Inconclusive,325495497.0,6256.0,0.318904,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4112,1159550,3,1,,252401966,126941,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
4113,1159551,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4114,1159551,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4115,1159552,1,1,,144210589,126941,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4116,1159552,1,1,,170464688,126941,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4117,1159553,2,1,,144210589,126941,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4118,1159553,2,1,,170464688,126941,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4119,1159555,1,1,,144210589,126941,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
4120,1159555,1,1,,170464688,126941,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
4121,1159585,1,2,,307068790,126941,Inactive,124801388.0,812762.0,,CDPK1_IC50_uM,Biochemical screen of P. falciparum CDPK1,Confirmatory,26934697.0,
4122,1159586,1,2,,307068790,126941,Inactive,124513486.0,813740.0,,PK6_IC50_uM,Biochemical screen of P. falciparum PK6,Confirmatory,26934697.0,
4123,1159587,1,2,,307068790,126941,Inactive,124801229.0,812721.0,,PK7_IC50_uM,Biochemical screen of P. falciparum PK7,Confirmatory,26934697.0,
4124,1159588,1,2,,307068790,126941,Inactive,124511890.0,2655116.0,,CDPK4_IC50_uM,Biochemical screen of P. falciparum CDPK4,Confirmatory,26934697.0,
4125,1159589,1,2,,307068790,126941,Inactive,124803797.0,810694.0,,,Biochemical screen of P. falciparum MAPK2,Other,26934697.0,
4126,1159606,1,1,,56463665,126941,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
4127,1159607,2,1,,312309745,126941,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
4128,1159614,1,2,,170464688,126941,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
4129,1159620,1,1,,104234169,126941,Active,,,,,Summary of drug indications.,Other,,
4130,1161364,1,1,,104234169,126941,Inactive,,,,,"Antiinflammatory activity in DBA/1 mouse assessed as inhibition of carrageenan-induced arthritis at 0.3 mg/kg, ip treatment started on day 21 after second carrageenan challenge measured on day 32 to 41",Other,25152071.0,
4131,1161365,1,1,,104234169,126941,Inactive,,,,,"Antiinflammatory activity in DBA/1 mouse carrageenan-induced arthritis model assessed as reduction in articular cavity at 7.5 mg/kg, ip treatment started on day 21 after second carrageenan challenge measured on day 32",Other,25152071.0,
4132,1161366,1,1,,104234169,126941,Inactive,,,,,"Antiinflammatory activity in DBA/1 mouse carrageenan-induced arthritis model assessed as reduction in peripheral tissue inflammatory cell infiltration at 7.5 mg/kg, ip treatment started on day 21 after second carrageenan challenge measured on day 32",Other,25152071.0,
4133,1161367,1,1,,104234169,126941,Inactive,,,,,"Antiinflammatory activity in DBA/1 mouse carrageenan-induced arthritis model assessed as reduction in capillary and synovial hyperplasia at 7.5 mg/kg, ip treatment started on day 21 after second carrageenan challenge measured on day 32",Other,25152071.0,
4134,1161371,1,1,,104234169,126941,Active,,,,,"Reduction in PGE2 level in DBA/1 mouse plasma at 0.3 mg/kg, ip by EIA analysis relative to control",Other,25152071.0,
4135,1164831,1,2,,104234169,126941,Active,12643280.0,6573.0,0.012,IC50,Inhibition of RFC (unknown origin) expressed in Chinese hamster PC43-10 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay,Confirmatory,25234128.0,
4136,1164832,1,1,,104234169,126941,Active,,,0.21600000000000003,IC50,Cytotoxicity against Chinese hamster R2 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay,Confirmatory,25234128.0,
4137,1164833,1,2,,104234169,126941,Active,544337.0,2348.0,0.114,IC50,Inhibition of FRalpha (unknown origin) expressed in Chinese hamster RT16 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay,Confirmatory,25234128.0,
4138,1164834,1,2,,104234169,126941,Active,544337.0,2348.0,0.461,IC50,Inhibition of FRalpha (unknown origin) expressed in Chinese hamster RT16 cells assessed as cell growth inhibition incubated up to 96 hrs in presence of 200 nM folic acid by Celltiter-blue cell viability assay,Confirmatory,25234128.0,
4139,1164835,1,2,,104234169,126941,Active,116241366.0,2350.0,0.106,IC50,Inhibition of FRbeta (unknown origin) expressed in Chinese hamster D4 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay,Confirmatory,25234128.0,
4140,1164836,1,2,,104234169,126941,Active,116241366.0,2350.0,0.21100000000000002,IC50,Inhibition of FRbeta (unknown origin) expressed in Chinese hamster D4 cells assessed as cell growth inhibition incubated up to 96 hrs in presence of 200 nM folic acid by Celltiter-blue cell viability assay,Confirmatory,25234128.0,
4141,1164837,1,2,,104234169,126941,Active,74732636.0,113235.0,0.1205,IC50,Inhibition of PCFT (unknown origin) expressed in Chinese hamster R2/PCFT4 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay,Confirmatory,25234128.0,
4142,1164838,1,1,,104234169,126941,Unspecified,,,1.0,IC50,Cytotoxicity against Chinese hamster R2 cells expressing empty vector assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay,Confirmatory,25234128.0,
4143,1164839,1,2,,104234169,126941,Active,,,0.006,IC50,Cytotoxicity against human KB cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay,Confirmatory,25234128.0,
4144,1164840,1,2,,104234169,126941,Active,,,0.02,IC50,Cytotoxicity against human KB cells assessed as cell growth inhibition incubated up to 96 hrs in presence of 200 nM folic acid by Celltiter-blue cell viability assay,Confirmatory,25234128.0,
4145,1164841,1,2,,104234169,126941,Inactive,544337.0,2348.0,,,Inhibition of [3H]folic acid binding to FRalpha (unknown origin) expressed in Chinese hamster RT16 cells,Other,25234128.0,
4146,1164842,1,2,,104234169,126941,Inactive,116241366.0,2350.0,,,Inhibition of [3H]folic acid binding to FRbeta (unknown origin) expressed in Chinese hamster D4 cells,Other,25234128.0,
4147,1176668,1,1,,104234169,126941,Unspecified,,,,,"Reduction in ankle diameter in Lewis rat collagen-induced arthritis model at 0.075 mg/kg, po qd measured on day 17 (Rvb = +/- inches)",Other,25516790.0,
4148,1176669,1,1,,104234169,126941,Unspecified,,,,,"Induction of body weight regain in Lewis rat collagen-induced arthritis model at 0.075 mg/kg, po qd measured on day 17 (Rvb = 160.3 +/- 2.3 g)",Other,25516790.0,
4149,1182805,1,1,,104234169,126941,Active,,,3.66,IC50,Antitrypanosomal activity against bloodstream forms of Trypanosoma brucei brucei Lister 427 grown in HMI-9 medium after 48 hrs by Alamar blue assay,Confirmatory,25007262.0,
4150,1182806,1,1,,104234169,126941,Active,,,0.011000000000000001,IC50,Antitrypanosomal activity against bloodstream forms of Trypanosoma brucei brucei Lister 427 grown in Creek's minimal medium after 48 hrs by Alamar blue assay,Confirmatory,25007262.0,
4151,1188542,1,2,,104234169,126941,Active,109940075.0,508809.0,0.008,IC50,Inhibition of bovine liver DHFR,Confirmatory,25139568.0,
4152,1195047,1,1,,104234169,126941,Unspecified,,,,,Anti-arthritic activity in po dosed CD-1 mouse assessed as inhibition of carrageenan-kaolin-induced arthritis at treated for 8 days relative to vehicle treated control,Other,25863493.0,
4153,1195048,1,1,,104234169,126941,Unspecified,,,,,"Anti-arthritic activity in CD-1 mouse assessed as inhibition of carrageenan-kaolin-induced arthritis at 1 mg/kg, po for 8 days relative to vehicle treated control",Other,25863493.0,
4154,1195050,1,2,,104234169,126941,Unspecified,,,,,"Anti-arthritic activity against carrageenan-kaolin-induced arthritis CD-1 mouse model assessed as decrease in spleen index at 1 mg/kg, po for 8 days relative to vehicle treated control",Other,25863493.0,
4155,1195052,1,2,,104234169,126941,Unspecified,,,,,"Anti-arthritic activity against carrageenan-kaolin-induced arthritis CD-1 mouse model assessed as decrease in TNF-alpha level in serum at 1 mg/kg, po for 8 days relative to vehicle treated control",Other,25863493.0,
4156,1195053,1,2,,104234169,126941,Unspecified,,,,,"Anti-arthritic activity against carrageenan-kaolin-induced arthritis CD-1 mouse model assessed as decrease in IL-1beta level in serum at 1 mg/kg, po for 8 days relative to vehicle treated control",Other,25863493.0,
4157,1195054,1,2,,104234169,126941,Unspecified,,,,,"Anti-arthritic activity against carrageenan-kaolin-induced arthritis CD-1 mouse model assessed as decrease in IL-6 level in serum at 1 mg/kg, po for 8 days relative to vehicle treated control",Other,25863493.0,
4158,1195058,1,2,,104234169,126941,Unspecified,,,,,"Antiinflammatory activity against carrageenan-kaolin-induced arthritis CD-1 mouse model assessed as decrease in PGE2 level in serum at 1 mg/kg, po for 8 days relative to vehicle treated control",Other,25863493.0,
4159,1195060,1,2,,104234169,126941,Unspecified,,,,,"Antiinflammatory activity against carrageenan-kaolin-induced arthritis CD-1 mouse model assessed as decrease in NO level in serum at 1 mg/kg, po for 8 days relative to vehicle treated control",Other,25863493.0,
4160,1196769,1,1,,104234169,126941,Unspecified,,,,,Toxicity in ip dosed bovine type-2 collagen-induced Wistar rat arthritic model assessed as change in body weight administered as qd for 28 days starting day after immunization,Other,25580811.0,
4161,1197746,1,2,,104234169,126941,Unspecified,27734563.0,28234.0,,,Stimulation of human OATP1B3-mediated [3H]CCK-8 at 100 uM after 5 mins relative to control,Other,25618019.0,
4162,1198263,1,2,,104234169,126941,Active,,,0.01,IC50,Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25668494.0,
4163,1198264,1,1,,104234169,126941,Active,,,0.013000000000000001,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25668494.0,
4164,1198265,1,1,,104234169,126941,Active,,,0.99,IC50,Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25668494.0,
4165,1209455,1,2,,104234169,126941,Unspecified,262527527.0,8647.0,1000.0,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
4166,1209456,1,2,,104234169,126941,Unspecified,12585136.0,83569.0,1000.0,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
4167,1209457,1,1,,104234169,126941,Active,,,,,Unbound Cmax in human plasma,Other,21965623.0,
4168,1209581,1,2,,104234169,126941,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
4169,1209582,1,1,,104234169,126941,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
4170,1209583,1,1,,104234169,126941,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
4171,1209592,1,1,,104234169,126941,Unspecified,,,,,"Dissociation constant, pKa of the basic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
4172,1209593,1,1,,104234169,126941,Unspecified,,,,,"Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
4173,1211802,1,1,,104234169,126941,Unspecified,,,,,Drug excretion in iv dosed rat assessed as compound excreted into bile,Other,23139379.0,
4174,1211810,1,2,,104234169,126941,Unspecified,,,,,Drug excretion in iv dosed human assessed as compound excreted into bile after 24 hrs by T-tube method,Other,23139379.0,
4175,1211829,1,1,,104234169,126941,Unspecified,,,,,Total biliary clearance in iv dosed human after 24 hrs by T-tube method,Other,23139379.0,
4176,1211849,1,1,,104234169,126941,Unspecified,,,,,Unbound biliary clearance in iv dosed human after 24 hrs by T-tube method,Other,23139379.0,
4177,1211870,1,1,,104234169,126941,Unspecified,,,,,Total biliary clearance in iv dosed rat,Other,23139379.0,
4178,1211878,1,1,,104234169,126941,Unspecified,,,,,Unbound biliary clearance in iv dosed rat,Other,23139379.0,
4179,1211884,1,1,,104234169,126941,Unspecified,,,,,Total biliary clearance in iv dosed dog,Other,23139379.0,
4180,1211886,1,1,,104234169,126941,Unspecified,,,,,Unbound biliary clearance in iv dosed dog,Other,23139379.0,
4181,1219351,1,1,,104234169,126941,Unspecified,,,,,"Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins in presence 100 mM benzylpenicillin OAT inhibitor",Other,23297298.0,
4182,1219352,1,1,,104234169,126941,Unspecified,,,,,"Drug uptake in mouse brain ipsilateral cerebrum assessed as radiolabelled compound after 30 mins at 0.1 uM, intracerebral microinjection in presence 100 mM probenecid OAT inhibitor",Other,23297298.0,
4183,1219353,1,1,,104234169,126941,Unspecified,,,,,"Drug uptake in mouse brain ipsilateral cerebrum assessed as radiolabelled compound after 30 mins at 0.1 uM, intracerebral microinjection in presence 100 mM benzylpenicillin OAT inhibitor",Other,23297298.0,
4184,1219354,1,1,,104234169,126941,Unspecified,,,,,"Brain efflux index in Mrp2 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 60 mins relative to wild type",Other,23297298.0,
4185,1219355,1,1,,104234169,126941,Unspecified,,,,,"Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins relative to wild type",Other,23297298.0,
4186,1219358,1,1,,104234169,126941,Unspecified,,,,,"Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins in presence 100 mM probenecid OAT inhibitor relative to wild type",Other,23297298.0,
4187,1219359,1,1,,104234169,126941,Unspecified,,,,,"Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins in presence 100 mM benzylpenicillin OAT inhibitor relative to wild type",Other,23297298.0,
4188,1219360,1,1,,104234169,126941,Unspecified,,,,,Volume of distribution in mouse brain per gm of tissue at 0.3 uCi/ml after 1 to 2 hrs by in vitro brain slice uptake technique,Other,23297298.0,
4189,1219361,1,1,,104234169,126941,Unspecified,,,,,Ratio of efflux clearance to clearance in brain measured in mouse at 0.3 uCi/ml by in vitro brain slice uptake technique,Other,23297298.0,
4190,1219362,1,1,,104234169,126941,Unspecified,,,,,Efflux clearance mouse brain measured per gm of tissue at 0.3 uCi/ml by in vitro brain slice uptake technique,Other,23297298.0,
4191,1219363,1,1,,104234169,126941,Unspecified,,,,,Elimination rate constant mouse brain at 0.3 uCi/ml,Other,23297298.0,
4192,1219364,1,1,,104234169,126941,Unspecified,,,,,Drug uptake in human cerebrum,Other,23297298.0,
4193,1219367,1,1,,104234169,126941,Unspecified,,,,,"Elimination half life in mouse brain at 10 nCi/ml, icv",Other,23297298.0,
4194,1219368,1,1,,104234169,126941,Unspecified,,,,,"Drug uptake in mouse brain ipsilateral cerebrum assessed as radiolabelled compound after 30 mins at 0.1 uM, intracerebral microinjection",Other,23297298.0,
4195,1219371,1,1,,104234169,126941,Unspecified,,,,,"Brain efflux index in wild type mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins",Other,23297298.0,
4196,1219372,1,1,,104234169,126941,Unspecified,,,,,"Brain efflux index in Mrp2 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 60 mins",Other,23297298.0,
4197,1219373,1,1,,104234169,126941,Unspecified,,,,,"Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins",Other,23297298.0,
4198,1219376,1,1,,104234169,126941,Unspecified,,,,,"Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins in presence 100 mM probenecid OAT inhibitor",Other,23297298.0,
4199,1221956,1,1,,104234169,126941,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
4200,1221957,1,1,,104234169,126941,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
4201,1221958,1,1,,104234169,126941,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
4202,1221971,1,1,,104234169,126941,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
4203,1221972,1,1,,104234169,126941,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
4204,1221973,1,1,,104234169,126941,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
4205,1221974,1,2,,104234169,126941,Unspecified,308153583.0,1244.0,,,Fold activity change at MRP2 ATPase (unknown origin) relative to control,Other,21051535.0,
4206,1221978,1,1,,104234169,126941,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
4207,1221979,1,1,,104234169,126941,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
4208,1221980,1,1,,104234169,126941,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
4209,1221982,1,1,,104234169,126941,Unspecified,,,,,Fraction absorbed in human,Other,21051535.0,
4210,1224818,1,1,,312344145,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
4211,1224819,1,1,,312344145,126941,Active,325495545.0,2101.0,0.0298,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
4212,1224820,1,1,,312344145,126941,Inactive,325495545.0,2101.0,0.0188,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
4213,1224821,1,1,,312344145,126941,Active,325495545.0,2101.0,0.1679,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
4214,1224822,1,1,,312344145,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
4215,1224823,1,1,,312344145,126941,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
4216,1224824,1,1,,174006964,126941,Inactive,,,1.177,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
4217,1224825,1,1,,174006964,126941,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
4218,1224834,3,1,,144210589,126941,Inconclusive,,,0.0611,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
4219,1224834,3,1,,170464688,126941,Inconclusive,,,0.0668,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
4220,1224835,1,1,,144210589,126941,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
4221,1224835,1,1,,170464688,126941,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
4222,1224836,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4223,1224836,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4224,1224837,1,1,,144210589,126941,Inconclusive,,,0.077,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4225,1224837,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
4226,1224838,1,1,,144210589,126941,Active,66775687.0,9970.0,0.0486,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4227,1224838,1,1,,170464688,126941,Active,66775687.0,9970.0,0.075,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4228,1224839,1,1,,144210589,126941,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4229,1224839,1,1,,170464688,126941,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
4230,1224840,3,1,,144210589,126941,Inconclusive,,,0.0433,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
4231,1224840,3,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
4232,1224841,3,1,,144210589,126941,Active,325495545.0,2101.0,0.0386,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4233,1224841,3,1,,170464688,126941,Active,325495545.0,2101.0,0.1188,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4234,1224842,3,1,,144210589,126941,Inactive,325495545.0,2101.0,0.0386,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4235,1224842,3,1,,170464688,126941,Inactive,325495545.0,2101.0,0.1188,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
4236,1224843,1,1,,144210589,126941,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4237,1224843,1,1,,170464688,126941,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4238,1224844,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
4239,1224844,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
4240,1224845,1,1,,144210589,126941,Inconclusive,344243002.0,100757539.0,126.79299999999999,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
4241,1224845,1,1,,170464688,126941,Inconclusive,344243002.0,100757539.0,39.0762,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
4242,1224846,1,1,,144210589,126941,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
4243,1224846,1,1,,170464688,126941,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
4244,1224847,1,1,,144210589,126941,Active,,,0.6355,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
4245,1224847,1,1,,170464688,126941,Active,,,1.1013,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
4246,1224848,3,1,,144210589,126941,Active,325495545.0,2101.0,0.0486,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
4247,1224848,3,1,,170464688,126941,Active,325495545.0,2101.0,0.0531,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
4248,1224849,3,1,,144210589,126941,Inactive,325495545.0,2101.0,0.0486,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
4249,1224849,3,1,,170464688,126941,Inactive,325495545.0,2101.0,0.0531,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
4250,1224857,2,1,,170464688,126941,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
4251,1224857,2,1,,174006964,126941,Inactive,,,37.2212,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
4252,1224857,2,1,,312344145,126941,Inactive,,,31.6228,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
4253,1224859,2,1,,90340825,126941,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
4254,1224859,2,1,,170464688,126941,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
4255,1224859,2,1,,174006964,126941,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
4256,1224865,1,2,,56463665,126941,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
4257,1224867,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
4258,1224867,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
4259,1224868,1,1,,144210589,126941,Active,,,0.1096,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
4260,1224868,1,1,,170464688,126941,Active,,,0.0674,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
4261,1224869,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
4262,1224869,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
4263,1224870,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
4264,1224870,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
4265,1224871,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
4266,1224871,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
4267,1224872,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
4268,1224872,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
4269,1224873,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
4270,1224873,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
4271,1224874,1,1,,144210589,126941,Active,,,0.049,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
4272,1224874,1,1,,170464688,126941,Active,,,0.0535,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
4273,1224875,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
4274,1224875,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
4275,1224876,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
4276,1224876,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
4277,1224877,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
4278,1224877,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
4279,1224878,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
4280,1224878,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
4281,1224879,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
4282,1224879,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
4283,1224880,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
4284,1224880,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
4285,1224881,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
4286,1224881,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
4287,1224882,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
4288,1224882,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
4289,1224883,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
4290,1224883,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
4291,1224884,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
4292,1224884,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
4293,1224885,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
4294,1224885,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
4295,1224886,1,1,,144210589,126941,Inconclusive,,,0.0776,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
4296,1224886,1,1,,170464688,126941,Inconclusive,,,0.1068,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
4297,1224887,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
4298,1224887,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
4299,1224888,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
4300,1224888,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
4301,1224889,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
4302,1224889,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
4303,1224890,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
4304,1224890,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
4305,1224892,1,1,,144210589,126941,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4306,1224892,1,1,,170464688,126941,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4307,1224893,1,1,,144210589,126941,Inconclusive,66775687.0,9970.0,0.0504574,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4308,1224893,1,1,,170464688,126941,Active,66775687.0,9970.0,0.0421632,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
4309,1224894,1,1,,144210589,126941,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
4310,1224894,1,1,,170464688,126941,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
4311,1224895,1,1,,144210589,126941,Inconclusive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4312,1224895,1,1,,170464688,126941,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4313,1224896,1,1,,144210589,126941,Active,344243002.0,100757539.0,7.130089999999999,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
4314,1224896,1,1,,170464688,126941,Active,344243002.0,100757539.0,1.38647,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
4315,1224905,2,1,,121360865,126941,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
4316,1224905,2,1,,121360865,126941,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
4317,1228777,1,1,,104234169,126941,Active,,,5.1,IC50,Cytotoxicity against mouse EL4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Confirmatory,25951057.0,
4318,1228778,1,1,,104234169,126941,Inconclusive,,,,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Confirmatory,25951057.0,
4319,1228779,1,1,,104234169,126941,Inconclusive,,,,IC50,Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay,Confirmatory,25951057.0,
4320,1228780,1,1,,104234169,126941,Inconclusive,,,,IC50,Cytotoxicity against mouse McCoy cells assessed as growth inhibition,Confirmatory,25951057.0,
4321,1228781,1,1,,104234169,126941,Unspecified,,,347.0,IC50,Cytotoxicity against mouse 3T3 cells assessed as growth inhibition,Confirmatory,25951057.0,
4322,1228782,1,1,,104234169,126941,Inconclusive,,,,IC50,Cytotoxicity against human MCF10A cells assessed as growth inhibition,Confirmatory,25951057.0,
4323,1259241,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
4324,1259241,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
4325,1259242,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
4326,1259242,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
4327,1259243,1,1,,144210589,126941,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
4328,1259243,1,1,,170464688,126941,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
4329,1259244,1,1,,144210589,126941,Inconclusive,348019627.0,2099.0,0.3857,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
4330,1259244,1,1,,170464688,126941,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
4331,1259247,1,1,,144210589,126941,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
4332,1259247,1,1,,170464688,126941,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
4333,1259248,1,1,,144210589,126941,Inconclusive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
4334,1259248,1,1,,170464688,126941,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
4335,1259252,1,1,,174006964,126941,Active,169655958.0,,0.0332,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
4336,1259253,1,1,,174006964,126941,Active,169655958.0,,0.0148,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
4337,1259255,1,1,,174006964,126941,Active,169655958.0,,0.0264,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
4338,1259256,1,1,,174006964,126941,Active,169655958.0,,0.0372,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
4339,1259310,1,1,,332949395,126941,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4340,1259310,1,1,,332949706,126941,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4341,1259310,1,1,,332949729,126941,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4342,1259310,1,1,,333472404,126941,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
4343,1259313,1,1,,56463665,126941,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
4344,1259318,1,1,,56463665,126941,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
4345,1259325,1,2,,336955332,126941,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
4346,1259344,1,1,,144204495,126941,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
4347,1259354,1,1,,348452017,126941,Inactive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
4348,1259355,1,1,,144204495,126941,Inconclusive,,,0.4467,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
4349,1259356,1,1,,144204495,126941,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
4350,1259364,1,1,,144210589,126941,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
4351,1259364,1,1,,170464688,126941,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
4352,1259365,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
4353,1259365,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
4354,1259366,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4355,1259366,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4356,1259367,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4357,1259367,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
4358,1259368,1,1,,144210589,126941,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4359,1259368,1,1,,170464688,126941,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4360,1259369,1,1,,144210589,126941,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4361,1259369,1,1,,170464688,126941,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
4362,1259370,2,2,,124633655,126941,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
4363,1259370,2,2,,124633655,126941,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
4364,1259370,2,2,,124633655,126941,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
4365,1259377,1,1,,144210589,126941,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4366,1259377,1,1,,170464688,126941,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4367,1259378,1,1,,144210589,126941,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4368,1259378,1,1,,170464688,126941,Inconclusive,54288833.0,2100.0,0.5956,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
4369,1259379,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4370,1259379,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4371,1259380,1,1,,144210589,126941,Active,,,0.1723,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4372,1259380,1,1,,170464688,126941,Active,,,0.1333,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4373,1259381,1,1,,144210589,126941,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
4374,1259381,1,1,,170464688,126941,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
4375,1259382,1,1,,144210589,126941,Inconclusive,,,0.2169,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4376,1259382,1,1,,170464688,126941,Inconclusive,,,0.1679,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
4377,1259383,1,1,,144210589,126941,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
4378,1259383,1,1,,170464688,126941,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
4379,1259384,1,1,,144210589,126941,Inconclusive,,,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
4380,1259384,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
4381,1259385,1,1,,144210589,126941,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4382,1259385,1,1,,170464688,126941,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
4383,1259386,1,1,,144210589,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4384,1259386,1,1,,170464688,126941,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
4385,1259387,1,1,,144210589,126941,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
4386,1259387,1,1,,170464688,126941,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
4387,1259388,1,1,,144210589,126941,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
4388,1259388,1,1,,170464688,126941,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
4389,1259389,1,1,,124633655,126941,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
4390,1259390,1,1,,144210589,126941,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4391,1259390,1,1,,170464688,126941,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4392,1259391,1,1,,144210589,126941,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
4393,1259391,1,1,,170464688,126941,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
4394,1259392,1,1,,144210589,126941,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4395,1259392,1,1,,170464688,126941,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
4396,1259393,1,1,,144210589,126941,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
4397,1259393,1,1,,170464688,126941,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
4398,1259394,1,1,,144210589,126941,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4399,1259394,1,1,,170464688,126941,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4400,1259395,1,1,,144210589,126941,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4401,1259395,1,1,,170464688,126941,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
4402,1259396,1,1,,144210589,126941,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4403,1259396,1,1,,170464688,126941,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
4404,1259400,1,1,,170464688,126941,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
4405,1259401,1,1,,144210589,126941,Active,325495545.0,2101.0,0.0416478,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4406,1259401,1,1,,170464688,126941,Active,325495545.0,2101.0,0.110053,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4407,1259402,1,1,,144210589,126941,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4408,1259402,1,1,,170464688,126941,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
4409,1259403,1,1,,144210589,126941,Inconclusive,325495545.0,2101.0,0.06113060000000001,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4410,1259403,1,1,,170464688,126941,Active,325495545.0,2101.0,0.0573149,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4411,1259404,1,1,,144210589,126941,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4412,1259404,1,1,,170464688,126941,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
4413,1259407,1,1,,363899059,126941,Active,,,,,CCRIS mutagenicity studies,Other,,
4414,1259408,1,1,,363894886,126941,Unspecified,,,,,GENE-TOX mutagenicity studies,Other,,
4415,1259416,1,2,,375178076,126941,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
4416,1259421,1,1,,340081771,126941,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
4417,1259421,1,1,,375178076,126941,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
4418,1259423,1,2,,354798908,126941,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
4419,1259423,1,2,,354807789,126941,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
4420,1259423,1,2,,354911208,126941,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
